


**CUMULATIVE
SUPPLEMENT 11
NOVEMBER 2012**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2012

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Cumulative Supplement 11

November 2012

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	.vi
1.5 Availability of the Edition	vii
1.6 Report of Counts for the Prescription Drug Product List	viii
1.7 Cumulative Supplement Legend	ix
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

**CUMULATIVE SUPPLEMENT 11
November 2012**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ABBOTT LABORATORIES (ABBOTT LABS) (ABBOTT)	ABBVIE INC (ABBVIE) (ABBVIE)
ABBOTT LABORATORIES HOSP PRODUCTS DIV (ABBOTT)	ABBVIE INC (ABBVIE)
ABBOTT LABORATORIES PHARMACEUTICAL (ABBOTT)	ABBVIE INC (ABBVIE)
ABBOTT PRODUCTS (ABBOTT)	ABBVIE INC (ABBVIE)
ABRAXIX PHARMACEUTICAL PRODUCTS (ABRAXIS PHARM)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)

APP PHARMACEUTICALS (APP PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
APP PHARMACEUTICALS LLC (APP PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
FOREST LABORATORIES (FOREST LABS)	PFIZER INC (PFIZER)
NEXUS PHARMACEUTICALS (NEXUS PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)
PFIZER CONSUMER HEALTHCARE (PFIZER CONS HLTHCARE)	PFIZER INC (PFIZER)
ROSS LABORATORIES DIV ABBOTT LABORATORIES (ROSS LABS)	ABBVIE INC (ABBVIE)
SOLVAY PHARMACEUTICALS (SOLVAY)	ABBVIE INC (ABBVIE)
UNIMED PHARMACEUTICALS INC (UNIMED PHARMS)	ABBVIE INC (ABBVIE)
WYETH CONSUMER HEALTHCARE (WYETH CONS)	PFIZER INC (PFIZER)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established

between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual

Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2011</u>	<u>MAR 2012</u>	<u>JUN 2012</u>	<u>SEPT 2012</u>	<u>DEC 2012</u>
DRUG PRODUCTS LISTED	14480	14711	14834	15160	
SINGLE SOURCE	2451	2446	2428	2429	
	(16.9%)	(16.6%)	(16.4%)	(16.0%)	
MULTISOURCE	11953	12187	12328	12653	
	(82.5%)	(82.8%)	(83.1%)	(83.5%)	
THERAPEUTICALLY	11792	12037	12187	12509	
EQUIVALENT	(81.4%)	(81.8%)	(82.2%)	(82.5%)	

NOT THERAPEUTICALLY EQUIVALENT	161 (1.1%)	150 (1.0%)	141 (1.0%)	144 (0.9%)
EXCEPTIONS ¹	76 (0.5%)	78 (0.5%)	78 (0.5%)	78 (0.5%)
NEW MOLECULAR ENTITIES APPROVED	6	8	7	9
NUMBER OF APPLICANTS	810	826	826	836

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 32ND EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

1-1

ABACAVIR SULFATE

TABLET; ORAL

ABACAVIR SULFATE

AB	MYLAN PHARMS INC	EQ 300MG BASE	A091294 001	Jun 18, 2012	Jun	NEWA
	ZIAGEN					
AB	+ VIIV HLTHCARE	EQ 300MG BASE	N020977 001	Dec 17, 1998	Jun	CFTG

ACARBOSE

TABLET; ORAL

ACARBOSE

AB	EMCURE PHARMS LTD	25MG	A202271 001	Feb 07, 2012	Jan	NEWA
AB		50MG	A202271 002	Feb 07, 2012	Jan	NEWA
AB		100MG	A202271 003	Feb 07, 2012	Jan	NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

BUTAPAP

	+ MIKART	325MG;50MG	A089987 001	Oct 26, 1992	Jun	CRLD
	PHRENILIN					
	@ VALEANT	325MG;50MG	A087811 001	Jun 19, 1985	Jun	DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	LANNETT HOLDINGS INC	325MG;50MG;40MG	A200243 001	Sep 13, 2012	Aug	NEWA
----	----------------------	-----------------	-------------	--------------	-----	------

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

	NEXGEN PHARMA INC	300MG;50MG;40MG;30MG	A076560 002	Jul 19, 2012	Jul	NEWA
--	-------------------	----------------------	-------------	--------------	-----	------

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+ PHARM ASSOC	120MG/5ML;12MG/5ML	A087508 001		Jan	CRLD
	SUSPENSION; ORAL					
	CAPITAL AND CODEINE					
	+ VALEANT	120MG/5ML;12MG/5ML	A086024 001		Jan	CTEC
	+ VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024 001		Jun	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@ NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366 001	Jan 23, 2002	Jun	DISC
AA	VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343 001	Jan 25, 2012	Jan	NEWA

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	AUROLIFE PHARMA LLC	325MG;5MG	A201013 001	Apr 11, 2012	Mar	NEWA
AA		325MG;7.5MG	A201013 002	Apr 11, 2012	Mar	NEWA
AA		325MG;10MG	A201013 003	Apr 11, 2012	Mar	NEWA
	@ VINTAGE PHARMS LLC	500MG;5MG	A040281 001	Sep 30, 1998	Sep	CAHN
	@	500MG;7.5MG	A040280 001	Sep 30, 1998	Sep	CAHN
	@	650MG;7.5MG	A040280 002	Sep 30, 1998	Sep	CAHN

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ VINTAGE PHARMS LLC	650MG;10MG	A040280	003	Sep 30, 1998	Sep	CAHN
----------------------	------------	---------	-----	--------------	-----	------

@	750MG;7.5MG	A040281	002	Sep 30, 1998	Sep	CAHN
---	-------------	---------	-----	--------------	-----	------

VICODIN

>D> AA +	ABBVIE	500MG;5MG	A088058	001	Jan 07, 1983	Nov	DISC
----------	--------	-----------	---------	-----	--------------	-----	------

>A> @		500MG;5MG	A088058	001	Jan 07, 1983	Nov	DISC
-------	--	-----------	---------	-----	--------------	-----	------

AA +		500MG;5MG	A088058	001	Jan 07, 1983	Sep	CAHN
------	--	-----------	---------	-----	--------------	-----	------

VICODIN ES

>D> AA +	ABBVIE	750MG;7.5MG	A089736	001	Dec 09, 1988	Nov	DISC
----------	--------	-------------	---------	-----	--------------	-----	------

>A> @		750MG;7.5MG	A089736	001	Dec 09, 1988	Nov	DISC
-------	--	-------------	---------	-----	--------------	-----	------

AA +		750MG;7.5MG	A089736	001	Dec 09, 1988	Sep	CAHN
------	--	-------------	---------	-----	--------------	-----	------

VICODIN HP

>D> AA	ABBVIE	660MG;10MG	A040117	001	Sep 23, 1996	Nov	DISC
--------	--------	------------	---------	-----	--------------	-----	------

>A> @		660MG;10MG	A040117	001	Sep 23, 1996	Nov	DISC
-------	--	------------	---------	-----	--------------	-----	------

AA		660MG;10MG	A040117	001	Sep 23, 1996	Sep	CAHN
----	--	------------	---------	-----	--------------	-----	------

ZYDONE

+ VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998	Sep	CAHN
----------------------	-----------	---------	-----	--------------	-----	------

+	400MG;7.5MG	A040288	002	Nov 27, 1998	Sep	CAHN
---	-------------	---------	-----	--------------	-----	------

+	400MG;10MG	A040288	003	Nov 27, 1998	Sep	CAHN
---	------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

@ VINTAGE PHARMS LLC	500MG;5MG	A040303	001	Dec 30, 1999	Sep	CAHN
----------------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ACTAVIS TOTOWA	325MG;7.5MG	A040800	001	Apr 03, 2012	Mar	NEWA
----	----------------	-------------	---------	-----	--------------	-----	------

AA		325MG;10MG	A040800	002	Apr 03, 2012	Mar	NEWA
----	--	------------	---------	-----	--------------	-----	------

AA	ALVOGEN INC	325MG;7.5MG	A202677	001	Jul 26, 2012	Jul	NEWA
----	-------------	-------------	---------	-----	--------------	-----	------

AA		325MG;10MG	A202677	002	Jul 26, 2012	Jul	NEWA
----	--	------------	---------	-----	--------------	-----	------

PERCOCET

AA +	VINTAGE PHARMS LLC	325MG;2.5MG	A040330	001	Jun 25, 1999	Sep	CAHN
------	--------------------	-------------	---------	-----	--------------	-----	------

AA +		325MG;5MG	A040330	002	Jun 25, 1999	Sep	CAHN
------	--	-----------	---------	-----	--------------	-----	------

@		325MG;5MG	A085106	002		Sep	CAHN
---	--	-----------	---------	-----	--	-----	------

AA +		325MG;7.5MG	A040434	001	Nov 23, 2001	Sep	CAHN
------	--	-------------	---------	-----	--------------	-----	------

AA +		325MG;10MG	A040434	002	Nov 23, 2001	Sep	CAHN
------	--	------------	---------	-----	--------------	-----	------

AA +		500MG;7.5MG	A040341	001	Jul 26, 1999	Sep	CAHN
------	--	-------------	---------	-----	--------------	-----	------

AA +		650MG;10MG	A040341	002	Jul 26, 1999	Sep	CAHN
------	--	------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

WYGESIC

@ CARACO	650MG;65MG	A084999	001		Oct	CAHN
----------	------------	---------	-----	--	-----	------

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ALVOGEN INC	325MG;37.5MG	A202076	001	Mar 30, 2012	Mar	NEWA
----	-------------	--------------	---------	-----	--------------	-----	------

AB	ZYDUS PHARMS USA INC	325MG;37.5MG	A090460	001	Sep 06, 2012	Aug	NEWA
----	----------------------	--------------	---------	-----	--------------	-----	------

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP	SAGENT STRIDES	EQ 500MG BASE/VIAL	A200880	001	May 09, 2012	Apr	NEWA
----	----------------	--------------------	---------	-----	--------------	-----	------

AP +	X GEN PHARMS	EQ 500MG BASE/VIAL	A040784	001	Dec 10, 2008	Apr	CRLD
------	--------------	--------------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

DIAMOX

@ TEVA WOMENS

EQ 500MG BASE/VIAL

N009388 001 Dec 05, 1990 Apr DISC

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTE

AP + CUMBERLAND PHARMS 6GM/30ML (200MG/ML)

N021539 001 Jan 23, 2004 Oct CFTG

ACETYLCYSTEINE

AP INNOPHARMA INC 6GM/30ML (200MG/ML)

A200644 001 Nov 07, 2012 Oct NEWA

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN INNOPHARMA INC 20%

A203853 001 Jun 21, 2012 Jun NEWA

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

+ FOREST LABS INC 0.375MG/INH

N202450 001 Jul 23, 2012 Jul NEWA

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

@ HERITAGE PHARMS INC 200MG

A074889 001 Oct 31, 1997 May CAHN

TABLET; ORAL

ACYCLOVIR

@ HERITAGE PHARMS INC 400MG

A074891 001 Oct 31, 1997 May CAHN

@

800MG

A074891 002 Oct 31, 1997 May CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

+ HIKMA MAPLE EQ 500MG BASE/VIAL

A074885 001 Dec 19, 1997 Oct CAHN

EQ 1GM BASE/VIAL

A074885 002 Dec 19, 1997 Oct CAHN

ACYCLOVIR SODIUM

AP HIKMA MAPLE EQ 500MG BASE/VIAL

A074913 001 Oct 15, 1997 Oct CAHN

AP EQ 1GM BASE/VIAL

A074913 002 Oct 15, 1997 Oct CAHN

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB FOUGERA PHARMS 0.1%

A090824 001 Jun 30, 2010 Jan CAHN

GEL; TOPICAL

ADAPALENE

AB TOLMAR 0.3%

A200298 001 Jun 14, 2012 Jun NEWA

DIFFERIN

AB + GALDERMA LABS LP 0.3%

N021753 001 Jun 19, 2007 Jun CFTG

LOTION; TOPICAL

DIFFERIN

+ GALDERMA LABS LP 0.1%

N022502 001 Mar 17, 2010 Apr CAHN

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

@ HIKMA MAPLE 3MG/ML

A076501 001 Jun 16, 2004 Oct CAHN

AP 3MG/ML

A076500 001 Jun 16, 2004 Oct CAHN

@ TEVA PARENTERAL 3MG/ML

A078676 001 Jul 31, 2008 Mar DISC

INJECTABLE; INJECTION

ADENOSINE

@ TEVA PARENTERAL

3MG/ML

A076564 001 Jun 16, 2004 Jan DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN TEVA PHARMS

EQ 0.083% BASE

A075343 001 Nov 09, 1999 Sep CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN RITEDOSE CORP

EQ 0.083% BASE;0.017%

A202496 001 Oct 01, 2012 Sep NEWA

@ SANDOZ INC

EQ 0.083% BASE;0.017%

A076867 001 Dec 21, 2006 Apr DISC

AN TEVA PHARMS

EQ 0.083% BASE;0.017%

A076724 001 Dec 31, 2007 Sep CAHN

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB FOUGERA PHARMS

0.05%

A076973 001 Jul 12, 2005 Jan CAHN

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

AB FOUGERA PHARMS

0.05%

A076884 001 Jul 18, 2005 Jan CAHN

ALENDRONATE SODIUM

TABLET, EFFERVESCENT; ORAL

BINOSTO

+ MISSION PHARMA

EQ 70MG BASE

N202344 001 Mar 12, 2012 Mar NEWA

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

AB AUROBINDO PHARMA LTD

10MG

A079060 001 Aug 30, 2012 Aug NEWA

AB INVAGEN PHARMS

10MG

A090284 001 Jan 17, 2012 Jan NEWA

AB WOCKHARDT LTD

10MG

A090221 001 Aug 10, 2012 Jul NEWA

ALGLUCERASE

INJECTABLE; INJECTION

CEREDASE

@ GENZYME

80 UNITS/ML

N020057 003 Apr 05, 1991 Mar DISC

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB MYLAN PHARMS INC

0.25MG

A074046 001 Oct 19, 1993 Sep CAHN

AB

0.5MG

A074046 002 Oct 19, 1993 Sep CAHN

AB

1MG

A074046 003 Oct 19, 1993 Sep CAHN

AB

2MG

A074046 004 May 07, 1997 Sep CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ SANDOZ INC

0.5MG

A077777 001 Jun 30, 2006 Mar DISC

@

1MG

A077777 002 Jun 30, 2006 Mar DISC

@

2MG

A077777 003 Jun 30, 2006 Mar DISC

@

3MG

A077777 004 Jun 30, 2006 Mar DISC

@ VINTAGE PHARMS

0.5MG

A078442 001 Oct 15, 2007 Jul DISC

@

1MG

A078442 002 Oct 15, 2007 Jul DISC

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ VINTAGE PHARMS

2MG

A078442 003 Oct 15, 2007 Jul DISC

@

3MG

A078442 004 Oct 15, 2007 Jul DISC

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

AB UCB INC

0.25MG

N021726 001 Jan 19, 2005 Jan CAHN

AB

0.5MG

N021726 002 Jan 19, 2005 Jan CAHN

AB +

1MG

N021726 003 Jan 19, 2005 Jan CAHN

AB

2MG

N021726 004 Jan 19, 2005 Jan CAHN

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+ CUBIST PHARMS

12MG

N021775 001 May 20, 2008 Feb CAHN

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB + FOUGERA PHARMS

0.1%

A076065 001 May 15, 2003 Jan CAHN

LOTION; TOPICAL

AMCINONIDE

+ FOUGERA PHARMS

0.1%

A076329 001 Nov 06, 2002 Jan CAHN

OINTMENT; TOPICAL

AMCINONIDE

AB + FOUGERA PHARMS

0.1%

A076096 001 Nov 19, 2002 Jan CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

@ HIKMA MAPLE

EQ 50MG BASE/ML

A063274 001 May 18, 1992 Oct CAHN

@

EQ 250MG BASE/ML

A063275 001 May 18, 1992 Oct CAHN

@ HOSPIRA

EQ 50MG BASE/ML

A063263 001 Nov 30, 1994 Jun DISC

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN

15%(150GM/1000ML)

A091112 001 Apr 13, 2012 Mar NEWA

15%(300GM/2000ML)

A091112 002 Apr 13, 2012 Mar NEWA

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER

BAXTER HLTHCARE

15% (15GM/100ML)

A020512 001 Aug 30, 1996 Jun CAHN

NOVAMINE 15%

@ HOSPIRA INC

15% (75GM/500ML)

N017957 004 Nov 28, 1986 Mar CPOT

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

@ CLOVER PHARMS

250MG/ML

N015229 002 Mar CAHN

SYRUP; ORAL

AMICAR

AA + CLOVER PHARMS

1.25GM/5ML

N015230 002 Mar CAHN

TABLET; ORAL

AMICAR

AB CLOVER PHARMS

500MG

N015197 001 Mar CAHN

+

1GM

N015197 002 Jun 24, 2004 Mar CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ BEDFORD	50MG/ML	A076018	001	Oct 15, 2002	Jun	DISC
@ BEDFORD LABS	50MG/ML	A076299	001	Oct 24, 2002	Jun	DISC
@ TEVA PARENTERAL	50MG/ML	A076163	001	Sep 05, 2003	Jan	DISC

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	MURTY PHARMS	200MG	A077069	001	Apr 08, 2005	May	CAHN
AB		400MG	A077069	002	Apr 08, 2005	May	CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	CARACO	10MG	A040816	002	Jun 27, 2008	Apr	NEWA
AB		50MG	A040816	003	Jun 27, 2008	Apr	NEWA
AB		75MG	A040816	004	Jun 27, 2008	Apr	NEWA
AB		100MG	A040816	005	Jun 27, 2008	Apr	NEWA
AB		150MG	A040816	006	Jun 27, 2008	Apr	NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297	002	Dec 10, 1986	Feb	CTEC
+	EQ 25MG BASE;10MG	A071297	001	Dec 10, 1986	Feb	CRLD
LIMBITROL						
@ VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949	001		Feb	DISC
LIMBITROL DS						
@ VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949	002		Feb	DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A201380	001	Apr 13, 2012	Mar	NEWA
AB		EQ 10MG BASE	A201380	002	Apr 13, 2012	Mar	NEWA
@ SANDOZ	EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Oct	DISC	
@	EQ 5MG BASE	A076859	002	Sep 10, 2007	Oct	DISC	
@	EQ 10MG BASE	A076859	003	Sep 10, 2007	Oct	DISC	

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 2.5MG BASE;10MG	A202239	001	Sep 05, 2012	Aug	NEWA
AB		EQ 5MG BASE;10MG	A202239	002	Sep 05, 2012	Aug	NEWA
AB		EQ 5MG BASE;20MG	A202239	003	Sep 05, 2012	Aug	NEWA
AB		EQ 5MG BASE;40MG	A202239	004	Sep 05, 2012	Aug	NEWA
AB		EQ 10MG BASE;20MG	A202239	005	Sep 05, 2012	Aug	NEWA
AB		EQ 10MG BASE;40MG	A202239	006	Sep 05, 2012	Aug	NEWA

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

EXFORGE HCT

AB	NOVARTIS	5MG;12.5MG;160MG	N022314	001	Apr 30, 2009	Sep	CFTG
AB		5MG;25MG;160MG	N022314	002	Apr 30, 2009	Sep	CFTG
AB		10MG;12.5MG;160MG	N022314	003	Apr 30, 2009	Sep	CFTG

TABLET; ORAL

EXFORGE HCT

AB	NOVARTIS	10MG;25MG;160MG	N022314 004	Apr 30, 2009	Sep	CFTG
AB	+	10MG;25MG;320MG	N022314 005	Apr 30, 2009	Sep	CFTG

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE,VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435 001	Sep 25, 2012	Sep	NEWA
AB		5MG;25MG;160MG	A200435 002	Sep 25, 2012	Sep	NEWA
AB		10MG;12.5MG;160MG	A200435 005	Sep 25, 2012	Sep	NEWA
AB		10MG;25MG;160MG	A200435 003	Sep 25, 2012	Sep	NEWA
AB		10MG;25MG;320MG	A200435 004	Sep 25, 2012	Sep	NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	WATSON LABS INC	EQ 12% BASE	A076829 001	Feb 07, 2006	Oct	CAHN
----	-----------------	-------------	-------------	--------------	-----	------

LOTION; TOPICAL

AMMONIUM LACTATE

AB	WATSON LABS INC	EQ 12% BASE	A075575 001	Jun 11, 2002	Oct	CAHN
----	-----------------	-------------	-------------	--------------	-----	------

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB	AM ANTIBIOTICS	250MG	A062058 001		Oct	CAHN
AB		500MG	A062058 002		Oct	CAHN

TABLET, FOR SUSPENSION; ORAL

DISPERMOX

@ RANBAXY LABS LTD

600MG

A065159 001	Dec 04, 2003	Apr	DISC
-------------	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SANDOZ INC	200MG/5ML;EQ 28.5MG BASE/5ML	A065098 001	Dec 16, 2002	Jul	CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065098 002	Dec 16, 2002	Jul	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065358 001	Aug 13, 2007	Jul	CAHN

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569 001	Jan 20, 2012	Jan	NEWA
AB		500MG;EQ 125MG BASE	A091569 002	Jan 20, 2012	Jan	NEWA
AB		875MG;EQ 125MG BASE	A091568 001	Jan 20, 2012	Jan	NEWA
AB	SANDOZ INC	500MG;EQ 125MG BASE	A065117 001	Nov 27, 2002	Jul	CAHN
AB		875MG;EQ 125MG BASE	A065093 001	Nov 21, 2002	Jul	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

AB	SHIRE	2.5MG;2.5MG;2.5MG;2.5MG	N021303 001	Oct 11, 2001	Jun	CFTG
----	-------	-------------------------	-------------	--------------	-----	------

ADDERALL XR 15

AB	SHIRE	3.75MG;3.75MG;3.75MG;3.75MG	N021303 006	May 22, 2002	Jun	CFTG
----	-------	-----------------------------	-------------	--------------	-----	------

ADDERALL XR 20

AB	SHIRE	5MG;5MG;5MG;5MG	N021303 002	Oct 11, 2001	Jun	CFTG
----	-------	-----------------	-------------	--------------	-----	------

ADDERALL XR 25

AB	SHIRE	6.25MG;6.25MG;6.25MG;6.25MG	N021303 004	May 22, 2002	Jun	CFTG
----	-------	-----------------------------	-------------	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 30								
AB	+	SHIRE	7.5MG;7.5MG;7.5MG;7.5MG	N021303 003	Oct 11, 2001	Jun	CFTG	
ADDERALL XR 5								
AB		SHIRE	1.25MG;1.25MG;1.25MG;1.25MG	N021303 005	May 22, 2002	Jun	CFTG	
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE								
AB		ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302 001	Jun 22, 2012	Jun	NEWA	
AB			2.5MG;2.5MG;2.5MG;2.5MG	A077302 002	Jun 22, 2012	Jun	NEWA	
AB			3.75MG;3.75MG;3.75MG;3.75MG	A077302 003	Jun 22, 2012	Jun	NEWA	
AB			5MG;5MG;5MG;5MG	A077302 004	Jun 22, 2012	Jun	NEWA	
AB			6.25MG;6.25MG;6.25MG;6.25MG	A077302 005	Jun 22, 2012	Jun	NEWA	
AB			7.5MG;7.5MG;7.5MG;7.5MG	A077302 006	Jun 22, 2012	Jun	NEWA	

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

		INDEPENDENCE PHARMS	5MG	A200166 001	Aug 09, 2012	Jul	NEWA	
	+		10MG	A200166 002	Aug 09, 2012	Jul	NEWA	

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

	+	ALKOPHARMA USA	50MG/VIAL	N050729 001	Nov 22, 1996	May	CAHN	
	+		100MG/VIAL	N050729 002	Nov 22, 1996	May	CAHN	

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP		ANTIBIOTICE	EQ 250MG BASE/VIAL	A090354 001	Dec 28, 2009	Aug	CAHN	
AP			EQ 500MG BASE/VIAL	A090354 002	Dec 28, 2009	Aug	CAHN	
AP			EQ 1GM BASE/VIAL	A090354 003	Dec 28, 2009	Aug	CAHN	
AP			EQ 2GM BASE/VIAL	A090354 004	Dec 28, 2009	Aug	CAHN	
	@	HIKMA MAPLE	EQ 125MG BASE/VIAL	A062692 001	Jun 24, 1986	Oct	CAHN	
	@		EQ 250MG BASE/VIAL	A062692 002	Jun 24, 1986	Oct	CAHN	
	@		EQ 500MG BASE/VIAL	A062692 003	Jun 24, 1986	Oct	CAHN	
	@		EQ 1GM BASE/VIAL	A062692 004	Jun 24, 1986	Oct	CAHN	
	@		EQ 2GM BASE/VIAL	A062692 005	Jun 24, 1986	Oct	CAHN	
	@		EQ 10GM BASE/VIAL	A062692 006	Jun 24, 1986	Oct	CAHN	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP		HIKMA MAPLE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074 001	Mar 19, 2002	Oct	CAHN	
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074 002	Mar 19, 2002	Oct	CAHN	
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065076 001	Mar 19, 2002	Oct	CAHN	

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

AB		SHIRE LLC	EQ 0.5MG BASE	N020333 001	Mar 14, 1997	Jan	CAHN	
ANAGRELIDE HYDROCHLORIDE								
AB		MYLAN PHARMS INC	EQ 0.5MG BASE	A077613 001	Jun 27, 2006	Sep	CAHN	
AB			EQ 1MG BASE	A077613 002	Jun 27, 2006	Sep	CAHN	
	@	SANDOZ INC	EQ 0.5MG BASE	A076683 001	Apr 18, 2005	Mar	DISC	

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

@ SANDOZ INC

EQ 1MG BASE

A076683 002 Apr 18, 2005 Mar DISC

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB APOTEX INC

1MG

A200654 001 May 11, 2012 Apr NEWA

AB IMPAX LABS INC

1MG

A091242 001 May 31, 2012 May NEWA

APREPITANT

CAPSULE; ORAL

APREPITANT

AB SANDOZ

40MG

A090999 001 Sep 24, 2012 Sep NEWA

AB

80MG

A090999 002 Sep 24, 2012 Sep NEWA

AB

125MG

A090999 003 Sep 24, 2012 Sep NEWA

EMEND

AB MERCK

40MG

N021549 003 Jun 30, 2006 Sep CFTG

AB

80MG

N021549 001 Mar 26, 2003 Sep CFTG

AB +

125MG

N021549 002 Mar 26, 2003 Sep CFTG

APROTININ

INJECTABLE; INJECTION

TRASYLOL

@ BAYER HLTHCARE

10,000KIU/ML

N020304 001 Dec 29, 1993 May DISC

ARGATROBAN

INJECTABLE; INJECTION

ACOVA

AP + PFIZER

250MG/2.5ML (100MG/ML)

N020883 001 Jun 30, 2000 Jan CTNA

ARGATROBAN

AP HIKMA PHARM CO LTD

250MG/2.5ML (100MG/ML)

N203049 001 Jan 05, 2012 Jan NEWA

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

AB MYLAN PHARMS INC

50MG

A200043 001 Jun 01, 2012 May NEWA

AB

150MG

A200043 002 Jun 01, 2012 May NEWA

AB

250MG

A200043 003 Jun 01, 2012 May NEWA

WATSON LABS INC

100MG

A200156 002 Aug 29, 2012 Aug NEWA

200MG

A200156 004 Aug 29, 2012 Aug NEWA

NUVIGIL

AB CEPHALON

50MG

N021875 001 Jun 15, 2007 May CFTG

AB

150MG

N021875 003 Jun 15, 2007 May CFTG

AB +

250MG

N021875 004 Jun 15, 2007 May CFTG

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

>D>	AA	NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9MG;2.691GM	A090145 001	Jan 25, 2012	Nov	CPOT
			;7.5GM				

>A>	AA		4.7GM;100GM;1.015GM;5.9MG;2.691GM	A090145 001	Jan 25, 2012	Nov	CPOT
			;7.5GM				

	AA		4.7GM;100GM;1.015GM;5.9MG;2.691GM	A090145 001	Jan 25, 2012	Jan	NEWA
			;7.5GM				

FOR SOLUTION; ORAL

MOVIPREP

AA	+	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM ;7.5GM	N021881	001	Aug 02, 2006	Jan	CFTG
----	---	--------------	---	---------	-----	--------------	-----	------

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

		ORGANON SUB MERCK	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jul	CAHN
	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Jul	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

		@ VINTAGE PHARMS LLC	325MG;50MG;40MG;30MG	A075351	001	Mar 05, 1999	Sep	CAHN
--	--	----------------------	----------------------	---------	-----	--------------	-----	------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

		@ SANDOZ	385MG;30MG;25MG	A074817	001	Nov 27, 1996	Oct	DISC
--	--	----------	-----------------	---------	-----	--------------	-----	------

INVAGESIC FORTE

		@ SANDOZ	770MG;60MG;50MG	A074817	002	Nov 27, 1996	Oct	DISC
--	--	----------	-----------------	---------	-----	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB		PROSAM LABS	325MG;200MG	A040252	001	Dec 10, 1997	Feb	CAHN
----	--	-------------	-------------	---------	-----	--------------	-----	------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb	CAHN
----	--	-------------	------------------	---------	-----	--------------	-----	------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

		@ ZYDUS PHARMS USA INC	18MG	A079017	001	Sep 17, 2010	Jun	DISC
--	--	------------------------	------	---------	-----	--------------	-----	------

		@	25MG	A079017	002	Sep 17, 2010	Jun	DISC
--	--	---	------	---------	-----	--------------	-----	------

		@	40MG	A079017	003	Sep 17, 2010	Jun	DISC
--	--	---	------	---------	-----	--------------	-----	------

		@	60MG	A079017	004	Sep 17, 2010	Jun	DISC
--	--	---	------	---------	-----	--------------	-----	------

		@	80MG	A079017	005	Sep 17, 2010	Jun	DISC
--	--	---	------	---------	-----	--------------	-----	------

		@	100MG	A079017	006	Sep 17, 2010	Jun	DISC
--	--	---	-------	---------	-----	--------------	-----	------

STRATTERA

		LILLY	10MG	N021411	002	Nov 26, 2002	Jun	CTEC
--	--	-------	------	---------	-----	--------------	-----	------

			18MG	N021411	003	Nov 26, 2002	Jun	CTEC
--	--	--	------	---------	-----	--------------	-----	------

			25MG	N021411	004	Nov 26, 2002	Jun	CTEC
--	--	--	------	---------	-----	--------------	-----	------

			40MG	N021411	005	Nov 26, 2002	Jun	CTEC
--	--	--	------	---------	-----	--------------	-----	------

	+		60MG	N021411	006	Nov 26, 2002	Jun	CTEC
--	---	--	------	---------	-----	--------------	-----	------

			80MG	N021411	007	Feb 14, 2005	Jun	CTEC
--	--	--	------	---------	-----	--------------	-----	------

			100MG	N021411	008	Feb 14, 2005	Jun	CTEC
--	--	--	-------	---------	-----	--------------	-----	------

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB		APOTEX INC	EQ 10MG BASE	A090548	001	May 29, 2012	May	NEWA
----	--	------------	--------------	---------	-----	--------------	-----	------

AB			EQ 20MG BASE	A090548	002	May 29, 2012	May	NEWA
----	--	--	--------------	---------	-----	--------------	-----	------

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	APOTEX INC	EQ 40MG BASE	A090548 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A090548 004	May 29, 2012	May	NEWA
AB	DR REDDYS LABS LTD	EQ 10MG BASE	A091650 001	Jul 17, 2012	Jul	NEWA
AB		EQ 20MG BASE	A091650 002	Jul 17, 2012	Jul	NEWA
AB		EQ 40MG BASE	A091650 003	Jul 17, 2012	Jul	NEWA
AB		EQ 80MG BASE	A202357 001	Jul 17, 2012	Jul	NEWA
AB	MYLAN PHARMS INC	EQ 10MG BASE	A091226 001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A091226 002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A091226 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A091226 004	May 29, 2012	May	NEWA
AB	SANDOZ INC	EQ 10MG BASE	A077575 001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A077575 002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A077575 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A077575 004	May 29, 2012	May	NEWA
>D>	AB	TEVA PHARMS	EQ 10MG BASE	A078773 001	May 29, 2012	Nov DISC
>A>	@	EQ 10MG BASE	A078773 001	May 29, 2012	Nov	DISC
	AB	EQ 10MG BASE	A078773 001	May 29, 2012	May	NEWA
>D>	AB	EQ 20MG BASE	A078773 002	May 29, 2012	Nov	DISC
>A>	@	EQ 20MG BASE	A078773 002	May 29, 2012	Nov	DISC
	AB	EQ 20MG BASE	A078773 002	May 29, 2012	May	NEWA
>D>	AB	EQ 40MG BASE	A078773 003	May 29, 2012	Nov	DISC
>A>	@	EQ 40MG BASE	A078773 003	May 29, 2012	Nov	DISC
	AB	EQ 40MG BASE	A078773 003	May 29, 2012	May	NEWA
>D>	AB	EQ 80MG BASE	A078773 004	May 29, 2012	Nov	DISC
>A>	@	EQ 80MG BASE	A078773 004	May 29, 2012	Nov	DISC
	AB	EQ 80MG BASE	A078773 004	May 29, 2012	May	NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	+	BEDFORD	10MG/ML	A074901 001	Jul 18, 1997	Feb	CTEC
AP		HOSPIRA INC	10MG/ML	A090761 001	Oct 18, 2012	Oct	NEWA
AP		SAGENT PHARMS	10MG/ML	A091489 001	Feb 17, 2012	Feb	NEWA
ATRACURIUM BESYLATE PRESERVATIVE FREE							
AP	+	BEDFORD	10MG/ML	A074900 001	Jul 18, 1997	Feb	CTEC
AP		HOSPIRA INC	10MG/ML	A090782 001	Oct 18, 2012	Oct	NEWA
AP		SAGENT PHARMS	10MG/ML	A091488 001	Feb 17, 2012	Feb	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	+	ROXANE	0.025MG/5ML; 2.5MG/5ML	A087708 001	May 03, 1982	Apr	CRLD
		LOMOTIL					
		@ GD SEARLE LLC	0.025MG/5ML; 2.5MG/5ML	N012699 001		Apr	DISC

AVANAFIL

TABLET; ORAL

STENDRA

VIVUS

		50MG	N202276 001	Apr 27, 2012	Apr	NEWA
		100MG	N202276 002	Apr 27, 2012	Apr	NEWA
+		200MG	N202276 003	Apr 27, 2012	Apr	NEWA

AXITINIB

TABLET; ORAL

INLYTA

PFIZER

1MG

N202324 001 Jan 27, 2012 Jan NEWA

+

5MG

N202324 002 Jan 27, 2012 Jan NEWA

AZELAIC ACID

GEL; TOPICAL

FINACEA

+ BAYER HLTHCARE

15%

N021470 001 Dec 24, 2002 Jun CAHN

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT

ALCON PHARMA

0.05%

A202305 001 May 31, 2012 May NEWA

SPRAY, METERED; NASAL

ASTEPRO

AB

+ MEDA PHARMS

EQ 0.1876MG BASE/SPRAY

N022371 001 Aug 31, 2009 Aug CFTG

AZELASTINE HYDROCHLORIDE

AB

APOTEX INC

EQ 0.1876MG BASE/SPRAY

A201846 001 Aug 31, 2012 Aug NEWA

AB

SUN PHARMA GLOBAL

EQ 0.125MG BASE/SPRAY

A090423 001 May 23, 2012 May NEWA

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

DYMISTA

+ MEDA PHARMS

EQ 0.125MG
BASE/SPRAY; 0.05MG/SPRAY

N202236 001 May 01, 2012 May NEWA

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

TAKEDA PHARMS USA

EQ 40MG MEDOXOMIL

N200796 001 Feb 25, 2011 Apr CAHN

+

EQ 80MG MEDOXOMIL

N200796 002 Feb 25, 2011 Apr CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

TAKEDA PHARMS USA

EQ 40MG MEDOXOMIL; 12.5MG

N202331 001 Dec 20, 2011 Apr CAHN

+

EQ 40MG MEDOXOMIL; 25MG

N202331 002 Dec 20, 2011 Apr CAHN

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

@ SANDOZ

EQ 100MG BASE/5ML

A065297 001 Sep 18, 2006 Oct DISC

@

EQ 200MG BASE/5ML

A065297 002 Sep 18, 2006 Oct DISC

INJECTABLE; INJECTION

AZITHROMYCIN

@ PLIVA HRVATSKA DOO

EQ 500MG BASE/VIAL

A065265 001 Jan 18, 2007 Jul DISC

@ TEVA PARENTERAL

EQ 500MG BASE/VIAL

N050809 001 Dec 19, 2006 Jun DISC

@

EQ 2.5GM BASE/VIAL

N050809 002 Dec 19, 2006 Jun DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT	AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213 001	Jul 25, 2012	Jul	NEWA
AT	+ BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068 001	Oct 30, 1995	Jul	CTEC

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

CNS THERAPS INC 1MG/ML

N022462 004 Jun 22, 2012 Jun NEWA

TABLET; ORAL

BACLOFEN

AB	MYLAN PHARMS INC	10MG	A090334 001	Feb 18, 2010	Sep	CAHN
AB		20MG	A090334 002	Feb 18, 2010	Sep	CAHN
AB	PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb	CAHN
AB		20MG	A077088 001	Oct 31, 2007	Feb	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

@ UCB INC 10MG

N021589 001 Oct 30, 2003 Jan CAHN

@ 20MG

N021589 002 Oct 30, 2003 Jan CAHN

BALSALAZIDE DISODIUM

TABLET; ORAL

GIAZO

+ SALIX PHARMS 1.1GM

N022205 001 Feb 03, 2012 Feb NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL

QNASL

+	TEVA BRANDED PHARM	0.08MG/ACTUATION
+		0.08MG/ACTIVATION

N202813 001 Mar 23, 2012 Sep CPOT

N202813 001 Mar 23, 2012 Mar NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

LOTENSIN

AB	US PHARMS HOLDINGS I	5MG	N019851 001	Jun 25, 1991	Sep	CAHN
AB		10MG	N019851 002	Jun 25, 1991	Sep	CAHN
AB		20MG	N019851 003	Jun 25, 1991	Sep	CAHN
AB	+	40MG	N019851 004	Jun 25, 1991	Sep	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ MYLAN PHARMS INC 5MG;6.25MG

A076612 001 Feb 11, 2004 Oct DISC

@ 10MG;12.5MG

A076612 002 Feb 11, 2004 Oct DISC

@ 20MG;12.5MG

A076612 003 Feb 11, 2004 Oct DISC

@ 20MG;25MG

A076612 004 Feb 11, 2004 Oct DISC

LOTENSIN HCT

AB	US PHARMS HOLDINGS I	5MG;6.25MG	N020033 001	May 19, 1992	Sep	CAHN
AB		10MG;12.5MG	N020033 002	May 19, 1992	Sep	CAHN
AB		20MG;12.5MG	N020033 004	May 19, 1992	Sep	CAHN
AB	+	20MG;25MG	N020033 003	May 19, 1992	Sep	CAHN

BENZONATATE

CAPSULE; ORAL

BENZONATATE

@ NESHER PHARMS

100MG

A040795 001 Oct 31, 2007 Jun DISC

@

200MG

A040795 002 Oct 31, 2007 Jun DISC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

AB VALEANT INTL 5%;EQ 1% BASE

N050756 001 Dec 21, 2000 Apr CAHN

BT + 5%;EQ 1% BASE

N050756 002 Apr 20, 2007 Apr CAHN

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB MYLAN PHARMS INC 5%;EQ 1% BASE

A065443 001 Aug 11, 2009 Sep CAHN

AB PERRIGO ISRAEL 5%;1.2%

A090979 001 Jun 26, 2012 Jun NEWA

DUAC

AB + STIEFEL 5%;1.2%

N050741 001 Aug 26, 2002 Jun CFTG

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB + VALEANT INTL 5%;3%

N050557 001 Oct 26, 1984 Jan CAHN

BENZAMYCIN PAK

+ VALEANT INTL 5%;3%

N050769 001 Nov 27, 2000 Jun CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA EMCURE PHARMS LTD 50MG

A202061 001 Jan 27, 2012 Jan NEWA

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP APP PHARMS LLC 1MG/ML

A090233 001 Jul 28, 2009 May CAHN

COGENTIN

AP + OAK PHARMS AKORN 1MG/ML

N012015 001 Feb CAHN

TABLET; ORAL

BENZTROPINE MESYLATE

>A> AA EXCELLIUM 0.5MG

A090168 001 Nov 28, 2012 Nov NEWA

>A> AA 1MG

A090168 002 Nov 28, 2012 Nov NEWA

>A> AA 2MG

A090168 003 Nov 28, 2012 Nov NEWA

@ LANNETT HOLDINGS INC 0.5MG

A088877 001 Apr 11, 1985 Jan DISC

@ 1MG

A088894 001 Apr 11, 1985 Jan DISC

@ 2MG

A088895 001 Apr 11, 1985 Jan DISC

AA PROSAM LABS 0.5MG

A040699 001 Feb 14, 2008 Feb CMFD

AA 1MG

A040705 001 Feb 14, 2008 Feb CMFD

AA 2MG

A040706 001 Feb 14, 2008 Feb CMFD

AA + USL PHARMA 0.5MG

A040103 001 Dec 12, 1996 Jan CRLD

AA + 1MG

A040103 002 Dec 12, 1996 Jan CRLD

AA + 2MG

A040103 003 Dec 12, 1996 Jan CRLD

BETAMETHASONE

SYRUP; ORAL

CELESTONE

@ SCHERING

0.6MG/5ML

N014215 002 May DISC

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	N019137	001	Jun 26, 1984	Jan	CAHN
----	---	----------------	---------------	---------	-----	--------------	-----	------

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A076215	001	Dec 09, 2003	Jan	CAHN
----	--	----------------	---------------	---------	-----	--------------	-----	------

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	A075276	001	May 13, 2003	Jan	CAHN
----	---	----------------	---------------	---------	-----	--------------	-----	------

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A077111	001	May 21, 2007	Jan	CAHN
----	--	----------------	---------------	---------	-----	--------------	-----	------

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A075373	001	Jun 22, 1999	Jan	CAHN
----	--	----------------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

SUSPENSION; TOPICAL

TACLONEX

	+	LEO PHARM	0.064%;0.005%	N022185	001	May 09, 2008	Oct	CTNA
--	---	-----------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A075502	001	Jun 05, 2001	Jan	CAHN
----	--	----------------	------------------	---------	-----	--------------	-----	------

LOTRISONE

AB	+	MERCK SHARP DOHME	EQ 0.05% BASE;1%	N018827	001	Jul 10, 1984	Oct	CAHN
----	---	-------------------	------------------	---------	-----	--------------	-----	------

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A076516	001	Jun 16, 2005	Jan	CAHN
----	--	----------------	------------------	---------	-----	--------------	-----	------

LOTRISONE

AB	+	SCHERING CORP	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb	CAHN
----	---	---------------	------------------	---------	-----	--------------	-----	------

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

>A>	AB	PERRIGO	EQ 0.12% BASE	A078337	001	Nov 26, 2012	Nov	NEWA
-----	----	---------	---------------	---------	-----	--------------	-----	------

LUXIQ

>D>	+	STIEFEL	EQ 0.12% BASE	N020934	001	Feb 28, 1999	Nov	CFTG
-----	---	---------	---------------	---------	-----	--------------	-----	------

>A>	AB	+	EQ 0.12% BASE	N020934	001	Feb 28, 1999	Nov	CFTG
-----	----	---	---------------	---------	-----	--------------	-----	------

	+		EQ 0.12% BASE	N020934	001	Feb 28, 1999	Jan	CAHN
--	---	--	---------------	---------	-----	--------------	-----	------

BISOPROLOL FUMARATE

TABLET; ORAL

ZEBETA

AB		TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Jan	CAHN
----	--	-------------	-----	---------	-----	--------------	-----	------

AB	+		10MG	N019982	001	Jul 31, 1992	Jan	CAHN
----	---	--	------	---------	-----	--------------	-----	------

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

	+	MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011	Mar	CAHN
--	---	-------------------	-------	---------	-----	--------------	-----	------

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS
VELCADE

+ MILLENNIUM PHARMS 3.5MG/VIAL N021602 001 May 13, 2003 Jan CDFR

BOSENTAN

TABLET; ORAL

TRACLEER

ACTELION PHARMS LTD 62.5MG N021290 001 Nov 20, 2001 May CAHN

+ 125MG N021290 002 Nov 20, 2001 May CAHN

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

WYETH PHARMS INC EQ 100MG BASE N203341 001 Sep 04, 2012 Sep NEWA

+ EQ 500MG BASE N203341 002 Sep 04, 2012 Sep NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

@ HIKMA MAPLE 50MG/ML A070545 001 May 14, 1986 Oct CAHN

@ 50MG/ML A070546 001 May 14, 1986 Oct CAHN

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

PARLODEL

AB + US PHARMS HOLDINGS I EQ 5MG BASE N017962 002 Mar 01, 1982 Sep CAHN

TABLET; ORAL

PARLODEL

AB + US PHARMS HOLDINGS I EQ 2.5MG BASE N017962 001 Sep CAHN

BUDESONIDE

POWDER, METERED; INHALATION

PULMICORT

@ ASTRAZENECA 0.16MG/INH N020441 002 Jun 24, 1997 Jun DISC

SUSPENSION; INHALATION

BUDESONIDE

AN TEVA PHARMS 0.25MG/2ML A077519 001 Nov 18, 2008 Sep CAHN

AN 0.5MG/2ML A077519 002 Nov 18, 2008 Sep CAHN

AN WATSON LABS INC 0.25MG/2ML A078404 001 Jul 31, 2012 Jul NEWA

AN 0.5MG/2ML A078404 002 Jul 31, 2012 Jul NEWA

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

SYMBICORT

+ ASTRAZENECA 0.08MG/INH;0.0045MG/INH N021929 001 Jul 21, 2006 Jan CDFR

+ 0.16MG/INH;0.0045MG/INH N021929 002 Jul 21, 2006 Jan CDFR

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP HIKMA MAPLE 0.25MG/ML A079196 001 Apr 30, 2008 Oct CAHN

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

@ PACIRA PHARMS INC 133MG/10ML (13.3MG/ML)

N022496 001 Oct 28, 2011 Jul DISC

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB + ROXANE EQ 8MG BASE

A078633 002 Oct 08, 2009 Aug CRLD

SUBUTEX

@ RECKITT BENCKISER EQ 2MG BASE

N020732 002 Oct 08, 2002 Aug DISC

@ EQ 8MG BASE

N020732 003 Oct 08, 2002 Aug DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER EQ 2MG BASE;EQ 0.5MG BASE

N022410 001 Aug 30, 2010 Apr CAIN

EQ 4MG BASE;EQ 1MG BASE

N022410 003 Aug 10, 2012 Aug NEWA

+ EQ 8MG BASE;EQ 2MG BASE

N022410 002 Aug 30, 2010 Apr CAIN

EQ 12MG BASE;EQ 3MG BASE

N022410 004 Aug 10, 2012 Aug NEWA

TABLET; SUBLINGUAL

SUBOXONE

RECKITT BENCKISER EQ 2MG BASE;EQ 0.5MG BASE

N020733 001 Oct 08, 2002 Apr CPOT

+ EQ 8MG BASE;EQ 2MG BASE

N020733 002 Oct 08, 2002 Apr CPOT

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

BX IMPAX LABS 300MG

A077415 002 Dec 15, 2006 Sep CTEC

AB1 WOCKHARDT LTD 100MG

A201331 001 Aug 30, 2012 Aug NEWA

>A> AB3 150MG

A202189 001 Nov 21, 2012 Nov NEWA

AB1 150MG

A201331 002 Aug 30, 2012 Aug NEWA

AB1 200MG

A201331 003 Aug 30, 2012 Aug NEWA

FORFIVO XL

+ EDMONT PHARMS LLC 450MG

N022497 001 Nov 10, 2011 Mar CAHN

WELLBUTRIN SR

AB1 GLAXOSMITHKLINE 150MG

N020358 003 Oct 04, 1996 Sep CRLD

AB1 + 200MG

N020358 004 Jun 14, 2002 Sep CRLD

WELLBUTRIN XL

AB3 VALEANT INTL 150MG

N021515 001 Aug 28, 2003 Sep CRLD

AB3 + 300MG

N021515 002 Aug 28, 2003 Sep CRLD

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

@ APOTEX 5MG

A075521 001 Apr 05, 2002 Mar DISC

@ 10MG

A075521 002 Apr 05, 2002 Mar DISC

@ 15MG

A075521 003 Apr 05, 2002 Mar DISC

@ EGIS 5MG

A075119 001 Mar 14, 2002 Mar DISC

@ 10MG

A075119 002 Mar 14, 2002 Mar DISC

@ 15MG

A075119 003 Jan 23, 2003 Mar DISC

@ NESHER PHARMS 5MG

A075572 001 Feb 27, 2002 Jun DISC

@ 10MG

A075572 002 Feb 27, 2002 Jun DISC

@ 15MG

A075572 003 Feb 27, 2002 Jun DISC

@ PROSAM LABS 5MG

A075388 001 May 09, 2002 Mar DISC

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	PROSAM LABS	5MG	A075388 001	May 09, 2002	Feb	CMFD
	@	10MG	A075388 002	May 09, 2002	Mar	DISC
AB		10MG	A075388 002	May 09, 2002	Feb	CMFD
	@	15MG	A075388 003	May 09, 2002	Mar	DISC
AB		15MG	A075388 003	May 09, 2002	Feb	CMFD
AB		30MG	A078302 001	Dec 17, 2007	Feb	CMFD

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

>D>	@ PERRIGO ISRAEL	2%	A200923 001	May 18, 2012	Nov	CMFD
>A>	AB	2%	A200923 001	May 18, 2012	Nov	CMFD
	@	2%	A200923 001	May 18, 2012	Apr	NEWA
	GYNAZOLE-1					
>D>	+ KV PHARM	2%	N019881 001	Feb 07, 1997	Nov	CTEC
>A>	AB +	2%	N019881 001	Feb 07, 1997	Nov	CTEC

>A> CABOZANTINIB S-MALATE

>A> CAPSULE; ORAL

>A> COMETRIQ

>A>	EXELIXIS	EQ 20MG BASE	N203756 001	Nov 29, 2012	Nov	NEWA
>A>	+	EQ 80MG BASE	N203756 002	Nov 29, 2012	Nov	NEWA

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

AP	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 001	Sep 21, 1999	Jan	CAHN
----	----------------	------------------------------------	-------------	--------------	-----	------

CAFFEINE CITRATE

AP	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090827 001	Aug 29, 2012	Aug	NEWA
----	---------------	------------------------------------	-------------	--------------	-----	------

SOLUTION; ORAL

CAFCIT

AA	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 002	Apr 12, 2000	Jan	CAHN
----	----------------	------------------------------------	-------------	--------------	-----	------

CAFFEINE CITRATE

AA	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A091102 001	Aug 29, 2012	Aug	NEWA
----	---------------	------------------------------------	-------------	--------------	-----	------

CALCIPOTRIENE

CREAM; TOPICAL

CALCIPOTRIENE

AB	TOLMAR	0.005%	A200935 001	May 30, 2012	May	NEWA
----	--------	--------	-------------	--------------	-----	------

DOVONEX

AB	+ LEO PHARMA AS	0.005%	N020554 001	Jul 22, 1996	May	CFTG
----	-----------------	--------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CALCIPOTRIENE

AT	FOUGERA PHARMS	0.005%	A078305 001	May 06, 2008	Jan	CAHN
----	----------------	--------	-------------	--------------	-----	------

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	PADDOCK LLC	EQ 169MG CALCIUM	A091312 001	Jun 01, 2012	May	NEWA
----	-------------	------------------	-------------	--------------	-----	------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	+	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N018681 001	Dec 27, 1982	Oct	CRLD
AT	+	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N019933 001	Aug 29, 1989	Oct	CRLD
AT	+		20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N018921 001	Apr 03, 1984	Oct	CRLD
AT	+	HOSPIRA	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N019416 001	Jan 17, 1986	Oct	CRLD

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

>D>		ASTRAZENECA	16MG;12.5MG	N021093 001	Sep 05, 2000	Nov	CFTG
>A>	AB		16MG;12.5MG	N021093 001	Sep 05, 2000	Nov	CFTG
>D>			32MG;12.5MG	N021093 002	Sep 05, 2000	Nov	CFTG
>A>	AB		32MG;12.5MG	N021093 002	Sep 05, 2000	Nov	CFTG
>D>	+		32MG;25MG	N021093 003	May 16, 2008	Nov	CFTG
>A>	AB	+	32MG;25MG	N021093 003	May 16, 2008	Nov	CFTG
>A>		CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE					
>A>	AB	APOTEX INC	16MG;12.5MG	A202884 001	Dec 04, 2012	Nov	NEWA
>A>	AB		32MG;12.5MG	A202884 002	Dec 04, 2012	Nov	NEWA
>A>	AB	MYLAN LABS	16MG;12.5MG	A090704 001	Dec 04, 2012	Nov	NEWA
>A>	AB		32MG;12.5MG	A090704 002	Dec 04, 2012	Nov	NEWA
>A>	AB		32MG;25MG	A090704 003	Dec 04, 2012	Nov	NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@	VINTAGE PHARMS LLC	12.5MG	A074418 001	Feb 13, 1996	Sep	CAHN
@		25MG	A074418 002	Feb 13, 1996	Sep	CAHN
@		50MG	A074418 003	Feb 13, 1996	Sep	CAHN
@		100MG	A074418 004	Feb 13, 1996	Sep	CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

@	VINTAGE PHARMS LLC	25MG;15MG	A074788 001	Dec 29, 1997	Sep	CAHN
@		25MG;25MG	A074788 002	Dec 29, 1997	Sep	CAHN
@		50MG;15MG	A074788 004	Dec 29, 1997	Sep	CAHN
@		50MG;25MG	A074788 003	Dec 29, 1997	Sep	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	TEVA PHARMS	100MG	A078592 001	Sep 20, 2012	Sep	NEWA
AB		200MG	A078592 002	Sep 20, 2012	Sep	NEWA
AB		300MG	A078592 003	Sep 20, 2012	Sep	NEWA

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085 001	May 10, 2012	Apr	NEWA
AB		37.5MG;200MG;150MG	A079085 002	May 10, 2012	Apr	NEWA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

>A>	AB	WOCKHARDT LTD	12.5MG;200MG;50MG	A090786 001	Nov 20, 2012	Nov	NEWA
>A>	AB		18.75MG;200MG;75MG	A090833 001	Nov 20, 2012	Nov	NEWA
>A>	AB		25MG;200MG;100MG	A090833 002	Nov 20, 2012	Nov	NEWA
>A>	AB		31.25MG;200MG;125MG	A090833 003	Nov 20, 2012	Nov	NEWA
>A>	AB		37.5MG;200MG;150MG	A090833 004	Nov 20, 2012	Nov	NEWA
>A>	AB		50MG;200MG;200MG	A090833 005	Nov 20, 2012	Nov	NEWA
		STALEVO 100					
	AB	ORION PHARMA	25MG;200MG;100MG	N021485 002	Jun 11, 2003	Apr	CFTG
		STALEVO 125					
>D>		ORION PHARMA	31.25MG;200MG;125MG	N021485 006	Aug 29, 2008	Nov	CFTG
>A>	AB		31.25MG;200MG;125MG	N021485 006	Aug 29, 2008	Nov	CFTG
		STALEVO 150					
	AB	ORION PHARMA	37.5MG;200MG;150MG	N021485 003	Jun 11, 2003	Apr	CFTG
		STALEVO 200					
>D>	+	ORION PHARMA	50MG;200MG;200MG	N021485 004	Aug 02, 2007	Nov	CFTG
>A>	AB	+	50MG;200MG;200MG	N021485 004	Aug 02, 2007	Nov	CFTG
		STALEVO 50					
>D>	+	ORION PHARMA	12.5MG;200MG;50MG	N021485 001	Jun 11, 2003	Nov	CFTG
>A>	AB	+	12.5MG;200MG;50MG	N021485 001	Jun 11, 2003	Nov	CFTG
		STALEVO 75					
>D>		ORION PHARMA	18.75MG;200MG;75MG	N021485 005	Aug 29, 2008	Nov	CFTG
>A>	AB		18.75MG;200MG;75MG	N021485 005	Aug 29, 2008	Nov	CFTG

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL

PARCOPA

AB	UCB INC	10MG;100MG	A076699 001	Aug 27, 2004	Jan	CAHN
AB		25MG;100MG	A076699 002	Aug 27, 2004	Jan	CAHN
AB	+	25MG;250MG	A076699 003	Aug 27, 2004	Jan	CAHN

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	CIPLA LTD	50MG/VIAL	A077383 001	Jan 27, 2006	Mar	CAHN
AP		150MG/VIAL	A077383 002	Jan 27, 2006	Mar	CAHN
AP		450MG/VIAL	A077383 003	Jan 27, 2006	Mar	CAHN
AP	ONCO THERAPIES LTD	50MG/VIAL	A091510 001	May 29, 2012	May	NEWA
AP		150MG/VIAL	A091510 002	May 29, 2012	May	NEWA
AP		450MG/VIAL	A091510 003	May 29, 2012	May	NEWA
	PARAPLATIN					
	@ CORDEN PHARMA	50MG/VIAL	N019880 001	Mar 03, 1989	Feb	CAHN
	@	150MG/VIAL	N019880 002	Mar 03, 1989	Feb	CAHN
	@	450MG/VIAL	N019880 003	Mar 03, 1989	Feb	CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732 001	Feb 06, 2012	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A078732 002	Feb 06, 2012	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A078732 003	Feb 06, 2012	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A078732 004	Feb 06, 2012	Jan	NEWA
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861 001	Jan 18, 2007	Mar	CAHN
AP		150MG/15ML (10MG/ML)	A077861 002	Jan 18, 2007	Mar	CAHN
AP		450MG/45ML (10MG/ML)	A077861 003	Jan 18, 2007	Mar	CAHN
AP		600MG/60ML (10MG/ML)	A077861 004	Jan 18, 2007	Mar	CAHN

CARFILZOMIBPOWDER; INTRAVENOUS
KYPROLIS

+ ONYX PHARMS 60MG/VIAL N202714 001 Jul 20, 2012 Jul NEWA

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA PROSAM LABS 350MG A040188 001 Mar 07, 1997 Feb CAHN

CEFACLOR

CAPSULE; ORAL

CEFACLOR

@ RANBAXY

EQ 250MG BASE

A064156 001 Aug 28, 1997 Apr DISC

@

EQ 500MG BASE

A064156 002 Aug 28, 1997 Apr DISC

FOR SUSPENSION; ORAL

CEFACLOR

@ RANBAXY

EQ 125MG BASE/5ML

A064166 001 Oct 02, 1997 Apr DISC

AB + EQ 125MG BASE/5ML A064166 001 Oct 02, 1997 Feb CTEC

@

EQ 187MG BASE/5ML

A064165 001 Oct 02, 1997 Apr DISC

AB + EQ 187MG BASE/5ML A064165 001 Oct 02, 1997 Feb CTEC

@

EQ 250MG BASE/5ML

A064164 001 Oct 02, 1997 Apr DISC

AB + EQ 250MG BASE/5ML A064164 001 Oct 02, 1997 Feb CTEC

@

EQ 375MG BASE/5ML

A064155 001 Oct 02, 1997 Apr DISC

AB + EQ 375MG BASE/5ML A064155 001 Oct 02, 1997 Feb CTEC

AB YUNG SHIN PHARM EQ 125MG BASE/5ML A065412 001 Feb 17, 2012 Feb NEWA

AB EQ 187MG BASE/5ML A065412 002 Feb 17, 2012 Feb NEWA

AB EQ 250MG BASE/5ML A065412 003 Feb 17, 2012 Feb NEWA

AB EQ 375MG BASE/5ML A065412 004 Feb 17, 2012 Feb NEWA

TABLET, CHEWABLE; ORAL

RANICLOR

@ RANBAXY LABS LTD

EQ 125MG BASE

A065092 001 Dec 22, 2003 Apr DISC

@

EQ 187MG BASE

A065092 002 Dec 22, 2003 Apr DISC

@

EQ 250MG BASE

A065092 003 Dec 22, 2003 Apr DISC

@

EQ 375MG BASE

A065092 004 Dec 22, 2003 Apr DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

@ RANBAXY LABS LTD

EQ 500MG BASE

A065015 001 Jun 22, 1999 Apr DISC

FOR SUSPENSION; ORAL

CEFADROXIL

>A> AB HIKMA PHARMS EQ 250MG BASE/5ML A091036 001 Nov 28, 2012 Nov NEWA

>A> AB EQ 500MG BASE/5ML A091036 002 Nov 28, 2012 Nov NEWA

TABLET; ORAL

CEFADROXIL

@ RANBAXY

EQ 1GM BASE

A065018 001 Apr 23, 1999 Apr DISC

+ TEVA PHARMS

EQ 1GM BASE

A062774 001 Apr 08, 1987 Aug CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

B BRAUN

EQ 2GM BASE/VIAL

N050779 003 Jan 13, 2012 May NEWA

CEFAZOLIN SODIUM

>D> AP CEPHAZONE PHARMA EQ 500MG BASE/VIAL A065280 001 Mar 18, 2009 Nov DISC

INJECTABLE; INJECTIONCEFAZOLIN SODIUM

>A>	@ CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	A065280 001	Mar 18, 2009	Nov	DISC
>D>	AP	EQ 1GM BASE/VIAL	A065280 002	Mar 18, 2009	Nov	DISC
>A>	@	EQ 1GM BASE/VIAL	A065280 002	Mar 18, 2009	Nov	DISC
>D>	AP	EQ 10GM BASE/VIAL	A065295 001	Mar 18, 2009	Nov	DISC
>A>	@	EQ 10GM BASE/VIAL	A065295 001	Mar 18, 2009	Nov	DISC
>D>	AP	EQ 20GM BASE/VIAL	A065296 001	Mar 18, 2009	Nov	DISC
>A>	@	EQ 20GM BASE/VIAL	A065296 001	Mar 18, 2009	Nov	DISC
	@ HIKMA MAPLE	EQ 250MG BASE/VIAL	A062807 001	Jan 12, 1988	Oct	CAHN
	@	EQ 500MG BASE/VIAL	A062807 002	Jan 12, 1988	Oct	CAHN
	@	EQ 1GM BASE/VIAL	A062807 003	Jan 12, 1988	Oct	CAHN
	@	EQ 5GM BASE/VIAL	A062807 004	Jan 12, 1988	Oct	CAHN
	@	EQ 10GM BASE/VIAL	A062807 005	Jan 12, 1988	Oct	CAHN
	@	EQ 20GM BASE/VIAL	A062807 006	Jan 12, 1988	Oct	CAHN
	@ TEVA PHARMS	EQ 250MG BASE/VIAL	A063016 001	Mar 14, 1989	Oct	CAHN
	@	EQ 500MG BASE/VIAL	A063016 002	Mar 14, 1989	Oct	CAHN
	@	EQ 1GM BASE/VIAL	A063016 003	Mar 14, 1989	Oct	CAHN
	@	EQ 5GM BASE/VIAL	A063018 001	Mar 05, 1990	Oct	CAHN
	@	EQ 10GM BASE/VIAL	A063018 002	Mar 05, 1990	Oct	CAHN

CEFDITOREN PIVOXILTABLET; ORALSPECTRACEF

	VANSEN PHARMA	200MG	N021222 001	Aug 29, 2001	Mar	CAHN
+		400MG	N021222 002	Jul 21, 2008	Mar	CAHN

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTIONCEFEPIME HYDROCHLORIDE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A202268 001	Jul 30, 2012	Jul	NEWA
AP		EQ 2GM BASE/VIAL	A202268 002	Jul 30, 2012	Jul	NEWA

CEFIXIMECAPSULE; ORALSUPRAX

+	LUPIN LTD	400MG	N203195 001	Jun 01, 2012	Jun	NEWA
---	-----------	-------	-------------	--------------	-----	------

CEFOTAXIME SODIUMINJECTABLE; INJECTIONCEFOTAXIME SODIUM

>D>	AP	CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348 001	Jan 25, 2010	Nov	DISC
>A>	@		EQ 10GM BASE/VIAL	A065348 001	Jan 25, 2010	Nov	DISC
		CLAFORAN					
AP	+	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659 001	Jan 13, 1987	Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	A062659 002	Jan 13, 1987	Mar	CRLD

CEFOXITIN SODIUMINJECTABLE; INJECTIONCEFOXITIN

AP	ANTIBIOTICOS BRASIL	EQ 1GM BASE/VIAL	A065467 001	Aug 31, 2011	Jul	CAIN
AP		EQ 2GM BASE/VIAL	A065467 002	Aug 31, 2011	Jul	CAIN
AP		EQ 10GM BASE/VIAL	A065464 001	Aug 31, 2011	Jul	CAIN
AP	HIKMA MAPLE	EQ 1GM BASE/VIAL	A065051 001	Sep 11, 2000	Oct	CAHN
AP		EQ 2GM BASE/VIAL	A065051 002	Sep 11, 2000	Oct	CAHN
AP		EQ 10GM BASE/VIAL	A065050 001	Sep 11, 2000	Oct	CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

>D>	AB	AUROBINDO PHARMA	EQ 50MG BASE/5ML	A065409 001	Jun 08, 2007	Nov	CAHN
>D>	AB	+	EQ 100MG BASE/5ML	A065409 002	Jun 08, 2007	Nov	CRLD
>A>	AB	AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409 001	Jun 08, 2007	Nov	CAHN
>A>	AB		EQ 100MG BASE/5ML	A065409 002	Jun 08, 2007	Nov	CRLD
>D>	AB	SANDOZ	EQ 100MG BASE/5ML	A090031 002	Jan 14, 2009	Nov	CRLD
>A>	AB	+	EQ 100MG BASE/5ML	A090031 002	Jan 14, 2009	Nov	CRLD

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

AB	APOTEX INC	125MG/5ML	A065351 001	Feb 29, 2012	Feb	NEWA
AB		250MG/5ML	A065351 002	Feb 29, 2012	Feb	NEWA
	@ RANBAXY LABS LTD	125MG/5ML	A065202 001	Jun 30, 2006	Apr	DISC
	@	250MG/5ML	A065202 002	Jun 30, 2006	Apr	DISC
	CEFZIL					
>D>	@ BRISTOL MYERS SQUIBB	125MG/5ML	N050665 001	Dec 23, 1991	Nov	CAHN
>D>	@	250MG/5ML	N050665 002	Dec 23, 1991	Nov	CAHN
>A>	@ CORDEN PHARMA	125MG/5ML	N050665 001	Dec 23, 1991	Nov	CAHN
>A>	@	250MG/5ML	N050665 002	Dec 23, 1991	Nov	CAHN

TABLET; ORAL

CEFPROZIL

@ RANBAXY LABS LTD

@

CEFZIL

@ CORDEN PHARMA

@

250MG

500MG

250MG

500MG

A065198 001 Dec 13, 2006 Apr DISC

A065198 002 Dec 13, 2006 Apr DISC

N050664 001 Dec 23, 1991 Feb CAHN

N050664 002 Dec 23, 1991 Feb CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

AP	+	COVIS PHARMA	500MG/VIAL	N050578 001	Jul 19, 1985	Apr	CAHN
AP	+		1GM/VIAL	N050578 002	Jul 19, 1985	Apr	CAHN
AP	+		2GM/VIAL	N050578 003	Jul 19, 1985	Apr	CAHN
AP	+		6GM/VIAL	N050578 004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

@ COVIS PHARMA

+

+

EQ 10MG BASE/ML

EQ 20MG BASE/ML

EQ 40MG BASE/ML

N050634 001 Apr 28, 1989 Apr CAHN

N050634 002 Apr 28, 1989 Apr CAHN

N050634 003 Apr 28, 1989 Apr CAHN

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAXONE

AP	AKORN INC	EQ 250MG BASE/VIAL	A065305 001	Jan 11, 2008	Oct	CAHN	
AP		EQ 500MG BASE/VIAL	A065305 002	Jan 11, 2008	Oct	CAHN	
AP		EQ 1GM BASE/VIAL	A065305 003	Jan 11, 2008	Oct	CAHN	
AP		EQ 2GM BASE/VIAL	A065305 004	Jan 11, 2008	Oct	CAHN	
>D>	AP	CEPHAZONE PHARMA	EQ 250MG BASE/VIAL	A065294 001	Mar 26, 2007	Nov	DISC
>A>	@	EQ 250MG BASE/VIAL	A065294 001	Mar 26, 2007	Nov	DISC	
>D>	AP	EQ 500MG BASE/VIAL	A065294 002	Mar 26, 2007	Nov	DISC	

INJECTABLE; IM-IV

CEFTRIAZONE

>A>	@ CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	A065294 002	Mar 26, 2007	Nov	DISC
>D>	AP	EQ 1GM BASE/VIAL	A065294 003	Mar 26, 2007	Nov	DISC
>A>	@	EQ 1GM BASE/VIAL	A065294 003	Mar 26, 2007	Nov	DISC
>D>	AP	EQ 2GM BASE/VIAL	A065294 004	Mar 26, 2007	Nov	DISC
>A>	@	EQ 2GM BASE/VIAL	A065294 004	Mar 26, 2007	Nov	DISC
	AP TEVA PHARMS	EQ 250MG BASE/VIAL	A065227 001	Mar 15, 2007	Oct	CAHN
	AP	EQ 500MG BASE/VIAL	A065227 002	Mar 15, 2007	Oct	CAHN
	AP	EQ 1GM BASE/VIAL	A065227 003	Mar 15, 2007	Oct	CAHN
	AP	EQ 2GM BASE/VIAL	A065227 004	Mar 15, 2007	Oct	CAHN

INJECTABLE; INJECTION

CEFTRIAZONE

	AP HOSPIRA INC	EQ 1GM BASE/VIAL	A202563 001	Aug 20, 2012	Aug	NEWA
	AP	EQ 2GM BASE/VIAL	A202563 002	Aug 20, 2012	Aug	NEWA
	AP + SANDOZ INC	EQ 1GM BASE/VIAL	A065204 001	May 03, 2005	Mar	CRLD
	AP +	EQ 2GM BASE/VIAL	A065204 002	May 03, 2005	Mar	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

	@ RANBAXY LABS LTD	EQ 125MG BASE	A065043 003	Feb 15, 2002	Apr	DISC
	@	EQ 250MG BASE	A065043 002	Feb 15, 2002	Apr	DISC
	@	EQ 500MG BASE	A065043 001	Feb 15, 2002	Apr	DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

AB	TEVA PHARMS	EQ 750MG BASE/VIAL	A064192 002	Apr 16, 1998	Oct	CAHN
AB	+ ZINACEF COVIS PHARMA	EQ 750MG BASE/VIAL	N050558 002	Oct 19, 1983	Apr	CAHN

INJECTABLE; INJECTION

CEFUROXIME SODIUM

AP	TEVA PHARMS	EQ 1.5GM BASE/VIAL	A064192 001	Apr 16, 1998	Oct	CAHN
AP		EQ 7.5GM BASE/VIAL	A064191 001	Apr 16, 1998	Oct	CAHN
	ZINACEF					
AP	+ COVIS PHARMA	EQ 1.5GM BASE/VIAL	N050558 003	Oct 19, 1983	Apr	CAHN
AP	+	EQ 7.5GM BASE/VIAL	N050558 004	Oct 23, 1986	Apr	CAHN
	ZINACEF IN PLASTIC CONTAINER					
	+ COVIS PHARMA	EQ 15MG BASE/ML	N050643 001	Apr 28, 1989	Apr	CAHN
	+	EQ 30MG BASE/ML	N050643 002	Apr 28, 1989	Apr	CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL

KEFLEX

	@ SHIONOGI INC	EQ 100MG BASE/ML	N050406 003		Jul	CAHN
	@	EQ 125MG BASE/5ML	N050406 001		Jul	CAHN
	@	EQ 250MG BASE/5ML	N050406 002		Jul	CAHN

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEPHAPIRIN SODIUM

	@ HIKMA MAPLE	EQ 500MG BASE/VIAL	A062720 001	Jul 02, 1987	Oct	CAHN
	@	EQ 1GM BASE/VIAL	A062720 002	Jul 02, 1987	Oct	CAHN
	@	EQ 2GM BASE/VIAL	A062720 003	Jul 02, 1987	Oct	CAHN
	@	EQ 20GM BASE/VIAL	A062720 004	Jul 02, 1987	Oct	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

	@ RANBAXY LABS LTD	5MG/5ML	A077472 001	Jun 18, 2008	Jul	DISC
AA	SILARX	5MG/5ML	A078876 001	May 11, 2012	Apr	NEWA

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+	ASPEN GLOBAL INC	2MG	N010669 002		May	CAHN
---	------------------	-----	-------------	--	-----	------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB	CORNERSTONE THERAP	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671 001	Jun 29, 2012	Jun	NEWA
----	--------------------	---	-------------	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

+	HIKMA MAPLE	25MG/ML	A083329 001		Oct	CAHN
---	-------------	---------	-------------	--	-----	------

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

>D>	@ CLONMEL HLTHCARE	25MG	A087451 001		Nov	CAHN
>D>	@	50MG	A087450 001		Nov	CAHN
>A>	@ DAVA PHARMS INC	25MG	A087451 001		Nov	CAHN
>A>	@	50MG	A087450 001		Nov	CAHN

CHOLESTYRAMINE

POWDER; ORAL

LOCHOLEST

@ SANDOZ	EQ 4GM RESIN/PACKET	A074561 001	Aug 15, 1996	Oct	DISC
----------	---------------------	-------------	--------------	-----	------

@	EQ 4GM RESIN/SCOOPFUL	A074561 002	Aug 15, 1996	Oct	DISC
---	-----------------------	-------------	--------------	-----	------

LOCHOLEST LIGHT

@ SANDOZ	EQ 4GM RESIN/SCOOPFUL	A074562 002	Aug 15, 1996	Oct	DISC
----------	-----------------------	-------------	--------------	-----	------

@	EQ 4GM RESIN/PACKET	A074562 001	Aug 15, 1996	Oct	DISC
---	---------------------	-------------	--------------	-----	------

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

+	MCPRF	4-33.1mCi/ML	N203155 001	Sep 12, 2012	Sep	NEWA
---	-------	--------------	-------------	--------------	-----	------

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

NYCOMED GMBH	0.08MG/INH	N021658 002	Jan 10, 2008	May	CAHN
--------------	------------	-------------	--------------	-----	------

+	0.16MG/INH	N021658 003	Jan 10, 2008	May	CAHN
---	------------	-------------	--------------	-----	------

AEROSOL, METERED; NASAL

ZETONNA

+	NYCOMED GMBH	0.037MG/INH	N202129 001	Jan 20, 2012	Jan	NEWA
---	--------------	-------------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

OMNARIS

+	NYCOMED GMBH	0.05MG/INH	N022004 001	Oct 20, 2006	May	CAHN
---	--------------	------------	-------------	--------------	-----	------

CICLOPIROX

CREAM; TOPICAL									
CICLOPIROX									
AB	FOUGERA PHARMS	0.77%	A076435	001	Dec 29, 2004	Jan	CAHN		
GEL; TOPICAL									
CICLOPIROX									
AB	FOUGERA PHARMS	0.77%	A077896	001	Jun 10, 2008	Jan	CAHN		
AB	GLENMARK GENERICS	0.77%	A091595	001	Feb 29, 2012	Feb	NEWA		
SHAMPOO; TOPICAL									
CICLOPIROX									
AT	FOUGERA PHARMS	1%	A090146	001	May 25, 2010	Jan	CAHN		
AT	WATSON LABS INC	1%	A090490	001	Nov 24, 2009	Oct	CAHN		
SOLUTION; TOPICAL									
CICLOPIROX									
AT	MYLAN PHARMS INC	8%	A078567	001	Sep 18, 2007	Feb	CAHN		
SUSPENSION; TOPICAL									
CICLOPIROX									
AB	FOUGERA PHARMS	0.77%	A076422	001	Aug 06, 2004	Jan	CAHN		

CIDOFOVIR

INJECTABLE; INJECTION									
CIDOFOVIR									
AP	EMCURE PHARMS LTD	EQ 75MG BASE/ML	A202501	001	Jul 26, 2012	Jul	NEWA		
AP	MYLAN LLC	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	Jun	NEWA		
VISTIDE									
AP	+ GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	Jun	CFTG		

CILOSTAZOL

TABLET; ORAL									
CILOSTAZOL									
AB	BIOKEY	50MG	A077722	001	Sep 24, 2012	Sep	NEWA		
AB		100MG	A077831	001	Sep 24, 2012	Sep	NEWA		
AB	MYLAN PHARMS INC	50MG	A077019	001	Nov 23, 2004	Sep	CAHN		
AB		100MG	A077019	002	Nov 23, 2004	Sep	CAHN		

CIMETIDINE

TABLET; ORAL									
CIMETIDINE									
	@ SANDOZ	200MG	A074506	001	Jan 24, 1996	Oct	DISC		
	@	300MG	A074506	002	Jan 24, 1996	Oct	DISC		
	@	400MG	A074506	003	Jan 24, 1996	Oct	DISC		
	@	800MG	A074506	004	Jan 24, 1996	Oct	DISC		
	@ VINTAGE PHARMS LLC	200MG	A074281	001	May 17, 1994	Sep	CAHN		
	@	300MG	A074281	002	May 17, 1994	Sep	CAHN		
	@	400MG	A074281	003	May 17, 1994	Sep	CAHN		
	@	800MG	A074329	001	May 17, 1994	Sep	CAHN		

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION									
CIMETIDINE HYDROCHLORIDE									
	@ HOSPIRA	EQ 300MG BASE/2ML	A074345	001	Jan 31, 1995	Jun	DISC		
	@	EQ 300MG BASE/2ML	A074344	001	Jan 31, 1995	Jun	DISC		
	@ VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005	001	Aug 31, 1994	Sep	CAHN		

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ VINTAGE PHARMS LLC EQ 300MG BASE/5ML

A074251 001 Dec 22, 1994 Sep CAHN

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

@ TEVA PARENTERAL 200MG/20ML (10MG/ML)

A077782 001 Aug 28, 2006 Mar DISC

@ 400MG/40ML (10MG/ML)

A077782 002 Aug 28, 2006 Jan DISC

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 200MG/100ML

A077888 001 Mar 18, 2008 Jun DISC

@ 400MG/200ML

A077888 002 Mar 18, 2008 Jun DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@ PLIVA EQ 100MG BASE

A076426 001 Jun 15, 2005 Jan DISC

@ EQ 250MG BASE

A076426 002 Jun 15, 2005 Jan DISC

@ EQ 500MG BASE

A076426 003 Jun 15, 2005 Jan DISC

@ EQ 750MG BASE

A076426 004 Jun 15, 2005 Jan DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB DR REDDYS LABS LTD 212.6MG;EQ 287.5MG BASE

A077701 002 Oct 31, 2007 Apr NEWA

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP SANDOZ INC EQ 2MG BASE/ML

A200159 001 Feb 03, 2012 Jan NEWA

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP SANDOZ INC EQ 2MG BASE/ML

A200154 001 Feb 03, 2012 Jan NEWA

AP EQ 10MG BASE/ML

A200154 002 Feb 03, 2012 Jan NEWA

NIMBEX

AP + ABBOTT EQ 2MG BASE/ML

N020551 001 Dec 15, 1995 Jan CFTG

NIMBEX PRESERVATIVE FREE

AP + ABBOTT EQ 2MG BASE/ML

N020551 003 Dec 15, 1995 Jan CFTG

AP + EQ 10MG BASE/ML

N020551 002 Dec 15, 1995 Jan CFTG

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP ONCO THERAPIES LTD 1MG/ML

A091062 001 Apr 18, 2012 Apr NEWA

@ TEVA PARENTERAL 1MG/ML

A074814 001 May 16, 2000 Mar DISC

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

MYLAN PHARMS INC EQ 10MG BASE

A077668 001 Feb 28, 2007 Sep CAHN

EQ 20MG BASE

A077668 002 Feb 28, 2007 Sep CAHN

+

EQ 40MG BASE

A077668 003 Feb 28, 2007 Sep CAHN

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB MYLAN PHARMS INC EQ 10MG BASE

A077037 001 Nov 05, 2004 Sep CAHN

AB EQ 20MG BASE

A077037 002 Nov 05, 2004 Sep CAHN

AB EQ 40MG BASE

A077037 003 Nov 05, 2004 Sep CAHN

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

	@ SANDOZ	EQ 10MG BASE	A077035 001	Oct 28, 2004	Aug	DISC
	@	EQ 20MG BASE	A077035 002	Oct 28, 2004	Aug	DISC
	@	EQ 40MG BASE	A077035 003	Oct 28, 2004	Aug	DISC
AB	TEVA PHARMS	EQ 10MG BASE	A077048 001	Nov 16, 2004	Aug	CAHN
AB		EQ 20MG BASE	A077048 002	Nov 16, 2004	Aug	CAHN
AB		EQ 40MG BASE	A077048 003	Nov 16, 2004	Aug	CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

+	FERRING PHARMS AS	12GM/PACKET;3.5GM/PACKET;10MG/PAC KET	N202535 001	Jul 16, 2012	Jul	NEWA
---	-------------------	--	-------------	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB	AUROBINDO	250MG	A065489 001	Jul 25, 2012	Jul	NEWA
AB		500MG	A065489 002	Jul 25, 2012	Jul	NEWA

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

	@ SANDOZ	500MG	A065250 001	Aug 25, 2005	Aug	DISC
--	----------	-------	-------------	--------------	-----	------

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 75MG BASE	A091225 001	May 31, 2011	Sep	CAHN
AB		EQ 150MG BASE	A091225 002	May 31, 2011	Sep	CAHN
AB		EQ 300MG BASE	A091225 003	May 31, 2011	Sep	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	LYNE	EQ 75MG BASE/5ML	A201821 001	Aug 28, 2012	Aug	NEWA
----	------	------------------	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 2% BASE	A065139 001	Dec 27, 2004	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A064160 001	Jan 28, 2000	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639 001	Aug 30, 1989	May	CFTG
AP	+		EQ 12MG BASE/ML	N050639 002	Aug 30, 1989	May	CFTG
AP	+		EQ 18MG BASE/ML	N050639 003	Apr 10, 1991	May	CFTG

CLINDAMYCIN PHOSPHATE

	@ HIKMA MAPLE	EQ 150MG BASE/ML	A062953 001	Apr 21, 1988	Oct	CAHN
	@	EQ 150MG BASE/ML	A062806 001	Oct 15, 1987	Oct	CAHN
	@	EQ 150MG BASE/ML	A063068 001	Aug 28, 1989	Oct	CAHN
AP		EQ 150MG BASE/ML	A062889 001	Apr 25, 1988	Oct	CAHN

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		SANDOZ INC	EQ 6MG BASE/ML	A201692 001	May 31, 2012	May	NEWA
AP			EQ 12MG BASE/ML	A201692 002	May 31, 2012	May	NEWA

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP	SANDOZ INC	EQ 18MG BASE/ML	A201692 003	May 31, 2012	May	NEWA
----	------------	-----------------	-------------	--------------	-----	------

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A065067 001	Jan 31, 2002	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT	FOUGERA PHARMS	EQ 1% BASE	A065254 001	Feb 14, 2006	Jan	CAHN
	@ G AND W LABS INC	EQ 1% BASE	A062811 001	Sep 01, 1988	Oct	CAHN
	@ RENAISSANCE PHARMA	EQ 1% BASE	A064108 001	Sep 27, 1996	Sep	CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX	+ STIEFEL GSK	1.2%;0.025%	N050803 001	Jul 16, 2010	May	CRLD
----	---------------	-------------	-------------	--------------	-----	------

CLOBAZAM

TABLET; ORAL

ONFI

LUNDBECK LLC

5MG

N202067 001	Oct 21, 2011	Mar	CAHN
-------------	--------------	-----	------

10MG

N202067 002	Oct 21, 2011	Mar	CAHN
-------------	--------------	-----	------

+

20MG

N202067 003	Oct 21, 2011	Mar	CAHN
-------------	--------------	-----	------

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

AB1	PERRIGO ISRAEL	0.05%	A077763 001	Mar 10, 2008	Jul	CTEC
-----	----------------	-------	-------------	--------------	-----	------

AB2		0.05%	A201402 001	Aug 14, 2012	Jul	NEWA
-----	--	-------	-------------	--------------	-----	------

OLUX

AB1	+ STIEFEL LABS INC	0.05%	N021142 001	May 26, 2000	Jul	CTEC
-----	--------------------	-------	-------------	--------------	-----	------

OLUX E

AB2	+ STIEFEL LABS INC	0.05%	N022013 001	Jan 12, 2007	Jul	CFTG
-----	--------------------	-------	-------------	--------------	-----	------

CREAM; TOPICAL

CLOBETASOL PROPIONATE

@ G AND W LABS INC

0.05%

A074139 001	Aug 03, 1994	Jun	CAHN
-------------	--------------	-----	------

@ RENAISSANCE PHARMA

0.05%

A075338 001	Feb 09, 2001	Aug	CAHN
-------------	--------------	-----	------

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	FOUGERA PHARMS	0.05%	A075430 001	May 26, 1999	Jan	CAHN
-----	----------------	-------	-------------	--------------	-----	------

@ RENAISSANCE PHARMA

0.05%

A075733 001	Aug 22, 2001	Aug	CAHN
-------------	--------------	-----	------

TEMOVATE

AB1	+ FOUGERA PHARMS	0.05%	N019322 001	Dec 27, 1985	Jan	CAHN
-----	------------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CLOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A075368 001	Feb 15, 2000	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

TEMOVATE

AB	+ FOUGERA PHARMS	0.05%	N020337 001	Apr 29, 1994	Jan	CAHN
----	------------------	-------	-------------	--------------	-----	------

LOTION; TOPICAL

CLOBETASOL PROPIONATE

AB	TARO	0.05%	A200302 001	Jul 02, 2012	Jun	NEWA
----	------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A074407 001	Feb 23, 1996	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

@ RENAISSANCE PHARMA

0.05%

A075057 001	Aug 12, 1998	Aug	CAHN
-------------	--------------	-----	------

TEMOVATE

AB	+ FOUGERA PHARMS	0.05%	N019323 001	Dec 27, 1985	Jan	CAHN
----	------------------	-------	-------------	--------------	-----	------

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

AB	PERRIGO ISRAEL	0.05%	A090974	001	Aug 09, 2012	Jul	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT	FOUGERA PHARMS	0.05%	A075391	001	Feb 08, 1999	Jan	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

@ G AND W LABS INC

0.05%

A074331 001 Dec 15, 1995 Jun CAHN

TEMOVATE

AT	+ FOUGERA PHARMS	0.05%	N019966	001	Feb 22, 1990	Jan	CAHN
----	------------------	-------	---------	-----	--------------	-----	------

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

AB	MYLAN PHARMS INC	0.5MG	A074940	001	Oct 30, 1997	Sep	CAHN
----	------------------	-------	---------	-----	--------------	-----	------

AB		1MG	A074940	002	Oct 30, 1997	Sep	CAHN
----	--	-----	---------	-----	--------------	-----	------

AB		2MG	A074940	003	Oct 30, 1997	Sep	CAHN
----	--	-----	---------	-----	--------------	-----	------

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

AP	MYLAN INSTITUTIONAL	1 MG/10 ML (0.1 MG/ML)	N020615	001	Oct 02, 1996	Feb	CAHN
----	---------------------	------------------------	---------	-----	--------------	-----	------

AP	+	5 MG/10 ML (0.5 MG/ML)	N020615	002	Apr 27, 1999	Feb	CAHN
----	---	------------------------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

KAPVAY

SHIONOGI INC

0.2MG

N022331 004 Sep 28, 2010 May CMFD

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	APOTEX INC	EQ 75MG BASE	A076274	001	May 17, 2012	Apr	NEWA
----	------------	--------------	---------	-----	--------------	-----	------

AB	AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540	001	May 17, 2012	Apr	NEWA
----	----------------------	--------------	---------	-----	--------------	-----	------

AB	DR REDDYS LABS INC	EQ 75MG BASE	A076273	001	Jan 14, 2008	Mar	CMFD
----	--------------------	--------------	---------	-----	--------------	-----	------

AB	DR REDDYS LABS LTD	EQ 300MG BASE	A091023	001	May 17, 2012	Apr	NEWA
----	--------------------	---------------	---------	-----	--------------	-----	------

AB	GATE PHARMS	EQ 300MG BASE	A091216	001	May 17, 2012	Apr	NEWA
----	-------------	---------------	---------	-----	--------------	-----	------

AB	MYLAN PHARMS INC	EQ 75MG BASE	A077665	001	May 17, 2012	Apr	NEWA
----	------------------	--------------	---------	-----	--------------	-----	------

AB		EQ 300MG BASE	A077665	002	May 17, 2012	Apr	NEWA
----	--	---------------	---------	-----	--------------	-----	------

AB	ROXANE	EQ 75MG BASE	A078004	001	May 17, 2012	Apr	NEWA
----	--------	--------------	---------	-----	--------------	-----	------

AB	SUN PHARMA GLOBAL	EQ 75MG BASE	A090494	001	May 17, 2012	Apr	NEWA
----	-------------------	--------------	---------	-----	--------------	-----	------

AB	TEVA	EQ 75MG BASE	A076999	001	May 17, 2012	Apr	NEWA
----	------	--------------	---------	-----	--------------	-----	------

AB	TEVA PHARMS	EQ 300MG BASE	A090625	001	May 17, 2012	Apr	NEWA
----	-------------	---------------	---------	-----	--------------	-----	------

AB	TORRENT PHARMS LTD	EQ 75MG BASE	A090844	001	May 17, 2012	Apr	NEWA
----	--------------------	--------------	---------	-----	--------------	-----	------

AB	WOCKHARDT LTD	EQ 75MG BASE	A202266	001	Aug 14, 2012	Jul	NEWA
----	---------------	--------------	---------	-----	--------------	-----	------

>A>	AB		EQ 300MG BASE	A202266	002	Nov 20, 2012	Nov	NEWA
-----	----	--	---------------	---------	-----	--------------	-----	------

AB	ZYDUS PHARMS USA INC	EQ 75MG BASE	A201686	001	Oct 10, 2012	Sep	NEWA
----	----------------------	--------------	---------	-----	--------------	-----	------

PLAVIX

AB	SANOFI AVENTIS US	EQ 75MG BASE	N020839	001	Nov 17, 1997	Mar	CTEC
----	-------------------	--------------	---------	-----	--------------	-----	------

AB	+	EQ 300MG BASE	N020839	002	Sep 20, 2007	Apr	CTEC
----	---	---------------	---------	-----	--------------	-----	------

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

@ LUNDBECK LLC

3.75MG

N017105 001 Mar CAHN

@

7.5MG

N017105 002 Mar CAHN

@

15MG

N017105 003 Mar CAHN

TABLET; ORAL

TRANXENE

AB	LUNDBECK LLC	3.75MG	N017105 006	Mar	CAHN
AB		7.5MG	N017105 007	Mar	CAHN
AB	+	15MG	N017105 008	Mar	CAHN
	TRANXENE SD				
	@ LUNDBECK LLC	11.25MG	N017105 005	Mar	CAHN
	@	22.5MG	N017105 004	Mar	CAHN

CLOTTRIMAZOLE

CREAM; TOPICAL

CLOTTRIMAZOLE

AB	FOUGERA PHARMS	1%	A078338 001	Sep 02, 2008	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

	JAZZ	12.5MG	N021590 004	May 30, 2007	Apr	CAHN
		25MG	N021590 001	Feb 10, 2004	Apr	CAHN
	@	50MG	N021590 003	Jun 03, 2005	Apr	CAHN
+		100MG	N021590 002	Feb 10, 2004	Apr	CAHN
		150MG	N021590 005	Jul 09, 2010	Apr	CAHN
		200MG	N021590 006	Jul 09, 2010	Apr	CAHN
	JAZZ PHARMS III	12.5MG	N021590 004	May 30, 2007	Jun	CAHN
		25MG	N021590 001	Feb 10, 2004	Jun	CAHN
	@	50MG	N021590 003	Jun 03, 2005	Jun	CAHN
+		100MG	N021590 002	Feb 10, 2004	Jun	CAHN
		150MG	N021590 005	Jul 09, 2010	Jun	CAHN
		200MG	N021590 006	Jul 09, 2010	Jun	CAHN

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

STRIBILD

+	GILEAD SCIENCES INC	150MG;150MG;200MG;300MG	N203100 001	Aug 27, 2012	Aug	NEWA
---	---------------------	-------------------------	-------------	--------------	-----	------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	TRIS PHARMA INC	10MG/5ML;6.25MG/5ML	A200386 001	Jun 29, 2012	Jun	NEWA
----	-----------------	---------------------	-------------	--------------	-----	------

COLCHICINE

TABLET; ORAL

COLCRYS

+	TAKEDA PHARMS USA	0.6MG	N022352 001	Jul 29, 2009	Oct	CAHN
---	-------------------	-------	-------------	--------------	-----	------

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP	EMCURE PHARMS LTD	EQ 150MG BASE/VIAL	A202359 001	Sep 28, 2012	Sep	NEWA
----	-------------------	--------------------	-------------	--------------	-----	------

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+	TEVA WOMENS	309MG/COPPER	N018680 001	Nov 15, 1984	May	CAHN
---	-------------	--------------	-------------	--------------	-----	------

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

AP	INNOPHARMA INC	0.25MG/VIAL	A202147 001	Jun 29, 2012	Jun	NEWA
AP	SANDOZ	0.25MG/VIAL	A202147 001	Jun 29, 2012	Sep	CAHN

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

@ KING PFIZER	0.8MG/INH	N018887 001	Dec 05, 1985	Jun	DISC
---------------	-----------	-------------	--------------	-----	------

CONCENTRATE; ORAL

GASTROCROM

AA	+	JAZZ PHARMS COMMERCL	100MG/5ML	N020479 001	Feb 29, 1996	Mar	CAHN	
>D>	AA	+	JAZZ PHARMS INTL	100MG/5ML	N020479 001	Feb 29, 1996	Nov	CAHN
	AA	+		100MG/5ML	N020479 001	Feb 29, 1996	Jun	CAHN
>A>	AA	+	MEDA PHARMS	100MG/5ML	N020479 001	Feb 29, 1996	Nov	CAHN

SOLUTION; INHALATION

CROMOLYN SODIUM

AN	+	TEVA PHARMS	10MG/ML	A075271 001	Jan 18, 2000	Sep	CAHN
----	---	-------------	---------	-------------	--------------	-----	------

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

@ HIKMA MAPLE	1MG/ML	A080515 002		Oct	CAHN
---------------	--------	-------------	--	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB		MYLAN PHARMS INC	5MG	A073144 002	Feb 03, 2006	Jul	CRLD
AB	+		10MG	A073144 001	May 30, 1991	Jul	CRLD
AB		PROSAM LABS	5MG	A077291 001	Feb 03, 2006	Feb	CAHN
AB			10MG	A077209 001	Oct 04, 2005	Feb	CAHN

FLEXERIL

@ JANSSEN RES AND DEV	5MG	N017821 001		Jul	DISC
-----------------------	-----	-------------	--	-----	------

@	10MG	N017821 002		Jul	DISC
---	------	-------------	--	-----	------

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142 003		Apr	CRLD
AP	+		1GM/VIAL	N012142 004	Aug 30, 1982	Apr	CRLD
AP	+		2GM/VIAL	N012142 005	Aug 30, 1982	Apr	CRLD

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1		WATSON LABS INC	25MG	A065044 002	Dec 20, 2000	May	CAHN
AB1			100MG	A065044 001	Dec 20, 2000	May	CAHN

SOLUTION; ORAL

CYCLOSPORINE

AB1		ABBVIE	100MG/ML	A065025 001	Mar 03, 2000	Sep	CAHN
-----	--	--------	----------	-------------	--------------	-----	------

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYSTARAN

+	SIGMA TAU	EQ 0.44% BASE	N200740	001	Oct 02, 2012	Oct	NEWA
---	-----------	---------------	---------	-----	--------------	-----	------

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	ONCO THERAPIES LTD	100MG/ML	A201784	001	Jan 30, 2012	Jan	NEWA
----	--------------------	----------	---------	-----	--------------	-----	------

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682	001		Mar	CAHN
----	---	--------------	------------	---------	-----	--	-----	------

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

@	MIKAH PHARMA	25MG	A076686	001	Oct 24, 2005	Jul	CAHN
---	--------------	------	---------	-----	--------------	-----	------

@		50MG	A076686	002	Oct 24, 2005	Jul	CAHN
---	--	------	---------	-----	--------------	-----	------

@		100MG	A076686	003	Oct 24, 2005	Jul	CAHN
---	--	-------	---------	-----	--------------	-----	------

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

@	FERA PHARMS	0.5%	N019849	001	Dec 31, 1990	Jul	CTNA
---	-------------	------	---------	-----	--------------	-----	------

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL

PREZISTA

+	JANSSEN PRODS	EQ 100MG BASE/ML	N202895	001	Dec 16, 2011	Feb	CAHN
---	---------------	------------------	---------	-----	--------------	-----	------

TABLET; ORAL

PREZISTA

JANSSEN PRODS	EQ 75MG BASE	N021976	004	Dec 18, 2008	Feb	CAHN
---------------	--------------	---------	-----	--------------	-----	------

	EQ 150MG BASE	N021976	005	Dec 18, 2008	Feb	CAHN
--	---------------	---------	-----	--------------	-----	------

@	EQ 300MG BASE	N021976	001	Jun 23, 2006	Feb	CAHN
---	---------------	---------	-----	--------------	-----	------

	EQ 400MG BASE	N021976	003	Oct 21, 2008	Feb	CAHN
--	---------------	---------	-----	--------------	-----	------

>D>	+	EQ 600MG BASE	N021976	002	Feb 25, 2008	Nov	CRLD
-----	---	---------------	---------	-----	--------------	-----	------

>A>		EQ 600MG BASE	N021976	002	Feb 25, 2008	Nov	CRLD
-----	--	---------------	---------	-----	--------------	-----	------

+	EQ 600MG BASE	N021976	002	Feb 25, 2008	Feb	CAHN
---	---------------	---------	-----	--------------	-----	------

>A>	+	EQ 800MG BASE	N021976	006	Nov 09, 2012	Nov	NEWA
-----	---	---------------	---------	-----	--------------	-----	------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

@	COREPHARMA	150MG	N050261	002		Jul	DISC
---	------------	-------	---------	-----	--	-----	------

@		300MG	N050261	003		Jul	DISC
---	--	-------	---------	-----	--	-----	------

DEMECLOCYCLINE HYDROCHLORIDE

AB	+	AMNEAL PHARM	300MG	A065425	002	Feb 27, 2008	Jul	CRLD
----	---	--------------	-------	---------	-----	--------------	-----	------

DESFLURANE

LIQUID; INHALATION

SUPRANE

+	BAXTER HLTHCARE	99.9%	N020118	001	Sep 18, 1992	Jul	CAHN
---	-----------------	-------	---------	-----	--------------	-----	------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

NORPRAMIN

AB	SANOFI AVENTIS US	50MG	N014399 003		Oct	CRLD
----	-------------------	------	-------------	--	-----	------

DESLORATADINE

TABLET; ORAL

DESLORATADINE

AB	BELCHER PHARMS	5MG	A078355 001	Apr 19, 2012	Apr	NEWA
----	----------------	-----	-------------	--------------	-----	------

AB	MYLAN PHARMS INC	5MG	A078351 001	Feb 10, 2012	Jan	NEWA
----	------------------	-----	-------------	--------------	-----	------

DESMOPRESSIN ACETATE

SOLUTION; NASAL

DDAVP

AB	+ SANOFI AVENTIS US	0.01%	N017922 001		Mar	CFTG
----	---------------------	-------	-------------	--	-----	------

DESMOPRESSIN ACETATE

AB	SUN PHARM INDS	0.01%	A077212 001	Apr 12, 2012	Mar	NEWA
----	----------------	-------	-------------	--------------	-----	------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

AB	VINTAGE PHARMS LLC	0.15MG;0.03MG	A076675 001	Feb 25, 2011	Sep	CAHN
----	--------------------	---------------	-------------	--------------	-----	------

MIRCETTE

AB	+ TEVA BRANDED PHARM	0.15MG,N/A;0.02MG,0.01MG	N020713 001	Apr 22, 1998	Jun	CAHN
----	----------------------	--------------------------	-------------	--------------	-----	------

VIORELE

AB	GLENMARK GENERICS	0.15MG,N/A;0.02MG,0.01MG	A091346 001	Apr 02, 2012	Mar	NEWA
----	-------------------	--------------------------	-------------	--------------	-----	------

DESONIDE

GEL; TOPICAL

DESONATE

>A>	+ BAYER HLTHCARE	0.05%	N021844 001	Oct 20, 2006	Nov	CAHN
-----	------------------	-------	-------------	--------------	-----	------

>D>	+ INTENDIS	0.05%	N021844 001	Oct 20, 2006	Nov	CAHN
-----	------------	-------	-------------	--------------	-----	------

LOTION; TOPICAL

DESONIDE

AB	FOUGERA PHARMS	0.05%	A075860 001	Mar 19, 2002	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

DESONIDE

AB	FOUGERA PHARMS	0.05%	A075751 001	Mar 12, 2001	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB	FOUGERA PHARMS	0.25%	A078369 001	Jun 29, 2010	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

TOPICORT

	+ TARO	0.05%	A073210 001	Nov 30, 1990	Apr	CTNA
--	--------	-------	-------------	--------------	-----	------

AB	+	0.25%	A073193 001	Nov 30, 1990	Sep	CTEC
----	---	-------	-------------	--------------	-----	------

	+	0.25%	A073193 001	Nov 30, 1990	Apr	CTNA
--	---	-------	-------------	--------------	-----	------

@ TARO PHARMS NORTH

		0.25%	N017856 001		Apr	DISC
--	--	-------	-------------	--	-----	------

TOPICORT LP

@ TARO PHARMS NORTH

		0.05%	N018309 001		Apr	DISC
--	--	-------	-------------	--	-----	------

GEL; TOPICAL

TOPICORT

AB	+ TARO	0.05%	A074904 001	Jul 14, 1998	Apr	CTNA
----	--------	-------	-------------	--------------	-----	------

@ TARO PHARMS NORTH

		0.05%	N018586 001	Mar 29, 1982	Apr	DISC
--	--	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

DESOXIMETASONE

AB		FOUGERA PHARMS	0.25%	A078657	001	Sep 28, 2012	Sep	NEWA
AB	+	TARO	0.25%	A074286	001	Jun 07, 1996	Mar	CRLD
TOPICORT								
AB	+	TARO	0.25%	A074286	001	Jun 07, 1996	Sep	CTEC
	+		0.25%	A074286	001	Jun 07, 1996	Apr	CTNA
		@ TARO PHARMS NORTH	0.25%	N018763	001	Sep 30, 1983	Mar	DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	+	APP PHARMS LLC	EQ 10MG PHOSPHATE/ML	A040572	001	Apr 22, 2005	Feb	CRLD
		@ HIKMA MAPLE	EQ 4MG PHOSPHATE/ML	A084282	001		Oct	CAHN
AP	+		EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Oct	CAHN

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

TOTECT

+	APRICUS PHARMS	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Jun	CAHN
---	----------------	--------------------	---------	-----	--------------	-----	------

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

>A>	AB	AMEDRA PHARMS	5MG	N017078	001		Nov	CAHN
>A>	AB		10MG	N017078	002		Nov	CAHN
>A>	AB	+	15MG	N017078	003		Nov	CAHN
>D>	AB	COREPHARMA	5MG	N017078	001		Nov	CAHN
>D>	AB		10MG	N017078	002		Nov	CAHN
>D>	AB	+	15MG	N017078	003		Nov	CAHN

DEXTROAMPHETAMINE SULFATE

>A>	AB	ACTAVIS ELIZABETH	5MG	A203901	001	Nov 30, 2012	Nov	NEWA
>A>	AB		10MG	A203901	002	Nov 30, 2012	Nov	NEWA
>A>	AB		15MG	A203901	003	Nov 30, 2012	Nov	NEWA

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

>D>	AA	NESHER PHARMS	5MG	A040365	001	Oct 31, 2002	Nov	DISC
>A>		@	5MG	A040365	001	Oct 31, 2002	Nov	DISC
>D>	AA		10MG	A040367	001	Oct 31, 2002	Nov	DISC
>A>		@	10MG	A040367	001	Oct 31, 2002	Nov	DISC
		@ VINTAGE PHARMS LLC	5MG	A040299	001	May 13, 1999	Sep	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		TRIS PHARMA INC	15MG/5ML; 6.25MG/5ML	A091687	001	Jun 28, 2012	Jun	NEWA
----	--	-----------------	----------------------	---------	-----	--------------	-----	------

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

	@	HIKMA MAPLE	5MG/ML	A071310	001	Jul 17, 1987	Jul	CAHN
	@		5MG/ML	A070311	001	Dec 16, 1985	Jul	CAHN
	@		5MG/ML	A070312	001	Dec 16, 1985	Jul	CAHN
	@		5MG/ML	A070313	001	Dec 16, 1985	Jul	CAHN
	@		5MG/ML	A071308	001	Jul 17, 1987	Jul	CAHN
	@		5MG/ML	A071309	001	Jul 17, 1987	Jul	CAHN

INJECTABLE; INJECTION

DIAZEPAM

@ HOSPIRA

5MG/ML

A071584 001 Oct 13, 1987 Apr DISC

DICLOFENAC POTASSIUM

CAPSULE; ORAL

ZIPSOR

+ DEPOMED INC

25MG

N022202 001 Jun 16, 2009 Jun CAHN

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB MYLAN PHARMS INC

50MG

A075281 002 Feb 12, 2002 Sep CAHN

AB 75MG

A075281 003 Feb 12, 2002 Sep CAHN

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

AB GD SEARLE LLC

50MG;0.2MG

N020607 001 Dec 24, 1997 Jun CFTG

AB + 75MG;0.2MG

N020607 002 Dec 24, 1997 Jun CFTG

DICLOFENAC SODIUM AND MISOPROSTOL

AB WATSON LABS INC

50MG;0.2MG

A201089 001 Jul 09, 2012 Jun NEWA

AB 75MG;0.2MG

A201089 002 Jul 09, 2012 Jun NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

AB MYLAN PHARMS INC

125MG

A090788 001 Apr 08, 2010 Sep CAHN

AB 200MG

A090788 002 Apr 08, 2010 Sep CAHN

AB 250MG

A090788 003 Apr 08, 2010 Sep CAHN

AB 400MG

A090788 004 Apr 08, 2010 Sep CAHN

TABLET, CHEWABLE; ORAL

DIDANOSINE

AUROBINDO

100MG

A077275 001 Aug 14, 2012 Jul NEWA

150MG

A077275 002 Aug 14, 2012 Jul NEWA

>D> 200MG

A077275 003 Aug 14, 2012 Nov CRLD

>A> + 200MG

A077275 003 Aug 14, 2012 Nov CRLD

200MG

A077275 003 Aug 14, 2012 Jul NEWA

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX + FOUGERA PHARMS

0.05%

A076263 001 Dec 20, 2002 Jan CAHN

AB1 + 0.05%

A075187 001 Mar 30, 1998 Jan CAHN

PSORCON

>D> @ SANOFI AVENTIS US

0.05%

N020205 001 Nov 20, 1992 Nov CAHN

>A> @ VALEANT PHARM NORTH

0.05%

N020205 001 Nov 20, 1992 Nov CAHN

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB FOUGERA PHARMS

0.05%

A075374 001 Apr 27, 1999 Jan CAHN

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB EMCURE PHARMS USA

500MG

A202845 001 Mar 08, 2012 Feb NEWA

AB + TEVA

500MG

A073673 001 Jul 31, 1992 Feb CTEC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP	HIKMA MAPLE	0.25MG/ML	A083391 001		Jul	CAHN
	@ HOSPIRA	0.25MG/ML	A040093 001	May 16, 1996	Jun	DISC

TABLET; ORAL

DIGOXIN

	@ MYLAN PHARMS INC	0.125MG	A040282 001	Dec 23, 1999	Jul	CAHN
	@	0.25MG	A040282 002	Dec 23, 1999	Jul	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

AB4	ACTAVIS ELIZABETH	120MG	A091022 001	Sep 28, 2012	Sep	NEWA
AB4		180MG	A091022 002	Sep 28, 2012	Sep	NEWA
AB4		240MG	A091022 003	Sep 28, 2012	Sep	NEWA
AB4		300MG	A091022 004	Sep 28, 2012	Sep	NEWA
AB4		360MG	A091022 005	Sep 28, 2012	Sep	NEWA
AB4		420MG	A091022 006	Sep 28, 2012	Sep	NEWA
>A> AB3	ACTAVIS INC	360MG	A202463 001	Dec 07, 2012	Nov	NEWA

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

AP	AGILA SPECLTS	5MG/ML	A075375 001	Sep 30, 1999	Sep	CAHN
AP	HIKMA FARMACEUTICA	5MG/ML	A202651 001	Aug 09, 2012	Jul	NEWA
AP	HIKMA MAPLE	5MG/ML	A078538 001	Dec 17, 2008	Jul	CAHN
	@ TEVA PARENTERAL	5MG/ML	A074894 001	Aug 26, 1997	Jan	DISC

DINOPROSTONEINSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

+	FERRING CONTROLLED	10MG	N020411 001	Mar 30, 1995	Jul	CAHN
---	--------------------	------	-------------	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENADRYL

	@ MCNEIL CONS	50MG/ML	N006146 002		Mar	DISC
--	---------------	---------	-------------	--	-----	------

BENADRYL PRESERVATIVE FREE

	@ MCNEIL CONS	50MG/ML	N009486 001		Mar	DISC
--	---------------	---------	-------------	--	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

AP	+	BAXTER HLTHCARE	50MG/ML	A080817 002	Apr	CRLD
AP	+	HIKMA MAPLE	50MG/ML	A080817 002	Jul	CAHN
	@	50MG/ML	A083183 001		Jul	CAHN

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

AP	HIKMA MAPLE	5MG/ML	A074521 001	Oct 18, 1996	Jul	CAHN
	@ TEVA PARENTERAL	5MG/ML	A074952 001	Nov 26, 1997	Jan	DISC

TABLET; ORAL

DIPYRIDAMOLE

AB	PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb	CAHN
AB		50MG	A040542 002	Apr 21, 2006	Feb	CAHN
AB		75MG	A040542 003	Apr 21, 2006	Feb	CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

@ NESHER PHARMS	EQ 150MG BASE	A071200 001	Dec 15, 1987	Jun	DISC
-----------------	---------------	-------------	--------------	-----	------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB	DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161 001	Mar 15, 2012	Feb	NEWA
AB	REDDYS	EQ 500MG VALPROIC ACID	A090070 001	Mar 12, 2012	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACCORD HLTHCARE	20MG/ML (20MG/ML)	N201195 003	Apr 20, 2012	Apr	NEWA
AP		20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011	Jan	CTEC
AP		80MG/4ML (20MG/ML)	N201195 004	Apr 20, 2012	Apr	NEWA
AP		80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011	Jan	CTEC
		160MG/8ML (20MG/ML)	N201195 005	Apr 20, 2012	Apr	NEWA
AP	APOTEX INC	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012	Jan	NEWA
AP		80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012	Jan	NEWA
	TAXOTERE					
AP	+ SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449 003	Aug 03, 2010	Apr	CTEC
AP	+	80MG/4ML (20MG/ML)	N020449 004	Aug 02, 2010	Apr	CTEC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	INDICUS PHARMA	5MG	A201634 001	Jun 13, 2012	Jul	NEWA
AB		10MG	A201634 002	Jun 13, 2012	Jul	NEWA
AB	MACLEODS PHARMS LTD	5MG	A201146 001	Aug 17, 2012	Aug	NEWA
AB		10MG	A201146 002	Aug 17, 2012	Aug	NEWA
AB	MYLAN PHARMS INC	5MG	A090521 001	May 31, 2011	Sep	CAHN
AB		10MG	A090521 002	May 31, 2011	Sep	CAHN
AB	PRINSTON INC	5MG	A200292 001	May 31, 2011	Jun	CAHN
AB		10MG	A200292 002	May 31, 2011	Jun	CAHN
AB	ZYDUS PHARMS USA INC	5MG	A090100 001	Oct 24, 2012	Oct	NEWA
AB		10MG	A090100 002	Oct 24, 2012	Oct	NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT PF

+	MERCK SHARP DOHME	EQ 2% BASE;EQ 0.5% BASE	N202667 001	Feb 01, 2012	Feb	NEWA
	DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE					
AT	TEVA PHARMS	EQ 2% BASE;EQ 0.5% BASE	A078704 001	Sep 28, 2009	Sep	CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@	NESHER PHARMS	EQ 1MG BASE	A075609 001	Oct 18, 2000	Feb	DISC
@		EQ 2MG BASE	A075609 002	Oct 18, 2000	Feb	DISC
@		EQ 4MG BASE	A075609 003	Oct 18, 2000	Feb	DISC
@		EQ 8MG BASE	A075609 004	Oct 18, 2000	Feb	DISC

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

>D>	@ CLONMEL HLTHCARE	EQ 10MG BASE	A071685	001	Jan 05, 1988	Nov	CAHN
>D>	@	EQ 50MG BASE	A071673	001	Jan 05, 1988	Nov	CAHN
>D>	@	EQ 75MG BASE	A071674	001	Jan 05, 1988	Nov	CAHN
>D>	@	EQ 100MG BASE	A071675	001	Jan 05, 1988	Nov	CAHN
>D>	@	EQ 150MG BASE	A071676	001	Jan 05, 1988	Nov	CAHN
>A>	@ DAVA PHARMS INC	EQ 10MG BASE	A071685	001	Jan 05, 1988	Nov	CAHN
>A>	@	EQ 50MG BASE	A071673	001	Jan 05, 1988	Nov	CAHN
>A>	@	EQ 75MG BASE	A071674	001	Jan 05, 1988	Nov	CAHN
>A>	@	EQ 100MG BASE	A071675	001	Jan 05, 1988	Nov	CAHN
>A>	@	EQ 150MG BASE	A071676	001	Jan 05, 1988	Nov	CAHN

CREAM; TOPICAL

ZONALON

+	FOUGERA PHARMS	5%	N020126	001	Apr 01, 1994	Jan	CAHN
---	----------------	----	---------	-----	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ALVOGEN INC	2MG/ML	A065515	001	Nov 08, 2012	Oct	NEWA
AP	ONCO THERAPIES LTD	2MG/ML	A200901	001	Feb 14, 2012	Jan	NEWA
AP	SANDOZ INC	2MG/ML	A200146	001	Jul 18, 2012	Jul	NEWA
AP	SUN PHARM INDS	2MG/ML	A091418	001	Feb 15, 2012	Jan	NEWA

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

+	JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Jan	CAHN
+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Jan	CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	MYLAN PHARMS INC	EQ 150MG BASE	A202778	001	Jun 08, 2012	May	NEWA
	@ SANDOZ INC	EQ 50MG BASE	A065032	001	Jun 30, 2000	Mar	DISC
	@	EQ 100MG BASE	A065032	002	Jun 30, 2000	Mar	DISC

MONODOX

AB	AQUA PHARMS	EQ 50MG BASE	N050641	002	Feb 10, 1992	Jul	CAHN
AB		EQ 75MG BASE	N050641	003	Oct 18, 2006	Jul	CAHN
AB	+	EQ 100MG BASE	N050641	001	Dec 29, 1989	Jul	CAHN

TABLET; ORAL

DOXYCYCLINE

	@ SANDOZ INC	EQ 50MG BASE	A065353	001	Nov 27, 2006	Mar	DISC
	@	EQ 75MG BASE	A065353	002	Nov 27, 2006	Mar	DISC
	@	EQ 100MG BASE	A065353	003	Nov 27, 2006	Mar	DISC

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION

DOXYCYCLINE

	@ HIKMA MAPLE	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jul	CAHN
	@	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jul	CAHN
AP	PFIZER	EQ 100MG BASE/VIAL	A091406	001	Aug 21, 2012	Aug	NEWA

DOXYCYCLINE HYCLATE

	@ HIKMA MAPLE	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989	Jul	CAHN
	@	EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989	Jul	CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB	LARKEN LABS	EQ 20MG BASE	A065287	001	Feb 28, 2006	Apr	CMFD
AB	WATSON LABS INC FL	EQ 100MG BASE	A062421	001	Feb 02, 1983	Oct	CAHN

TABLET, DELAYED RELEASE; ORAL

DORYX

AB	+	MAYNE PHARMA	EQ 150MG BASE	N050795	003	Jun 20, 2008	Jan	CTEC
DOXYCYCLINE HYCLATE								
AB		MYLAN PHARMS INC	EQ 150MG BASE	A091052	001	Feb 08, 2012	Jan	NEWA

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

		BAYER HLTHCARE	0.25MG;0.5MG	N021355	001	Feb 29, 2012	Feb	NEWA
--	--	----------------	--------------	---------	-----	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	+	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Jan	CAHN
----	---	----------------	----	---------	-----	--------------	-----	------

ELTROMBOPAG OLAMINE

TABLET; ORAL

PROMACTA

>A>		GLAXOSMITHKLINE	EQ 100MG ACID	N022291	005	Nov 16, 2012	Nov	NEWA
-----	--	-----------------	---------------	---------	-----	--------------	-----	------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+		GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011	Apr	CAIN
---	--	---------------------	--------------------------	---------	-----	--------------	-----	------

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

@	SANDOZ INC	2.5MG	A075621	001	Aug 22, 2000	Feb	DISC
@		2.5MG	A075496	001	Aug 22, 2000	Jan	DISC
@		5MG	A075621	002	Aug 22, 2000	Feb	DISC
@		5MG	A075496	002	Aug 22, 2000	Jan	DISC
@		10MG	A075621	003	Aug 22, 2000	Feb	DISC
@		10MG	A075459	001	Aug 22, 2000	Jan	DISC
@		20MG	A075621	004	Aug 22, 2000	Feb	DISC
@		20MG	A075459	002	Aug 22, 2000	Jan	DISC

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@	SANDOZ INC	5MG;12.5MG	A076116	001	Sep 19, 2001	Mar	DISC
@		10MG;25MG	A076116	002	Sep 19, 2001	Mar	DISC

ENFLURANE

LIQUID; INHALATION

ETHRANE

AN	+	BAXTER HLTHCARE	99.9%	N017087	001		Jul	CAHN
----	---	-----------------	-------	---------	-----	--	-----	------

ENTACAPONE

TABLET; ORAL

COMTAN

AB	+	ORION PHARMA	200MG	N020796	001	Oct 19, 1999	Jul	CFTG
	+		200MG	N020796	001	Oct 19, 1999	May	CAHN

ENTACAPONE

AB		SUN PHARMA GLOBAL	200MG	A090690	001	Jul 16, 2012	Jul	NEWA
AB		WOCKHARDT LTD	200MG	A078941	001	Aug 16, 2012	Jul	NEWA

ENZALUTAMIDE

CAPSULE; ORAL

XTANDI

+	ASTELLAS	40MG	N203415	001	Aug 31, 2012	Sep	CAHN
+	MEDIVATION	40MG	N203415	001	Aug 31, 2012	Aug	NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

AT		LUITPOLD	0.05%	A090951	001	Oct 31, 2011	Mar	CAHN
----	--	----------	-------	---------	-----	--------------	-----	------

EPINEPHRINE

INJECTABLE; IM-SC

ADRENALCLIC

BX	+	COREPHARMA	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009	Mar	CAHN
BX	+		EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009	Mar	CAHN

AUVI-Q

>D>	BX	+	INTELLIJECT	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Nov	CAHN
	BX	+		EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Aug	NEWA
>D>	BX			EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Nov	CAHN
	BX			EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Aug	NEWA
>A>	BX	+	SANOFI AVENTIS US	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012	Nov	CAHN
>A>	BX			EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012	Nov	CAHN

TWINJECT 0.15

BX	+	COREPHARMA	EQ 0.15MG/DELIVERY	N020800	002	May 28, 2004	Mar	CAHN
----	---	------------	--------------------	---------	-----	--------------	-----	------

TWINJECT 0.3

BX	+	COREPHARMA	EQ 0.3MG/DELIVERY	N020800	001	May 30, 2003	Mar	CAHN
----	---	------------	-------------------	---------	-----	--------------	-----	------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

@	HIKMA MAPLE	0.01MG/ML;1%	A080406	001		Sep	CAHN
---	-------------	--------------	---------	-----	--	-----	------

@		0.01MG/ML;2%	A080406	002		Sep	CAHN
---	--	--------------	---------	-----	--	-----	------

OCTOCAINE

AP	+	SEPTODONT	0.01MG/ML;2%	A084048	001		May	CRLD
----	---	-----------	--------------	---------	-----	--	-----	------

XYLOCAINE DENTAL WITH EPINEPHRINE

@	DENTSPLY PHARM	0.01MG/ML;2%	N021381	001		May	DISC
---	----------------	--------------	---------	-----	--	-----	------

@		0.02MG/ML;2%	N021381	002		May	DISC
---	--	--------------	---------	-----	--	-----	------

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP		CIPLA LTD	200MG/100ML (2MG/ML)	A065361	002	Oct 22, 2007	Mar	CAHN
AP			50MG/25ML (2MG/ML)	A065361	001	Oct 22, 2007	Mar	CAHN
AP		HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075	001	Mar 25, 2010	Mar	CAHN
AP			200MG/100ML (2MG/ML)	A090075	002	Mar 25, 2010	Mar	CAHN

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP	ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	Mar	NEWA
AP		200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	Mar	NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

VELETRI

	ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N022260	002	Jun 28, 2012	Jun	NEWA
+		EQ 1.5MG BASE/VIAL	N022260	001	Jun 27, 2008	May	CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB	WARNER CHILCOTT LLC	250MG	A062338	001		Jun	CAHN
----	---------------------	-------	---------	-----	--	-----	------

GEL; TOPICAL

E-GLADES

	@ COREPHARMA	2%	A065009	001	Mar 18, 2002	Jul	DISC
--	--------------	----	---------	-----	--------------	-----	------

	@ RENAISSANCE PHARMA	2%	A065009	001	Mar 18, 2002	Aug	CAHN
--	----------------------	----	---------	-----	--------------	-----	------

ERYTHROMYCIN

AT	FOUGERA PHARMS	2%	A064184	001	Sep 30, 1997	Jan	CAHN
----	----------------	----	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

C-SOLVE-2

AT	FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Jan	CMFD
----	----------------	----	---------	-----	--------------	-----	------

ERYTHROMYCIN

	@ RENAISSANCE PHARMA	2%	A064127	001	Feb 14, 1997	Aug	CAHN
--	----------------------	----	---------	-----	--------------	-----	------

SWAB; TOPICAL

ERYCETTE

	@ JOHNSON AND JOHNSON	2%	N050594	001	Feb 15, 1985	Apr	CAHN
--	-----------------------	----	---------	-----	--------------	-----	------

ERYTHROMYCIN

AT	+	FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006	Jan	CAHN
----	---	----------------	----	---------	-----	--------------	-----	------

		@ RENAISSANCE PHARMA	2%	A064128	001	Jul 03, 1996	Sep	CAHN
--	--	----------------------	----	---------	-----	--------------	-----	------

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

AA	AMNEAL PHARMS	EQ 5MG BASE/5ML	A202227	001	Mar 14, 2012	Feb	NEWA
----	---------------	-----------------	---------	-----	--------------	-----	------

AA	AUROBINDO PHARMA LTD	EQ 5MG BASE/5ML	A079062	001	Apr 02, 2012	Mar	NEWA
----	----------------------	-----------------	---------	-----	--------------	-----	------

AA	HETERO LABS LTD III	EQ 5MG BASE/5ML	A202221	001	Jun 12, 2012	May	NEWA
----	---------------------	-----------------	---------	-----	--------------	-----	------

AA	TARO	EQ 5MG BASE/5ML	A079121	001	May 03, 2012	Apr	NEWA
----	------	-----------------	---------	-----	--------------	-----	------

LEXAPRO

AA	+	FOREST LABS	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Feb	CFTG
----	---	-------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	ACCORD HLTHCARE	EQ 5MG BASE	A202389	001	Sep 11, 2012	Aug	NEWA
----	-----------------	-------------	---------	-----	--------------	-----	------

AB		EQ 10MG BASE	A202389	002	Sep 11, 2012	Aug	NEWA
----	--	--------------	---------	-----	--------------	-----	------

AB		EQ 20MG BASE	A202389	003	Sep 11, 2012	Aug	NEWA
----	--	--------------	---------	-----	--------------	-----	------

AB	APOTEX INC	EQ 5MG BASE	A078777	001	Sep 11, 2012	Aug	NEWA
----	------------	-------------	---------	-----	--------------	-----	------

AB		EQ 10MG BASE	A078777	002	Sep 11, 2012	Aug	NEWA
----	--	--------------	---------	-----	--------------	-----	------

AB		EQ 20MG BASE	A078777	003	Sep 11, 2012	Aug	NEWA
----	--	--------------	---------	-----	--------------	-----	------

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A090432	001	Sep 11, 2012	Aug	NEWA
----	----------------------	-------------	---------	-----	--------------	-----	------

AB		EQ 10MG BASE	A090432	002	Sep 11, 2012	Aug	NEWA
----	--	--------------	---------	-----	--------------	-----	------

AB		EQ 20MG BASE	A090432	003	Sep 11, 2012	Aug	NEWA
----	--	--------------	---------	-----	--------------	-----	------

AB	HIKMA PHARMS	EQ 5MG BASE	A078766	001	Sep 11, 2012	Aug	NEWA
----	--------------	-------------	---------	-----	--------------	-----	------

AB		EQ 10MG BASE	A078766	002	Sep 11, 2012	Aug	NEWA
----	--	--------------	---------	-----	--------------	-----	------

AB		EQ 20MG BASE	A078766	003	Sep 11, 2012	Aug	NEWA
----	--	--------------	---------	-----	--------------	-----	------

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	INVAGEN PHARMS	EQ 5MG BASE	A078604 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A078604 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A078604 003	Sep 11, 2012	Aug	NEWA
AB	IVAX SUB TEVA PHARMS	EQ 5MG BASE	A076765 001	Mar 14, 2012	Feb	NEWA
AB		EQ 10MG BASE	A076765 002	Mar 14, 2012	Feb	NEWA
AB		EQ 20MG BASE	A076765 003	Mar 14, 2012	Feb	NEWA
AB	JUBILANT ORGANOSYS	EQ 5MG BASE	A202280 001	Sep 12, 2012	Aug	NEWA
AB		EQ 10MG BASE	A202280 002	Sep 12, 2012	Aug	NEWA
AB		EQ 20MG BASE	A202280 003	Sep 12, 2012	Aug	NEWA
AB	LUPIN LTD	EQ 5MG BASE	A078169 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A078169 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A078169 003	Sep 11, 2012	Aug	NEWA
AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A202210 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A202210 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A202210 003	Sep 11, 2012	Aug	NEWA
AB	STI PHARMA LLC	EQ 5MG BASE	A077512 001	Sep 12, 2012	Aug	NEWA
AB		EQ 10MG BASE	A077512 002	Sep 12, 2012	Aug	NEWA
AB		EQ 20MG BASE	A077512 003	Sep 12, 2012	Aug	NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE	A090939 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A090939 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A090939 003	Sep 11, 2012	Aug	NEWA
AB	ZYDUS PHARMS USA INC	EQ 5MG BASE	A077734 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A077734 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A077734 003	Sep 11, 2012	Aug	NEWA
LEXAPRO						
AB	FOREST LABS	EQ 5MG BASE	N021323 001	Aug 14, 2002	Feb	CFTG
AB		EQ 10MG BASE	N021323 002	Aug 14, 2002	Feb	CFTG
AB	+	EQ 20MG BASE	N021323 003	Aug 14, 2002	Feb	CFTG

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

	@ BAXTER HLTHCARE	10MG/ML	N019386 003	Aug 15, 1988	Jun	CAHN
AP	+	10MG/ML	N019386 006	Feb 25, 2003	Jun	CAHN
	@	20MG/ML	N019386 007	May 28, 2003	Jun	CAHN
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	2GM/100ML	N019386 005	Jan 27, 2003	Jun	CAHN
BREVIBLOC IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	1GM/100ML	N019386 004	Feb 16, 2001	Jun	CAHN

ESOMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

ASTRAZENECA

EQ 2.5MG BASE/PACKET

N021957 003 Dec 15, 2011 Jun NEWA

EQ 5MG BASE/PACKET

N021957 004 Dec 15, 2011 Jun NEWA

ESTRADIOL

CREAM; VAGINAL

ESTRACE

+	WARNER CHILCOTT US	0.01%	A086069 001	Jan 31, 1984	Jun	CAHN
---	--------------------	-------	-------------	--------------	-----	------

FILM, EXTENDED RELEASE; TRANSDERMAL

MINIVELLE

NOVEN

0.0375MG/24HR

N203752 001 Oct 29, 2012 Oct NEWA

0.05MG/24HR

N203752 003 Oct 29, 2012 Oct NEWA

FILM, EXTENDED RELEASE; TRANSDERMAL

MINIVELLE

NOVEN	0.075MG/24HR	N203752	002	Oct 29, 2012	Oct	NEWA
+	0.1MG/24HR	N203752	004	Oct 29, 2012	Oct	NEWA

GEL, METERED; TRANSDERMAL

ELESTRIN

+	JAZZ PHARMS COMMERCL	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Jun	CAHN
+	JAZZ PHARMS II	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Sep	CAHN
+	MEDA PHARMS	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Oct	CAHN

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

WARNER IRELAND	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	May	CAHN
+	EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	May	CAHN

TABLET; ORAL

FEMTRACE

WARNER CHILCOTT LLC	0.45MG	N021633	001	Aug 20, 2004	Jun	CAHN
	0.9MG	N021633	002	Aug 20, 2004	Jun	CAHN
+	1.8MG	N021633	003	Aug 20, 2004	Jun	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB	TEVA PHARMS USA	0.5MG;0.1MG	A200747	001	Mar 08, 2012	Feb	NEWA
----	-----------------	-------------	---------	-----	--------------	-----	------

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Jun	CAHN
	0.45MG	N020992	005	Feb 05, 2004	Jun	CAHN
	0.625MG	N020992	002	Mar 24, 1999	Jun	CAHN
	0.9MG	N020992	003	Mar 24, 1999	Jun	CAHN
+	1.25MG	N020992	004	Mar 13, 2000	Jun	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	LUPIN LTD	0.03MG;0.15MG	A091440	001	Oct 23, 2012	Oct	NEWA	
+	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	May	CRLD	
	LOSEASONIQUE							
AB	TEVA BRANDED PHARM	0.02MG,0.01MG;0.1MG,N/A	N022262	001	Oct 24, 2008	Jun	CAHN	
	LYBREL							
	@ WYETH PHARMS INC	0.02MG;0.09MG	N021864	001	May 22, 2007	May	DISC	
	PREVEN EMERGENCY CONTRACEPTIVE KIT							
	@ TEVA BRANDED PHARM	0.05MG;0.25MG	N020946	001	Sep 01, 1998	Jun	CAHN	
	SEASONALE							
AB	+	TEVA BRANDED PHARM	0.03MG;0.15MG	N021544	001	Sep 05, 2003	Jul	CAHN
	SEASONIQUE							
AB	+	TEVA BRANDED PHARM	0.03MG,0.01MG;0.15MG,N/A	N021840	001	May 25, 2006	Jun	CAHN
	TABLET; ORAL-21							
	NORDETTE-21							
	@ TEVA BRANDED PHARM	0.03MG;0.15MG	N018668	001	May 10, 1982	Jun	CAHN	
	TABLET; ORAL-28							
	FALMINA							
AB1	NOVAST LABS LTD	0.02MG;0.1MG	A090721	001	Mar 28, 2012	Mar	NEWA	

TABLET; ORAL-28

	KURVELO								
AB	LUPIN LTD	0.03MG;0.15MG	A091408	001	Oct 17, 2012	Oct	NEWA		
	MARLISSA								
AB	GLENMARK GENERICS	0.03MG;0.15MG	A091452	001	Feb 29, 2012	Feb	NEWA		
	MYZILRA								
AB	VINTAGE PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	A077502	001	Nov 23, 2011	May	CDFR		
AB	VINTAGE PHARMS LLC	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	A077502	001	Nov 23, 2011	Sep	CAHN		
	NORDETTE-28								
AB	+ TEVA BRANDED PHARM	0.03MG;0.15MG	N018782	001	Jul 21, 1982	Jun	CAHN		
	ORSYTHIA								
AB1	VINTAGE PHARMS LLC	0.02MG;0.1MG	A077099	001	May 11, 2011	Sep	CAHN		

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL
ORTHO EVRA

+	JANSSEN PHARMS	0.75MG;6MG	N021180	001	Nov 20, 2001	Jun	CPOT		
---	----------------	------------	---------	-----	--------------	-----	------	--	--

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

	ALYACEN 1/35								
AB	GLENMARK GENERICS	0.035MG;1MG	A091634	001	Jan 19, 2012	Jan	NEWA		
	ALYACEN 7/7/7								
AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.7 5MG,1MG	A091636	001	Jan 19, 2012	Jan	NEWA		
	CYCLAFEM 1/35								
AB	VINTAGE PHARMS LLC	0.035MG;1MG	A076337	001	Nov 12, 2010	Sep	CAHN		
	CYCLAFEM 7/7/7								
AB	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.5MG,0.7 5MG,1MG	A076338	001	Nov 16, 2010	Sep	CAHN		
>A>	GILDAGIA								
>A>	AB	VINTAGE PHARMS	0.035MG;0.4MG	A078376	001	Nov 06, 2012	Nov	CTNA	
>D>	NORETHINDRONE AND ETHINYL ESTRADIOL								
>D>	AB	VINTAGE PHARMS	0.035MG;0.4MG	A078376	001	Nov 06, 2012	Nov	CTNA	
	AB		0.035MG;0.4MG	A078376	001	Nov 06, 2012	Oct	NEWA	
	OVCON-35								
AB	+ WARNER CHILCOTT LLC	0.035MG;0.4MG	N017716	001		Jun	CAHN		
	OVCON-50								
	+ WARNER CHILCOTT LLC	0.05MG;1MG	N017576	001		Jun	CAHN		
	WERA								
AB	NOVAST LABS LTD	0.035MG;0.5MG	A091204	001	Mar 27, 2012	Mar	NEWA		
	TABLET, CHEWABLE; ORAL								
	FEMCON FE								
AB	+ WARNER CHILCOTT LLC	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jun	CAHN		

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

	FEMHRT								
	WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jun	CAHN		
AB	+	0.005MG;1MG	N021065	002	Oct 15, 1999	Jun	CAHN		
	LO LOESTRIN FE								
	+ WARNER CHILCOTT LLC	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jun	CAHN		
	TABLET; ORAL-21								
	ESTROSTEP 21								
	@ WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	001	Oct 09, 1996	Jun	CAHN		

TABLET; ORAL-21

	LOESTRIN 21 1.5/30								
AB	WARNER CHILCOTT LLC	0.03MG;1.5MG		N017875 001			Jun	CAHN	

	LOESTRIN 21 1/20								
AB	WARNER CHILCOTT LLC	0.02MG;1MG		N017876 001			Jun	CAHN	

TABLET; ORAL-28

	ESTROSTEP FE								
AB	+ WARNER CHILCOTT LLC	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130 002	Oct 09, 1996	Jun	CAHN			

	GILDESS FE 1.5/30								
AB	VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075 001	Apr 28, 2005	Sep	CAHN			

	GILDESS FE 1/20								
AB	VINTAGE PHARMS LLC	0.02MG;1MG	A077077 001	May 20, 2005	Sep	CAHN			

	LOESTRIN FE 1.5/30								
AB	+ WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355 001		Jun	CAHN			

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

	MONO-LINYAH								
AB	NOVAST LABS LTD	0.035MG;0.25MG	A090523 001	May 23, 2012	May	NEWA			

	NORGESTIMATE AND ETHINYL ESTRADIOL								
AB	GLENMARK GENERICS	0.035MG;0.25MG	A200538 001	Apr 05, 2012	Mar	NEWA			

AB	LUPIN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A200541 001	Jun 25, 2012	Jun	NEWA			
----	--------------	---	-------------	--------------	-----	------	--	--	--

	PREVIFEM								
AB	VINTAGE PHARMS LLC	0.035MG;0.25MG	A076334 001	Jan 09, 2004	Sep	CAHN			

	TRI-LINYAH								
AB	NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090524 001	May 30, 2012	May	NEWA			

	TRI-PREVIFEM								
AB	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076335 001	Mar 26, 2004	Sep	CAHN			

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

	ELINEST								
AB	NOVAST LABS LTD	0.03MG;0.3MG	A091105 001	Mar 28, 2012	Mar	NEWA			

ETHOSUXIMIDE

CAPSULE; ORAL

	ETHOSUXIMIDE								
AB	ZYDUS PHARMS USA INC	250MG	A200892 001	Sep 25, 2012	Sep	NEWA			

ETHOTOIN

TABLET; ORAL

	PEGANONE								
	+ LUNDBECK LLC	250MG	N010841 001		Aug	CAHN			
	@	500MG	N010841 003		Aug	CAHN			

ETODOLAC

CAPSULE; ORAL

	ETODOLAC								
	@ VINTAGE PHARMS LLC	200MG	A074842 001	Jul 17, 1997	Sep	CAHN			
	@	300MG	A074842 002	Jul 17, 1997	Sep	CAHN			

TABLET; ORAL

	ETODOLAC								
AB	PROSAM LABS	400MG	A074819 001	Feb 28, 1997	Feb	CMFD			
AB		500MG	A074819 002	Apr 28, 1998	Feb	CMFD			

TABLET; ORAL									
ETODOLAC									
	@ VINTAGE PHARMS LLC	400MG			A074841	001	Jun 27, 1997	Sep	CAHN
TABLET, EXTENDED RELEASE; ORAL									
ETODOLAC									
	@ ACTAVIS ELIZABETH	400MG			A075696	001	Jul 31, 2000	Oct	CAHN
<u>ETOMIDATE</u>									
INJECTABLE; INJECTION									
ETOMIDATE									
AP	MYLAN INSTITUTIONAL	2MG/ML			A091297	001	Jun 20, 2012	Jun	NEWA
<u>ETOPOSIDE</u>									
CAPSULE; ORAL									
VEPESID									
	@ CORDEN PHARMA	50MG			N019557	001	Dec 30, 1986	Feb	CAHN
	@	100MG			N019557	002	Dec 30, 1986	Feb	CAHN
INJECTABLE; INJECTION									
ETOPOSIDE									
AP	+ APP PHARMS LLC	20MG/ML			A074983	001	Sep 30, 1998	Mar	CRLD
AP	BEDFORD	20MG/ML			A074290	001	Jul 17, 1995	Mar	CRLD
VEPESID									
	@ CORDEN PHARMA	20MG/ML			N018768	001	Nov 10, 1983	Feb	CAHN
<u>ETRAVIRINE</u>									
TABLET; ORAL									
INTELENCE									
	JANSSEN R AND D	25MG			N022187	003	Mar 26, 2012	Mar	NEWA
		100MG			N022187	001	Jan 18, 2008	Feb	CAHN
	+	200MG			N022187	002	Dec 22, 2010	Feb	CAHN
<u>EVEROLIMUS</u>									
TABLET; ORAL									
AFINITOR									
	NOVARTIS	7.5MG			N022334	004	Mar 30, 2012	Apr	NEWA
TABLET, FOR SUSPENSION; ORAL									
AFINITOR DISPERZ									
	NOVARTIS PHARM	2MG			N203985	001	Aug 29, 2012	Aug	NEWA
		3MG			N203985	002	Aug 29, 2012	Aug	NEWA
	+	5MG			N203985	003	Aug 29, 2012	Aug	NEWA
<u>EXENATIDE SYNTHETIC</u>									
FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS									
BYDUREON									
	+ AMYLIN	2MG/VIAL			N022200	001	Jan 27, 2012	Jan	NEWA
<u>EZETIMIBE</u>									
TABLET; ORAL									
ZETIA									
	+ MSD INTL GMBH	10MG			N021445	001	Oct 25, 2002	Feb	CAHN
	+ MSP SINGAPORE	10MG			N021445	001	Oct 25, 2002	Jan	CAHN
<u>EZETIMIBE; SIMVASTATIN</u>									
TABLET; ORAL									
VYTORIN									
	MSD INTL	10MG;10MG			N021687	001	Jul 23, 2004	Jan	CAHN

TABLET; ORAL

VYTORIN

MSD INTL	10MG; 20MG	N021687 002	Jul 23, 2004	Jan	CAHN
	10MG; 40MG	N021687 003	Jul 23, 2004	Jan	CAHN
+	10MG; 80MG	N021687 004	Jul 23, 2004	Jan	CAHN

EZOGABINE

TABLET; ORAL

POTIGA

GLAXOSMITHKLINE	50MG	N022345 001	Jun 10, 2011	May	CAHN
	200MG	N022345 002	Jun 10, 2011	May	CAHN
	300MG	N022345 003	Jun 10, 2011	May	CAHN
+	400MG	N022345 004	Jun 10, 2011	May	CAHN

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB	MACLEODS PHARMS LTD	125MG	A201022 001	Jan 12, 2012	Jan	NEWA
AB		250MG	A201022 002	Jan 12, 2012	Jan	NEWA
AB		500MG	A201022 003	Jan 12, 2012	Jan	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP	+	HIKMA MAPLE	10MG/ML	A075799 001	Apr 30, 2002	Jul	CAHN
AP	+		10MG/ML	A075488 001	Apr 16, 2001	Jul	CAHN
		FAMOTIDINE PRESERVATIVE FREE					
AP	+	HIKMA MAPLE	10MG/ML	A075486 001	Apr 16, 2001	Jul	CAHN
AP	+		10MG/ML	A075789 001	Apr 30, 2002	Jul	CAHN

TABLET; ORAL

FAMOTIDINE

	@	MYLAN PHARMS INC	20MG	A075457 001	Apr 18, 2001	Oct	DISC
	@		40MG	A075457 002	Apr 18, 2001	Oct	DISC
	@	SANDOZ	20MG	A075607 001	May 10, 2001	Oct	DISC
	@		40MG	A075607 002	May 10, 2001	Oct	DISC
		PEPCID					
AB		MARATHON PHARMS	20MG	N019462 001	Oct 15, 1986	Jan	CAHN
AB	+		40MG	N019462 002	Oct 15, 1986	Jan	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

	@	UCB INC	20MG	N021712 001	Sep 24, 2004	Jan	CAHN
	@		40MG	N021712 002	Sep 24, 2004	Jan	CAHN

FEBUXOSTAT

TABLET; ORAL

ULORIC

TAKEDA PHARMS USA	40MG	N021856 001	Feb 13, 2009	Apr	CAHN
+	80MG	N021856 002	Feb 13, 2009	Apr	CAHN

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

AB	VINTAGE PHARMS LLC	2.5MG	A200815 001	Oct 28, 2011	Sep	CAHN
AB		5MG	A200815 002	Oct 28, 2011	Sep	CAHN
AB		10MG	A200815 003	Oct 28, 2011	Sep	CAHN
AB	WOCKHARDT LTD	2.5MG	A091484 001	Aug 15, 2012	Jul	NEWA

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

AB	WOCKHARDT LTD	5MG	A091484	002	Aug 15, 2012	Jul	NEWA
AB		10MG	A091484	003	Aug 15, 2012	Jul	NEWA

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

AB	LUPIN ATLANTIS	43MG	N021695	001	Nov 30, 2004	Feb	CFTG
AB	+	130MG	N021695	003	Nov 30, 2004	Feb	CFTG

FENOFIBRATE (MICRONIZED)

AB	DR REDDYS LABS SA	43MG	A090859	001	Mar 01, 2012	Feb	NEWA
AB		130MG	A090859	002	Mar 01, 2012	Feb	NEWA
AB	MYLAN PHARMS INC	67MG	A202676	001	Oct 23, 2012	Oct	NEWA
AB		134MG	A202676	002	Oct 23, 2012	Oct	NEWA
AB		200MG	A202676	003	Oct 23, 2012	Oct	NEWA

TABLET; ORAL

FENOFIBRATE

AB	IMPAX LABS	160MG	A076509	002	Mar 26, 2008	May	CRLD
AB	+	160MG	A076509	002	Mar 26, 2008	Mar	CRLD
>A>	AB	MYLAN PHARMS INC	A202856	001	Dec 07, 2012	Nov	NEWA
>A>	AB		A202856	002	Dec 07, 2012	Nov	NEWA
AB	TEVA	54MG	A076433	001	May 13, 2005	May	CMFD
	@	54MG	A076433	001	May 13, 2005	Mar	DISC
AB	+	160MG	A076433	002	May 13, 2005	May	CMFD
	@	160MG	A076433	002	May 13, 2005	Mar	DISC
AB	VALEANT INTL	48MG	A090715	001	Apr 05, 2012	Mar	NEWA
AB		145MG	A090715	002	Apr 05, 2012	Mar	NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

+	XSPIRE	EQ 200MG BASE	N017604	003		Aug	CAHN
	@	EQ 300MG BASE	N017604	002		Aug	CAHN
		EQ 400MG BASE	N017604	004	Jul 21, 2009	Aug	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

>D>	AB	ACTAVIS	100MCG/HR	A077062	004	Aug 20, 2007	Nov	CAHN
	AB	AVEVA	100MCG/HR	A077449	004	Oct 20, 2008	Jun	CAHN
>A>	AB	PAR PHARM INC	100MCG/HR	A077062	004	Aug 20, 2007	Nov	CAHN

FENTANYL-25

>D>	AB	ACTAVIS	25MCG/HR	A077062	001	Aug 20, 2007	Nov	CAHN
	AB	AVEVA	25MCG/HR	A077449	001	Oct 20, 2008	Jun	CAHN
>A>	AB	PAR PHARM INC	25MCG/HR	A077062	001	Aug 20, 2007	Nov	CAHN

FENTANYL-50

>D>	AB	ACTAVIS	50MCG/HR	A077062	002	Aug 20, 2007	Nov	CAHN
	AB	AVEVA	50MCG/HR	A077449	002	Oct 20, 2008	Jun	CAHN
>A>	AB	PAR PHARM INC	50MCG/HR	A077062	002	Aug 20, 2007	Nov	CAHN

FENTANYL-75

>D>	AB	ACTAVIS	75MCG/HR	A077062	003	Aug 20, 2007	Nov	CAHN
	AB	AVEVA	75MCG/HR	A077449	003	Oct 20, 2008	Jun	CAHN
>A>	AB	PAR PHARM INC	75MCG/HR	A077062	003	Aug 20, 2007	Nov	CAHN

SPRAY; SUBLINGUAL

SUBSYS

	INSYS THERAP	0.1MG	N202788 001	Jan 04, 2012	Mar	CPOT
		0.1MCG	N202788 001	Jan 04, 2012	Jan	NEWA
		0.2MG	N202788 002	Jan 04, 2012	Mar	CPOT
		0.2MCG	N202788 002	Jan 04, 2012	Jan	NEWA
+		0.4MG	N202788 003	Jan 04, 2012	Mar	CPOT
+		0.4MCG	N202788 003	Jan 04, 2012	Jan	NEWA
		0.6MG	N202788 004	Jan 04, 2012	Mar	CPOT
		0.6MCG	N202788 004	Jan 04, 2012	Jan	NEWA
		0.8MG	N202788 005	Jan 04, 2012	Mar	CPOT
		0.8MCG	N202788 005	Jan 04, 2012	Jan	NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

	ARCHIMEDES	EQ 0.1MG BASE	N022569 001	Jun 30, 2011	Jan	CPOT
+		EQ 0.4MG BASE	N022569 002	Jun 30, 2011	Jan	CPOT

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

AB	PAR PHARM	EQ 0.2MG BASE	A077312 001	Oct 30, 2009	Feb	CAHN
AB		EQ 0.4MG BASE	A077312 002	Oct 30, 2009	Feb	CAHN
AB		EQ 0.6MG BASE	A077312 003	Oct 30, 2009	Feb	CAHN
AB		EQ 0.8MG BASE	A077312 004	Oct 30, 2009	Feb	CAHN
AB		EQ 1.2MG BASE	A077312 005	Oct 30, 2009	Feb	CAHN
AB		EQ 1.6MG BASE	A077312 006	Oct 30, 2009	Feb	CAHN

FERUMOXIDES

INJECTABLE; INJECTION

FERIDEX I.V.

	@ AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416 001	Aug 30, 1996	Jun	DISC
--	-------------------	-------------------	-------------	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

ALLEGRA

AB	+	SANOFI AVENTIS US	30MG/5ML	N021963 001	Oct 16, 2006	Jul	CFTG
		FEXOFENADINE HYDROCHLORIDE					
AB		ACTAVIS MID ATLANTIC	30MG/5ML	A201311 001	Jul 25, 2012	Jul	NEWA

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+	AVID RADIOPHARMS INC	10-50ML (13.5-51MCI/ML)	N202008 003	Apr 06, 2012	Jun	CPOT
+		10-30ML (13.5-51MCI/ML)	N202008 002	Apr 06, 2012	Apr	NEWA
+		10-50ML (13.5-51CMI/ML)	N202008 003	Apr 06, 2012	Apr	NEWA
+		10ML (13.5-51MCI/ML)	N202008 001	Apr 06, 2012	Apr	NEWA

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888 001	Mar 25, 2005	Aug	CAHN
AP		400MG/200ML (2MG/ML)	A076888 002	Mar 25, 2005	Aug	CAHN
AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764 001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078764 002	Jan 30, 2012	Jan	NEWA
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	@ AGILA SPECLTS	200MG/100ML (2MG/ML)	A076889 001	Mar 25, 2005	Aug	CAHN

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@ AGILA SPECLTS	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005	Aug	CAHN
AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698	001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078698	002	Jan 30, 2012	Jan	NEWA
AP	TEVA PHARMS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005	Oct	CAHN
AP		400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005	Oct	CAHN

TABLET; ORAL

FLUCONAZOLE

AB	HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	Jul	CAHN
AB		100MG	A078423	002	Mar 07, 2011	Jul	CAHN
AB		150MG	A078423	003	Mar 07, 2011	Jul	CAHN
AB		200MG	A078423	004	Mar 07, 2011	Jul	CAHN
	@ MYLAN PHARMS INC	50MG	A076042	001	Jul 29, 2004	Oct	DISC
	@	100MG	A076042	002	Jul 29, 2004	Oct	DISC
	@	150MG	A076042	003	Jul 29, 2004	Oct	DISC
	@	200MG	A076042	004	Jul 29, 2004	Oct	DISC
	@ PLIVA	50MG	A076424	001	Jul 29, 2004	Feb	DISC
	@	100MG	A076424	002	Jul 29, 2004	Feb	DISC
	@	150MG	A076424	003	Jul 29, 2004	Feb	DISC
	@	200MG	A076424	004	Jul 29, 2004	Feb	DISC
	@ RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004	Apr	DISC
	@	100MG	A076386	002	Jul 29, 2004	Apr	DISC
	@	150MG	A076386	003	Jul 29, 2004	Apr	DISC
	@	200MG	A076386	004	Jul 29, 2004	Apr	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

	@ GENZYME CORP	50MG/VIAL	N020038	001	Apr 18, 1991	Mar	DISC
	FLUDARABINE PHOSPHATE						
AP	+ HOSPIRA	50MG/VIAL	A077790	001	Apr 06, 2007	Mar	CRLD
AP	ONCO THERAPIES LTD	50MG/VIAL	A200648	001	Oct 16, 2012	Oct	NEWA

TABLET; ORAL

OFORTA

	@ SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008	May	DISC
--	---------------------	------	---------	-----	--------------	-----	------

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	HIKMA MAPLE	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jul	CAHN
AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jul	CAHN
AP	SAGENT PHARMS	0.5MG/5ML (0.1MG/ML)	A090584	001	Aug 28, 2012	Aug	NEWA
AP		1MG/10ML (0.1MG/ML)	A090584	002	Aug 28, 2012	Aug	NEWA
	@ TEVA PARENTERAL	0.5MG/5ML (0.1MG/ML)	A076589	002	Oct 12, 2004	Jan	DISC
	@	1MG/10ML (0.1MG/ML)	A076589	001	Oct 12, 2004	Jan	DISC

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+	ACTON PHARMS	EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Jul	CPOT
---	--------------	------------------	---------	-----	--------------	-----	------

SPRAY, METERED; NASAL

FLUNISOLIDE

AB	HI TECH PHARMA CO	0.025MG/SPRAY	A077704	001	Aug 03, 2006	Aug	CAHN
----	-------------------	---------------	---------	-----	--------------	-----	------

FLUOCINOLONE ACETONIDE

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT	IDENTI PHARMS INC	0.01%	A091306 001	Oct 17, 2011	Jan	CPOT
----	-------------------	-------	-------------	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

AB1	G AND W LABS INC	0.05%	A073085 001	Feb 14, 1992	Sep	CAHN
-----	------------------	-------	-------------	--------------	-----	------

AB1	+	TARO	0.05%	N019117 001	Jun 26, 1984	Oct	CRLD
-----	---	------	-------	-------------	--------------	-----	------

FLUOCINONIDE EMULSIFIED BASE

AB2	FOUGERA PHARMS	0.05%	A076586 001	Jun 23, 2004	Jan	CAHN
-----	----------------	-------	-------------	--------------	-----	------

@ G AND W LABS INC

A074204 001	Jun 13, 1995	May	CAHN
-------------	--------------	-----	------

AB2	+	TARO	0.05%	A072494 001	Jan 19, 1989	Oct	CRLD
-----	---	------	-------	-------------	--------------	-----	------

LIDEX

@ MEDICIS

N016908 002		Oct	DISC
-------------	--	-----	------

LIDEX-E

@ MEDICIS

N016908 003		Oct	DISC
-------------	--	-----	------

OINTMENT; TOPICAL

FLUOCINONIDE

AB	FOUGERA PHARMS	0.05%	A074905 001	Aug 26, 1997	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

SOLUTION; TOPICAL

FLUOCINONIDE

AT	G AND W LABS INC	0.05%	A071535 001	Dec 02, 1988	Sep	CAHN
----	------------------	-------	-------------	--------------	-----	------

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 25%

AKORN

EQ 500MG BASE/2ML (EQ 250MG
BASE/ML)

N022186 002	Aug 08, 2008	Oct	CMFD
-------------	--------------	-----	------

FLUOROURACIL

CREAM; TOPICAL

CARAC

+	VALEANT INTL	0.5%
---	--------------	------

N020985 001	Oct 27, 2000	Jul	CAHN
-------------	--------------	-----	------

FLUOROPLEX

+	AQUA PHARMS	1%
---	-------------	----

N016988 001		Jan	CAHN
-------------	--	-----	------

INJECTABLE; INJECTION

FLUOROURACIL

AP	ONCO THERAPIES LTD	500MG/10ML (50MG/ML)	A202668 001	Jul 17, 2012	Jul	NEWA
----	--------------------	----------------------	-------------	--------------	-----	------

AP		1GM/20ML (50MG/ML)	A202668 002	Jul 17, 2012	Jul	NEWA
----	--	--------------------	-------------	--------------	-----	------

AP		2.5GM/50ML (50MG/ML)	A202669 001	Jul 17, 2012	Jul	NEWA
----	--	----------------------	-------------	--------------	-----	------

AP		5GM/100ML (50MG/ML)	A202669 002	Jul 17, 2012	Jul	NEWA
----	--	---------------------	-------------	--------------	-----	------

@ SPECTRUM PHARMS

A087792 001	Oct 13, 1982	Sep	CAHN
-------------	--------------	-----	------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1	HERITAGE PHARMS INC	EQ 10MG BASE	A201336 001	Oct 01, 2012	Sep	NEWA
-----	---------------------	--------------	-------------	--------------	-----	------

AB1		EQ 20MG BASE	A201336 002	Oct 01, 2012	Sep	NEWA
-----	--	--------------	-------------	--------------	-----	------

AB		EQ 40MG BASE	A201336 003	Oct 01, 2012	Sep	NEWA
----	--	--------------	-------------	--------------	-----	------

AB1	MYLAN PHARMS INC	EQ 10MG BASE	A075577 001	Jan 29, 2002	Sep	CAHN
-----	------------------	--------------	-------------	--------------	-----	------

AB1		EQ 20MG BASE	A075577 002	Jan 29, 2002	Sep	CAHN
-----	--	--------------	-------------	--------------	-----	------

PROZAC

AB1	ELI LILLY AND CO	EQ 10MG BASE	N018936 006	Dec 23, 1992	Apr	CAHN
-----	------------------	--------------	-------------	--------------	-----	------

CAPSULE; ORAL

PROZAC

AB1	ELI LILLY AND CO	EQ 20MG BASE	N018936 001	Dec 29, 1987	Apr	CAHN
AB	+	EQ 40MG BASE	N018936 003	Jun 15, 1999	Apr	CAHN
	@	EQ 60MG BASE	N018936 004	Jun 15, 1999	Apr	CAHN

SARAFEM

AB2	ELI LILLY AND CO	EQ 10MG BASE	N018936 007	Jul 06, 2000	Apr	CAHN
AB2	+	EQ 20MG BASE	N018936 008	Jul 06, 2000	Apr	CAHN

TABLET; ORAL

SARAFEM

	WARNER CHILCOTT LLC	EQ 10MG BASE	N021860 001	May 19, 2006	Jun	CAHN
		EQ 15MG BASE	N021860 002	May 19, 2006	Jun	CAHN
+		EQ 20MG BASE	N021860 003	May 19, 2006	Jun	CAHN

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB	PAR PHARM	EQ 25MG BASE;EQ 3MG BASE	A077742 001	Nov 02, 2012	Oct	NEWA
AB		EQ 25MG BASE;EQ 6MG BASE	A077742 002	Nov 02, 2012	Oct	NEWA
AB		EQ 25MG BASE;EQ 12MG BASE	A077742 003	Nov 02, 2012	Oct	NEWA
AB		EQ 50MG BASE;EQ 6MG BASE	A077742 004	Nov 02, 2012	Oct	NEWA
AB		EQ 50MG BASE;EQ 12MG BASE	A077742 005	Nov 02, 2012	Oct	NEWA
>A>	AB	EQ 25MG BASE;EQ 3MG BASE	A078901 005	Nov 16, 2012	Nov	NEWA
>A>	AB	EQ 25MG BASE;EQ 6MG BASE	A078901 001	Nov 16, 2012	Nov	NEWA
>A>	AB	EQ 25MG BASE;EQ 12MG BASE	A078901 003	Nov 16, 2012	Nov	NEWA
>A>	AB	EQ 50MG BASE;EQ 6MG BASE	A078901 002	Nov 16, 2012	Nov	NEWA
>A>	AB	EQ 50MG BASE;EQ 12MG BASE	A078901 004	Nov 16, 2012	Nov	NEWA
AB	TEVA PHARMS	EQ 25MG BASE;EQ 6MG BASE	A077528 001	Jun 19, 2012	Jun	NEWA
AB		EQ 25MG BASE;EQ 12MG BASE	A077528 002	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE;EQ 6MG BASE	A077528 003	Jun 19, 2012	Jun	NEWA
AB		EQ 50MG BASE;EQ 12MG BASE	A077528 004	Jun 19, 2012	Jun	NEWA

SYMBYAX

AB	LILLY	EQ 25MG BASE;EQ 3MG BASE	N021520 001	Apr 09, 2007	Oct	CFTG
AB		EQ 25MG BASE;EQ 6MG BASE	N021520 002	Dec 24, 2003	Jun	CFTG
AB		EQ 25MG BASE;EQ 12MG BASE	N021520 004	Dec 24, 2003	Jun	CFTG
AB	+	EQ 50MG BASE;EQ 6MG BASE	N021520 003	Dec 24, 2003	Jun	CFTG
AB		EQ 50MG BASE;EQ 12MG BASE	N021520 005	Dec 24, 2003	Jun	CFTG

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

+	AQUA PHARMS	0.025%	N012806 003		Aug	CRLD
		0.025%	N012806 003		Jul	CAHN
+		0.05%	N012806 002		Aug	CRLD
		0.05%	N012806 002		Jul	CAHN
	WATSON PHARMS	0.05%	N012806 002		Apr	CMFD

LOTION; TOPICAL

CORDRAN

+	AQUA PHARMS	0.05%	N013790 001		Jul	CAHN
---	-------------	-------	-------------	--	-----	------

OINTMENT; TOPICAL

CORDRAN

@	AQUA PHARMS	0.025%	N012806 004		Jul	CAHN
@		0.05%	N012806 001		Jul	CAHN

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	+	IVAX SUB TEVA PHARMS	125MG	A075780	001	Sep 19, 2001	Mar	CRLD
		@ SANDOZ	125MG	A075818	001	Sep 18, 2001	Oct	DISC
AB		SANDOZ INC	125MG	A075818	001	Sep 18, 2001	Mar	CRLD
AB		WATSON LABS INC FL	125MG	A075820	001	Sep 18, 2001	Sep	CAHN

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	0.05%	N019958	001	Dec 18, 1990	Jan	CAHN
		FLUTICASONE PROPIONATE						
AB		FOUGERA PHARMS	0.05%	A076451	001	May 14, 2004	Jan	CAHN
		@ NESHER PHARMS	0.05%	A076865	001	Sep 10, 2004	Jun	DISC

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB		FOUGERA PHARMS	0.005%	A076300	001	May 14, 2004	Jan	CAHN
----	--	----------------	--------	---------	-----	--------------	-----	------

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB		MYLAN PHARMS INC	EQ 20MG BASE	A090595	001	Apr 11, 2012	Mar	NEWA
AB			EQ 40MG BASE	A090595	002	Apr 11, 2012	Mar	NEWA
AB		TEVA PHARMS	EQ 20MG BASE	A078407	001	Jun 12, 2012	May	NEWA
AB			EQ 40MG BASE	A078407	002	Jun 12, 2012	May	NEWA
		LESCOL						
AB		NOVARTIS	EQ 20MG BASE	N020261	001	Dec 31, 1993	Mar	CFTG
AB	+		EQ 40MG BASE	N020261	002	Dec 31, 1993	Mar	CFTG

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

LUVOX CR

		JAZZ PHARMS	100MG	N022033	001	Feb 28, 2008	Jun	CAHN
	+		150MG	N022033	002	Feb 28, 2008	Jun	CAHN

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

AP		MYLAN LLC	1.5GM/1.5ML (1GM/ML)	A078639	001	Mar 03, 2008	Sep	CAHN
----	--	-----------	----------------------	---------	-----	--------------	-----	------

FORMOTEROL FUMARATE

SOLUTION; INHALATION

PERFORMIST

	+	MYLAN SPECLT	0.02MG/2ML	N022007	001	May 11, 2007	Sep	CAHN
--	---	--------------	------------	---------	-----	--------------	-----	------

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

	+	MERCK SHARP DOHME	0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010	Jun	CAHN
	+		0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010	Jun	CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@ RANBAXY LABS LTD	10MG	A076580 001	Apr 23, 2004	Apr	DISC
@	20MG	A076580 002	Apr 23, 2004	Apr	DISC
@	40MG	A076580 003	Apr 23, 2004	Apr	DISC

MONOPRIL

@ BRISTOL MYERS SQUIBB	10MG	N019915 002	May 16, 1991	Mar	DISC
@	20MG	N019915 003	May 16, 1991	Mar	DISC
@	40MG	N019915 004	Mar 28, 1995	Mar	DISC

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	EMCURE PHARMS INDIA	10MG;12.5MG	A079025 001	Sep 17, 2010	Oct	CAHN
AB		20MG;12.5MG	A079025 002	Sep 17, 2010	Oct	CAHN

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	HIKMA MAPLE	EQ 50MG PHENYTOIN NA/ML	A077989 001	Aug 06, 2007	Jul	CAHN
	@ TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886 001	Aug 06, 2007	Mar	DISC

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

@ EISAI INC	1050MG/30ML (35MG/ML)	N022244 001	Dec 12, 2008	Jul	DISC
-------------	-----------------------	-------------	--------------	-----	------

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@ HIKMA MAPLE	10MG/ML	A071439 001	Sep 14, 1990	Sep	CAHN
@	10MG/ML	N018267 001		Sep	CAHN
@ HOSPIRA	10MG/ML	A070578 001	Jul 08, 1987	Jun	DISC

GABAPENTIN

SOLUTION; ORAL

GABAPENTIN

AA	ACELLA PHARMS LLC	250MG/5ML	A076403 001	May 01, 2012	Jun	CAHN
AA	AMNEAL PHARMS	250MG/5ML	A202024 001	Mar 23, 2012	Mar	NEWA
AA	KIEL	250MG/5ML	A076403 001	May 01, 2012	Apr	NEWA

TABLET; ORAL

GABAPENTIN

AB	INVAGEN PHARMS	600MG	A202764 001	Oct 16, 2012	Oct	NEWA
AB		800MG	A202764 002	Oct 16, 2012	Oct	NEWA
AB	MYLAN PHARMS INC	600MG	A090335 001	Jun 01, 2010	Sep	CAHN
AB		800MG	A090335 002	Jun 01, 2010	Sep	CAHN

GANCICLOVIR

CAPSULE; ORAL

GANCICLOVIR

@ RANBAXY LABS LTD	250MG	A076457 001	Jun 27, 2003	Apr	DISC
@	500MG	A076457 002	Jun 27, 2003	Apr	DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP	EMCURE PHARMS LTD	EQ 200MG BASE/VIAL	A202063 001	Sep 11, 2012	Aug	NEWA
AP		EQ 1GM BASE/VIAL	A202063 002	Sep 11, 2012	Aug	NEWA
AP	HAMELN RDS GMBH	EQ 200MG BASE/VIAL	A090663 001	Sep 10, 2012	Aug	NEWA
AP		EQ 1GM BASE/VIAL	A090663 002	Sep 10, 2012	Aug	NEWA
	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795 001	Aug 04, 2011	Apr CTNA
	+		1GM/26.3ML (38MG/ML)	N200795 002	Aug 04, 2011	Apr CTNA
	+		2GM/52.6ML (38MG/ML)	N200795 003	Aug 04, 2011	Apr CTNA
AP	TEVA PHARMS	EQ 200MG BASE/VIAL	A077983 002	Jan 25, 2011	Oct	CAHN
AP		EQ 1GM BASE/VIAL	A077983 001	Jan 25, 2011	Oct	CAHN

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

@	HIKMA MAPLE	EQ 10MG BASE/ML	A062251 002		Sep	CAHN
@		EQ 40MG BASE/ML	A062251 001		Sep	CAHN

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	AUROBINDO PHARMA LTD	1MG	A202759 001	Jun 29, 2012	Jun	NEWA
AB		2MG	A202759 002	Jun 29, 2012	Jun	NEWA
AB		4MG	A202759 003	Jun 29, 2012	Jun	NEWA
AB	MICRO LABS USA	1MG	A091220 001	Jun 29, 2012	Jun	NEWA
AB		2MG	A091220 002	Jun 29, 2012	Jun	NEWA
		3MG	A091220 003	Jun 29, 2012	Jun	NEWA
AB		4MG	A091220 004	Jun 29, 2012	Jun	NEWA
		6MG	A091220 005	Jun 29, 2012	Jun	NEWA
AB		8MG	A091220 006	Jun 29, 2012	Jun	NEWA
	@	RANBAXY LABS LTD	1MG	A076875 001	Oct 06, 2005	Apr DISC
	@		2MG	A076875 002	Oct 06, 2005	Apr DISC
	@		4MG	A076875 003	Oct 06, 2005	Apr DISC
	@		8MG	A076875 004	Oct 06, 2005	Apr DISC

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

+	TAKEDA PHARMS USA	2MG;30MG	N021925 001	Jul 28, 2006	Aug	CAHN
		4MG;30MG	N021925 002	Jul 28, 2006	Aug	CAHN

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

@	VINTAGE PHARMS LLC	5MG	A074378 001	Nov 28, 1994	Sep	CAHN
@		10MG	A074378 002	Nov 28, 1994	Sep	CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB	HERITAGE PHARMS INC	1.25MG;250MG	A079009 001	Jun 03, 2009	Sep	CAHN
AB		2.5MG;500MG	A079009 002	Jun 03, 2009	Sep	CAHN
AB		5MG;500MG	A079009 003	Jun 03, 2009	Sep	CAHN

GLYCOPYRROLATE

SOLUTION; ORAL

CUVPOSA

+	MERZ PHARMS	1MG/5ML	N022571	001	Jul 28, 2010	Aug	CAHN
---	-------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

GLYCOPYRROLATE

AA	EXCELLIUM	1MG	A090195	001	Sep 21, 2012	Sep	NEWA
AA		2MG	A090195	002	Sep 21, 2012	Sep	NEWA
AA	NEXGEN PHARMA	1.5MG	A091522	001	Mar 12, 2012	Feb	NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	Mar	CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	Mar	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	Mar	CAHN
AP	HIKMA MAPLE	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Sep	CAHN
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE							
AP	+ APP PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078096	001	Jun 30, 2008	Apr	CRLD
	@ TEVA PARENTERAL	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007	Apr	DISC

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

AB	+ VALEANT PHARM NORTH	125MG/5ML	A062483	001	Jan 26, 1984	Feb	CAHN
TABLET; ORAL							
GRIFULVIN V							
	@ VALEANT INTL	125MG	A062279	001		Jul	CAHN
	@	250MG	A062279	002		Jul	CAHN
	+	500MG	A062279	003		Jul	CAHN
	@ VALEANT LUXEMBOURG	125MG	A062279	001		Oct	CAHN
	@	250MG	A062279	002		Oct	CAHN

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRIFULVIN V

AB	+ VALEANT PHARM NORTH	125MG/5ML	A062483	001	Jan 26, 1984	Oct	CAIN
GRISEOFULVIN							
AB	ACTAVIS MID ATLANTIC	125MG/5ML	A065394	001	Jul 06, 2007	Oct	CAIN
AB	IVAX SUB TEVA PHARMS	125MG/5ML	A065354	001	Sep 10, 2007	Oct	CAIN
AB	PERRIGO CO TENNESSEE	125MG/5ML	A065200	001	Mar 02, 2005	Oct	CAIN
AB	VINTAGE PHARMS	125MG/5ML	A065438	001	Oct 08, 2010	Oct	CAIN
TABLET; ORAL							
GRIFULVIN V							
AB	+ VALEANT LUXEMBOURG	500MG	A062279	003		Oct	CAHN
GRISEOFULVIN							
AB	SIGMAPHARM LABS LLC	500MG	A202482	001	Oct 22, 2012	Oct	NEWA

GRISEOFULVIN, ULTRAMICROSIZE

TABLET; ORAL

GRISEOFULVIN, ULTRAMICROSIZE

AB	SIGMAPHARM LABS LLC	125MG	A202545	001	Oct 22, 2012	Oct	NEWA
AB		250MG	A202545	002	Oct 22, 2012	Oct	NEWA

TABLET; ORAL

GRIS-PEG

AB	PEDINOL	125MG	N050475 001	Oct	CTEC
AB	+	250MG	N050475 002	Oct	CTEC

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 1MG BASE	A200881 001	Oct 05, 2012	Sep	NEWA
AB		EQ 2MG BASE	A200881 002	Oct 05, 2012	Sep	NEWA
AB		EQ 3MG BASE	A200881 003	Oct 05, 2012	Sep	NEWA
AB		EQ 4MG BASE	A200881 004	Oct 05, 2012	Sep	NEWA
INTUNIV						
AB	SHIRE	EQ 1MG BASE	N022037 001	Sep 02, 2009	Sep	CFTG
AB		EQ 2MG BASE	N022037 002	Sep 02, 2009	Sep	CFTG
AB		EQ 3MG BASE	N022037 003	Sep 02, 2009	Sep	CFTG
AB	+	EQ 4MG BASE	N022037 004	Sep 02, 2009	Sep	CFTG

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A077001 001	Dec 16, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A076903 001	Dec 16, 2004	Jan	CAHN
	@ VENUS PHARMS	0.05%	A077109 001	Jun 14, 2005	Jun	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	B BRAUN	200 UNITS/100ML	N019953 001	Jul 20, 1992	Jul	CRLD
HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER							
		@ BAXTER HLTHCARE	2,000 UNITS/100ML	N018814 002	Jul 09, 1985	Mar	DISC
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER							
		@ BAXTER HLTHCARE	4,000 UNITS/100ML	N018814 001	Oct 31, 1983	Mar	DISC
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	+	B BRAUN	4,000 UNITS/100ML	N019952 001	Jul 20, 1992	Jul	CRLD
HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER							
		@ BAXTER HLTHCARE	5,000 UNITS/100ML	N018814 003	Jul 09, 1985	Mar	DISC
		@	10,000 UNITS/100ML	N018814 004	Jul 02, 1987	Mar	DISC
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER							
AP	+	B BRAUN	5,000 UNITS/100ML	N019952 004	Jul 20, 1992	Jul	CRLD
AP	+		10,000 UNITS/100ML	N019952 005	Jul 20, 1992	Jul	CRLD

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

+	PHOTOCURE ASA	100MG/VIAL	N022555 001	May 28, 2010	May	CAHN
---	---------------	------------	-------------	--------------	-----	------

HYALURONIDASE

INJECTABLE; INJECTION

HYDASE

@	AKORN INC	150 UNITS/ML	N021716 001	Oct 25, 2005	Jun	DISC
---	-----------	--------------	-------------	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

>A>	AB	ALKEM LABS LTD	10MG	A200737 001	Dec 07, 2012	Nov	NEWA
>A>	AB		25MG	A200737 002	Dec 07, 2012	Nov	NEWA
>A>	AB		50MG	A200737 003	Dec 07, 2012	Nov	NEWA
>A>	AB		100MG	A200737 004	Dec 07, 2012	Nov	NEWA

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB		LANNETT HOLDINGS INC	12.5MG	A091662 001	Jan 27, 2012	Jan	NEWA
----	--	----------------------	--------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB		ACCORD HLTHCARE	12.5MG	A202556 001	Sep 24, 2012	Sep	NEWA
AB			25MG	A202556 002	Sep 24, 2012	Sep	NEWA
AB			50MG	A202556 003	Sep 24, 2012	Sep	NEWA

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

AB	+	SANOFI AVENTIS	12.5MG;150MG	N020758 002	Sep 30, 1997	Mar	CFTG
AB	+		12.5MG;300MG	N020758 003	Aug 31, 1998	Mar	CFTG
	+		12.5MG;300MG	N020758 003	Aug 31, 1998	Feb	CRLD

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC LTD	12.5MG;150MG	A091370 001	Oct 15, 2012	Oct	NEWA
AB			12.5MG;300MG	A091370 002	Oct 15, 2012	Oct	NEWA
AB		APOTEX INC	12.5MG;150MG	A201505 001	Oct 15, 2012	Oct	NEWA
AB			12.5MG;300MG	A201505 002	Oct 15, 2012	Oct	NEWA
AB		DR REDDYS LABS LTD	12.5MG;150MG	A203500 001	Sep 27, 2012	Sep	NEWA
AB			12.5MG;300MG	A203500 002	Sep 27, 2012	Sep	NEWA
AB		MACLEODS PHARMS LTD	12.5MG;150MG	A202414 001	Sep 27, 2012	Sep	NEWA
AB			12.5MG;300MG	A202414 002	Sep 27, 2012	Sep	NEWA
AB		MYLAN PHARMS INC	12.5MG;150MG	A077969 001	Sep 27, 2012	Sep	NEWA
AB			12.5MG;300MG	A077969 002	Sep 27, 2012	Sep	NEWA
AB		ROXANE	12.5MG;150MG	A090351 001	Oct 15, 2012	Oct	NEWA
AB			12.5MG;300MG	A090351 002	Oct 15, 2012	Oct	NEWA
AB		SANDOZ	12.5MG;150MG	A077446 001	Sep 27, 2012	Sep	NEWA
AB			12.5MG;300MG	A077446 002	Sep 27, 2012	Sep	NEWA
AB		TEVA	12.5MG;150MG	A077369 001	Mar 30, 2012	Mar	NEWA
AB			12.5MG;300MG	A077369 002	Mar 30, 2012	Mar	NEWA
	@		25MG;300MG	A077369 003	Mar 30, 2012	Apr	DISC
			25MG;300MG	A077369 003	Mar 30, 2012	Mar	NEWA
AB		WATSON LABS INC	12.5MG;150MG	A091539 001	Oct 22, 2012	Oct	NEWA
AB			12.5MG;300MG	A091539 002	Oct 22, 2012	Oct	NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC LTD	12.5MG;50MG	A091617 001	Feb 17, 2012	Feb	NEWA
AB			12.5MG;100MG	A091617 002	Feb 17, 2012	Feb	NEWA
AB			25MG;100MG	A091617 003	Feb 17, 2012	Feb	NEWA
AB		ALEMBIC PHARMS LTD	12.5MG;50MG	A091617 001	Feb 17, 2012	Sep	CAHN
AB			12.5MG;100MG	A091617 002	Feb 17, 2012	Sep	CAHN
AB			25MG;100MG	A091617 003	Feb 17, 2012	Sep	CAHN

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	CADISTA PHARMS	12.5MG;50MG	A201845 001	Sep 18, 2012	Sep	NEWA
AB		12.5MG;100MG	A201845 002	Sep 18, 2012	Sep	NEWA
AB		25MG;100MG	A201845 003	Sep 18, 2012	Sep	NEWA
AB	MACLEODS PHARMS LTD	12.5MG;50MG	A202289 001	Aug 09, 2012	Jul	NEWA
AB		12.5MG;100MG	A202289 002	Aug 09, 2012	Jul	NEWA
AB		25MG;100MG	A202289 003	Aug 09, 2012	Jul	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

	ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956 001	Aug 28, 2006	Jan	CMFD
		12.5MG;EQ 50MG TARTRATE	N021956 002	Aug 28, 2006	Jan	CMFD
+		12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006	Apr	CRLD
		12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006	Jan	CMFD

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

AB	US PHARMS HOLDINGS I	25MG;50MG	N018303 001	Dec 31, 1984	Sep	CAHN
AB	+	25MG;100MG	N018303 002	Dec 31, 1984	Sep	CAHN
	@	50MG;100MG	N018303 003	Dec 31, 1984	Sep	CAHN
	METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE					
AB	MYLAN	50MG;100MG	A076792 003	Aug 20, 2004	Jan	CTEC
AB	SUN PHARM INDS	25MG;50MG	A090654 001	Jan 19, 2012	Jan	NEWA
AB		25MG;100MG	A090654 002	Jan 19, 2012	Jan	NEWA
AB		50MG;100MG	A090654 003	Jan 19, 2012	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ PADDOCK LLC	12.5MG;7.5MG	A090096 001	Sep 25, 2008	Jan	DISC
	@	12.5MG;15MG	A090096 002	Sep 25, 2008	Jan	DISC
	@	25MG;15MG	A090096 003	Sep 25, 2008	Jan	DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

AB	NOVARTIS	12.5MG;80MG	N020818 001	Mar 06, 1998	Sep	CFTG
AB		12.5MG;160MG	N020818 002	Mar 06, 1998	Sep	CFTG
AB		12.5MG;320MG	N020818 004	Apr 28, 2006	Sep	CFTG
AB		25MG;160MG	N020818 003	Jan 17, 2002	Sep	CFTG
AB	+	25MG;320MG	N020818 005	Apr 28, 2006	Sep	CFTG

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	MYLAN PHARMS INC	12.5MG;80MG	A078020 001	Sep 21, 2012	Sep	NEWA
AB		12.5MG;160MG	A078020 002	Sep 21, 2012	Sep	NEWA
AB		12.5MG;320MG	A078020 004	Sep 21, 2012	Sep	NEWA
AB		25MG;160MG	A078020 003	Sep 21, 2012	Sep	NEWA
AB		25MG;320MG	A078020 005	Sep 21, 2012	Sep	NEWA

HYDROCORTISONE

CREAM; TOPICAL

HYTONE

	@ VALEANT INTL	1%	A080472 003		Sep	CAHN
	@	2.5%	A080472 004		Sep	CAHN

CREAM; TOPICAL									
NUTRACORT									
	@	DOW PHARM	0.5%		A080442	002		Jun	CAHN
	@		1%		A080442	003		Jun	CAHN
LOTION; TOPICAL									
CETACORT									
	@	DOW PHARM	0.5%		A080426	002		Jun	CAHN
	@		1%		A080426	001		Jun	CAHN
HYDROCORTISONE									
AT	+	FOUGERA PHARMS	2.5%		A040351	001	Jul 25, 2000	Jan	CAHN
HYTONE									
	@	VALEANT INTL	1%		A080473	003		Sep	CAHN
	@		2.5%		A080473	004	Nov 30, 1982	Sep	CAHN
NUTRACORT									
	@	DOW PHARM	0.5%		A080443	002		Jun	CAHN
AT			1%		A080443	003		Jun	CAHN
AT			2.5%		A087644	001	Aug 24, 1982	Jun	CAHN
OINTMENT; TOPICAL									
HYDROCORTISONE									
AT	+	FOUGERA PHARMS	1%		A080692	001		Jan	CAHN
TABLET; ORAL									
HYDROCORTISONE									
>A>	AB	AMEDRA PHARMS	5MG		A040646	001	Mar 30, 2007	Nov	CAHN
>A>	AB		10MG		A040646	002	Mar 30, 2007	Nov	CAHN
>A>	AB		20MG		A040646	003	Mar 30, 2007	Nov	CAHN
>D>	AB	COREPHARMA	5MG		A040646	001	Mar 30, 2007	Nov	CAHN
>D>	AB		10MG		A040646	002	Mar 30, 2007	Nov	CAHN
>D>	AB		20MG		A040646	003	Mar 30, 2007	Nov	CAHN
<u>HYDROCORTISONE ACETATE; UREA</u>									
CREAM; TOPICAL									
CARMOL HC									
AT		FOUGERA PHARMS	1%;10%		A080505	001		Jan	CAHN
<u>HYDROCORTISONE BUTYRATE</u>									
CREAM; TOPICAL									
LOCOID									
AB	+	PRECISION DERMAT	0.1%		N018514	001	Mar 31, 1982	Jun	CAHN
LOCOID LIPOCREAM									
	+	PRECISION DERMAT	0.1%		N020769	001	Sep 08, 1997	Jun	CAHN
LOTION; TOPICAL									
LOCOID									
	+	PRECISION DERMAT	0.1%		N022076	001	May 18, 2007	May	CAHN
OINTMENT; TOPICAL									
LOCOID									
AB	+	PRECISION DERMAT	0.1%		N018652	001	Oct 29, 1982	May	CAHN
SOLUTION; TOPICAL									
LOCOID									
AT	+	PRECISION DERMAT	0.1%		N019116	001	Feb 25, 1987	Jun	CAHN
<u>HYDROCORTISONE VALERATE</u>									
CREAM; TOPICAL									
HYDROCORTISONE VALERATE									
AB	+	TARO	0.2%		A075042	001	Aug 25, 1998	Mar	CRLD
WESTCORT									
	@	RANBAXY	0.2%		N017950	001		Mar	DISC

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB	FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	ALCON PHARMS LTD	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423	001	Aug 25, 1983	Sep	CAHN
----	------------------	-------------------------------------	---------	-----	--------------	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

AB	+ SHIRE LLC	50MG	N011949	001		Jan	CAHN
----	-------------	------	---------	-----	--	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

	@ NESHER PHARMS	2MG	A077311	001	Nov 09, 2005	Jun	DISC
--	-----------------	-----	---------	-----	--------------	-----	------

	@	4MG	A077311	002	Nov 09, 2005	Jun	DISC
--	---	-----	---------	-----	--------------	-----	------

	@	8MG	A077311	003	Nov 09, 2005	Jun	DISC
--	---	-----	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

EXALGO

	MALLINCKRODT INC	32MG	N021217	004	Aug 24, 2012	Aug	NEWA
--	------------------	------	---------	-----	--------------	-----	------

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

	@ SANDOZ	200MG	A040150	001	Jan 27, 1996	Oct	DISC
--	----------	-------	---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

	@ STI PHARMA LLC	10MG/5ML	A086880	001		Feb	CAHN
--	------------------	----------	---------	-----	--	-----	------

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

	@ MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Jul	CAHN
--	----------------	------	---------	-----	--------------	-----	------

	@	25MG	A040602	001	Dec 28, 2004	Jul	CAHN
--	---	------	---------	-----	--------------	-----	------

	@	50MG	A040604	001	Dec 28, 2004	Jul	CAHN
--	---	------	---------	-----	--------------	-----	------

HYDROXYZINE PAMOATE

SUSPENSION; ORAL

VISTARIL

	@ PFIZER	EQ 25MG HCL/5ML	N011795	001		Jul	DISC
--	----------	-----------------	---------	-----	--	-----	------

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

AB	+ HOFFMANN LA ROCHE	EQ 150MG BASE	N021455	002	Mar 24, 2005	Mar	CFTG
----	---------------------	---------------	---------	-----	--------------	-----	------

IBANDRONATE SODIUM

AB	APOTEX INC	EQ 150MG BASE	A078948	001	Mar 19, 2012	Mar	NEWA
----	------------	---------------	---------	-----	--------------	-----	------

AB	DR REDDYS LABS LTD	EQ 150MG BASE	A078997	001	Apr 30, 2012	Apr	NEWA
----	--------------------	---------------	---------	-----	--------------	-----	------

AB	MUTUAL PHARM CO INC	EQ 150MG BASE	A078996	001	Aug 15, 2012	Jul	NEWA
----	---------------------	---------------	---------	-----	--------------	-----	------

AB	MYLAN PHARMS INC	EQ 150MG BASE	A078995	001	Mar 19, 2012	Mar	NEWA
----	------------------	---------------	---------	-----	--------------	-----	------

AB	ORCHID HLTHCARE	EQ 150MG BASE	A078998	001	Mar 19, 2012	Mar	NEWA
----	-----------------	---------------	---------	-----	--------------	-----	------

AB	WATSON LABS INC	EQ 150MG BASE	A079003	001	Mar 20, 2012	Mar	NEWA
----	-----------------	---------------	---------	-----	--------------	-----	------

IBUPROFEN

TABLET; ORAL

IBUPROFEN

@ NORTHSTAR HLTHCARE	400MG	A078132 001	Sep 10, 2007	Jun	DISC
@	600MG	A078132 002	Sep 10, 2007	Jun	DISC
@	800MG	A078132 003	Sep 10, 2007	Jun	DISC
@ OHM LABS	400MG	A070818 001	Dec 26, 1985	Jun	DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903 001	Apr 13, 2006	Mar	CAHN
----------------	------------------------------------	-------------	--------------	-----	------

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+ AMARIN PHARMA INC	1GM	N202057 001	Jul 26, 2012	Jul	NEWA
---------------------	-----	-------------	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

AP ONCO THERAPIES LTD	1MG/ML	A200144 001	Oct 11, 2012	Sep	NEWA
@ TEVA PARENTERAL	5MG/VIAL	A065037 003	May 01, 2002	Mar	DISC
@	10MG/VIAL	A065037 002	May 01, 2002	Mar	DISC
@	20MG/VIAL	A065037 001	May 01, 2002	Mar	DISC

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

>A> AP ONCO THERAPIES LTD	1GM/20ML (50MG/ML)	A201689 001	Nov 26, 2012	Nov	NEWA
>A> AP	3GM/60ML (50MG/ML)	A201689 002	Nov 26, 2012	Nov	NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB EXCELLIUM	10MG	A040903 001	Oct 24, 2012	Oct	NEWA
AB	25MG	A040903 002	Oct 24, 2012	Oct	NEWA
AB	50MG	A040903 003	Oct 24, 2012	Oct	NEWA
AB PROSAM LABS	10MG	A040753 001	Feb 28, 2008	Feb	CMFD
AB	25MG	A040752 001	Feb 28, 2008	Feb	CMFD
AB	50MG	A040751 001	Feb 28, 2008	Feb	CMFD

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB APOTEX INC	5%	A091308 001	Apr 06, 2012	Mar	NEWA
AB FOUGERA PHARMS	5%	A078548 001	Feb 25, 2010	Jan	CAHN
AB GLENMARK GENERICS	5%	A201994 001	Mar 06, 2012	Feb	NEWA

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

AB MYLAN PHARMS INC	1.25MG	A075105 001	Jul 23, 1998	Sep	CAHN
AB	2.5MG	A075105 002	Jul 23, 1998	Sep	CAHN

TABLET; ORAL

INDAPAMIDE

@ SANDOZ 1.25MG
 @ 2.5MG

A074594 001 May 23, 1996 Oct DISC
 A074594 002 May 23, 1996 Oct DISC

INDOMETHACIN

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB HETERO LABS LTD III 75MG

A201807 001 Sep 28, 2012 Sep NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOCIN

AP + LUNDBECK LLC EQ 1MG BASE/VIAL

N018878 001 Jan 30, 1985 Mar CAHN

INGENOL MEBUTATE

GEL; TOPICAL

PICATO

LEO PHARMA AS 0.015%
 + 0.05%

N202833 001 Jan 23, 2012 Jan NEWA
 N202833 002 Jan 23, 2012 Jan NEWA

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG MIX 70/30

>D> + NOVO NORDISK INC 70 UNITS/ML; 30 UNITS/ML N021172 001 Nov 01, 2001 Nov CPOT
 >A> + 700 UNITS/10ML; 300 UNITS/10ML (70 UNITS/ML; 30 UNITS/ML) N021172 001 Nov 01, 2001 Nov CPOT
 >A> NOVOLOG MIX 70/30 FLEXPEN
 >A> + NOVO NORDISK INC 210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML) N021172 004 May 03, 2002 Nov NEWA
 >A> NOVOLOG MIX 70/30 PENFILL
 >A> @ NOVO NORDISK INC 210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML) N021172 003 Nov 01, 2001 Nov NEWA
 >A> @ 210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML) N021172 002 Nov 01, 2001 Nov NEWA

INSULIN ASPART RECOMBINANT

INJECTABLE; SUBCUTANEOUS

NOVOLOG

>D> + NOVO NORDISK INC 100 UNITS/ML N020986 001 Jun 07, 2000 Nov CPOT
 >A> + 1000 UNITS/10ML (100 UNITS/ML) N020986 001 Jun 07, 2000 Nov CPOT
 >A> NOVOLOG FLEXPEN
 >A> + NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N020986 003 Jan 19, 2001 Nov NEWA
 >A> NOVOLOG INNOLET
 >A> @ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N020986 004 Apr 23, 2004 Nov NEWA
 >A> NOVOLOG PENFILL
 >A> + NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N020986 002 Jun 07, 2000 Nov NEWA

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR

>D> + NOVO NORDISK INC 100 UNITS/ML N021536 001 Jun 16, 2005 Nov CPOT
 >A> + 1000 UNITS/10ML (100 UNITS/ML) N021536 001 Jun 16, 2005 Nov CPOT
 >A> LEVEMIR FLEXPEN
 >A> + NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N021536 002 Jun 16, 2005 Nov NEWA
 >A> LEVEMIR INNOLET
 >A> @ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N021536 003 Jun 16, 2005 Nov NEWA

INJECTABLE; SUBCUTANEOUS

>A> LEVEMIR PENFILL

>A> @ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N021536 004 Jun 16, 2005 Nov NEWA

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50 PEN

@ LILLY 50 UNITS/ML;50 UNITS/ML N021018 003 Dec 22, 1999 Jun DISC

HUMALOG MIX 75/25 PEN

@ LILLY 75 UNITS/ML;25 UNITS/ML N021017 003 Dec 22, 1999 Jun DISC

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG PEN

@ LILLY 100 UNITS/ML N020563 002 Aug 06, 1998 Jun DISC

IOTHALAMATE SODIUM I-125

INJECTABLE; INJECTION

GLOFIL-125

ISOTEX 250-300uCi/ML N017279 001 Oct CMFD

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

AN TEVA PHARMS 0.02% A075313 001 Feb 07, 2000 Sep CAHN

IRBESARTAN

TABLET; ORAL

AVAPRO

AB SANOFI AVENTIS US 75MG N020757 001 Sep 30, 1997 Mar CFTG

AB 150MG N020757 002 Sep 30, 1997 Mar CFTG

AB + 300MG N020757 003 Sep 30, 1997 Mar CFTG

IRBESARTAN

AB ALEMBIC PHARMS LTD 75MG A091236 001 Oct 15, 2012 Oct NEWA

AB 150MG A091236 002 Oct 15, 2012 Oct NEWA

AB 300MG A091236 003 Oct 15, 2012 Oct NEWA

AB APOTEX INC 75MG A200832 001 Oct 15, 2012 Oct NEWA

AB 150MG A200832 002 Oct 15, 2012 Oct NEWA

AB 300MG A200832 003 Oct 15, 2012 Oct NEWA

AB AUROBINDO PHARMA LTD 75MG A203081 001 Sep 27, 2012 Sep NEWA

AB 150MG A203081 002 Sep 27, 2012 Sep NEWA

AB 300MG A203081 003 Sep 27, 2012 Sep NEWA

AB CIPLA LTD 75MG A077205 001 Nov 14, 2012 Oct NEWA

AB 150MG A077205 002 Nov 14, 2012 Oct NEWA

AB 300MG A077205 003 Nov 14, 2012 Oct NEWA

AB DR REDDYS LABS LTD 75MG A203161 001 Sep 27, 2012 Sep NEWA

AB 150MG A203161 002 Sep 27, 2012 Sep NEWA

AB 300MG A203161 003 Sep 27, 2012 Sep NEWA

AB HETERO LABS LTD V 75MG A202910 001 Sep 27, 2012 Sep NEWA

AB 150MG A202910 002 Sep 27, 2012 Sep NEWA

AB 300MG A202910 003 Sep 27, 2012 Sep NEWA

AB LUPIN LTD 75MG A201531 001 Oct 15, 2012 Oct NEWA

AB 150MG A201531 002 Oct 15, 2012 Oct NEWA

AB 300MG A201531 003 Oct 15, 2012 Oct NEWA

AB MACLEODS PHARMS LTD 75MG A202254 001 Oct 03, 2012 Sep NEWA

AB 150MG A202254 002 Oct 03, 2012 Sep NEWA

TABLET; ORAL

IRBESARTAN

AB	MACLEODS PHARMS LTD	300MG	A202254	003	Oct 03, 2012	Sep	NEWA
AB	MYLAN PHARMS INC	75MG	A200461	001	Sep 27, 2012	Sep	NEWA
AB		150MG	A200461	002	Sep 27, 2012	Sep	NEWA
AB		300MG	A200461	003	Sep 27, 2012	Sep	NEWA
AB	PRINSTON INC	75MG	A203071	001	Sep 27, 2012	Sep	NEWA
AB		150MG	A203071	002	Sep 27, 2012	Sep	NEWA
AB		300MG	A203071	003	Sep 27, 2012	Sep	NEWA
AB	ROXANE	75MG	A090201	001	Oct 15, 2012	Oct	NEWA
AB		150MG	A090201	002	Oct 15, 2012	Oct	NEWA
AB		300MG	A090201	003	Oct 15, 2012	Oct	NEWA
AB	SANDOZ	75MG	A077466	001	Sep 27, 2012	Sep	NEWA
AB		150MG	A077466	002	Sep 27, 2012	Sep	NEWA
AB		300MG	A077466	003	Sep 27, 2012	Sep	NEWA
AB	TEVA PHARMS	75MG	A077159	001	Mar 30, 2012	Mar	NEWA
AB		150MG	A077159	002	Mar 30, 2012	Mar	NEWA
AB		300MG	A077159	003	Mar 30, 2012	Mar	NEWA
AB	WATSON LABS INC	75MG	A090720	001	Oct 12, 2012	Sep	NEWA
AB		150MG	A090720	002	Oct 12, 2012	Sep	NEWA
AB		300MG	A090720	003	Oct 12, 2012	Sep	NEWA
AB	ZYDUS PHARMS USA INC	75MG	A079213	001	Sep 27, 2012	Sep	NEWA
AB		150MG	A079213	002	Sep 27, 2012	Sep	NEWA
AB		300MG	A079213	003	Sep 27, 2012	Sep	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	CIPLA LTD	40MG/2ML (20MG/ML)	A077219	001	Feb 20, 2008	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A077219	002	Feb 20, 2008	Mar	CAHN
AP	EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771	001	Feb 14, 2012	Jan	NEWA
AP		100MG/5ML (20MG/ML)	A200771	002	Feb 14, 2012	Jan	NEWA
AP	HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016	001	Jan 28, 2009	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A090016	002	Jan 28, 2009	Mar	CAHN
AP	TEVA PARENTERAL	40MG/2ML (20MG/ML)	A090101	002	Feb 27, 2008	Jun	NEWA
AP		100MG/5ML (20MG/ML)	A090101	003	Feb 27, 2008	Jun	NEWA
AP		500MG/25ML (20MG/ML)	A090101	001	Nov 26, 2008	Jun	CMFD
	@	500MG/25ML (20MG/ML)	A090101	001	Nov 26, 2008	Mar	DISC

ISOFLURANE

LIQUID; INHALATION

FORANE

AN	+	BAXTER HLTHCARE	99.9%	N017624	001		Jul	CAHN
----	---	-----------------	-------	---------	-----	--	-----	------

ISOSORBIDE MONONITRATE

TABLET; ORAL

MONOKET

AB	KREMERS URBAN PHARMS	10MG	N020215	002	Jun 30, 1993	Oct	CAHN
AB	+	20MG	N020215	001	Jun 30, 1993	Oct	CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB	ALKERMES GAINESVILLE	60MG	A075041	001	Sep 22, 1998	Jun	CAHN
	@ SKYEPHARMA AG	60MG	A075166	001	Oct 07, 1999	Jan	DISC

ISOSULFAN BLUE

INJECTABLE; INJECTION
ISOSULFAN BLUE

AP	MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	Oct	CAHN
----	---------------------	----	---------	-----	--------------	-----	------

ISOTRETINOIN

CAPSULE; ORAL
ABSORICA

BX	CIPHER	10MG	N021951	001	May 25, 2012	Sep	CTEC
		10MG	N021951	001	May 25, 2012	May	NEWA
BX		20MG	N021951	002	May 25, 2012	Sep	CTEC
		20MG	N021951	002	May 25, 2012	May	NEWA
BX		30MG	N021951	003	May 25, 2012	Sep	CTEC
		30MG	N021951	003	May 25, 2012	May	NEWA
BX		40MG	N021951	004	May 25, 2012	Sep	CTEC
		40MG	N021951	004	May 25, 2012	May	NEWA

MYORISAN

AB	DOUGLAS PHARMS	10MG	A076485	001	Jan 19, 2012	Jan	NEWA
AB		20MG	A076485	002	Jan 19, 2012	Jan	NEWA
AB		40MG	A076485	003	Jan 19, 2012	Jan	NEWA

ITRACONAZOLE

CAPSULE; ORAL
ITRACONAZOLE

AB	MYLAN PHARMS INC	100MG	A200463	001	Jul 20, 2012	Jul	NEWA
----	------------------	-------	---------	-----	--------------	-----	------

IVACAFTOR

TABLET; ORAL
KALYDECO

+	VERTEX PHARMS	150MG	N203188	001	Jan 31, 2012	Jan	NEWA
---	---------------	-------	---------	-----	--------------	-----	------

IVERMECTIN

LOTION; TOPICAL
SKLICE

+	SANOFI PASTEUR	0.5%	N202736	001	Feb 07, 2012	Feb	NEWA
---	----------------	------	---------	-----	--------------	-----	------

TABLET; ORAL
STROMECTOL

>D>	+	MERCK	3MG	N050742	002	Oct 08, 1998	Nov	CAHN
>D>		@	6MG	N050742	001	Nov 22, 1996	Nov	CAHN
>A>	+	MERCK SHARP DOHME	3MG	N050742	002	Oct 08, 1998	Nov	CAHN
>A>		@	6MG	N050742	001	Nov 22, 1996	Nov	CAHN

KANAMYCIN SULFATE

INJECTABLE; INJECTION
KANAMYCIN

@	HIKMA MAPLE	EQ 75MG BASE/2ML	A062324	001		Sep	CAHN
@		EQ 500MG BASE/2ML	A062324	002		Sep	CAHN
@		EQ 1GM BASE/3ML	A062324	003		Sep	CAHN

KETOCONAZOLE

CREAM; TOPICAL
KETOCONAZOLE

AB	FOUGERA PHARMS	2%	A076294	001	Apr 28, 2004	Jan	CAHN
----	----------------	----	---------	-----	--------------	-----	------

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

	DORADO PHARMA	25MG	A074014 001	Jan 29, 1993	Jul	CAHN
AB		50MG	A074014 002	Jan 29, 1993	Jul	CAHN
AB		75MG	A074014 003	Jan 29, 1993	Jul	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

	@ ALKERMES GAINESVILLE	200MG	A074879 001	Dec 10, 1997	Oct	DISC
AB		200MG	A074879 001	Dec 10, 1997	Jun	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	HIKMA MAPLE	15MG/ML	A075772 001	Jul 21, 2004	Sep	CAHN
AP		15MG/ML	A075299 001	Nov 03, 1999	Sep	CAHN
AP		30MG/ML	A075772 002	Jul 21, 2004	Sep	CAHN
AP		30MG/ML	A075299 002	Nov 03, 1999	Sep	CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP	GLAND PHARMA LTD	5MG/ML	A090699 001	Apr 03, 2012	Mar	NEWA
----	------------------	--------	-------------	--------------	-----	------

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	PAR FORM	100MG	A200908 001	Jul 10, 2012	Jun	NEWA
AB		200MG	A200908 002	Jul 10, 2012	Jun	NEWA
AB		300MG	A200908 003	Jul 10, 2012	Jun	NEWA

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

+	CUMBERLAND PHARMS	10GM/PACKET	A074712 001	Dec 10, 1997	Jun	CAHN
+		20GM/PACKET	A074712 002	Dec 10, 1997	Jun	CAHN

SOLUTION; ORAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090503 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

SOLUTION; ORAL, RECTAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090502 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG;300MG	A202418 001	May 15, 2012	Apr	NEWA
AB	LUPIN LTD	150MG;300MG	A090246 001	May 15, 2012	Apr	NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	GLENMARK GENERICS	25MG	A090169 001	May 12, 2012	Apr	NEWA
AB		100MG	A090169 002	May 12, 2012	Apr	NEWA
AB		150MG	A090169 003	May 12, 2012	Apr	NEWA
AB		200MG	A090169 004	May 12, 2012	Apr	NEWA
BX	UPSHER SMITH	25MG	A078310 001	Feb 04, 2009	Aug	CTEC

TABLET; ORAL

LAMOTRIGINE

BX	UPSHER SMITH	100MG	A078310 002	Feb 04, 2009	Aug	CTEC
BX		150MG	A078310 003	Feb 04, 2009	Aug	CTEC
BX		200MG	A078310 004	Feb 04, 2009	Aug	CTEC

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SOMATULINE DEPOT

+	IPSEN INC	EQ 60MG BASE	N022074 001	Aug 30, 2007	Apr	CAHN
+		EQ 90MG BASE	N022074 002	Aug 30, 2007	Apr	CAHN
+		EQ 120MG BASE	N022074 003	Aug 30, 2007	Apr	CAHN
+	IPSEN PHARMA	EQ 60MG BASE	N022074 001	Aug 30, 2007	May	CAHN
+		EQ 90MG BASE	N022074 002	Aug 30, 2007	May	CAHN
+		EQ 120MG BASE	N022074 003	Aug 30, 2007	May	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

AB	MYLAN PHARMS INC	15MG	A090763 001	Nov 10, 2009	Sep	CAHN
AB		30MG	A090763 002	Nov 10, 2009	Sep	CAHN
AB	WOCKHARDT USA	15MG	A202176 001	Sep 14, 2012	Aug	NEWA
AB		30MG	A202176 002	Sep 14, 2012	Aug	NEWA

PREVACID

AB	TAKEDA PHARMS USA	15MG	N020406 001	May 10, 1995	Mar	CAHN
AB	+	30MG	N020406 002	May 10, 1995	Mar	CAHN

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

@	TEVA PHARMS	15MG	A078730 001	Oct 15, 2010	Mar	DISC
@		30MG	A078730 002	Oct 15, 2010	Mar	DISC

PREVACID

	TAKEDA PHARMS USA	15MG	N021428 001	Aug 30, 2002	Mar	CTEC
+		30MG	N021428 002	Aug 30, 2002	Mar	CTEC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

@	SHIRE LLC	EQ 250MG BASE	N021468 001	Oct 26, 2004	Feb	CAHN
		EQ 500MG BASE	N021468 002	Oct 26, 2004	Feb	CAHN
		EQ 750MG BASE	N021468 003	Nov 23, 2005	Feb	CAHN
+		EQ 1GM BASE	N021468 004	Nov 23, 2005	Feb	CAHN

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT	AKORN	0.005%	A090887 001	Jul 19, 2011	Sep	CAHN
----	-------	--------	-------------	--------------	-----	------

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

	CELGENE	15MG	N021880 003	Jun 29, 2006	Sep	CRLD
--	---------	------	-------------	--------------	-----	------

LETROZOLE

TABLET; ORAL

LETROZOLE

AB	APOTEX INC	2.5MG	A091303 001	Apr 19, 2012	Apr	NEWA
----	------------	-------	-------------	--------------	-----	------

TABLET; ORAL

LETROZOLE

AB	VINTAGE PHARMS LLC	2.5MG	A090789	001	Jun 03, 2011	Sep	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

@ TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278	001	Sep 28, 1993	Mar	DISC
-------------------	-------------------	---------	-----	--------------	-----	------

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	SAGENT PHARMS	EQ 50MG BASE/VIAL	A200753	001	Sep 06, 2012	Aug	NEWA
AP		EQ 100MG BASE/VIAL	A200753	002	Sep 06, 2012	Aug	NEWA
AP		EQ 200MG BASE/VIAL	A200753	003	Sep 06, 2012	Aug	NEWA
AP		EQ 350MG BASE/VIAL	A200855	001	Sep 06, 2012	Aug	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

+	ABBOTT ENDOCRINE	3.75MG/VIAL	N020011	001	Oct 22, 1990	May	CAHN
+		7.5MG/VIAL	N019732	001	Jan 26, 1989	May	CAHN
+		11.25MG/VIAL	N020708	001	Mar 07, 1997	May	CAHN

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	APP PHARMS LLC	500MG/5ML (100MG/ML)	A090813	001	May 26, 2010	May	CAHN
AP	HOSPIRA INC	500MG/ML (100MG/ML)	A202869	001	Apr 06, 2012	Mar	NEWA
AP	LUITPOLD	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012	Aug	CAHN
AP	PHARMAFORCE	500MG/5ML (100MG/ML)	A202143	001	Jan 31, 2012	Jan	NEWA
AP	X GEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Jul	CAHN

SOLUTION; ORAL

LEVETIRACETAM

AA	HI-TECH PHARMACAL	100MG/ML	A090601	001	Feb 28, 2012	Feb	NEWA
AA	VINTAGE PHARMS	100MG/ML	A090079	001	Apr 11, 2012	Mar	NEWA

TABLET; ORAL

LEVETIRACETAM

AB	LOTUS PHARM CO LTD	500MG	A090906	001	Nov 05, 2010	Jul	CAHN
AB	WATSON LABS INC	250MG	A078797	002	Jan 15, 2009	Apr	NEWA
AB		500MG	A078797	003	Jan 15, 2009	Apr	NEWA
AB		750MG	A078797	004	Jan 15, 2009	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	BOCA PHARMA	500MG	A201464	001	May 25, 2012	May	NEWA
AB		750MG	A201464	002	May 25, 2012	May	NEWA
AB	ROUSES POINT PHARMS	500MG	A202524	001	Aug 27, 2012	Aug	NEWA
AB		750MG	A202524	002	Aug 27, 2012	Aug	NEWA
AB	SANDOZ	500MG	A091668	001	Nov 01, 2012	Oct	NEWA
AB		750MG	A091668	002	Nov 01, 2012	Oct	NEWA
AB	TORRENT PHARMS LTD	500MG	A091338	001	May 29, 2012	May	NEWA
AB		750MG	A091338	002	May 29, 2012	May	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	HETERO LABS LTD III	5MG	A091264	001	Jun 29, 2012	Jun	NEWA
----	---------------------	-----	---------	-----	--------------	-----	------

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

AB	CIPLA LTD	250MG	A076890 001	Mar 30, 2012	Mar	NEWA
AB		500MG	A076890 002	Mar 30, 2012	Mar	NEWA
AB		750MG	A076890 003	Mar 30, 2012	Mar	NEWA
AB	MACLEODS PHARMS LTD	250MG	A200839 001	Mar 22, 2012	Mar	NEWA
AB		500MG	A200839 002	Mar 22, 2012	Mar	NEWA
AB		750MG	A200839 003	Mar 22, 2012	Mar	NEWA
AB	ORCHID HLTHCARE	250MG	A202200 001	Jan 30, 2012	Jan	NEWA
AB		500MG	A202200 002	Jan 30, 2012	Jan	NEWA
AB		750MG	A202200 003	Jan 30, 2012	Jan	NEWA
AB	ZYDUS PHARMS USA INC	250MG	A077652 001	Sep 07, 2012	Aug	NEWA
AB		500MG	A077652 002	Sep 07, 2012	Aug	NEWA
AB		750MG	A077652 003	Sep 07, 2012	Aug	NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

FUSILEV

@ SPECTRUM PHARMS	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140 003	Apr 29, 2011	Jun	DISC
-------------------	--------------------------------------	-------------	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

AB	WATSON LABS INC	1.5MG	A200670 001	Jul 12, 2012	Jun	NEWA	
	PLAN B						
	@ TEVA BRANDED PHARM	0.75MG	N021045 001	Jul 28, 1999	May	CAHN	
AB	+	0.75MG	N021045 002	Aug 24, 2006	May	CAHN	
	PLAN B ONE-STEP						
AB	+	DURAMED	1.5MG	N021998 001	Jul 10, 2009	Jun	CFTG

LIDOCAINE

PATCH; TOPICAL

LIDOCAINE

AB		WATSON LABS INC	5%		A200675 001	Aug 23, 2012	Aug	NEWA
		LIDODERM						
AB	+	TEIKOKU PHARMA USA	5%		N020612 001	Mar 19, 1999	Aug	CFTG

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

	@ HIKMA MAPLE	1%	A080407 001		Sep	CAHN
	@	2%	A080407 002		Sep	CAHN
AP	PFIZER	0.5%	A091056 001	Dec 08, 2010	Sep	CAHN
AP		0.5%	A091058 001	Sep 30, 2010	Sep	CAHN
AP		1%	A091056 002	Dec 08, 2010	Sep	CAHN
AP		1%	A091058 002	Sep 30, 2010	Sep	CAHN
	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					
	@ HIKMA MAPLE	1%	A084625 001		Sep	CAHN
	@	2%	A084625 002		Sep	CAHN
AP	PFIZER	2%	A090665 001	Sep 27, 2010	Sep	CAHN
	XYLOCAINE DENTAL					
	@ DENTSPLY PHARM	2%	N021380 001		May	DISC

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB	FOUGERA PHARMS	2.5%;2.5%	A076453 001	Aug 18, 2003	Jan	CAHN
----	----------------	-----------	-------------	--------------	-----	------

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+	GALDERMA LABS LP	7%;7%	N021717 001	Jun 29, 2006	Jun	CTNA
---	------------------	-------	-------------	--------------	-----	------

LINACLOTIDE

CAPSULE; ORAL

LINZESS

	FOREST LABS INC	145MCG	N202811 001	Aug 30, 2012	Aug	NEWA
+		290MCG	N202811 002	Aug 30, 2012	Aug	NEWA

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

	BOEHRINGER INGELHEIM	2.5MG;500MG	N201281 001	Jan 30, 2012	Jan	NEWA
		2.5MG;850MG	N201281 002	Jan 30, 2012	Jan	NEWA
+		2.5MG;1GM	N201281 003	Jan 30, 2012	Jan	NEWA

LINEZOLID

INJECTABLE; INJECTION

LINEZOLID

AP	TEVA PHARMS	200MG/100ML	A200222 001	Jun 22, 2012	Jun	NEWA
AP	+	ZYVOX				
	PHARMACIA AND UPJOHN	200MG/100ML	N021131 001	Apr 18, 2000	Jun	CFTG

LIOETHYRONINE SODIUM

TABLET; ORAL

LIOETHYRONINE SODIUM

>A>	AB	SIGMAPHARM LABS LLC	EQ 0.005MG BASE	A200295 001	Nov 29, 2012	Nov	NEWA
>A>	AB		EQ 0.025MG BASE	A200295 002	Nov 29, 2012	Nov	NEWA
>A>	AB		EQ 0.05MG BASE	A200295 003	Nov 29, 2012	Nov	NEWA

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	MYLAN PHARMS INC	300MG	A202288 001	Jun 29, 2012	Jun	NEWA
AB		450MG	A202219 001	Aug 08, 2012	Jul	NEWA

LOMUSTINE

CAPSULE; ORAL

CEENU

	BRISTOL MYERS SQUIBB	10MG	N017588 001		Jun	CMFD
	@	10MG	N017588 001		May	DISC
		40MG	N017588 002		Jun	CMFD
	@	40MG	N017588 002		May	DISC
+		100MG	N017588 003		Jun	CMFD
	@	100MG	N017588 003		May	DISC

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA	HI-TECH PHARMA CO	2MG/ML	A200169	001	Jan 30, 2012	Jan	NEWA
----	-------------------	--------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

LORAZEPAM

@	BEDFORD	2MG/ML	A077076	001	Jul 13, 2005	Jun	DISC
@		4MG/ML	A077076	002	Jul 13, 2005	Jun	DISC
@	HIKMA MAPLE	2MG/ML	A074496	001	Sep 28, 1998	Sep	CAHN
@		4MG/ML	A074496	002	Sep 28, 1998	Sep	CAHN
@	HOSPIRA	2MG/ML	A074300	001	Apr 12, 1994	Jun	DISC

TABLET; ORAL

LORAZEPAM

>D>	AB	ACTAVIS ELIZABETH	0.5MG	A071403	001	Apr 21, 1987	Nov	CAHN
>D>	AB		1MG	A071404	001	Apr 21, 1987	Nov	CAHN
>D>	AB		2MG	A071141	001	Apr 21, 1987	Nov	CAHN
>A>	AB	SANDOZ	0.5MG	A071403	001	Apr 21, 1987	Nov	CAHN
>A>	AB		1MG	A071404	001	Apr 21, 1987	Nov	CAHN
>A>	AB		2MG	A071141	001	Apr 21, 1987	Nov	CAHN

LORCASERIN HYDROCHLORIDE

TABLET; ORAL

BELVIQ

+	ARENA PHARMS INC	10MG	N022529	001	Jun 27, 2012	Jun	NEWA
+	EISAI INC	10MG	N022529	001	Jun 27, 2012	Jul	CAHN

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	CADISTA PHARMS	25MG	A201170	001	Sep 18, 2012	Sep	NEWA
AB		50MG	A201170	002	Sep 18, 2012	Sep	NEWA
AB		100MG	A201170	003	Sep 18, 2012	Sep	NEWA
AB	MACLEODS PHARMS LTD	25MG	A202230	001	May 30, 2012	May	NEWA
AB		50MG	A202230	002	May 30, 2012	May	NEWA
AB		100MG	A202230	003	May 30, 2012	May	NEWA
AB	MICRO LABS LTD INDIA	25MG	A091541	001	Sep 24, 2012	Sep	NEWA
AB		50MG	A091541	002	Sep 24, 2012	Sep	NEWA
AB		100MG	A091541	003	Sep 24, 2012	Sep	NEWA

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC

LOTEMAX

+	BAUSCH AND LOMB	0.5%	N202872	001	Sep 28, 2012	Sep	NEWA
---	-----------------	------	---------	-----	--------------	-----	------

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

@	MIKAH PHARMA	EQ 5MG BASE	A076868	001	Aug 04, 2005	Jul	CAHN
@		EQ 10MG BASE	A076868	002	Aug 04, 2005	Jul	CAHN
@		EQ 25MG BASE	A076868	003	Aug 04, 2005	Jul	CAHN
@		EQ 50MG BASE	A076868	004	Aug 04, 2005	Jul	CAHN

LUCINACTANT

SUSPENSION; INTRATRACHEAL
SURFAXIN

+	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	Apr	NEWA
---	----------------	-------	---------	-----	--------------	-----	------

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

	SUNOVION PHARMS INC	20MG	N200603	003	Dec 07, 2011	Oct	CRLD
+		20MG	N200603	003	Dec 07, 2011	Aug	CRLD
		20MG	N200603	003	Dec 07, 2011	Apr	NEWA
+		40MG	N200603	001	Oct 28, 2010	Oct	CRLD
		40MG	N200603	001	Oct 28, 2010	Aug	CRLD
+		40MG	N200603	001	Oct 28, 2010	Apr	CRLD
		80MG	N200603	002	Oct 28, 2010	Apr	CRLD
		120MG	N200603	004	Apr 26, 2012	Apr	NEWA

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS

LUVERIS

@	EMD SERONO	75 IU/VIAL	N021322	001	Oct 08, 2004	Jun	DISC
---	------------	------------	---------	-----	--------------	-----	------

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLON

+	MYLAN LLC	EQ 85MG BASE/GM	N016763	001		Jun	CAHN
---	-----------	-----------------	---------	-----	--	-----	------

FOR SOLUTION; TOPICAL

SULFAMYLON

+	MYLAN LLC	5%	N019832	003	Jun 05, 1998	Jun	CAHN
---	-----------	----	---------	-----	--------------	-----	------

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

@	SANTARUS	343MG;20MG;750MG	N022456	001	Dec 04, 2009	Jun	DISC
---	----------	------------------	---------	-----	--------------	-----	------

@	SANTARUS	343MG;40MG;750MG	N022456	002	Dec 04, 2009	Jun	DISC
---	----------	------------------	---------	-----	--------------	-----	------

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

HOSPIRA	20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Jan	NEWA
---------	----------------------	---------	-----	--------------	-----	------

HOSPIRA	40GM/1000ML(40MG/ML)	N020309	005	Jan 18, 1995	Jan	NEWA
---------	----------------------	---------	-----	--------------	-----	------

MALATHION

LOTION; TOPICAL

MALATHION

AT	MYLAN PHARMS INC	0.5%	A078743	001	Mar 06, 2009	Feb	CAHN
----	------------------	------	---------	-----	--------------	-----	------

AT	SUVEN LIFE	0.5%	A091559	001	May 23, 2012	May	NEWA
----	------------	------	---------	-----	--------------	-----	------

MANNITOL

POWDER; INHALATION

ARIDOL KIT

+	PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010	May	CAHN
---	---------------	----------------------------	---------	-----	--------------	-----	------

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS

INCRELEX

+	IPSEN INC	40MG/4ML (10MG/ML)	N021839	001	Aug 30, 2005	May	CAHN
---	-----------	--------------------	---------	-----	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	12.5MG	A200294	001	Apr 13, 2012	Mar	NEWA
AA		25MG	A200294	002	Apr 13, 2012	Mar	NEWA
AA	MYLAN PHARMS INC	12.5MG	A202640	001	Sep 17, 2012	Sep	NEWA
AA		25MG	A202640	002	Sep 17, 2012	Sep	NEWA
AA		50MG	A202640	003	Sep 17, 2012	Sep	NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

@	TEVA PARENTERAL	150MG/ML	A076552	001	Oct 27, 2004	Apr	DISC
---	-----------------	----------	---------	-----	--------------	-----	------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090270	001	Jun 09, 2009	Sep	CAHN
----	---------------------	-------------------	---------	-----	--------------	-----	------

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

	@ ORCHID HLTHCARE	5MG	A090044	001	Mar 12, 2012	Mar	DISC
AB		5MG	A090044	001	Mar 12, 2012	Feb	NEWA
	@	10MG	A090044	002	Mar 12, 2012	Mar	DISC
AB		10MG	A090044	002	Mar 12, 2012	Feb	NEWA
	NAMENDA						
	FOREST LABS	5MG	N021487	001	Oct 16, 2003	Mar	CTEC
AB		5MG	N021487	001	Oct 16, 2003	Feb	CTEC
	+	10MG	N021487	002	Oct 16, 2003	Mar	CTEC
AB	+	10MG	N021487	002	Oct 16, 2003	Feb	CTEC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

AP	HIKMA MAPLE	25MG/ML	A080445	001		Sep	CAHN
AP		25MG/ML	A080455	007		Sep	CAHN
AP		50MG/ML	A080445	002		Sep	CAHN
AP		50MG/ML	A080455	008		Sep	CAHN
AP		75MG/ML	A080445	003		Sep	CAHN
AP		75MG/ML	A080455	009		Sep	CAHN
AP		100MG/ML	A080445	004		Sep	CAHN
AP		100MG/ML	A080455	010		Sep	CAHN
	MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE						
AP	HIKMA MAPLE	10MG/ML	A081002	001	Jul 30, 1993	Sep	CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

@	DENTSPLY PHARM	3%	A088653	001	Aug 21, 1984	May	DISC
---	----------------	----	---------	-----	--------------	-----	------

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

@ AQUA PHARMS	2%;0.01%	N020922 001	Dec 10, 1999	Jun	DISC
---------------	----------	-------------	--------------	-----	------

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

@ APTALIS PHARMA US	500MG	N021252 001	Jan 05, 2001	Jul	CAHN
	1GM	N021252 002	Nov 05, 2004	Jul	CAHN

ROWASA

@ MEDA PHARMS	500MG	N019919 001	Dec 18, 1990	Jan	CAHN
---------------	-------	-------------	--------------	-----	------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	MYLAN INSTITUTIONAL	100MG/ML	A076488 001	Mar 08, 2012	Feb	NEWA
AP	SAGENT AGILA	100MG/ML	A090913 001	Apr 13, 2010	Oct	CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	MARKSANS PHARMA	500MG	A090888 001	Mar 12, 2012	Feb	NEWA
AB		850MG	A090888 002	Mar 12, 2012	Feb	NEWA
AB		1GM	A090888 003	Mar 12, 2012	Feb	NEWA
AB	MYLAN PHARMS INC	500MG	A075969 001	Jan 29, 2002	Sep	CAHN
AB		850MG	A075969 002	Jan 29, 2002	Sep	CAHN
AB		1GM	A075969 003	Jan 29, 2002	Sep	CAHN

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1	AUROBINDO PHARMA LTD	500MG	A079118 001	Jul 20, 2012	Jul	NEWA
AB		750MG	A079118 002	Jul 20, 2012	Jul	NEWA
AB1	INVENTIA HLTHCARE	500MG	A201991 001	Jan 18, 2012	Jan	NEWA
AB2	MYLAN PHARMS INC	500MG	A200690 001	Aug 01, 2012	Jul	NEWA
AB		1GM	A200690 002	Aug 01, 2012	Jul	NEWA
AB1	NOSTRUM PHARMS LLC	500MG	A076756 001	Jul 26, 2006	Oct	CAHN
>A> AB		750MG	A076756 002	Dec 12, 2011	Nov	NEWA
	@ RANBAXY LABS LTD	500MG	A076413 001	Jun 18, 2004	Apr	DISC
	@	750MG	A077211 001	Jun 29, 2005	Apr	DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

AB	TAKEDA PHARMS USA	500MG;EQ 15MG BASE	N021842 001	Aug 29, 2005	Aug	CAHN
AB	+	850MG;EQ 15MG BASE	N021842 002	Aug 29, 2005	Aug	CAHN

TABLET, EXTENDED RELEASE; ORAL

ACTOPLUS MET XR

	TAKEDA PHARMS USA	1GM;EQ 15MG BASE	N022024 001	May 12, 2009	Aug	CAHN
+		1GM;EQ 30MG BASE	N022024 002	May 12, 2009	Aug	CAHN

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	BRISTOL MYERS SQUIBB	500MG;EQ 5MG BASE	N200678 001	Nov 05, 2010	Apr	CAIN
		1GM;EQ 2.5MG BASE	N200678 003	Nov 05, 2010	Apr	CAIN

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

+	BRISTOL MYERS SQUIBB	1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Apr	CAIN
---	----------------------	-----------------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007	May	CAHN
+		1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	Feb	NEWA
		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	Feb	NEWA
+		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	Feb	NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	BOCA PHARMA	5MG	A202068	001	Mar 07, 2012	Feb	NEWA
AB		10MG	A202068	002	Mar 07, 2012	Feb	NEWA

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	SOLCO HLTHCARE	500MG	A086989	001		Mar	CMFD
AA		750MG	A086988	001		Mar	CMFD

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266	001	Feb 26, 1999	Jan	CMFD
AP	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171	001	Feb 27, 2012	Feb	NEWA

METHOTREXATE SODIUM

AP	+	BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Feb	CTEC
----	---	---------	-------------------------------------	---------	-----	--------------	-----	------

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+	MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767	001	Apr 30, 2007	Feb	CAHN
AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040768	001	Apr 30, 2007	Sep	CAHN
AP	+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A040716	001	Apr 30, 2007	Sep	CAHN
AP		ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Mar	NEWA
AP			EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Mar	NEWA
AP			EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Mar	NEWA
AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012	Mar	NEWA
AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012	Mar	NEWA

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

AA	BAYSHORE PHARMS LLC	2.5MG	A200602	001	Sep 24, 2012	Sep	NEWA
AA		5MG	A200602	002	Sep 24, 2012	Sep	NEWA

METHYCLOTHIAZIDE

TABLET; ORAL

ENDURON

@ ABBOTT LABS PHARM

2.5MG

N012524 001

Mar DISC

@

5MG

N012524 004

Mar DISC

METHYCLOTHIAZIDE

AB + MYLAN PHARMS INC

5MG

A087672 001 Aug 17, 1982 Mar CRLD

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

@ TEVA PARENTERAL

50MG/ML

A072974 001 Nov 22, 1991 Mar DISC

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

AP + US PHARMS HOLDINGS I

0.2MG/ML

N006035 004

Sep CAHN

TABLET; ORAL

METHERGINE

AB + US PHARMS HOLDINGS I

0.2MG

N006035 003

Sep CAHN

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

SALIX PHARMS

8MG/0.4ML

N021964 002 Sep 27, 2010 May CAHN

+

12MG/0.6ML (12MG/0.6ML)

N021964 003 Apr 24, 2008 Jun NEWA

SOLUTION; SUBCUTANEOUS

RELISTOR

+ SALIX PHARMS

12MG/0.6ML (12MG/0.6ML)

N021964 001 Apr 24, 2008 May CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

AB UCB INC

10MG

N021259 003 May 27, 2003 Jul CFTG

AB2

20MG

N021259 001 Apr 03, 2001 Jul CFTG

AB2

30MG

N021259 002 Jun 19, 2003 Jul CFTG

AB2

40MG

N021259 004 Feb 19, 2006 Jul CFTG

AB

50MG

N021259 005 Feb 19, 2006 Jul CFTG

AB +

60MG

N021259 006 Feb 19, 2006 Jul CFTG

METHYLPHENIDATE HYDROCHLORIDE

AB1 ACTAVIS

20MG

A078458 001 Dec 01, 2011 Jul CTEC

AB1

30MG

A078458 002 Dec 01, 2011 Jul CTEC

AB1

40MG

A078458 003 Dec 01, 2011 Jul CTEC

AB1 BARR LABS INC

20MG

A079031 001 Jul 13, 2012 Jul CTEC

AB

20MG

A079031 001 Jul 13, 2012 Jun NEWA

AB1

30MG

A079031 002 Jul 13, 2012 Jul CTEC

AB

30MG

A079031 002 Jul 13, 2012 Jun NEWA

AB1

40MG

A079031 003 Jul 13, 2012 Jul CTEC

AB

40MG

A079031 003 Jul 13, 2012 Jun NEWA

AB TEVA PHARMS

10MG

A077707 001 Jul 19, 2012 Jul NEWA

AB2

20MG

A077707 002 Jul 19, 2012 Jul NEWA

AB2

30MG

A077707 003 Jul 19, 2012 Jul NEWA

AB2

40MG

A078873 001 Jul 19, 2012 Jul NEWA

AB

50MG

A078873 002 Jul 19, 2012 Jul NEWA

AB

60MG

A078873 003 Jul 19, 2012 Jul NEWA

CAPSULE, EXTENDED RELEASE; ORAL

RITALIN LA

AB1	NOVARTIS	20MG	N021284 001	Jun 05, 2002	Jul	CTEC
AB1		30MG	N021284 002	Jun 05, 2002	Jul	CTEC
AB1 +		40MG	N021284 003	Jun 05, 2002	Jul	CTEC

FOR SUSPENSION, EXTENDED RELEASE; ORAL

QUILLIVANT XR

+	NEXTWAVE PHARMS	5MG/ML	N202100 001	Sep 27, 2012	Sep	NEWA
---	-----------------	--------	-------------	--------------	-----	------

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS INC	5MG	A090710 001	Mar 15, 2012	Feb	NEWA
AB		10MG	A090710 002	Mar 15, 2012	Feb	NEWA
AB		20MG	A090710 003	Mar 15, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

@	UCB INC	10MG	A040306 001	Oct 20, 1999	Jul	DISC
---	---------	------	-------------	--------------	-----	------

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	HOSPIRA INC	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008	Aug	CAHN
AP		EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008	Aug	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

@	BEDFORD LABS	EQ 40MG BASE/VIAL	A040662 001	Feb 21, 2007	Jun	DISC
@		EQ 125MG BASE/VIAL	A040641 002	Feb 21, 2007	Jun	DISC
@		EQ 500MG BASE/VIAL	A040641 003	Feb 21, 2007	Jun	DISC
@		EQ 500MG BASE/VIAL	A040709 001	Feb 21, 2007	Jun	DISC
@		EQ 1GM BASE/VIAL	A040641 004	Feb 21, 2007	Jun	DISC
@		EQ 1GM BASE/VIAL	A040709 002	Feb 21, 2007	Jun	DISC
@	TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992	Mar	DISC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

>D>	@	TEVA PARENTERAL	EQ 5MG BASE/ML	A073135 001	Nov 27, 1991	Nov	CMFD
>A>	AP		EQ 5MG BASE/ML	A073135 001	Nov 27, 1991	Nov	CMFD
	@		EQ 5MG BASE/ML	A073135 001	Nov 27, 1991	Jan	DISC

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB	PAR PHARM INC	EQ 10MG BASE	A070581 001	Oct 17, 1985	Oct	CAHN
----	---------------	--------------	-------------	--------------	-----	------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	DR REDDYS LABS LTD	EQ 25MG TARTRATE	A090617 001	Aug 01, 2012	Jul	NEWA	
AB		EQ 50MG TARTRATE	A090617 002	Aug 01, 2012	Jul	NEWA	
	@	NESHER PHARMS	EQ 100MG TARTRATE	A076640 002	May 18, 2007	Jun	DISC
	@		EQ 200MG TARTRATE	A076640 001	May 18, 2007	Jun	DISC
AB	REDDYS	EQ 100MG BASE	A078889 001	Aug 15, 2012	Jul	NEWA	
AB		EQ 200MG BASE	A078889 002	Aug 15, 2012	Jul	NEWA	
	@	SANDOZ	EQ 25MG TARTRATE	A076969 001	Jul 31, 2006	Aug	DISC
	@		EQ 50MG TARTRATE	A076969 002	May 18, 2007	Aug	DISC
	@		EQ 100MG TARTRATE	A076969 003	Mar 20, 2008	Aug	DISC
	@		EQ 200MG TARTRATE	A076969 004	Mar 20, 2008	Aug	DISC

METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR

AB	US PHARMS HOLDINGS I	50MG	N017963 001	Sep	CAHN
AB		100MG	N017963 002	Sep	CAHN

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A076408 001	May 28, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

NORITATE

>A>	+	VALEANT BERMUDA	1%	N020743 001	Sep 26, 1997	Nov	CAHN
-----	---	-----------------	----	-------------	--------------	-----	------

>D>	+	VALEANT INTL	1%	N020743 001	Sep 26, 1997	Nov	CAHN
-----	---	--------------	----	-------------	--------------	-----	------

	+		1%	N020743 001	Sep 26, 1997	Apr	CAHN
--	---	--	----	-------------	--------------	-----	------

GEL; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A077018 001	Jun 06, 2006	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

INJECTABLE; INJECTION

METRONIDAZOLE

	@ HIKMA MAPLE	500MG/100ML	N018907 001	Mar 30, 1984	Sep	CAHN
--	---------------	-------------	-------------	--------------	-----	------

LOTION; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A077197 001	May 24, 2006	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

METYRAPONE

CAPSULE; ORAL

METOPIRONE

	+	HRA PHARMA	250MG	N012911 002	Aug 09, 1996	Jun	CAHN
--	---	------------	-------	-------------	--------------	-----	------

TABLET; ORAL

METOPIRONE

	@ HRA PHARMA	250MG	N012911 001		Jun	CAHN
--	--------------	-------	-------------	--	-----	------

METYROSINE

CAPSULE; ORAL

DEMSE

	+	BIOVAIL TECHNOLOGIES	250MG	N017871 001		May	CAHN
--	---	----------------------	-------	-------------	--	-----	------

MICONAZOLE

TABLET; BUCCAL

ORAVIG

	+	VESTIQ PHARMS	50MG	N022404 001	Apr 16, 2010	Sep	CAHN
--	---	---------------	------	-------------	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696 001	Feb 29, 2012	Feb	NEWA
AP		EQ 5MG BASE/ML	A090850 001	Jan 25, 2012	Jan	NEWA
AP	HIKMA MAPLE	EQ 1MG BASE/ML	A075243 001	Jun 20, 2000	Sep	CAHN
AP		EQ 1MG BASE/ML	A075324 001	Jun 20, 2000	Sep	CAHN
AP		EQ 5MG BASE/ML	A075243 002	Jun 20, 2000	Sep	CAHN
AP		EQ 5MG BASE/ML	A075324 002	Jun 20, 2000	Sep	CAHN

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

>A>	PROAMATINE								
>A>	@ SHIRE LLC	2.5MG	N019815	001	Sep 06, 1996	Nov	NEWA		
>A>	@	2.5MG	N019815	001	Sep 06, 1996	Nov	NEWA		
>A>	@	2.5MG	N019815	001	Sep 06, 1996	Nov	NEWA		
>A>	@	2.5MG	N019815	001	Sep 06, 1996	Nov	NEWA		
>A>	@	2.5MG	N019815	001	Sep 06, 1996	Nov	NEWA		
>A>	@	2.5MG	N019815	001	Sep 06, 1996	Nov	NEWA		
>A>	@	2.5MG	N019815	001	Sep 06, 1996	Nov	NEWA		
>A>	@	2.5MG	N019815	001	Sep 06, 1996	Nov	NEWA		
>A>	@	2.5MG	N019815	001	Sep 06, 1996	Nov	NEWA		
	AB	2.5MG	N019815	001	Sep 06, 1996	Jan	CAHN		
>D>	AB +	5MG	N019815	002	Sep 06, 1996	Nov	DISC		
>A>	@	5MG	N019815	002	Sep 06, 1996	Nov	DISC		
	AB +	5MG	N019815	002	Sep 06, 1996	Jan	CAHN		
>A>	@	10MG	N019815	003	Mar 20, 2002	Nov	NEWA		
>A>	@	10MG	N019815	003	Mar 20, 2002	Nov	NEWA		
>A>	@	10MG	N019815	003	Mar 20, 2002	Nov	NEWA		
>A>	@	10MG	N019815	003	Mar 20, 2002	Nov	NEWA		
>A>	@	10MG	N019815	003	Mar 20, 2002	Nov	NEWA		
>A>	@	10MG	N019815	003	Mar 20, 2002	Nov	NEWA		
>A>	@	10MG	N019815	003	Mar 20, 2002	Nov	NEWA		
>A>	@	10MG	N019815	003	Mar 20, 2002	Nov	NEWA		
	AB	10MG	N019815	003	Mar 20, 2002	Jan	CAHN		

MIFEPRISTONE

TABLET; ORAL

KORLYM

+	CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012	Feb	NEWA		
---	----------------	-------	---------	-----	--------------	-----	------	--	--

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP	HIKMA MAPLE	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Sep	CAHN		
	@	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Sep	CAHN		
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER								
	@ HIKMA MAPLE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002	Sep	CAHN		

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB	PRECISION DERMAT	EQ 50MG BASE	N050649	001	May 31, 1990	May	CAHN		
	@	EQ 75MG BASE	N050649	003	Feb 12, 2001	May	CAHN		
AB		EQ 100MG BASE	N050649	002	May 31, 1990	May	CAHN		

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

	RANBAXY LABS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Jul	NEWA		
		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Jul	NEWA		
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Jul	NEWA		
		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Jul	NEWA		
+		EQ 135MG BASE	N201922	005	Jul 11, 2012	Jul	NEWA		

INJECTABLE; INJECTION

MINOCIN

>D>	+	PRECISION DERMAT	EQ 100MG BASE/VIAL	N050444 001		Nov	CAHN
	+		EQ 100MG BASE/VIAL	N050444 001		May	CAHN
>A>	+	REMPEX PHARMS INC	EQ 100MG BASE/VIAL	N050444 001		Nov	CAHN

SUSPENSION; ORAL

MINOCIN

	@	PRECISION DERMAT	EQ 50MG BASE/5ML	N050445 001		May	CAHN
--	---	------------------	------------------	-------------	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

>A>	AB	AUROBINDO PHARMA LTD	EQ 45MG BASE	A202261 001	Nov 19, 2012	Nov	NEWA
>A>	AB		EQ 90MG BASE	A202261 003	Nov 19, 2012	Nov	NEWA
>A>	AB		EQ 135MG BASE	A202261 005	Nov 19, 2012	Nov	NEWA
	AB	BARR LABS INC	EQ 65MG BASE	A065485 004	May 18, 2012	Sep	NEWA
	AB		EQ 115MG BASE	A065485 005	May 18, 2012	Sep	NEWA
	AB	MYLAN PHARMS INC	EQ 45MG BASE	A090911 001	Jul 20, 2010	Sep	CAHN
	AB		EQ 90MG BASE	A090911 002	Jul 20, 2010	Sep	CAHN
	AB		EQ 135MG BASE	A090911 003	Jul 20, 2010	Sep	CAHN
		SOLODYN					
	AB	MEDICIS	EQ 65MG BASE	N050808 004	Jul 23, 2009	Sep	CFTG
	AB		EQ 115MG BASE	N050808 005	Jul 23, 2009	Sep	CFTG

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MYRBETRIQ

	APGDI	25MG	N202611 001	Jun 28, 2012	Jun	NEWA
+		50MG	N202611 002	Jun 28, 2012	Jun	NEWA

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

	AB	MYLAN PHARMS INC	15MG	A076176 001	Jun 19, 2003	Sep	CAHN
	AB		30MG	A076176 002	Jun 19, 2003	Sep	CAHN
	AB		45MG	A076176 003	Jun 19, 2003	Sep	CAHN

MISOPROSTOL

TABLET; ORAL

MISOPROSTOL

	AB	NOVEL LABS INC	0.1MG	A091667 001	Jul 25, 2012	Jul	NEWA
	AB		0.2MG	A091667 002	Jul 25, 2012	Jul	NEWA

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

+	MOBIUS THERAP	0.2MG/VIAL	N022572 001	Feb 07, 2012	Feb	NEWA
---	---------------	------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

MITOMYCIN

	AP	HIKMA MAPLE	5MG/VIAL	A064180 001	Dec 23, 1999	Sep	CAHN
	AP		20MG/VIAL	A064180 002	Dec 23, 1999	Sep	CAHN

MITOXANTRONE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

>A>	AP	ONCO THERAPIES LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014 001	Dec 11, 2012	Nov	NEWA
-----	----	--------------------	------------------------------------	-------------	--------------	-----	------

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

@	FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606 001	May 14, 2008	Jun	DISC
@		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606 002	May 14, 2008	Jun	DISC
@		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606 003	May 14, 2008	Jun	DISC

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

@	STRIDES ARCOLAB LTD	EQ 2MG BASE/ML	A078562 001	Apr 30, 2009	Jun	CAHN
---	---------------------	----------------	-------------	--------------	-----	------

MODAFINIL

TABLET; ORAL

MODAFINIL

AB	ALEMBIC LTD	100MG	A202700 001	Oct 18, 2012	Oct	NEWA
AB		200MG	A202700 002	Oct 18, 2012	Oct	NEWA
AB	AUROBINDO PHARMA LTD	100MG	A202566 001	Sep 27, 2012	Sep	NEWA
AB		200MG	A202566 002	Sep 27, 2012	Sep	NEWA
AB	CARLSBAD	100MG	A076715 001	Nov 01, 2012	Oct	NEWA
AB		200MG	A076715 002	Nov 01, 2012	Oct	NEWA
AB	HIKMA PHARMS	100MG	A090543 001	Sep 26, 2012	Sep	NEWA
AB		200MG	A090543 002	Sep 26, 2012	Sep	NEWA
AB	MYLAN PHARMS INC	100MG	A076594 001	Jul 16, 2012	Jun	NEWA
AB		200MG	A076594 002	Jul 16, 2012	Jun	NEWA
AB	ORCHID HLTHCARE	100MG	A078963 001	Sep 26, 2012	Sep	NEWA
AB		200MG	A078963 002	Sep 26, 2012	Sep	NEWA
	PROVIGIL					
AB	CEPHALON	100MG	N020717 001	Dec 24, 1998	Jun	CFTG
AB	+	200MG	N020717 002	Dec 24, 1998	Jun	CFTG

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

AB	+	MERCK SHARP DOHME	0.1%	N019625 001	May 06, 1987	Jun	CAHN
		MOMETASONE FUROATE					
AB		FOUGERA PHARMS	0.1%	A076171 001	Apr 08, 2005	Jan	CAHN
		LOTION; TOPICAL					
		ELOCON					
AB	+	MERCK SHARP DOHME	0.1%	N019796 001	Mar 30, 1989	Jul	CAHN
		MOMETASONE FUROATE					
AB		FOUGERA PHARMS	0.1%	A075919 001	Nov 29, 2007	Jan	CAHN
		OINTMENT; TOPICAL					
		ELOCON					
AB	+	MERCK SHARP DOHME	0.1%	N019543 001	Apr 30, 1987	May	CAHN
		MOMETASONE FUROATE					
AB		FOUGERA PHARMS	0.1%	A077061 001	Mar 28, 2005	Jan	CAHN

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

AB	DR REDDYS LABS LTD	EQ 4MG BASE/PACKET	A202906 001	Sep 17, 2012	Sep	NEWA
AB	TEVA PHARMS	EQ 4MG BASE/PACKET	A090955 001	Aug 03, 2012	Jul	NEWA

GRANULE; ORAL

SINGULAIR

AB	+	MERCK	EQ 4MG BASE/PACKET	N021409 001	Jul 26, 2002	Jul	CFTG
----	---	-------	--------------------	-------------	--------------	-----	------

TABLET; ORAL

MONTELUKAST SODIUM

AB		ACCORD HLTHCARE	EQ 10MG BASE	A202717 001	Sep 21, 2012	Sep	NEWA
AB		APOTEX CORP	EQ 10MG BASE	A201294 001	Aug 03, 2012	Jul	NEWA
AB		AUROBINDO PHARMA LTD	EQ 10MG BASE	A202468 001	Aug 03, 2012	Jul	NEWA
AB		DR REDDYS LABS LTD	EQ 10MG BASE	A201582 001	Aug 06, 2012	Jul	NEWA
AB		ENDO PHARMS	EQ 10MG BASE	A091576 001	Aug 03, 2012	Jul	NEWA
AB		GLENMARK GENERICS	EQ 10MG BASE	A090926 001	Aug 03, 2012	Jul	NEWA
AB		KUDCO IRELAND	EQ 10MG BASE	A201522 001	Aug 03, 2012	Jul	NEWA
AB		MYLAN PHARMS INC	EQ 10MG BASE	A079103 001	Aug 03, 2012	Jul	NEWA
AB		ROXANE	EQ 10MG BASE	A090655 001	Aug 03, 2012	Jul	NEWA
AB		SANDOZ INC	EQ 10MG BASE	A200889 001	Aug 03, 2012	Jul	NEWA
AB		TEVA PHARMS	EQ 10MG BASE	A078605 001	Aug 03, 2012	Jul	NEWA
AB		TORRENT PHARMS LTD	EQ 10MG BASE	A201515 001	Aug 03, 2012	Jul	NEWA
AB		VINTAGE PHARMS LLC	EQ 10MG BASE	A091576 001	Aug 03, 2012	Oct	CAHN

SINGULAIR

AB	+	MERCK	EQ 10MG BASE	N020829 002	Feb 20, 1998	Jul	CFTG
----	---	-------	--------------	-------------	--------------	-----	------

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB		APOTEX INC	EQ 4MG BASE	A201508 001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A201508 002	Aug 03, 2012	Jul	NEWA
AB		AUROBINDO PHARMA LTD	EQ 4MG BASE	A202096 001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A202096 002	Aug 03, 2012	Jul	NEWA
AB		DR REDDYS LABS LTD	EQ 4MG BASE	A201581 001	Aug 06, 2012	Jul	NEWA
AB			EQ 5MG BASE	A201581 002	Aug 06, 2012	Jul	NEWA
AB		ENDO PHARMS	EQ 4MG BASE	A091588 001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A091588 002	Aug 03, 2012	Jul	NEWA
AB		KUDCO IRELAND	EQ 4MG BASE	A200405 001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A200405 002	Aug 03, 2012	Jul	NEWA
AB		MYLAN PHARMS INC	EQ 4MG BASE	A079142 001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A079142 002	Aug 03, 2012	Jul	NEWA
AB		ROXANE	EQ 4MG BASE	A091128 001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A091128 002	Aug 03, 2012	Jul	NEWA
AB		SANDOZ INC	EQ 4MG BASE	A091414 001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A091414 002	Aug 03, 2012	Jul	NEWA
AB		TEVA PHARMS	EQ 4MG BASE	A078723 001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A078723 002	Aug 03, 2012	Jul	NEWA
AB		TORRENT PHARMS LTD	EQ 4MG BASE	A090984 001	Aug 03, 2012	Jul	NEWA
AB			EQ 5MG BASE	A090984 002	Aug 03, 2012	Jul	NEWA
AB		VINTAGE PHARMS LLC	EQ 4MG BASE	A091588 001	Aug 03, 2012	Oct	CAHN
AB			EQ 5MG BASE	A091588 002	Aug 03, 2012	Oct	CAHN

SINGULAIR

AB		MERCK	EQ 4MG BASE	N020830 002	Mar 03, 2000	Jul	CFTG
AB	+		EQ 5MG BASE	N020830 001	Feb 20, 1998	Jul	CFTG

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

		ACTAVIS ELIZABETH	40MG	N020616 009	Jul 09, 2012	Jul	NEWA
			70MG	N020616 010	Jul 09, 2012	Jul	NEWA
			130MG	N020616 011	Jul 09, 2012	Jul	NEWA
			150MG	N020616 012	Jul 09, 2012	Jul	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

>A>	AB	PAR PHARM INC	20MG	A200812 001	Nov 10, 2011	Nov	CAHN
>A>	AB		30MG	A200812 002	Nov 10, 2011	Nov	CAHN
>A>	AB		50MG	A200812 003	Nov 10, 2011	Nov	CAHN
>A>	AB		60MG	A200812 004	Nov 10, 2011	Nov	CAHN
>A>	AB		80MG	A200812 005	Nov 10, 2011	Nov	CAHN
>A>	AB		100MG	A200812 006	Nov 10, 2011	Nov	CAHN
>D>	AB	WATSON LABS	20MG	A200812 001	Nov 10, 2011	Nov	CAHN
>D>	AB		30MG	A200812 002	Nov 10, 2011	Nov	CAHN
>D>	AB		50MG	A200812 003	Nov 10, 2011	Nov	CAHN
>D>	AB		60MG	A200812 004	Nov 10, 2011	Nov	CAHN
>D>	AB		80MG	A200812 005	Nov 10, 2011	Nov	CAHN
>D>	AB		100MG	A200812 006	Nov 10, 2011	Nov	CAHN

INJECTABLE; INJECTION

DURAMORPH PF

AP	+	HIKMA MAPLE	0.5MG/ML	N018565 001	Sep 18, 1984	Jun	CAHN
AP	+		1MG/ML	N018565 002	Sep 18, 1984	Jun	CAHN

INFUMORPH

+	HIKMA MAPLE	10MG/ML	N018565 003	Jul 19, 1991	Jun	CAHN
+		25MG/ML	N018565 004	Jul 19, 1991	Jun	CAHN

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

@	PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671 001	May 18, 2004	May	CAHN
@		15MG/1.5ML (10MG/ML)	N021671 002	May 18, 2004	May	CAHN
@		20MG/2ML (10MG/ML)	N021671 003	May 18, 2004	May	CAHN

SOLUTION; ORAL

MORPHINE SULFATE

AA		PADDOCK LLC	100MG/5ML	A201574 001	Aug 06, 2012	Jul	NEWA
----	--	-------------	-----------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB		RANBAXY LABS LTD	15MG	A078761 001	May 11, 2012	Apr	NEWA
AB			30MG	A078761 002	May 11, 2012	Apr	NEWA
AB			60MG	A078761 003	May 11, 2012	Apr	NEWA
AB			100MG	A078761 004	May 11, 2012	Apr	NEWA
AB			200MG	A078761 005	May 11, 2012	Apr	NEWA
AB		VINTAGE PHARMS LLC	15MG	A075295 001	Oct 28, 1998	Sep	CAHN
AB			30MG	A075295 002	Oct 28, 1998	Sep	CAHN
AB			60MG	A075295 003	Oct 28, 1998	Sep	CAHN
AB			100MG	A075295 004	Sep 15, 2000	Sep	CAHN
AB			200MG	A075295 005	Sep 15, 2000	Sep	CAHN
		ORAMORPH SR					
	@	XANODYNE PHARMS INC	15MG	N019977 004	Nov 23, 1994	May	DISC
	@		30MG	N019977 001	Aug 15, 1991	May	DISC
	@		60MG	N019977 002	Aug 15, 1991	May	DISC
	@		100MG	N019977 003	Aug 15, 1991	May	DISC

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

AB		FOUGERA PHARMS	2%	A065192 001	Nov 30, 2005	Jan	CAHN
----	--	----------------	----	-------------	--------------	-----	------

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

AB		VINTAGE PHARMS LLC	250MG	A090111 001	Dec 22, 2009	Sep	CAHN
----	--	--------------------	-------	-------------	--------------	-----	------

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

@ ZYDUS PHARMS USA INC 250MG

A065433 001 May 04, 2009 Sep DISC

TABLET; ORAL

MYCOPHENOLATE MOFETIL

AB VINTAGE PHARMS LLC 500MG

A090606 001 Jul 16, 2010 Sep CAHN

@ ZYDUS PHARMS USA INC 500MG

A065477 001 May 04, 2009 Sep DISC

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC ACID

AB APOTEX INC 180MG

A091558 001 Aug 21, 2012 Aug NEWA

MYFORTIC

AB NOVARTIS 180MG

N050791 001 Feb 27, 2004 Aug CFTG

NABUMETONE

TABLET; ORAL

NABUMETONE

AB MYLAN PHARMS INC 500MG

A090516 001 Jul 12, 2010 Sep CAHN

AB 750MG

A090516 002 Jul 12, 2010 Sep CAHN

AB PROSAM LABS 500MG

A079093 001 Feb 27, 2009 Feb CMFD

AB 750MG

A079093 002 Feb 27, 2009 Feb CMFD

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP ANTIBIOTICE EQ 1GM BASE

A090560 001 Oct 03, 2011 Aug CAHN

AP EQ 2GM BASE

A090560 002 Oct 03, 2011 Aug CAHN

>D> AP ASTRAL PHARM INDS EQ 1GM BASE/VIAL

A090582 001 Aug 24, 2012 Nov CAHN

AP EQ 1GM BASE/VIAL

A090582 001 Aug 24, 2012 Aug NEWA

>D> AP EQ 2GM BASE/VIAL

A090582 002 Aug 24, 2012 Nov CAHN

AP EQ 2GM BASE/VIAL

A090582 002 Aug 24, 2012 Aug NEWA

>D> AP EQ 10GM BASE/VIAL

A090580 001 Aug 24, 2012 Nov CAHN

AP EQ 10GM BASE/VIAL

A090580 001 Aug 24, 2012 Aug NEWA

>A> AP SAGENT PHARMS EQ 1GM BASE/VIAL

A090582 001 Aug 24, 2012 Nov CAHN

>A> AP EQ 2GM BASE/VIAL

A090582 002 Aug 24, 2012 Nov CAHN

>A> AP EQ 10GM BASE/VIAL

A090580 001 Aug 24, 2012 Nov CAHN

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+ MERZ PHARMS 2%

N019599 002 Jan 13, 2012 Jan NEWA

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@ HIKMA MAPLE 0.4MG/ML

A070299 001 Sep 24, 1986 Jun CAHN

@ 0.4MG/ML

A070298 001 Sep 24, 1986 Jun CAHN

@ 0.4MG/ML

A070496 001 Sep 24, 1986 Jun CAHN

NALOXONE HYDROCHLORIDE

@ HIKMA MAPLE 0.02MG/ML

A071272 001 May 24, 1988 Jun CAHN

@ 1MG/ML

A071287 001 May 24, 1988 Jun CAHN

@ 1MG/ML

A071273 001 May 24, 1988 Jun CAHN

@ 1MG/ML

A071274 001 May 24, 1988 Jun CAHN

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	50MG	A090356 001	Feb 24, 2012	Feb	NEWA
----	-------------------	------	-------------	--------------	-----	------

NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN

AB	MYLAN PHARMS INC	375MG	A075390 001	Apr 19, 2001	Sep	CAHN
AB		500MG	A075390 002	Apr 19, 2001	Sep	CAHN

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

AB	HOFFMANN LA ROCHE	EQ 250MG BASE	N018164 001		May	CAHN
----	-------------------	---------------	-------------	--	-----	------

ANAPROX DS

AB	+	HOFFMANN LA ROCHE	EQ 500MG BASE	N018164 003	Sep 30, 1987	May	CAHN
----	---	-------------------	---------------	-------------	--------------	-----	------

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

	+	SMITHKLINE BEECHAM	500MG;EQ 85MG BASE	N021926 001	Apr 15, 2008	May	CAHN
--	---	--------------------	--------------------	-------------	--------------	-----	------

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	MYLAN PHARMS INC	EQ 1MG BASE	A202431 001	May 31, 2012	May	NEWA
AB		EQ 2.5MG BASE	A202431 002	May 31, 2012	May	NEWA
AB	ORCHID HLTHCARE	EQ 1MG BASE	A091441 001	Apr 30, 2012	Apr	NEWA
AB		EQ 2.5MG BASE	A091441 002	Apr 30, 2012	Apr	NEWA

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

	@	TEVA PHARMS	60MG	A077467 001	Sep 09, 2009	Jul	DISC
--	---	-------------	------	-------------	--------------	-----	------

	@		120MG	A077467 002	Sep 09, 2009	Jul	DISC
--	---	--	-------	-------------	--------------	-----	------

NEDOCROMIL SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALOCRIL

AT	+	ALLERGAN	2%	N021009 001	Dec 08, 1999	Aug	CFTG
----	---	----------	----	-------------	--------------	-----	------

NEDOCROMIL SODIUM

AT		AKORN	2%	A090638 001	Aug 22, 2012	Aug	NEWA
----	--	-------	----	-------------	--------------	-----	------

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

NEPAFENAC

	+	ALCON RES LTD	0.3%	N203491 001	Oct 16, 2012	Oct	NEWA
--	---	---------------	------	-------------	--------------	-----	------

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

AA		AUROBINDO	50MG/5ML	A077702 001	May 22, 2012	May	NEWA
----	--	-----------	----------	-------------	--------------	-----	------

VIRAMUNE

AA	+	BOEHRINGER INGELHEIM	50MG/5ML	N020933 001	Sep 11, 1998	May	CFTG
----	---	----------------------	----------	-------------	--------------	-----	------

TABLET; ORAL

NEVIRAPINE

AB	APOTEX INC	200MG	A203021	001	May 22, 2012	May	NEWA
AB	AUROBINDO	200MG	A077521	001	May 22, 2012	May	NEWA
AB	CIPLA	200MG	A077956	001	May 22, 2012	May	NEWA
AB	HETERO LABS LTD III	200MG	A078584	001	May 22, 2012	May	NEWA
AB	MICRO LABS LTD	200MG	A203080	001	May 22, 2012	May	NEWA
AB	MYLAN LABS	200MG	A078864	001	May 22, 2012	May	NEWA
AB	MYLAN PHARMS INC	200MG	A202523	001	May 22, 2012	May	NEWA
AB	PRINSTON INC	200MG	A078644	001	May 22, 2012	May	NEWA
AB	SCIEGEN PHARMS INC	200MG	A203176	001	May 22, 2012	May	NEWA
AB	STRIDES	200MG	A078195	001	May 22, 2012	May	NEWA

VIRAMUNE

AB	+ BOEHRINGER INGELHEIM	200MG	N020636	001	Jun 21, 1996	May	CFTG
----	------------------------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

VIRAMUNE XR

>A>	BOEHRINGER INGELHEIM	100MG	N201152	002	Nov 08, 2012	Nov	NEWA
-----	----------------------	-------	---------	-----	--------------	-----	------

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB1	ACTAVIS	90MG	A077899	003	May 25, 2012	May	NEWA
-----	---------	------	---------	-----	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

AB	ALMATICA	25MG	N016620	003		Jul	CAHN
AB		50MG	N016620	001		Jul	CAHN
AB	+	100MG	N016620	002		Jul	CAHN

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB	+ ALMATICA	75MG;25MG	N020064	001	Dec 24, 1991	Jul	CAHN
	NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)						
	@ RANBAXY LABS LTD	75MG;25MG	A076951	001	Mar 30, 2005	Apr	DISC

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

AB1	MEDICIS	0.1MG/HR	A089771	001	Aug 30, 1996	Jul	CAHN
AB1		0.2MG/HR	A089772	001	Aug 30, 1996	Jul	CAHN
AB1		0.4MG/HR	A089773	001	Aug 30, 1996	Jul	CAHN
AB1		0.6MG/HR	A089774	001	Aug 30, 1996	Jul	CAHN

NITROGLYCERIN

AB2	HERCON PHARM	0.2MG/HR	A089884	001	Oct 30, 1998	Oct	CAHN
AB2		0.4MG/HR	A089885	001	Oct 30, 1998	Oct	CAHN
AB2		0.6MG/HR	A089886	001	Oct 30, 1998	Oct	CAHN

OINTMENT; INTRA-ANAL

RECTIV

+	APTALIS PHARMA	0.4%	N021359	001	Jun 21, 2011	Jan	CAHN
---	----------------	------	---------	-----	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL

AXID

	@ SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988	Mar	DISC
--	----------------------	-------	---------	-----	--------------	-----	------

CAPSULE; ORAL

AXID

@ SMITHKLINE BEECHAM 300MG

N019508 002 Apr 12, 1988 Mar DISC

NIZATIDINE

@ MYLAN PHARMS INC 150MG

A075934 001 Jul 09, 2002 Apr DISC

AB + 300MG

A075806 002 Jul 05, 2002 Apr CRLD

@ 300MG

A075934 002 Jul 09, 2002 Apr DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP CLARIS LIFESCIENCES EQ 1MG BASE/ML

A040859 001 Mar 27, 2012 May CAHN

AP SINTETICA EQ 1MG BASE/ML

A040859 001 Mar 27, 2012 Mar NEWA

NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE

AB AMNEAL PHARMS 5MG

A200275 001 Jul 30, 2012 Jul NEWA

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT FOUGERA PHARMS 100,000 UNITS/GM

A062129 001 Jan CAHN

AT + TARO 100,000 UNITS/GM

A064022 001 Jan 29, 1993 Aug CRLD

OINTMENT; TOPICAL

NYSTATIN

AT + FOUGERA PHARMS 100,000 UNITS/GM

A062124 002 Sep 23, 1982 Jan CAHN

POWDER; TOPICAL

NYSTATIN

@ NESHER PHARMS 100,000 UNITS/GM

A065321 001 Aug 18, 2006 Jun DISC

TABLET; ORAL

NYSTATIN

AA HERITAGE PHARMS INC 500,000 UNITS

A062474 001 Dec 22, 1983 Oct CMFD

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

@ G AND W LABS INC 100,000 UNITS/GM;0.1%

A062367 001 May 28, 1985 Jun CAHN

OINTMENT; TOPICAL

MYKACET

@ G AND W LABS INC 100,000 UNITS/GM;0.1%

A062733 001 Mar 09, 1987 Jun CAHN

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

@ SANDOZ 0.3%

A076848 001 Nov 25, 2008 Aug DISC

TABLET; ORAL

OFLOXACIN

@ RANBAXY LABS LTD 200MG

A076220 001 Sep 02, 2003 Apr DISC

@ 300MG

A076220 002 Sep 02, 2003 Apr DISC

@ 400MG

A076220 003 Sep 02, 2003 Apr DISC

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

AP LUITPOLD 10MG/VIAL

A201741 001 Mar 20, 2012 Sep CAHN

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

AP	PHARMAFORCE	10MG/VIAL	A201741	001	Mar 20, 2012	Mar	NEWA
AP	SANDOZ INC	10MG/VIAL	A201588	001	Oct 24, 2011	Mar	CAHN

TABLET; ORAL

OLANZAPINE

AB	APOTEX INC	2.5MG	A090798	001	Apr 23, 2012	Apr	NEWA
AB		5MG	A090798	002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A090798	003	Apr 23, 2012	Apr	NEWA
AB		10MG	A090798	004	Apr 23, 2012	Apr	NEWA
AB		15MG	A090798	005	Apr 23, 2012	Apr	NEWA
AB		20MG	A090798	006	Apr 23, 2012	Apr	NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A202050	001	Apr 23, 2012	Apr	NEWA
AB		5MG	A202050	002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A202050	003	Apr 23, 2012	Apr	NEWA
AB		10MG	A202050	004	Apr 23, 2012	Apr	NEWA
AB		15MG	A202050	005	Apr 23, 2012	Apr	NEWA
AB		20MG	A202050	006	Apr 23, 2012	Apr	NEWA
AB	DR REDDYS LABS LTD	2.5MG	A076255	001	Apr 23, 2012	Apr	NEWA
AB		5MG	A076255	002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A076255	003	Apr 23, 2012	Apr	NEWA
AB		10MG	A076255	004	Apr 23, 2012	Apr	NEWA
AB		15MG	A076133	001	Apr 23, 2012	Apr	NEWA
AB	MYLAN	2.5MG	A076866	001	Apr 23, 2012	Apr	NEWA
AB		5MG	A076866	002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A076866	003	Apr 23, 2012	Apr	NEWA
AB		10MG	A076866	004	Apr 23, 2012	Apr	NEWA
AB		15MG	A076866	005	Apr 23, 2012	Apr	NEWA
AB		20MG	A076866	006	Apr 23, 2012	Apr	NEWA
AB	ORCHID HLTHCARE	2.5MG	A202287	001	Apr 23, 2012	Apr	NEWA
AB		5MG	A202287	002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A202287	003	Apr 23, 2012	Apr	NEWA
AB		10MG	A202287	004	Apr 23, 2012	Apr	NEWA
AB		15MG	A202287	005	Apr 23, 2012	Apr	NEWA
AB		20MG	A202287	006	Apr 23, 2012	Apr	NEWA
AB	SUN PHARM INDS	2.5MG	A091038	001	Apr 23, 2012	Apr	NEWA
AB		5MG	A091038	002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091038	003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091038	004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091038	005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091038	006	Apr 23, 2012	Apr	NEWA
AB	TORRENT PHARMS LTD	2.5MG	A091434	001	Apr 23, 2012	Apr	NEWA
AB		5MG	A091434	002	Apr 23, 2012	Apr	NEWA
AB		7.5MG	A091434	003	Apr 23, 2012	Apr	NEWA
AB		10MG	A091434	004	Apr 23, 2012	Apr	NEWA
AB		15MG	A091434	005	Apr 23, 2012	Apr	NEWA
AB		20MG	A091434	006	Apr 23, 2012	Apr	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	BARR LABS INC	5MG	A077243	001	Jan 30, 2012	Jan	NEWA
AB		10MG	A077243	002	Jan 30, 2012	Jan	NEWA
AB		15MG	A077243	003	Jan 30, 2012	Jan	NEWA
AB		20MG	A077243	004	Jan 30, 2012	Jan	NEWA
AB	JUBILANT ORGANOSYS	5MG	A200221	001	Sep 12, 2012	Aug	NEWA
AB		10MG	A200221	002	Sep 12, 2012	Aug	NEWA
AB		15MG	A200221	003	Sep 12, 2012	Aug	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	JUBILANT ORGANOSYS	20MG	A200221	004	Sep 12, 2012	Aug	NEWA
AB	SUN PHARM INDS	5MG	A090881	001	Feb 28, 2012	Feb	NEWA
AB		10MG	A090881	002	Feb 28, 2012	Feb	NEWA
AB		15MG	A090881	003	Feb 28, 2012	Feb	NEWA
AB		20MG	A090881	004	Feb 28, 2012	Feb	NEWA

OMACETAXINE MEPESUCCINATE

POWDER; SUBCUTANEOUS

SYNRIBO

+	IVAX INTL	3.5MG/VIAL	N203585	001	Oct 26, 2012	Oct	NEWA
---	-----------	------------	---------	-----	--------------	-----	------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	DR REDDYS LABS LTD	10MG	A078490	002	Mar 16, 2009	Apr	NEWA
AB		20MG	A078490	003	Mar 16, 2009	Apr	NEWA
AB	SANDOZ	10MG	A075757	001	Jan 28, 2003	Aug	CAHN
AB		20MG	A075757	002	Jan 28, 2003	Aug	CAHN
>A>	AB	ZYDUS PHARMS USA INC	A091352	001	Nov 19, 2012	Nov	NEWA
>A>	AB		A091352	002	Nov 19, 2012	Nov	NEWA
>A>	AB		A091352	003	Nov 19, 2012	Nov	NEWA

ONDANSETRON

FILM; ORAL

ZUPLLENZ

	VESTIQ PHARMS	4MG	N022524	001	Jul 02, 2010	Sep	CAHN
+		8MG	N022524	002	Jul 02, 2010	Sep	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

@	NESHER PHARMS	4MG	A077717	001	Jun 25, 2007	Jun	DISC
@		8MG	A077717	002	Jun 25, 2007	Jun	DISC
@	PAR PHARM	4MG	A076506	001	Dec 26, 2006	Aug	DISC
@		8MG	A076506	002	Dec 26, 2006	Aug	DISC
@		16MG	A077406	001	Dec 26, 2006	Aug	DISC
@		24MG	A077406	002	Dec 26, 2006	Aug	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 2MG BASE/ML	A090648	001	Jun 15, 2012	Jun	NEWA
AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun	CAHN
@	SAGENT PHARMS	EQ 2MG BASE/ML	A078180	001	Mar 26, 2007	Aug	DISC
ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER							
@	BAXTER HLTHCARE	EQ 0.64MG BASE/ML	N021915	002	Dec 27, 2006	Sep	DISC
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE							
AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun	CAHN

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

	DR REDDYS LABS LTD	EQ 16MG BASE	A076183	004	Dec 26, 2006	Sep	NEWA
@	PAR PHARM	EQ 4MG BASE	A077303	001	Jun 25, 2007	Aug	DISC
@		EQ 8MG BASE	A077303	002	Jun 25, 2007	Aug	DISC
@		EQ 24MG BASE	A077303	004	Jun 25, 2007	Aug	DISC
@	WEST WARD PHARM CORP	EQ 4MG BASE	A077545	001	Sep 06, 2007	Sep	DISC
@		EQ 8MG BASE	A077545	002	Sep 06, 2007	Sep	DISC

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

@ WEST WARD PHARM CORP EQ 24MG BASE

A077545 003 Sep 06, 2007 Sep DISC

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB CNTY LINE PHARMS 100MG

A040249 001 Jan 29, 1999 Jul CAHN

AB INVAGEN PHARMS 100MG

A091158 001 Jul 27, 2012 Jul NEWA

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

+ ROCHE EQ 6MG BASE/ML

N021246 002 Mar 21, 2011 Jan CRLD

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP SAGENT PHARMS EQ 1GM BASE/VIAL

A091246 001 Mar 30, 2012 Mar NEWA

AP EQ 2GM BASE/VIAL

A091246 002 Mar 30, 2012 Mar NEWA

AP EQ 10GM BASE/VIAL

A091245 001 Mar 30, 2012 Mar NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP ACTAVIS TOTOWA 50MG/VIAL

A078803 001 Aug 08, 2012 Jul NEWA

AP 100MG/VIAL

A078803 002 Aug 08, 2012 Jul NEWA

AP ONCO THERAPIES LTD 50MG/VIAL

A200979 001 Aug 08, 2012 Jul NEWA

AP 50MG/10ML (5MG/ML)

A091358 001 Aug 07, 2012 Jul NEWA

AP 100MG/20ML (5MG/ML)

A091358 002 Aug 07, 2012 Jul NEWA

AP 100MG/VIAL

A200979 002 Aug 08, 2012 Jul NEWA

>D> AP SANDOZ 50MG/VIAL

A090849 001 Apr 28, 2011 Nov DISC

>A> @ 50MG/VIAL

A090849 001 Apr 28, 2011 Nov DISC

>D> AP 100MG/VIAL

A090849 002 Apr 28, 2011 Nov DISC

>A> @ 100MG/VIAL

A090849 002 Apr 28, 2011 Nov DISC

AP + TEVA PHARMS 50MG/10ML (5MG/ML)

N022160 001 Aug 07, 2009 Mar CRLD

AP + 100MG/20ML (5MG/ML)

N022160 002 Aug 07, 2009 Mar CRLD

OXAPROZIN

TABLET; ORAL

OXAPROZIN

@ MYLAN PHARMS INC 600MG

A075847 001 Feb 28, 2001 Oct DISC

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

AB AMNEAL PHARMS 300MG/5ML

A202961 001 Sep 17, 2012 Aug NEWA

AB ROXANE 300MG/5ML

A201193 001 Oct 03, 2012 Sep NEWA

TABLET, EXTENDED RELEASE; ORAL

OXTELLAR XR

SUPERNUS PHARMS 150MG

N202810 001 Oct 19, 2012 Oct NEWA

300MG

N202810 002 Oct 19, 2012 Oct NEWA

+ 600MG

N202810 003 Oct 19, 2012 Oct NEWA

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+	FOUGERA PHARMS	EQ 1% BASE	N019828	001	Dec 30, 1988	Jan	CAHN
---	----------------	------------	---------	-----	--------------	-----	------

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

+	WARNER CHILCOTT LLC	400MG	A087863	001	May 24, 1983	Jun	CAHN
---	---------------------	-------	---------	-----	--------------	-----	------

+		600MG	A086742	001		Jun	CAHN
---	--	-------	---------	-----	--	-----	------

OXYBUTYNIN

GEL, METERED; TRANSDERMAL

ANTUROL

>D>	+	ARROW INTL	3%	N202513	001	Dec 07, 2011	Nov	CAHN
-----	---	------------	----	---------	-----	--------------	-----	------

	+		3%	N202513	001	Dec 07, 2011	Apr	CAHN
--	---	--	----	---------	-----	--------------	-----	------

>A>	+	WATSON LABS INC	3%	N202513	001	Dec 07, 2011	Nov	CAHN
-----	---	-----------------	----	---------	-----	--------------	-----	------

	+		3%	N202513	001	Dec 07, 2011	Feb	CAHN
--	---	--	----	---------	-----	--------------	-----	------

OXYBUTYNIN CHLORIDE

TABLET; ORAL

DITROPAN

@ JANSSEN PHARMS

5MG

N017577	001		Mar	DISC
---------	-----	--	-----	------

OXYBUTYNIN CHLORIDE

AB	+	VINTAGE PHARMS	5MG	A075079	001	Oct 31, 1997	Mar	CRLD
----	---	----------------	-----	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB		MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Mar	NEWA
----	--	------------------	------	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

AB		COASTAL PHARMS	5MG	A203107	001	Jul 26, 2012	Jul	NEWA
----	--	----------------	-----	---------	-----	--------------	-----	------

AB	+	LEHIGH VALLEY	5MG	N200534	001	Oct 20, 2010	Jul	CFTG
----	---	---------------	-----	---------	-----	--------------	-----	------

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

AA	+	LEHIGH VALLEY	100MG/5ML	N200535	001	Oct 20, 2010	Jul	CFTG
----	---	---------------	-----------	---------	-----	--------------	-----	------

	+	VISTAPHARM	5MG/5ML	N201194	001	Jan 12, 2012	Jan	NEWA
--	---	------------	---------	---------	-----	--------------	-----	------

AA			100MG/5ML	A202537	001	Jul 30, 2012	Jul	NEWA
----	--	--	-----------	---------	-----	--------------	-----	------

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

>A>	AB	AUROLIFE PHARMA LLC	5MG	A202160	001	Nov 19, 2012	Nov	NEWA
-----	----	---------------------	-----	---------	-----	--------------	-----	------

>A>	AB		15MG	A202160	002	Nov 19, 2012	Nov	NEWA
-----	----	--	------	---------	-----	--------------	-----	------

>A>	AB		30MG	A202160	003	Nov 19, 2012	Nov	NEWA
-----	----	--	------	---------	-----	--------------	-----	------

	AB	MALLINCKRODT INC	5MG	A076758	003	Mar 19, 2007	Apr	NEWA
--	----	------------------	-----	---------	-----	--------------	-----	------

>A>	AB	SUN PHARM INDS INC	10MG	A090659	005	Nov 06, 2012	Nov	NEWA
-----	----	--------------------	------	---------	-----	--------------	-----	------

>A>	AB		20MG	A090659	004	Nov 06, 2012	Nov	NEWA
-----	----	--	------	---------	-----	--------------	-----	------

ROXICODONE

	AB	MALLINCKRODT INC	5MG	N021011	003	May 15, 2009	Oct	CAHN
--	----	------------------	-----	---------	-----	--------------	-----	------

	AB	+	15MG	N021011	001	Aug 31, 2000	Oct	CAHN
--	----	---	------	---------	-----	--------------	-----	------

	AB		30MG	N021011	002	Aug 31, 2000	Oct	CAHN
--	----	--	------	---------	-----	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

	@ ENDO PHARMS	5MG	N021610 001	Jun 22, 2006	May	DISC
>D>	@	7.5MG	N201655 002	Dec 09, 2011	Nov	CMFD
>A>		7.5MG	N201655 002	Dec 09, 2011	Nov	CMFD
	@	7.5MG	N201655 002	Dec 09, 2011	Oct	DISC
	@	10MG	N021610 002	Jun 22, 2006	May	DISC
>D>	@	15MG	N201655 004	Dec 09, 2011	Nov	CMFD
>A>		15MG	N201655 004	Dec 09, 2011	Nov	CMFD
	@	15MG	N201655 004	Dec 09, 2011	Oct	DISC
	@	20MG	N021610 003	Jun 22, 2006	May	DISC
	@	30MG	N021610 007	Feb 29, 2008	May	DISC
	+	40MG	N201655 007	Dec 09, 2011	Aug	CRLD
	@	40MG	N021610 004	Jun 22, 2006	May	DISC

OXYMORPHONE HYDROCHLORIDE

IMPAX LABS

5MG	A079087 001	Jun 14, 2010	May	CTEC
10MG	A079087 003	Jun 14, 2010	May	CTEC
20MG	A079087 005	Jun 14, 2010	May	CTEC
30MG	A079087 006	Jul 22, 2010	May	CTEC
40MG	A079087 007	Jun 14, 2010	May	CTEC

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

@ TEVA PARENTERAL	10USP UNITS/ML (10USP UNITS/ML)	A077453 001	Jan 24, 2008	Jan	DISC
@	100USP UNITS/10ML (10USP UNITS/ML)	A077453 002	Jan 24, 2008	Mar	DISC

PITOCIN

JHP PHARMS

500USP UNITS/50ML (10USP UNITS/ML)	N018261 003	Sep 05, 2012	Aug	NEWA
------------------------------------	-------------	--------------	-----	------

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

AP	TEVA PHARMS	6MG/ML	A075184 001	Jan 25, 2002	Oct	CAHN
	TAXOL					
	@ CORDEN PHARMA	6MG/ML	N020262 001	Dec 29, 1992	Mar	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

@ NOVARTIS	30MG/VIAL	N020036 001	Oct 31, 1991	Mar	DISC
------------	-----------	-------------	--------------	-----	------

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBOTT LABS

	15,000USP UNITS;3,000USP UNITS;9,500USP UNITS	N020725 004	Jul 12, 2011	Jun	NEWA
	30,000USP UNITS;6,000USP UNITS;19,000USP UNITS	N020725 001	Apr 30, 2009	Feb	CAHN
	60,000USP UNITS;12,000USP UNITS;38,000USP UNITS	N020725 002	Apr 30, 2009	Feb	CAHN
+	120,000USP UNITS;24,000USP UNITS;76,000USP UNITS	N020725 003	Apr 30, 2009	Feb	CAHN

PERTZYE

DIGESTIVE CARE INC

30,250USP/UNITS;8,000USP/UNITS;28,750USP/UNITS	N022175 001	May 17, 2012	May	NEWA
--	-------------	--------------	-----	------

CAPSULE, DELAYED RELEASE; ORAL

PERTZYE

+	DIGESTIVE CARE INC	60,500USP/UNITS;16,000USP/UNITS;5 7,500USP/UNITS	N022175 002	May 17, 2012	May	NEWA
---	--------------------	---	-------------	--------------	-----	------

ULTRESA

	APTALIS PHARMA US	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222 001	Mar 01, 2012	Mar	NEWA
		41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222 002	Mar 01, 2012	Mar	NEWA
+		46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222 003	Mar 01, 2012	Mar	NEWA

ZENPEP

	APTALIS PHARMA US	16,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210 005	Jun 15, 2011	Apr	NEWA
		109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210 004	Aug 27, 2009	Apr	CRLD
+		136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210 006	Jul 13, 2011	Apr	NEWA

TABLET; ORAL

VIOKACE

	APTALIS PHARMA US	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542 001	Mar 01, 2012	Mar	NEWA
+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542 002	Mar 01, 2012	Mar	NEWA

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

PANTOPRAZOLE SODIUM

AP	AKORN INC	EQ 40MG BASE/VIAL	A079197 001	Nov 08, 2012	Oct	NEWA
----	-----------	-------------------	-------------	--------------	-----	------

PROTONIX IV

AP	+ WYETH PHARMS INC	EQ 40MG BASE/VIAL	N020988 001	Mar 22, 2001	Oct	CFTG
----	--------------------	-------------------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	APOTEX INC	EQ 20MG BASE	A090807 001	May 02, 2012	Apr	NEWA
AB		EQ 40MG BASE	A090807 002	May 02, 2012	Apr	NEWA
AB	AUROBINDO PHARMA LTD	EQ 20MG BASE	A202038 001	Sep 28, 2012	Sep	NEWA
AB		EQ 40MG BASE	A202038 002	Sep 28, 2012	Sep	NEWA
AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A200821 001	Feb 16, 2012	Jan	NEWA
AB		EQ 40MG BASE	A200821 002	Feb 16, 2012	Jan	NEWA
AB	MYLAN PHARMS INC	EQ 20MG BASE	A090970 001	Jan 19, 2011	Sep	CAHN
AB		EQ 40MG BASE	A090970 002	Jan 19, 2011	Sep	CAHN
AB	RANBAXY LABS LTD	EQ 20MG BASE	A200794 001	May 02, 2012	Apr	NEWA
AB		EQ 40MG BASE	A200794 002	May 02, 2012	Apr	NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 10MG BASE	A076968 001	Jun 21, 2010	Feb	CMFD
AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Feb	CMFD
AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Feb	CMFD
AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Feb	CMFD
AB	MYLAN PHARMS INC	EQ 10MG BASE	A075716 001	Mar 08, 2004	Sep	CAHN
AB		EQ 20MG BASE	A075716 002	Mar 08, 2004	Sep	CAHN
AB		EQ 30MG BASE	A075716 003	Mar 08, 2004	Sep	CAHN
AB		EQ 40MG BASE	A075716 004	Mar 08, 2004	Sep	CAHN
AB	PROSAM LABS	EQ 10MG BASE	A076968 001	Jun 21, 2010	Sep	CAHN
AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Sep	CAHN
AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Sep	CAHN
AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Sep	CAHN

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756	001	Dec 17, 2004	May	CAHN
---	--------------------	----------------------	---------	-----	--------------	-----	------

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

+	AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799	007	Mar 27, 2012	Mar	NEWA
---	---------	-----------------------------------	---------	-----	--------------	-----	------

+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799	008	Mar 27, 2012	Mar	NEWA
---	--	------------------------------------	---------	-----	--------------	-----	------

OMONTYS PRESERVATIVE FREE

+	AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799	001	Mar 27, 2012	Mar	NEWA
---	---------	---------------------------------------	---------	-----	--------------	-----	------

+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799	002	Mar 27, 2012	Mar	NEWA
---	--	---------------------------------------	---------	-----	--------------	-----	------

+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799	003	Mar 27, 2012	Mar	NEWA
---	--	---------------------------------------	---------	-----	--------------	-----	------

+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799	004	Mar 27, 2012	Mar	NEWA
---	--	---------------------------------------	---------	-----	--------------	-----	------

+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799	005	Mar 27, 2012	Mar	NEWA
---	--	---------------------------------------	---------	-----	--------------	-----	------

+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799	006	Mar 27, 2012	Mar	NEWA
---	--	---------------------------------------	---------	-----	--------------	-----	------

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

AP	IBI	5,000,000 UNITS/VIAL	A065448	001	Aug 18, 2009	Sep	CAHN
----	-----	----------------------	---------	-----	--------------	-----	------

AP		20,000,000 UNITS/VIAL	A065448	002	Aug 18, 2009	Sep	CAHN
----	--	-----------------------	---------	-----	--------------	-----	------

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+	OAK PHARMS	50MG/ML	A083246	001		Feb	CAHN
---	------------	---------	---------	-----	--	-----	------

PERAMPANEL

TABLET; ORAL

FYCOMPA

EISAI INC

2MG	N202834	001	Oct 20, 2012	Oct	NEWA
-----	---------	-----	--------------	-----	------

4MG	N202834	002	Oct 22, 2012	Oct	NEWA
-----	---------	-----	--------------	-----	------

6MG	N202834	003	Oct 22, 2012	Oct	NEWA
-----	---------	-----	--------------	-----	------

8MG	N202834	004	Oct 22, 2012	Oct	NEWA
-----	---------	-----	--------------	-----	------

10MG	N202834	005	Oct 22, 2012	Oct	NEWA
------	---------	-----	--------------	-----	------

+	12MG	N202834	006	Oct 22, 2012	Oct	NEWA
---	------	---------	-----	--------------	-----	------

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AB	XOMA	2MG	N020184	001	Dec 30, 1993	Jan	CAHN
----	------	-----	---------	-----	--------------	-----	------

AB		4MG	N020184	002	Dec 30, 1993	Jan	CAHN
----	--	-----	---------	-----	--------------	-----	------

AB	+	8MG	N020184	003	Dec 30, 1993	Jan	CAHN
----	---	-----	---------	-----	--------------	-----	------

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB	+	RENAISSANCE PHARMA	5%	N019855	001	Aug 25, 1989	May	CAHN
----	---	--------------------	----	---------	-----	--------------	-----	------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

AB	+	WELLSPRING PHARM	10MG	N008708 001		Jun	CFTG
		PHENOXYBENZAMINE HYDROCHLORIDE					
AB		ROXANE	10MG	A201050 001	Jul 16, 2012	Jun	NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA		ELITE LABS	15MG	A202248 001	Sep 28, 2012	Sep	NEWA
AA			30MG	A202248 002	Sep 28, 2012	Sep	NEWA
AA		LANNETT	15MG	A087022 002	Jan 20, 2012	Feb	NEWA
	@	MIKAH PHARMA	15MG	A040460 001	Jan 14, 2003	Jul	CAHN
	@		30MG	A040227 001	Jun 18, 1997	Jul	CAHN
	@		30MG	A040448 001	Jan 22, 2003	Jul	CAHN
	@		37.5MG	A040228 001	Jun 19, 1997	Jul	CAHN

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

	@	ACTAVIS ELIZABETH	37.5MG	A040276 001	Nov 25, 1998	Oct	DISC
	@	MIKAH PHARMA	37.5MG	A040190 001	May 30, 1997	Jul	CAHN
AA		MIRROR PHARMS	37.5MG	A091451 001	Sep 21, 2012	Sep	NEWA
	@	SANDOZ INC	30MG	A088605 001	Sep 28, 1987	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

		CITIUS PHARMS	30MG	N202088 002	Jun 13, 2011	Apr	CRLD
+			37.5MG	N202088 003	Mar 27, 2012	Apr	CRLD
			37.5MG	N202088 003	Mar 27, 2012	Mar	NEWA

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

VIVUS

		EQ 3.75MG BASE;23MG	N022580 001	Jul 17, 2012	Jul	NEWA
		EQ 7.5MG BASE;46MG	N022580 002	Jul 17, 2012	Jul	NEWA
		EQ 11.25MG BASE;69MG	N022580 003	Jul 17, 2012	Jul	NEWA
+		EQ 15MG BASE;92MG	N022580 004	Jul 17, 2012	Jul	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

+		LANNETT HOLDINGS INC	EQ 15MG BASE	A040872 001	Jul 28, 2011	Jan	CRLD
+			EQ 30MG BASE	A040872 002	Jul 28, 2011	Jan	CRLD

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP	+	HIKMA MAPLE	50MG/ML	A084307 001		Jun	CAHN
----	---	-------------	---------	-------------	--	-----	------

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722 001		Feb	CRLD
----	---	-----------------	-----------	-------------	--	-----	------

TABLET; ORAL

MEPHYTON

+		VALEANT PHARMS	5MG	N010104 003		Jun	CAHN
---	--	----------------	-----	-------------	--	-----	------

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL

+	VALEANT BERMUDA	1%	N021302	001	Dec 13, 2001	Oct	CAHN
---	-----------------	----	---------	-----	--------------	-----	------

PINDOLOL

TABLET; ORAL

PINDOLOL

@	MYLAN PHARMS INC	5MG	A074013	001	Sep 24, 1992	May	CAHN
---	------------------	-----	---------	-----	--------------	-----	------

@		10MG	A074018	001	Sep 24, 1992	May	CAHN
---	--	------	---------	-----	--------------	-----	------

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

AB	TAKEDA PHARMS USA	EQ 15MG BASE	N021073	001	Jul 15, 1999	Aug	CFTG
		EQ 15MG BASE	N021073	001	Jul 15, 1999	Mar	CAHN
AB		EQ 30MG BASE	N021073	002	Jul 15, 1999	Aug	CFTG
		EQ 30MG BASE	N021073	002	Jul 15, 1999	Mar	CAHN
AB	+	EQ 45MG BASE	N021073	003	Jul 15, 1999	Aug	CFTG
	+	EQ 45MG BASE	N021073	003	Jul 15, 1999	Mar	CAHN

PIOGLITAZONE HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 15MG BASE	A076801	001	Aug 17, 2012	Aug	NEWA
AB		EQ 30MG BASE	A076801	002	Aug 17, 2012	Aug	NEWA
AB		EQ 45MG BASE	A076801	003	Aug 17, 2012	Aug	NEWA
AB	WATSON LABS	EQ 15MG BASE	A076798	001	Oct 26, 2012	Oct	NEWA
AB		EQ 30MG BASE	A076798	002	Oct 26, 2012	Oct	NEWA
AB		EQ 45MG BASE	A076798	003	Oct 26, 2012	Oct	NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

@	PADDOCK LLC	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5	A090769	001	Jun 07, 2010	Sep	DISC
		.86GM/BOT;22.74GM/BOT					

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

@	PADDOCK LLC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5	A090712	001	Feb 25, 2010	Sep	DISC
		.84GM/BOT;22.72GM/BOT					

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

K+10

@	FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987	Mar	DISC
---	------------	-------	---------	-----	--------------	-----	------

KAON CL-10

@	SAVAGE LABS	10MEQ	N017046	002		Mar	DISC
---	-------------	-------	---------	-----	--	-----	------

KLOR-CON M20

AB	+	UPSHER SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Mar	CRLD
----	---	-------------------	-------	---------	-----	--------------	-----	------

KLOTRIX

@	APOTHECON	10MEQ	N017850	001		Mar	DISC
---	-----------	-------	---------	-----	--	-----	------

POTASSIUM CHLORIDE

@	NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002	Mar	DISC
---	---------------	-------	---------	-----	--------------	-----	------

@	SCHERING	10MEQ	N019439	002	Jun 13, 1986	Mar	DISC
---	----------	-------	---------	-----	--------------	-----	------

@		20MEQ	N019439	001	Jun 13, 1986	Mar	DISC
---	--	-------	---------	-----	--------------	-----	------

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

@ NOVA K 10MEQ/PACKET

N019647 002 Oct 13, 1988 Feb CAHN

@ 20MEQ/PACKET

N019647 001 Oct 13, 1988 Feb CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB APOTEX INC 0.125MG

A090151 001 Apr 30, 2012 Apr NEWA

AB 0.25MG

A090151 002 Apr 30, 2012 Apr NEWA

AB 0.5MG

A090151 003 Apr 30, 2012 Apr NEWA

AB 0.75MG

A090151 006 Apr 30, 2012 Apr NEWA

AB 1MG

A090151 004 Apr 30, 2012 Apr NEWA

AB 1.5MG

A090151 005 Apr 30, 2012 Apr NEWA

AB AUROBINDO PHARMA LTD 0.125MG

A202633 001 Oct 26, 2012 Oct NEWA

AB 0.25MG

A202633 002 Oct 26, 2012 Oct NEWA

AB 0.5MG

A202633 003 Oct 26, 2012 Oct NEWA

AB 0.75MG

A202633 004 Oct 26, 2012 Oct NEWA

AB 1MG

A202633 005 Oct 26, 2012 Oct NEWA

AB 1.5MG

A202633 006 Oct 26, 2012 Oct NEWA

AB MACLEODS PHARMS LTD 0.125MG

A202164 001 Sep 20, 2012 Sep NEWA

AB 0.25MG

A202164 002 Sep 20, 2012 Sep NEWA

AB 0.5MG

A202164 003 Sep 20, 2012 Sep NEWA

AB 1MG

A202164 004 Sep 20, 2012 Sep NEWA

AB 1.5MG

A202164 005 Sep 20, 2012 Sep NEWA

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

AB MYLAN PHARMS INC 10MG

A079187 001 May 27, 2010 Oct CAHN

AB 20MG

A079187 002 May 27, 2010 Oct CAHN

AB 40MG

A079187 003 May 27, 2010 Oct CAHN

AB 80MG

A079187 004 May 27, 2010 Oct CAHN

@ PLIVA HRVATSKA DOO 10MG

A077730 001 Nov 21, 2006 Jun DISC

@ 20MG

A077730 002 Nov 21, 2006 Jun DISC

@ 30MG

A077730 003 Nov 21, 2006 Jun DISC

@ 40MG

A077730 005 Nov 21, 2006 Jun DISC

@ RANBAXY LABS LTD 10MG

A076445 001 Apr 23, 2007 Apr DISC

@ 20MG

A076445 002 Apr 23, 2007 Apr DISC

@ 40MG

A076445 003 Apr 23, 2007 Apr DISC

@ 80MG

A076445 004 Apr 23, 2007 Apr DISC

PRazosin HYDROCHLORIDE

CAPSULE; ORAL

PRazosin HYDROCHLORIDE

>D> AB IVAX SUB TEVA PHARMS EQ 2MG BASE

A071995 001 Sep 12, 1988 Nov CAHN

>D> AB EQ 5MG BASE

A071745 001 Sep 12, 1988 Nov CAHN

>A> AB TEVA PHARMS EQ 2MG BASE

A071995 001 Sep 12, 1988 Nov CAHN

>A> AB EQ 5MG BASE

A071745 001 Sep 12, 1988 Nov CAHN

PREDNICARBATE

CREAM; TOPICAL

PREDNICARBATE

AB FOUGERA PHARMS 0.1%

A077287 001 Sep 19, 2006 Jan CAHN

OINTMENT; TOPICAL

PREDNICARBATE

AB		FOUGERA PHARMS	0.1%	A077236	001	Mar 09, 2007	Jan	CAHN
----	--	----------------	------	---------	-----	--------------	-----	------

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA	+	HI TECH PHARMA CO	15MG/5ML	A040401	001	Feb 27, 2003	Jul	CRLD
		@ NESHER PHARMS	5MG/5ML	A040423	001	Oct 22, 2001	Jun	DISC
		@	15MG/5ML	A040364	001	Apr 10, 2002	Jun	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED

AA	+	SETON PHARM	EQ 5MG BASE/5ML	N019157	001	May 28, 1986	Sep	CAHN
		PREDNISOLONE SODIUM PHOSPHATE						
	+	MISSION PHARMA	EQ 25MG BASE/5ML	A091396	001	Sep 13, 2010	Jul	CAHN
		@ NESHER PHARMS	EQ 5MG BASE/5ML	A076982	001	May 24, 2005	Jun	DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

AB		WEST WARD PHARM CORP	50MG	A088465	001	Jun 01, 1984	Oct	CMFD
		TABLET, DELAYED RELEASE; ORAL						
		RAYOS						
		HORIZON PHARMA	1MG	N202020	001	Jul 26, 2012	Jul	NEWA
			2MG	N202020	002	Jul 26, 2012	Jul	NEWA
	+		5MG	N202020	003	Jul 26, 2012	Jul	NEWA

PREGABALIN

CAPSULE; ORAL

LYRICA

AB		PF PRISM	25MG	N021446	001	Dec 30, 2004	Jun	CFTG
			25MG	N021446	001	Dec 30, 2004	Jan	CAHN
AB			50MG	N021446	002	Dec 30, 2004	Jun	CFTG
			50MG	N021446	002	Dec 30, 2004	Jan	CAHN
AB			75MG	N021446	003	Dec 30, 2004	Jun	CFTG
			75MG	N021446	003	Dec 30, 2004	Jan	CAHN
AB			100MG	N021446	004	Dec 30, 2004	Oct	CFTG
			100MG	N021446	004	Dec 30, 2004	Jan	CAHN
AB			150MG	N021446	005	Dec 30, 2004	Jun	CFTG
			150MG	N021446	005	Dec 30, 2004	Jan	CAHN
AB			200MG	N021446	006	Dec 30, 2004	Jun	CFTG
			200MG	N021446	006	Dec 30, 2004	Jan	CAHN
AB			225MG	N021446	007	Dec 30, 2004	Jun	CFTG
			225MG	N021446	007	Dec 30, 2004	Jan	CAHN
AB	+		300MG	N021446	008	Dec 30, 2004	Jun	CFTG
	+		300MG	N021446	008	Dec 30, 2004	Jan	CAHN

PREGABALIN

AB		LUPIN LTD	25MG	A091040	001	Jul 03, 2012	Jun	NEWA
AB			50MG	A091040	002	Jul 03, 2012	Jun	NEWA
AB			75MG	A091040	003	Jul 03, 2012	Jun	NEWA
AB			100MG	A091040	004	Jul 03, 2012	Jun	NEWA
AB			150MG	A091040	005	Jul 03, 2012	Jun	NEWA
AB			200MG	A091040	006	Jul 03, 2012	Jun	NEWA
AB			225MG	A091040	007	Jul 03, 2012	Jun	NEWA

CAPSULE; ORAL

PREGABALIN

AB	LUPIN LTD	300MG	A091040	008	Jul 03, 2012	Jun	NEWA
AB	TEVA PHARMS	25MG	A091219	001	Jul 03, 2012	Jun	NEWA
AB		50MG	A091219	002	Jul 03, 2012	Jun	NEWA
AB		75MG	A091224	001	Jul 03, 2012	Jun	NEWA
AB		100MG	A091224	002	Jul 03, 2012	Jun	NEWA
AB		150MG	A091224	003	Jul 03, 2012	Jun	NEWA
AB		200MG	A091224	004	Jul 03, 2012	Jun	NEWA
AB		225MG	A091224	005	Jul 03, 2012	Jun	NEWA
AB		300MG	A091224	006	Jul 03, 2012	Jun	NEWA
AB	WATSON LABS INC	25MG	A091221	001	Jul 03, 2012	Jun	NEWA
AB		50MG	A091221	002	Jul 03, 2012	Jun	NEWA
AB		75MG	A091221	003	Jul 03, 2012	Jun	NEWA
AB		100MG	A091221	004	Jul 03, 2012	Jun	NEWA
AB		150MG	A091221	005	Jul 03, 2012	Jun	NEWA
AB		200MG	A091221	006	Jul 03, 2012	Jun	NEWA
AB		225MG	A091221	007	Jul 03, 2012	Jun	NEWA
AB		300MG	A091221	008	Jul 03, 2012	Jun	NEWA

SOLUTION; ORAL

LYRICA

+	PF PRISM	20MG/ML	N022488	001	Jan 04, 2010	Jan	CAHN
---	----------	---------	---------	-----	--------------	-----	------

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST PLAIN DENTAL

@	DENTSPLY PHARM	4%	N021382	001		May	DISC
---	----------------	----	---------	-----	--	-----	------

PRILOCAINE HYDROCHLORIDE

+	SEPTODONT INC	4%	A079235	001	Sep 29, 2010	May	CRLD
---	---------------	----	---------	-----	--------------	-----	------

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

@	HIKMA MAPLE	100MG/ML	A089029	001	Apr 17, 1986	Jun	CAHN
---	-------------	----------	---------	-----	--------------	-----	------

@		500MG/ML	A089030	001	Apr 17, 1986	Jun	CAHN
---	--	----------	---------	-----	--------------	-----	------

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATE

@	HIKMA MAPLE	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jun	CAHN
---	-------------	----------------	---------	-----	--------------	-----	------

AP	+	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jun	CAHN
----	---	----------------	---------	-----	--------------	-----	------

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

AB	SOFGEN PHARMS	100MG	A200456	001	Sep 28, 2012	Sep	NEWA
AB		200MG	A200456	002	Sep 28, 2012	Sep	NEWA
AB	TEVA PHARMS	100MG	A202121	001	Feb 29, 2012	Feb	NEWA
AB		200MG	A202121	002	Feb 29, 2012	Feb	NEWA
	PROMETRIUM						
AB	ABBOTT LABS	100MG	N019781	001	May 14, 1998	Feb	CFTG
AB	+	200MG	N019781	002	Oct 15, 1999	Feb	CFTG

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	HIKMA MAPLE	25MG/ML	A083312 001		Oct	CAHN
AP		50MG/ML	A083312 002		Oct	CAHN

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

AB	WATSON LABS INC	12.5MG	A040479 001	Jun 24, 2003	Oct	CAHN
AB		25MG	A040479 002	Jun 24, 2003	Oct	CAHN

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA	TRIS PHARMA INC	6.25MG/5ML	A091675 001	Jun 28, 2012	Jun	NEWA
----	-----------------	------------	-------------	--------------	-----	------

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

@	NESHER PHARMS	150MG	A076193 001	Feb 07, 2002	Jun	DISC
@		225MG	A076193 002	Feb 07, 2002	Jun	DISC
@		300MG	A076193 003	Feb 07, 2002	Jun	DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	APTALIS PHARMATECH	60MG	A078703 001	Jul 15, 2011	Sep	CAHN
AB		80MG	A078703 002	Jul 15, 2011	Sep	CAHN
AB		120MG	A078703 003	Jul 15, 2011	Sep	CAHN
AB		160MG	A078703 004	Jul 15, 2011	Sep	CAHN

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

@	HIKMA MAPLE	10MG/ML	A089474 001	Nov 05, 1986	Oct	CAHN
@		10MG/ML	A089475 001	Nov 05, 1986	Oct	CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

>A>	AB	EPIC PHARMA LLC	5MG	A202220 001	Nov 19, 2012	Nov	NEWA
>A>	AB		10MG	A202220 002	Nov 19, 2012	Nov	NEWA

VIVACTIL

@	TEVA WOMENS R AND D	5MG	N016012 001		Jul	CAHN
@		10MG	N016012 002		Jul	CAHN

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

MESTINON

AB	+	VALEANT PHARMS LLC	60MG	N009829 002		Jun	CAHN
----	---	--------------------	------	-------------	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

MESTINON

	+	VALEANT PHARMS LLC	180MG	N011665 001		Jun	CAHN
--	---	--------------------	-------	-------------	--	-----	------

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE INC	EQ 25MG BASE	A202152 001	Mar 27, 2012	Mar	NEWA
----	--	---------------------	--------------	-------------	--------------	-----	------

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE INC	EQ 50MG BASE	A202152 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A202152 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A202152 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A202152 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A202152 006	Mar 27, 2012	Mar	NEWA
AB	APOTEX INC	EQ 25MG BASE	A090960 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090960 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090960 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090960 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090960 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090960 006	Mar 27, 2012	Mar	NEWA
AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A091388 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A091388 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A091388 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A091388 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A091388 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A091388 007	Mar 27, 2012	Mar	NEWA
AB	DR REDDYS LABS LTD	EQ 25MG BASE	A077380 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077380 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077380 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077380 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077380 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077380 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077380 007	Mar 27, 2012	Mar	NEWA
AB	LUPIN LTD	EQ 25MG BASE	A201109 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201109 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201109 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201109 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201109 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201109 006	Mar 27, 2012	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 25MG BASE	A090323 001	Mar 27, 2012	Mar	NEWA
AB	ROXANE	EQ 25MG BASE	A090120 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090749 001	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090749 002	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090749 003	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090749 004	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090749 005	Mar 27, 2012	Mar	NEWA
AB	SUN PHARMA GLOBAL	EQ 25MG BASE	A201190 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201190 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201190 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201190 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201190 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201190 006	Mar 27, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 25MG BASE	A077745 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077745 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077745 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077745 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077745 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077745 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077745 007	Mar 27, 2012	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 25MG BASE	A200363 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A200363 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A200363 003	Mar 27, 2012	Mar	NEWA

TABLET; ORAL

QUETIAPINE FUMARATE

AB		TORRENT PHARMS LTD	EQ 200MG BASE	A200363 004	Mar 27, 2012	Mar	NEWA
AB			EQ 300MG BASE	A200363 005	Mar 27, 2012	Mar	NEWA
AB			EQ 400MG BASE	A200363 006	Mar 27, 2012	Mar	NEWA

SEROQUEL

AB	+	ASTRAZENECA	EQ 25MG BASE	N020639 001	Sep 26, 1997	Mar	CFTG
AB			EQ 50MG BASE	N020639 007	Oct 04, 2005	Mar	CFTG
AB			EQ 100MG BASE	N020639 002	Sep 26, 1997	Mar	CFTG
AB			EQ 200MG BASE	N020639 003	Sep 26, 1997	Mar	CFTG
AB	+		EQ 300MG BASE	N020639 005	Jul 26, 2000	Mar	CFTG
AB			EQ 400MG BASE	N020639 006	Oct 04, 2005	Mar	CFTG

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

@	SANDOZ	EQ 5MG BASE	A076803 001	Mar 02, 2005	Aug	DISC
@		EQ 10MG BASE	A076803 002	Mar 02, 2005	Aug	DISC
@		EQ 20MG BASE	A076803 003	Mar 02, 2005	Aug	DISC
@		EQ 40MG BASE	A076803 004	Mar 02, 2005	Aug	DISC

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

>D>	AB	+	AR HOLDING CO INC	324MG	N021799 001	Aug 12, 2005	Nov	CAHN
	AB	+		324MG	N021799 001	Aug 12, 2005	Sep	CFTG
>A>	AB	+	MUTUAL PHARM CO INC	324MG	N021799 001	Aug 12, 2005	Nov	CAHN

QUININE SULFATE

AB		TEVA PHARMS	324MG	A091661 001	Sep 28, 2012	Sep	NEWA
----	--	-------------	-------	-------------	--------------	-----	------

RAMELTEON

TABLET; ORAL

ROZEREM

+	TAKEDA PHARMS USA	8MG	N021782 001	Jul 22, 2005	Jul	CAHN
---	-------------------	-----	-------------	--------------	-----	------

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

@	RANBAXY LABS LTD	5MG	A078849 001	Mar 06, 2009	Apr	DISC
@		10MG	A078849 002	Mar 06, 2009	Apr	DISC

TABLET; ORAL

ALTACE

@	KING PFIZER	1.25MG	N022021 001	Feb 27, 2007	Jan	DISC
@		2.5MG	N022021 002	Feb 27, 2007	Jan	DISC
@		5MG	N022021 003	Feb 27, 2007	Jan	DISC
@		10MG	N022021 004	Feb 27, 2007	Jan	DISC

RAMIPRIL

AB		MYLAN PHARMS INC	1.25MG	A090650 001	Jun 30, 2011	Sep	CAHN
AB			2.5MG	A090650 002	Jun 30, 2011	Sep	CAHN
AB			5MG	A090650 003	Jun 30, 2011	Sep	CAHN
AB			10MG	A090650 004	Jun 30, 2011	Sep	CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

AP	+	COVIS PHARMA	EQ 25MG BASE/ML	N019090 001	Oct 19, 1984	Mar	CAHN
----	---	--------------	-----------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

ZANTAC IN PLASTIC CONTAINER

+	COVIS PHARMA	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Mar	CAHN
@		EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Mar	CAHN

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

@	RANBAXY	EQ 15MG BASE/ML	A078448	001	Dec 13, 2007	Sep	DISC
---	---------	-----------------	---------	-----	--------------	-----	------

REGORAFENIB

TABLET; ORAL

STIVARGA

+	BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012	Sep	NEWA
---	----------------	------	---------	-----	--------------	-----	------

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

AB	PROSAM LABS	300MG	N050429	001		Feb	CMFD
----	-------------	-------	---------	-----	--	-----	------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011	Feb	CAHN
---	---------------	--------------	---------	-----	--------------	-----	------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB	WARNER CHILCOTT LLC	5MG	N020835	002	Apr 14, 2000	Jun	CAHN
AB		30MG	N020835	001	Mar 27, 1998	Jun	CAHN
AB	+	35MG	N020835	003	May 25, 2002	Jun	CAHN
	@	75MG	N020835	004	Apr 16, 2007	Jun	CAHN
	+	150MG	N020835	005	Apr 22, 2008	Jun	CAHN

TABLET, DELAYED RELEASE; ORAL

ATELVIA

+	WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010	Jun	CAHN
---	---------------------	------	---------	-----	--------------	-----	------

RISPERIDONE

SOLUTION; ORAL

RISPERIDONE

>A>	AA	TRIS PHARMA INC	1MG/ML	A079059	001	Dec 12, 2012	Nov	NEWA
-----	----	-----------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

RISPERIDONE

AB	PROSAM LABS	0.25MG	A078071	001	Jun 17, 2009	Feb	CMFD
AB		0.5MG	A078071	002	Jun 17, 2009	Feb	CMFD
AB		1MG	A078071	003	Jun 17, 2009	Feb	CMFD
AB		2MG	A078071	004	Jun 17, 2009	Feb	CMFD
AB		3MG	A078071	005	Jun 17, 2009	Feb	CMFD
AB		4MG	A078071	006	Jun 17, 2009	Feb	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB	TEVA	0.5MG	A076908	001	Mar 12, 2012	Feb	NEWA
AB		1MG	A076908	002	Mar 12, 2012	Feb	NEWA
AB		2MG	A076908	003	Mar 12, 2012	Feb	NEWA

RIVAROXABAN

TABLET; ORAL

XARELTO

>A>	JANSSEN PHARMS	15MG	N022406 002	Nov 04, 2011	Nov	CMS1
>A>	+	20MG	N022406 003	Nov 04, 2011	Nov	CMS1

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EXELON

NOVARTIS

13.3MG/24HR

N022083 005 Aug 31, 2012 Aug NEWA

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

AB	ALEMBIC PHARMS LTD	EQ 1.5MG BASE	A091689 001	Jun 12, 2012	May	NEWA
AB		EQ 3MG BASE	A091689 002	Jun 12, 2012	May	NEWA
AB		EQ 4.5MG BASE	A091689 003	Jun 12, 2012	May	NEWA
AB		EQ 6MG BASE	A091689 004	Jun 12, 2012	May	NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP	TAMARANG	50MG/5ML (10MG/ML)	A091115 001	Aug 27, 2012	Aug	NEWA
AP		100MG/10ML (10MG/ML)	A091115 002	Aug 27, 2012	Aug	NEWA
AP	TEVA PHARMS	50MG/5ML (10MG/ML)	A078717 001	Nov 26, 2008	Sep	CAHN
AP		100MG/10ML (10MG/ML)	A078717 002	Nov 26, 2008	Sep	CAHN

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	APOTEX	EQ 0.25MG BASE	A079165 001	Feb 07, 2012	Jan	NEWA
AB		EQ 0.5MG BASE	A079165 002	Feb 07, 2012	Jan	NEWA
AB		EQ 1MG BASE	A079165 003	Feb 07, 2012	Jan	NEWA
AB		EQ 2MG BASE	A079165 004	Feb 07, 2012	Jan	NEWA
AB		EQ 3MG BASE	A079165 005	Feb 07, 2012	Jan	NEWA
AB		EQ 4MG BASE	A079165 006	Feb 07, 2012	Jan	NEWA
AB		EQ 5MG BASE	A079165 007	Feb 07, 2012	Jan	NEWA
>A>	AB ORCHID HLTHCARE	EQ 0.25MG BASE	A079229 001	Nov 28, 2012	Nov	NEWA
>A>	AB	EQ 0.5MG BASE	A079229 002	Nov 28, 2012	Nov	NEWA
>A>	AB	EQ 1MG BASE	A079229 003	Nov 28, 2012	Nov	NEWA
>A>	AB	EQ 2MG BASE	A079229 004	Nov 28, 2012	Nov	NEWA
>A>	AB	EQ 3MG BASE	A079229 005	Nov 28, 2012	Nov	NEWA
>A>	AB	EQ 4MG BASE	A079229 006	Nov 28, 2012	Nov	NEWA
>A>	AB	EQ 5MG BASE	A079229 007	Nov 28, 2012	Nov	NEWA

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

AB	+ SMITHKLINE BEECHAM	EQ 2MG BASE	N022008 001	Jun 13, 2008	Apr	CFTG
AB		EQ 4MG BASE	N022008 003	Jun 13, 2008	Apr	CFTG
AB		EQ 6MG BASE	N022008 006	Apr 10, 2009	Apr	CFTG
AB		EQ 8MG BASE	N022008 004	Jun 13, 2008	Apr	CFTG
AB		EQ 12MG BASE	N022008 005	Oct 31, 2008	Apr	CFTG

ROPINIROLE HYDROCHLORIDE

AB	ACTAVIS	EQ 2MG BASE	A090869 001	May 17, 2012	Apr	NEWA
AB		EQ 4MG BASE	A090869 002	May 17, 2012	Apr	NEWA
AB		EQ 6MG BASE	A090869 003	May 17, 2012	Apr	NEWA

TABLET, EXTENDED RELEASE; ORAL

ROPINIROLE HYDROCHLORIDE

AB	ACTAVIS	EQ 8MG BASE	A090869 004	May 17, 2012	Apr	NEWA
AB		EQ 12MG BASE	A090869 005	May 17, 2012	Apr	NEWA
AB	DR REDDYS LABS LTD	EQ 2MG BASE	A201576 001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A201576 002	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A201576 003	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A201576 004	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A201576 005	Jun 06, 2012	May	NEWA
AB	MYLAN PHARMS INC	EQ 2MG BASE	A200462 001	Oct 15, 2012	Oct	NEWA
		EQ 3MG BASE	A200462 002	Oct 15, 2012	Oct	NEWA
AB		EQ 4MG BASE	A200462 003	Oct 15, 2012	Oct	NEWA
AB		EQ 6MG BASE	A200462 004	Oct 15, 2012	Oct	NEWA
AB		EQ 8MG BASE	A200462 005	Oct 15, 2012	Oct	NEWA
AB		EQ 12MG BASE	A200462 006	Oct 15, 2012	Oct	NEWA
AB	SANDOZ INC	EQ 2MG BASE	A201047 001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A201047 003	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A201047 004	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A201047 005	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A201047 006	Jun 06, 2012	May	NEWA
AB	WATSON LABS INC	EQ 2MG BASE	A200431 001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A200431 002	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A200431 003	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A200431 004	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A200431 005	Jun 06, 2012	May	NEWA
AB	WOCKHARDT LTD	EQ 2MG BASE	A091395 001	Aug 27, 2012	Aug	NEWA
AB		EQ 4MG BASE	A091395 002	Aug 27, 2012	Aug	NEWA
AB		EQ 6MG BASE	A091395 003	Aug 27, 2012	Aug	NEWA
AB		EQ 8MG BASE	A091395 004	Aug 27, 2012	Aug	NEWA
AB		EQ 12MG BASE	A091395 005	Aug 27, 2012	Aug	NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

	UCB INC	1MG/24HR	N021829 004	Apr 02, 2012	Apr	NEWA
		2MG/24HR	N021829 001	May 09, 2007	Apr	CMFD
		3MG/24HR	N021829 005	Apr 02, 2012	Apr	NEWA
		4MG/24HR	N021829 002	May 09, 2007	Apr	CMFD
		6MG/24HR	N021829 003	May 09, 2007	Apr	CMFD
+		8MG/24HR	N021829 006	Apr 02, 2012	Apr	NEWA

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+	JAZZ EUSA PHARMA	50mCi/ML	N020570 001	Mar 28, 1997	Jul	CAHN
---	------------------	----------	-------------	--------------	-----	------

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

	@ VINTAGE PHARMS LLC	5MG	A074565 001	Aug 02, 1996	Sep	CAHN
--	----------------------	-----	-------------	--------------	-----	------

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	VALEANT INTL	2%	N021385 001	Dec 10, 2003	Jan	CAHN
---	--------------	----	-------------	--------------	-----	------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@ RANBAXY LABS LTD	EQ 20MG BASE/ML	A078053	001	Feb 05, 2007	Aug	DISC
--------------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

	@ MYLAN PHARMS INC	EQ 25MG BASE	A076540	001	Mar 20, 2007	Oct	DISC
AB		EQ 25MG BASE	A078626	001	Jan 31, 2008	Sep	CAHN
	@	EQ 50MG BASE	A076540	002	Mar 20, 2007	Oct	DISC
AB		EQ 50MG BASE	A078626	002	Jan 31, 2008	Sep	CAHN
	@	EQ 100MG BASE	A076540	003	Mar 20, 2007	Oct	DISC
AB		EQ 100MG BASE	A078626	003	Jan 31, 2008	Sep	CAHN
AB	PROSAM LABS	EQ 25MG BASE	A078175	001	Jul 21, 2010	Feb	CMFD
AB		EQ 50MG BASE	A078175	002	Jul 21, 2010	Feb	CMFD
AB		EQ 100MG BASE	A078175	003	Jul 21, 2010	Feb	CMFD

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

REVATIO

+ PFIZER	10MG/ML	N203109	001	Aug 30, 2012	Aug	NEWA
----------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

REVATIO

AB	+ PFIZER	EQ 20MG BASE	N021845	001	Jun 03, 2005	Oct	CFTG
	SILDENAFIL CITRATE						
AB	APOTEX CORP	EQ 20MG BASE	A091379	001	Nov 06, 2012	Oct	NEWA
AB	DR REDDYS LABS LTD	EQ 20MG BASE	A202598	001	Nov 06, 2012	Oct	NEWA
AB	MYLAN PHARMS INC	EQ 20MG BASE	A201150	001	Nov 09, 2012	Oct	NEWA
AB	TORRENT PHARMS LTD	EQ 20MG BASE	A091479	001	Nov 06, 2012	Oct	NEWA
AB	WATSON LABS INC	EQ 20MG BASE	A202503	001	Nov 06, 2012	Oct	NEWA

SILODOSIN

CAPSULE; ORAL

RAPAFLO

+ WATSON LABS	4MG	N022206	001	Oct 08, 2008	Oct	CRLD
	8MG	N022206	002	Oct 08, 2008	Oct	CRLD

SILVER SULFADIAZINE

CREAM; TOPICAL

THERMAZENE

AB	THEPHARMANETWORK LLC	1%	N018810	001	Dec 23, 1985	Jun	CAHN
----	----------------------	----	---------	-----	--------------	-----	------

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB	MYLAN PHARMS INC	5MG	A090868	001	Jun 08, 2010	Sep	CAHN
AB		10MG	A090868	002	Jun 08, 2010	Sep	CAHN
AB		20MG	A090868	003	Jun 08, 2010	Sep	CAHN
AB		40MG	A090868	004	Jun 08, 2010	Sep	CAHN
AB		80MG	A090868	005	Jun 08, 2010	Sep	CAHN
AB	PROSAM LABS	5MG	A078735	001	Aug 30, 2010	Feb	CMFD
AB		10MG	A078735	002	Aug 30, 2010	Feb	CMFD
AB		20MG	A078735	003	Aug 30, 2010	Feb	CMFD
AB		40MG	A078735	004	Aug 30, 2010	Feb	CMFD
AB		80MG	A078735	005	Aug 30, 2010	Feb	CMFD

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYNC

MERCK SHARP DOHME	10MG;EQ 50MG BASE	N202343 004	Sep 18, 2012	Sep	NEWA
	20MG;EQ 50MG BASE	N202343 005	Sep 18, 2012	Sep	NEWA
	40MG;EQ 50MG BASE	N202343 006	Sep 18, 2012	Sep	NEWA

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

MERCK SHARP DOHME	EQ 25MG BASE	N021995 001	Oct 16, 2006	May	CAHN
	EQ 50MG BASE	N021995 002	Oct 16, 2006	May	CAHN
+	EQ 100MG BASE	N021995 003	Oct 16, 2006	May	CAHN

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

@ MALLINCKRODT INC	460MG/GM;420MG/GM	N018509 001	Aug 07, 1985	Jan	CAHN
--------------------	-------------------	-------------	--------------	-----	------

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP	HIKMA (MAPLE)	9MG/ML	A201850 001	Jan 20, 2012	Jan	NEWA
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	MEDEFIL	9MG/ML	N202832 001	Jan 06, 2012	Jan	NEWA

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPES SODIUM

@ BRACCO	200uCi/ML	N013993 001		Jun	DISC
----------	-----------	-------------	--	-----	------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB	HIKMA PHARMS	62.5MG/5ML	A078215 001	Mar 31, 2011	May	CAHN
----	--------------	------------	-------------	--------------	-----	------

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

@ GE HEALTHCARE	100uCi	N017630 001		May	DISC
SYNCOR PHARMS	400uCi	N018671 003	May 27, 1982	Oct	CMFD

SOLUTION; ORAL

SODIUM IODIDE I 123

@ GE HEALTHCARE	2mCi/ML	N017630 002		Jul	DISC
-----------------	---------	-------------	--	-----	------

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE	9-100mCi	N021305 006	May 19, 2005	Feb	CAHN
@	2-200mCi	N021305 004	Nov 18, 2004	Jan	DISC

SOLUTION; ORAL

HICON

@ JUBILANT DRAXIMAGE	1-500mCi/0.5ML	N021305 003	Jan 24, 2003	Feb	DISC
@	1-1000mCi/ML	N021305 005	Apr 04, 2006	Feb	DISC
@	1-250mCi/0.25ML	N021305 002	Jan 24, 2003	Feb	DISC

SOLUTION; ORAL

HICON

+	JUBILANT DRAXIMAGE	250-1000mCi	N021305	007	Dec 05, 2011	Jan	NEWA
---	--------------------	-------------	---------	-----	--------------	-----	------

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+	HOPE PHARMS	300MG/10ML (30MG/ML)	N203922	001	Feb 14, 2012	Feb	NEWA
---	-------------	----------------------	---------	-----	--------------	-----	------

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+	JAZZ PHARMS	500MG/ML	N021196	001	Jul 17, 2002	Jun	CAHN
---	-------------	----------	---------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

@ CITRUSPHRMA

454GM/BOT

A040909	001	Dec 03, 2008	Jun	DISC
---------	-----	--------------	-----	------

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+	HOPE PHARMS	12.5GM/50ML (250MG/ML)	N203923	001	Feb 14, 2012	Feb	NEWA
---	-------------	------------------------	---------	-----	--------------	-----	------

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN

@ NOVO NORDISK INC

5MG/1.5ML

N021148	001	Jun 20, 2000	Jul	DISC
---------	-----	--------------	-----	------

@

10MG/1.5ML

N021148	002	Jun 20, 2000	Jul	DISC
---------	-----	--------------	-----	------

@

15MG/1.5ML

N021148	003	Jun 20, 2000	Jul	DISC
---------	-----	--------------	-----	------

NORDITROPIN NORDIFLEX

@ NOVO NORDISK INC

5MG/1.5ML

N021148	004	Oct 01, 2004	Sep	DISC
---------	-----	--------------	-----	------

@

10MG/1.5ML

N021148	005	Oct 01, 2004	Sep	DISC
---------	-----	--------------	-----	------

@

15MG/1.5ML

N021148	006	Oct 01, 2004	Sep	DISC
---------	-----	--------------	-----	------

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

AB2	EPIC PHARMA INC	80MG	A077070	001	Nov 04, 2005	Jun	CAHN
-----	-----------------	------	---------	-----	--------------	-----	------

AB2		120MG	A077070	002	Nov 04, 2005	Jun	CAHN
-----	--	-------	---------	-----	--------------	-----	------

AB2		160MG	A077070	003	Nov 04, 2005	Jun	CAHN
-----	--	-------	---------	-----	--------------	-----	------

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+	PARAPRO LLC	0.9%	N022408	001	Jan 18, 2011	May	CAHN
---	-------------	------	---------	-----	--------------	-----	------

SUCCIMER

CAPSULE; ORAL

CHEMET

+	LUNDBECK LLC	100MG	N019998	002	Jan 30, 1991	Mar	CAHN
---	--------------	-------	---------	-----	--------------	-----	------

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

AP	HIKMA MAPLE	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Oct	CAHN
----	-------------	-------------------	---------	-----	--------------	-----	------

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB	FOUGERA PHARMS	10%	A077015	001	Nov 17, 2006	Jan	CAHN
----	----------------	-----	---------	-----	--------------	-----	------

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

	@ HIKMA MAPLE	80MG/ML;16MG/ML	A070627	001	Dec 29, 1987	Oct	CAHN
--	---------------	-----------------	---------	-----	--------------	-----	------

	@	80MG/ML;16MG/ML	A070628	001	Dec 29, 1987	Oct	CAHN
--	---	-----------------	---------	-----	--------------	-----	------

SUSPENSION; ORAL

SULFATRIM

	@ STI PHARMA LLC	200MG/5ML;40MG/5ML	N018615	002	Jan 07, 1983	Aug	CAHN
--	------------------	--------------------	---------	-----	--------------	-----	------

SULFATRIM PEDIATRIC

AB	STI PHARMA LLC	200MG/5ML;40MG/5ML	N018615	001	Jan 07, 1983	Aug	CAHN
----	----------------	--------------------	---------	-----	--------------	-----	------

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH

>D>	AB	PLANTEX	400MG;80MG	A070030	001	Jun 02, 1987	Nov	CAHN
-----	----	---------	------------	---------	-----	--------------	-----	------

>A>	AB	TEVA PHARMS	400MG;80MG	A070030	001	Jun 02, 1987	Nov	CAHN
-----	----	-------------	------------	---------	-----	--------------	-----	------

SULFANILAMIDE

CREAM; VAGINAL

AVC

	+	JAZZ PHARMS COMMERCL	15%	N006530	003	Jan 27, 1987	Mar	CAHN
--	---	----------------------	-----	---------	-----	--------------	-----	------

	+	JAZZ PHARMS II	15%	N006530	003	Jan 27, 1987	Jul	CAHN
--	---	----------------	-----	---------	-----	--------------	-----	------

	+	JAZZ PHARMS III	15%	N006530	003	Jan 27, 1987	Jun	CAHN
--	---	-----------------	-----	---------	-----	--------------	-----	------

>A>	+	MEDA PHARMS	15%	N006530	003	Jan 27, 1987	Nov	CAHN
-----	---	-------------	-----	---------	-----	--------------	-----	------

>D>	+	MEDPOINTE	15%	N006530	003	Jan 27, 1987	Nov	CAHN
-----	---	-----------	-----	---------	-----	--------------	-----	------

	+		15%	N006530	003	Jan 27, 1987	Oct	CAHN
--	---	--	-----	---------	-----	--------------	-----	------

SUPPOSITORY; VAGINAL

AVC

	@	JAZZ PHARMS COMMERCL	1.05GM	N006530	004	Jan 27, 1987	Mar	CAHN
--	---	----------------------	--------	---------	-----	--------------	-----	------

	@	JAZZ PHARMS II	1.05GM	N006530	004	Jan 27, 1987	Jul	CAHN
--	---	----------------	--------	---------	-----	--------------	-----	------

	@	JAZZ PHARMS III	1.05GM	N006530	004	Jan 27, 1987	Jun	CAHN
--	---	-----------------	--------	---------	-----	--------------	-----	------

>A>	@	MEDA PHARMS	1.05GM	N006530	004	Jan 27, 1987	Nov	CAHN
-----	---	-------------	--------	---------	-----	--------------	-----	------

>D>	@	MEDPOINTE	1.05GM	N006530	004	Jan 27, 1987	Nov	CAHN
-----	---	-----------	--------	---------	-----	--------------	-----	------

	@		1.05GM	N006530	004	Jan 27, 1987	Oct	CAHN
--	---	--	--------	---------	-----	--------------	-----	------

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

BX	MERIDIAN MEDCL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022377	001	Jun 29, 2010	Jun	CRLD
----	----------------	-------------------------------------	---------	-----	--------------	-----	------

SUMATRIPTAN SUCCINATE

AP	INJECTALIA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090310	001	Aug 11, 2010	Mar	CAHN
----	------------	-------------------------------------	---------	-----	--------------	-----	------

AB	SUN PHARMA GLOBAL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358	001	Jun 21, 2011	Oct	CAHN
----	-------------------	-------------------------------------	---------	-----	--------------	-----	------

SUMAVEL DOSEPRO

BX	+	ZOGENIX INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009	Jun	CTEC
----	---	-------------	-------------------------------------	---------	-----	--------------	-----	------

TABLET; ORAL

SUMATRIPTAN SUCCINATE

AB	APOTEX INC	EQ 25MG BASE	A200263	001	Jun 19, 2012	Jun	NEWA
----	------------	--------------	---------	-----	--------------	-----	------

AB		EQ 50MG BASE	A200263	002	Jun 19, 2012	Jun	NEWA
----	--	--------------	---------	-----	--------------	-----	------

AB		EQ 100MG BASE	A200263	003	Jun 19, 2012	Jun	NEWA
----	--	---------------	---------	-----	--------------	-----	------

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

AB	ACCORD HLTHCARE	EQ 0.5MG BASE	A091195 001	Aug 31, 2011	Sep	CPOT
AB		EQ 1MG BASE	A091195 002	Aug 31, 2011	Sep	CPOT
AB		EQ 5MG BASE	A091195 003	Aug 31, 2011	Sep	CPOT
AB	PANACEA BIOTEC LTD	EQ 0.5MG BASE	A090802 001	Sep 28, 2012	Sep	NEWA
AB		EQ 1MG BASE	A090802 002	Sep 28, 2012	Sep	NEWA
AB		EQ 5MG BASE	A090802 003	Sep 28, 2012	Sep	NEWA

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+	MERCK SHARP DOHME	0.0015%	N202514 001	Feb 10, 2012	Feb	NEWA
---	-------------------	---------	-------------	--------------	-----	------

TALIGLUCERASE ALFA

POWDER; IV (INFUSION)

ELELYSO

+	PFIZER	200 UNITS/VIAL	N022458 001	May 01, 2012	May	NEWA
---	--------	----------------	-------------	--------------	-----	------

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

	ONCOGENERIX PHARMS	EQ 10MG BASE/5ML	N021807 001	Oct 29, 2005	Aug	CMFD
--	--------------------	------------------	-------------	--------------	-----	------

TABLET; ORAL

TAMOXIFEN CITRATE

@	AEGIS PHARMS	EQ 10MG BASE	A076398 001	Mar 31, 2003	Jun	DISC
---	--------------	--------------	-------------	--------------	-----	------

@		EQ 20MG BASE	A076398 002	Mar 31, 2003	Jun	DISC
---	--	--------------	-------------	--------------	-----	------

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL

NUCYNТА

+	JANSSEN PHARMS	EQ 20MG BASE/ML	N203794 001	Oct 15, 2012	Oct	NEWA
---	----------------	-----------------	-------------	--------------	-----	------

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+	STIEFEL LABS INC	0.1%	N202428 001	May 11, 2012	May	NEWA
---	------------------	------	-------------	--------------	-----	------

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

@	JUBILANT DRAXIMAGE	N/A	N018035 001		May	CAHN
---	--------------------	-----	-------------	--	-----	------

DRAXIMAGE MDP-25

+	JUBILANT DRAXIMAGE	N/A	N018035 002	Feb 27, 2004	May	CAHN
---	--------------------	-----	-------------	--------------	-----	------

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB	NOVEL LABS INC	7.5MG	A071457 002	Jun 22, 2012	Jun	NEWA
AB		22.5MG	A071457 003	Jun 22, 2012	Jun	NEWA

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

AB	MERCK SHARP DOHME	5MG	N021029 001	Aug 11, 1999	Jun	CAHN
AB		20MG	N021029 002	Aug 11, 1999	Jun	CAHN
AB		100MG	N021029 003	Aug 11, 1999	Jun	CAHN
AB		140MG	N021029 005	Oct 19, 2006	Jun	CAHN
AB		180MG	N021029 006	Oct 19, 2006	Jun	CAHN
AB	+	250MG	N021029 004	Aug 11, 1999	Jun	CAHN

POWDER; INTRAVENOUS

TEMODAR

+	MERCK SHARP DOHME	100MG/VIAL	N022277 001	Feb 27, 2009	Jun	CAHN
---	-------------------	------------	-------------	--------------	-----	------

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577 001	Jan 18, 2012	Jan	NEWA
---	---------------------	---------------	-------------	--------------	-----	------

TABLET; ORAL

VIREAD

	GILEAD SCIENCES INC	150MG	N021356 002	Jan 18, 2012	Apr	NEWA
		200MG	N021356 003	Jan 18, 2012	Apr	NEWA
		250MG	N021356 004	Jan 18, 2012	Apr	NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

@	RANBAXY LABS LTD	EQ 1MG BASE	A076021 001	Aug 22, 2002	Apr	DISC
@		EQ 2MG BASE	A076021 002	Aug 22, 2002	Apr	DISC
@		EQ 5MG BASE	A076021 003	Aug 22, 2002	Apr	DISC
@		EQ 10MG BASE	A076021 004	Aug 22, 2002	Apr	DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

@	TEVA PARENTERAL	1MG/ML	A076853 001	Jul 20, 2004	Jan	DISC
---	-----------------	--------	-------------	--------------	-----	------

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

AB	FOUGERA PHARMS	0.4%	A076712 001	Feb 18, 2005	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

SUPPOSITORY; VAGINAL

TERCONAZOLE

AB	FOUGERA PHARMS	80MG	A076850 001	Jul 12, 2006	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

TERIFLUNOMIDE

TABLET; ORAL

AUBAGIO

	SANOFI AVENTIS US	7MG	N202992 001	Sep 12, 2012	Sep	NEWA
+		14MG	N202992 002	Sep 12, 2012	Sep	NEWA

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

@	EMD SERONO	EQ 1MG BASE/VIAL	N022505 001	Nov 10, 2010	Jun	DISC
+		EQ 1MG BASE/VIAL	N022505 001	Nov 10, 2010	May	CAHN

POWDER; SUBCUTANEOUS

EGRIFTA

+	EMD SERONO	EQ 2MG BASE/VIAL	N022505 002	Nov 29, 2011	Jun	NEWA
---	------------	------------------	-------------	--------------	-----	------

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

BX	+	ABBOTT LABS	1% (50MG/5GM PACKET)	N021015 002	Feb 28, 2000	Feb	CPOT
			1% (25MG/2.5GM PACKET)	N021015 001	Feb 28, 2000	Feb	CPOT
		ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309 002	Sep 07, 2012	Sep	NEWA
	+		1.62% (40.5MG/2.5GM PACKET)	N022309 003	Sep 07, 2012	Sep	NEWA

TESTIM

BX	+	AUXILIUM PHARMS	1% (50MG/5GM PACKET)	N021454 001	Oct 31, 2002	Feb	CPOT
		TESTOSTERONE					
		TEVA PHARMS	25MG/2.5GM PACKET	N202763 001	Feb 14, 2012	Feb	NEWA
			50MG/5GM PACKET	N202763 002	Feb 14, 2012	Feb	NEWA

GEL, METERED; TRANSDERMAL

ANDROGEL

+	ABBOTT LABS	1% (1.25GM/ACTUATION)	N021015 003	Sep 26, 2003	Jun	CPOT
FORTESTA						
+	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463 001	Dec 29, 2010	Sep	CPOT

PELLET; IMPLANTATION

TESTOPEL

+	ACTIENT PHARMS	75MG	A080911 001		May	CAHN
---	----------------	------	-------------	--	-----	------

SOLUTION, METERED; TRANSDERMAL

AXIRON

+	ELI LILLY AND CO	30MG/1.5ML ACTUATION	N022504 001	Nov 23, 2010	Sep	CPOT
---	------------------	----------------------	-------------	--------------	-----	------

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

AO	HIKMA FARMACEUTICA	200MG/ML	A091244 001	May 01, 2012	Apr	NEWA
AO	MYLAN INSTITUTIONAL	200MG/ML	A040652 001	Dec 11, 2006	Feb	CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

TESTOSTERONE ENANTHATE

AO	HIKMA FARMACEUTICA	200MG/ML	A091120 001	Sep 18, 2012	Sep	NEWA
AO	MYLAN INSTITUTIONAL	200MG/ML	A040647 001	Oct 05, 2009	Feb	CAHN

TETRABENAZINE

TABLET; ORAL

XENAZINE

	VALEANT BERMUDA	12.5MG	N021894 001	Aug 15, 2008	Oct	CAHN
+		25MG	N021894 002	Aug 15, 2008	Oct	CAHN
	VALEANT PHARMS	12.5MG	N021894 001	Aug 15, 2008	Apr	CAHN
+		25MG	N021894 002	Aug 15, 2008	Apr	CAHN

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+	FOUGERA PHARMS	0.05%	A086576 002		Jan	CAHN
		0.1%	A086576 001		Jan	CAHN

SPRAY; NASAL

TYZINE

+	FOUGERA PHARMS	0.1%	A086576 003		Jan	CAHN
---	----------------	------	-------------	--	-----	------

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

>A>	ACTIENT PHARMS	100MG	A087942 001	Aug 22, 1983	Nov	CAHN
>A>		200MG	A087943 001	Aug 22, 1983	Nov	CAHN
>A>		300MG	A087944 001	Aug 22, 1983	Nov	CAHN
>A>	+	400MG	A081034 001	Feb 28, 1992	Nov	CAHN
>D>	UCB INC	100MG	A087942 001	Aug 22, 1983	Nov	CAHN
		100MG	A087942 001	Aug 22, 1983	May	CTEC
>D>		200MG	A087943 001	Aug 22, 1983	Nov	CAHN
		200MG	A087943 001	Aug 22, 1983	May	CTEC
>D>		300MG	A087944 001	Aug 22, 1983	Nov	CAHN
		300MG	A087944 001	Aug 22, 1983	May	CTEC
>D>	+	400MG	A081034 001	Feb 28, 1992	Nov	CAHN
	+	400MG	A081034 001	Feb 28, 1992	May	CRLD

THEOPHYLLINE

@	INWOOD LABS	100MG	A040052 001	Feb 14, 1994	May	DISC
@		125MG	A040052 002	Feb 14, 1994	May	DISC
@		200MG	A040052 003	Feb 14, 1994	May	DISC
@		300MG	A040052 004	Feb 14, 1994	May	DISC

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	4MG/ML	N018649 007	Jul 26, 1982	Mar	DISC
@		40MG/100ML	N018649 001	Jul 26, 1982	Mar	DISC
@		80MG/100ML	N018649 002	Jul 26, 1982	Mar	DISC
@		160MG/100ML	N018649 003	Jul 26, 1982	Mar	DISC
@		200MG/100ML	N018649 004	Jul 26, 1982	Mar	DISC
@		320MG/100ML	N018649 006	Nov 13, 1985	Mar	DISC
@		400MG/100ML	N018649 005	Jul 26, 1982	Mar	DISC

SOLUTION; ORAL

THEOPHYLLINE

AA	+	SILARX	80MG/15ML	A091156 001	Apr 13, 2011	Jun	CTEC
AA		TRIS PHARMA INC	80MG/15ML	A091586 001	Jun 15, 2012	Jun	NEWA

TABLET; ORAL

THEOLAIR

+	MEDICIS	125MG	A086399 001		Jul	CAHN
+		250MG	A086399 002		Jul	CAHN

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

@	INWOOD LABS	450MG	A040034 001	Apr 28, 1995	Oct	DISC
	UNIPHYL					
@	RHODES PHARMS	400MG	A087571 001	Sep 01, 1982	Sep	CAHN
@		600MG	A040086 001	Apr 15, 1996	Sep	CAHN

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

	@	HIKMA MAPLE	100MG/ML	A080575 001		Oct	CAHN
AP		MYLAN INSTITUTIONAL	100MG/ML	A091623 001	Jun 25, 2012	Jun	NEWA

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

@	CEPHALON	6MG	N020646 006	Nov 29, 2005	Jan	DISC
@		8MG	N020646 007	Nov 29, 2005	Jan	DISC

TABLET; ORAL

GABITRIL

@ CEPHALON

10MG

N020646 008 Nov 29, 2005 Jan DISC

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

@ SANDOZ

250MG

A075326 001 Aug 20, 1999 Oct DISC

TINIDAZOLE

TABLET; ORAL

TINDAMAX

AB MISSION PHARMA

250MG

N021618 001 May 17, 2004 Apr CFTG

AB +

500MG

N021618 002 May 17, 2004 Apr CFTG

TINIDAZOLE

AB NOVEL LABS INC

250MG

A202044 001 Apr 30, 2012 Apr NEWA

AB

500MG

A202044 002 Apr 30, 2012 Apr NEWA

AB

ROXANE

250MG

A201172 001 Apr 30, 2012 Apr NEWA

AB

500MG

A201172 002 Apr 30, 2012 Apr NEWA

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

@ LEO PHARMA AS

20,000 IU/ML

N020484 001 Jul 14, 2000 Jun DISC

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB APOTEX INC

EQ 2MG BASE

A078868 001 Feb 03, 2012 Jan NEWA

AB

EQ 4MG BASE

A078868 002 Feb 03, 2012 Jan NEWA

AB

EQ 6MG BASE

A078868 003 Feb 03, 2012 Jan NEWA

AB MYLAN LABS

EQ 2MG BASE

A091502 001 Nov 09, 2012 Oct NEWA

AB

EQ 4MG BASE

A091502 002 Nov 09, 2012 Oct NEWA

AB

EQ 6MG BASE

A091502 003 Nov 09, 2012 Oct NEWA

ZANAFLEX

AB ACORDA

EQ 2MG BASE

N021447 001 Aug 29, 2002 Jan CFTG

AB

EQ 4MG BASE

N021447 002 Aug 29, 2002 Jan CFTG

AB +

EQ 6MG BASE

N021447 003 Aug 29, 2002 Jan CFTG

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB MYLAN PHARMS INC

EQ 2MG BASE

A076282 001 Dec 16, 2003 Sep CAHN

AB

EQ 4MG BASE

A076282 002 Dec 16, 2003 Sep CAHN

AB PROSAM LABS

EQ 2MG BASE

A076281 001 Oct 20, 2003 Feb CMFD

AB

EQ 4MG BASE

A076281 002 Oct 20, 2003 Feb CMFD

AB SANDOZ INC

EQ 2MG BASE

A076280 001 Nov 26, 2002 Feb NEWA

>A> AB

UNICHEM LABS LTD

EQ 2MG BASE

A091283 001 Nov 28, 2012 Nov NEWA

>A> AB

EQ 4MG BASE

A091283 002 Nov 28, 2012 Nov NEWA

TOBRAMYCIN

SOLUTION; INHALATION

BETHKIS

>D> CHIESI PHARMS INC

300MG/4ML

N201820 001 Oct 12, 2012 Nov CAHN

300MG/4ML

N201820 001 Oct 12, 2012 Oct NEWA

>A> CORNERSTONE THERAP

300MG/4ML

N201820 001 Oct 12, 2012 Nov CAHN

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

	@ APOTHECON	EQ 10MG BASE/ML	A064021 001	May 31, 1994	Sep	DISC
	@ HIKMA MAPLE	EQ 10MG BASE/ML	A063128 001	Nov 27, 1991	Oct	CAHN
	@	EQ 10MG BASE/ML	A063113 001	Apr 26, 1991	Oct	CAHN
	@	EQ 40MG BASE/ML	A063118 001	Jul 29, 1991	Oct	CAHN
AP		EQ 40MG BASE/ML	A063117 001	Apr 26, 1991	Oct	CAHN
	@	EQ 40MG BASE/ML	A063127 001	Nov 27, 1991	Oct	CAHN
AP	PFIZER	EQ 40MG BASE/ML	A065407 001	Mar 11, 2008	Sep	CAHN

>A> TOFACITINIB CITRATE

>A> TABLET; ORAL

>A> XELJANZ

>A>	+	PFIZER	EQ 5MG BASE	N203214 001	Nov 06, 2012	Nov	NEWA
-----	---	--------	-------------	-------------	--------------	-----	------

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

+	MYLAN PHARMS INC	500MG	A086445 001		Mar	CRLD
@	WATSON LABS	500MG	A087318 001		Mar	DISC
@		500MG	A086109 001		Mar	DISC

TOLCAPONE

TABLET; ORAL

TASMAR

+	VALEANT PHARMS LLC	100MG	N020697 001	Jan 29, 1998	May	CAHN
@		200MG	N020697 002	Jan 29, 1998	May	CAHN

TOLTERODINE TARTRATE

TABLET; ORAL

DETROL

AB	PHARMACIA AND UPJOHN	1MG	N020771 001	Mar 25, 1998	Sep	CFTG
AB	+	2MG	N020771 002	Mar 25, 1998	Sep	CFTG

TOLTERODINE TARTRATE

AB	APOTEX CORP	1MG	A200164 001	Sep 25, 2012	Sep	NEWA	
AB		2MG	A200164 002	Sep 25, 2012	Sep	NEWA	
>A>	AB	MYLAN PHARMS INC	1MG	A202641 001	Nov 27, 2012	Nov	NEWA
>A>	AB		2MG	A202641 002	Nov 27, 2012	Nov	NEWA

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP	INNOPHARMA INC	EQ 4MG BASE/VIAL	A201166 001	Aug 08, 2012	Jul	NEWA
AP	ONCO THERAPIES LTD	EQ 4MG BASE/VIAL	A091542 001	Aug 28, 2012	Aug	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

>A>	AB	IPCA LABS LTD	50MG	A201973 001	Nov 16, 2012	Nov	NEWA
AB	MYLAN PHARMS INC	50MG	A075980 001	Nov 21, 2002	Sep	CAHN	
	@ SANDOZ	50MG	A075968 001	Jun 25, 2002	Aug	DISC	

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

AB2	ACTAVIS	100MG	A091609 001	Jun 27, 2012	Jun	NEWA
-----	---------	-------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

AB2	ACTAVIS	200MG	A091609 002	Jun 27, 2012	Jun	NEWA
AB2		300MG	A091609 003	Jun 27, 2012	Jun	NEWA
AB2	ANCHEN PHARMS	100MG	A200491 001	Jun 27, 2012	Jun	NEWA
AB2		200MG	A200491 002	Jun 27, 2012	Jun	NEWA
AB2		300MG	A200491 003	Jun 27, 2012	Jun	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

+	SHIONOGI INC	50MG	N021693 001	May 05, 2005	Mar	CTNA
---	--------------	------	-------------	--------------	-----	------

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP	APP PHARMS LLC	100MG/ML	A091596 001	Mar 02, 2012	May	CAHN
AP	LUITPOLD	100MG/ML	A201885 001	Aug 10, 2011	Sep	CAHN
AP	NEXUS PHARMS	100MG/ML	A091596 001	Mar 02, 2012	Feb	NEWA

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

AB	+	COVIS PHARMA	EQ 10MG BASE	N012342 003	Aug 16, 1985	Jan	CAHN
----	---	--------------	--------------	-------------	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB	MYLAN PHARMS INC	50MG	A090514 001	Jun 02, 2009	Sep	CAHN
AB		100MG	A090514 002	Jun 02, 2009	Sep	CAHN
AB		150MG	A090514 003	Jun 02, 2009	Sep	CAHN
AB		300MG	A090514 004	Jun 02, 2009	Sep	CAHN

TRETINOIN

CAPSULE; ORAL

TRETINOIN

AB	ANCHEN PHARMS	10MG	A201687 001	Oct 24, 2012	Oct	NEWA	
AB	+	BARR LABS INC	10MG	A077684 001	Jun 22, 2007	Oct	CTEC

CREAM; TOPICAL

AVITA

AB	MYLAN PHARMS INC	0.025%	N020404 003	Jan 14, 1997	Jun	CAHN
----	------------------	--------	-------------	--------------	-----	------

RENOVA

+	VALEANT INTL	0.02%	N021108 001	Aug 31, 2000	Jan	CAHN
AB2	+	0.05%	N019963 001	Dec 29, 1995	Jan	CAHN

RETIN-A

AB	+	VALEANT INTL	0.025%	N019049 001	Sep 16, 1988	Jan	CAHN
AB1	+		0.05%	N017522 001		Jan	CAHN
AB	+		0.1%	N017340 001		Jan	CAHN

TRETINOIN

AB	PRECISION DERMAT	0.025%	A075264 001	Dec 24, 1998	May	CAHN
+		0.0375%	A090098 001	Mar 22, 2010	May	CAHN
AB1		0.05%	A075265 001	Dec 24, 1998	May	CAHN
		0.075%	A202209 001	Oct 11, 2012	Sep	NEWA
AB		0.1%	A075213 001	Dec 24, 1998	May	CAHN
AB2	SUNEVA MEDCL	0.05%	A076498 001	Sep 15, 2005	May	CAHN

GEL; TOPICAL

RETIN-A

AB	+	VALEANT INTL	0.01%	N017955 001		Jan	CAHN
----	---	--------------	-------	-------------	--	-----	------

GEL; TOPICAL									
RETIN-A									
AB	+	VALEANT INTL	0.025%		N017579 002		Jan	CAHN	
TRETINOIN									
AB		PRECISION DERMAT	0.01%		A075589 001	Jun 11, 2002	May	CAHN	
AB			0.025%		A075529 001	Feb 22, 2000	May	CAHN	
SOLUTION; TOPICAL									
RETIN-A									
AT	+	VALEANT INTL	0.05%		N016921 001		Jan	CAHN	
SWAB; TOPICAL									
RETIN-A									
	@	VALEANT INTL	0.05%		N016921 002		Jan	CAHN	
<u>TRIAMCINOLONE ACETONIDE</u>									
AEROSOL, METERED; INHALATION									
AZMACORT									
	@	ABBOTT	0.1MG/INH		N018117 001	Apr 23, 1982	May	DISC	
CREAM; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT		FOUGERA PHARMS	0.025%		A085692 001		Jan	CAHN	
AT			0.1%		A085692 003		Jan	CAHN	
AT	+		0.5%		A085692 002		Jan	CAHN	
LOTION; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT		FOUGERA PHARMS	0.025%		A040467 001	Apr 21, 2003	Jan	CAHN	
AT			0.1%		A040467 002	Apr 21, 2003	Jan	CAHN	
AT	+	MORTON GROVE	0.025%		A088450 001	Apr 01, 1985	Oct	CRLD	
OINTMENT; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT		FOUGERA PHARMS	0.025%		A085691 001		Jan	CAHN	
AT			0.1%		A085691 003		Jan	CAHN	
AT			0.5%		A085691 002		Jan	CAHN	
SPRAY, METERED; NASAL									
TRIAMCINOLONE ACETONIDE									
AB		TEVA PHARMS	0.055MG/SPRAY		A078104 001	Jul 30, 2009	Mar	CAHN	
<u>TRIAZOLAM</u>									
TABLET; ORAL									
TRIAZOLAM									
AB		MYLAN PHARMS INC	0.125MG		A074031 001	Mar 25, 1994	Sep	CAHN	
AB			0.25MG		A074031 002	Mar 25, 1994	Sep	CAHN	
<u>TRIFLURIDINE</u>									
SOLUTION/DROPS; OPHTHALMIC									
TRIFLURIDINE									
AT		ALCON PHARMS LTD	1%		A074311 001	Oct 06, 1995	Sep	CAHN	
<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
TRIMETHOBENZAMIDE HYDROCHLORIDE									
	@	HOSPIRA	100MG/ML		A088804 001	Apr 03, 1987	Jun	DISC	
<u>TROSPIMUM CHLORIDE</u>									
CAPSULE, EXTENDED RELEASE; ORAL									
SANCTURA XR									
AB	+	ALLERGAN	60MG		N022103 001	Aug 03, 2007	Sep	CFTG	

CAPSULE, EXTENDED RELEASE; ORAL

TROSPIUM CHLORIDE

AB	WATSON LABS INC FL	60MG	A091289	001	Oct 12, 2012	Sep	NEWA
----	--------------------	------	---------	-----	--------------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	JUBILANT ORGANOSYS	EQ 500MG BASE	A201506	001	Apr 03, 2012	Mar	NEWA
AB		EQ 1GM BASE	A201506	002	Apr 03, 2012	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 500MG BASE	A078518	001	May 24, 2010	Sep	CAHN
AB		EQ 1GM BASE	A078518	002	May 24, 2010	Sep	CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

+	HOFFMANN LA ROCHE	50MG/ML	N022257	001	Aug 28, 2009	May	CAHN
---	-------------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

VALCYTE

+	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304	001	Mar 29, 2001	May	CAHN
---	-------------------	---------------	---------	-----	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

AB	VIROPHARMA	EQ 125MG BASE	N050606	001	Apr 15, 1986	Mar	CFTG
AB	+	EQ 250MG BASE	N050606	002	Apr 15, 1986	Mar	CFTG

VANCOMYCIN HYDROCHLORIDE

AB	AKORN	EQ 125MG BASE	A065478	001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065478	002	Apr 09, 2012	Mar	NEWA
AB	APP PHARMS LLC	EQ 125MG BASE	A065453	001	Jun 18, 2012	Jun	NEWA
AB		EQ 250MG BASE	A065453	002	Jun 18, 2012	Jun	NEWA
AB	STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490	001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065490	002	Apr 09, 2012	Mar	NEWA
AB	WATSON LABS	EQ 125MG BASE	A065510	001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065510	002	Apr 09, 2012	Mar	NEWA

INJECTABLE; INJECTION

VANCOLED

@	HIKMA MAPLE	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Oct	CAHN
@		EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Oct	CAHN
@		EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Oct	CAHN
@		EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Oct	CAHN
@		EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Oct	CAHN

VANCOMYCIN HYDROCHLORIDE

@	HIKMA MAPLE	EQ 500MG BASE/VIAL	A062879	001	Aug 02, 1988	Oct	CAHN
@		EQ 1GM BASE/VIAL	A062879	002	Aug 02, 1988	Oct	CAHN
AP	SAGENT PHARMS	EQ 5GM BASE/VIAL	A200837	001	Aug 10, 2012	Jul	NEWA
AP	SANDOZ INC	EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Jul	NEWA
AP		EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Jul	NEWA

VANDETANIB

TABLET; ORAL

CAPRELSA

	IPR PHARMS INC	100MG	N022405	001	Apr 06, 2011	Feb	CTNA
+		300MG	N022405	002	Apr 06, 2011	Feb	CTNA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

AB	BAYER HLTHCARE	2.5MG	N021400 003	Aug 19, 2003	Apr	CFTG
AB		5MG	N021400 001	Aug 19, 2003	Apr	CFTG
AB		10MG	N021400 002	Aug 19, 2003	Apr	CFTG
AB	+	20MG	N021400 004	Aug 19, 2003	Apr	CFTG

VARDENAFIL HYDROCHLORIDE

AB	TEVA PHARMS	2.5MG	A091347 001	May 03, 2012	Apr	NEWA
AB		5MG	A091347 002	May 03, 2012	Apr	NEWA
AB		10MG	A091347 003	May 03, 2012	Apr	NEWA
AB		20MG	A091347 004	May 03, 2012	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	BEDFORD	10MG/VIAL	A075549 001	Jun 13, 2000	Jun	CRLD
>D>		20MG/VIAL	A075549 002	Jun 13, 2000	Nov	CTEC
>A>	AP	20MG/VIAL	A075549 002	Jun 13, 2000	Nov	CTEC
		20MG/VIAL	A075549 002	Jun 13, 2000	Jun	CRLD
	@ HIKMA MAPLE	10MG/VIAL	A075218 001	Aug 23, 1999	Oct	CAHN
	@	20MG/VIAL	A075218 002	Aug 23, 1999	Oct	CAHN
AP	+	SUN PHARMA GLOBAL	A079001 001	Jun 17, 2009	Jun	CRLD
AP	+		A079001 002	Jun 17, 2009	Jun	CRLD

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ANCHEN PHARMS	EQ 37.5MG BASE	A078087 001	Mar 16, 2012	Mar	NEWA
AB		EQ 75MG BASE	A078087 002	Mar 16, 2012	Mar	NEWA
AB		EQ 150MG BASE	A078087 003	Mar 16, 2012	Mar	NEWA

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	HERITAGE PHARMS INC	EQ 25MG BASE	A078554 001	Jan 09, 2009	Aug	CAHN
AB		EQ 37.5MG BASE	A078554 002	Jan 09, 2009	Aug	CAHN
AB		EQ 50MG BASE	A078554 003	Jan 09, 2009	Aug	CAHN
AB		EQ 75MG BASE	A078554 004	Jan 09, 2009	Aug	CAHN
AB		EQ 100MG BASE	A078554 005	Jan 09, 2009	Aug	CAHN

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

AB	+	PFIZER	120MG	N019152 003	Mar 06, 1991	Feb	CTNA
AB	+		180MG	N019152 002	Dec 15, 1989	Feb	CTNA
AB	+		240MG	N019152 001	Dec 16, 1986	Feb	CTNA

VERAPAMIL HYDROCHLORIDE

AB	APOTEX CORP	120MG	A200878 001	Apr 20, 2012	Apr	NEWA
AB		180MG	A200878 002	Apr 20, 2012	Apr	NEWA
AB		240MG	A200878 003	Apr 20, 2012	Apr	NEWA

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

+	LUNDBECK LLC	500MG/PACKET	N022006 001	Aug 21, 2009	Apr	CAHN
---	--------------	--------------	-------------	--------------	-----	------

TABLET; ORAL

SABRIL

+	LUNDBECK LLC	500MG	N020427	001	Aug 21, 2009	Apr	CAHN
---	--------------	-------	---------	-----	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

+	FOREST LABS INC	10MG	N022567	001	Jan 21, 2011	Apr	CRLD
		40MG	N022567	003	Jan 21, 2011	Apr	CRLD

VINCRIStINE SULFATE

INJECTABLE, LIPOSOMAL; INTRAVENOUS

MARQIBO KIT

+	TALON THERAP	5MG/5ML (1MG/ML)	N202497	001	Aug 09, 2012	Aug	NEWA
---	--------------	------------------	---------	-----	--------------	-----	------

VINORELBINE

INJECTABLE; INJECTION

VINORELBINE

AP	ONCO THERAPIES LTD	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Aug	NEWA
----	--------------------	-----------------	---------	-----	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

AP	HIKMA MAPLE	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Oct	CAHN
AP	JIANGSU HANSOH PHARM	EQ 10MG BASE/ML	A091106	001	Sep 26, 2012	Sep	NEWA

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+	GENENTECH	150MG	N203388	001	Jan 30, 2012	Jan	NEWA
---	-----------	-------	---------	-----	--------------	-----	------

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

AP	+	PFIZER	200MG/VIAL	N021267	001	May 24, 2002	May	CFTG
----	---	--------	------------	---------	-----	--------------	-----	------

VORICONAZOLE

AP	SANDOZ INC	200MG/VIAL	A090862	001	May 30, 2012	May	NEWA
----	------------	------------	---------	-----	--------------	-----	------

TABLET; ORAL

VORICONAZOLE

AB	MYLAN PHARMS INC	50MG	A090547	001	Apr 22, 2010	Oct	CAHN
AB		200MG	A090547	002	Apr 22, 2010	Oct	CAHN
AB	TEVA PHARMS	50MG	A091658	001	Apr 06, 2012	Mar	NEWA
AB		200MG	A091658	002	Apr 06, 2012	Mar	NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

@	JAZZ PHARMS COMMERCL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Mar	CAHN
---	----------------------	------------------------	---------	-----	--------------	-----	------

@	JAZZ PHARMS INTL	200MCG/2ML (100MCG/ML)	N021060	003	Dec 28, 2004	Jun	CAHN
---	------------------	------------------------	---------	-----	--------------	-----	------

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+	JAZZ PHARMS COMMERCL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Mar	CAHN
+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Mar	CAHN
+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Mar	CAHN

INJECTABLE; INTRATHECAL

PRIALT

+	JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004	Jun	CAHN
+		500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004	Jun	CAHN
+		500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004	Jun	CAHN

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

AB	HEC PHARM USA INC	300MG	A202058 001	Oct 07, 2011	Oct	CAHN
AB	MYLAN PHARMS INC	300MG	A078922 001	Feb 14, 2008	Sep	CAHN
	@ RANBAXY LABS LTD	300MG	A077327 001	Sep 19, 2005	Apr	DISC

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+	PFIZER	EQ 20MG BASE	N020825 001	Feb 05, 2001	Feb	CFTG
AB			EQ 40MG BASE	N020825 002	Feb 05, 2001	Feb	CFTG
AB			EQ 60MG BASE	N020825 003	Feb 05, 2001	Feb	CFTG
AB			EQ 80MG BASE	N020825 004	Feb 05, 2001	Feb	CFTG

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX CORP	EQ 20MG BASE	A077561 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077561 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077561 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077561 004	Mar 02, 2012	Feb	NEWA
AB		DR REDDYS LABS INC	EQ 20MG BASE	A077565 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077565 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077565 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077565 004	Mar 02, 2012	Feb	NEWA
AB		LUPIN PHARMS	EQ 20MG BASE	A077560 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077560 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077560 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077560 004	Mar 02, 2012	Feb	NEWA
AB		SANDOZ INC	EQ 20MG BASE	A077562 001	Jun 01, 2012	May	NEWA
AB			EQ 40MG BASE	A077562 002	Jun 01, 2012	May	NEWA
AB			EQ 60MG BASE	A077562 003	Jun 01, 2012	May	NEWA
AB			EQ 80MG BASE	A077562 004	Jun 01, 2012	May	NEWA
AB		WOCKHARDT LTD	EQ 20MG BASE	A090348 001	Sep 05, 2012	Aug	NEWA
AB			EQ 40MG BASE	A090348 002	Sep 05, 2012	Aug	NEWA
AB			EQ 60MG BASE	A090348 003	Sep 05, 2012	Aug	NEWA
AB			EQ 80MG BASE	A090348 004	Sep 05, 2012	Aug	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB		CIPLA LTD	5MG	A077388 001	Jul 30, 2012	Jul	NEWA
AB			10MG	A077388 002	Jul 30, 2012	Jul	NEWA
		@ MYLAN PHARMS INC	5MG	A078016 001	Apr 23, 2007	Oct	DISC
		@	10MG	A078016 002	Apr 23, 2007	Oct	DISC

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

AB		MYLAN PHARMS INC	25MG	A077647 001	Dec 22, 2005	Sep	CAHN
AB			50MG	A077647 002	Dec 22, 2005	Sep	CAHN
AB			100MG	A077647 003	Dec 22, 2005	Sep	CAHN

OTC DRUG PRODUCT LIST - 32ND EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

2-1

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

+	MCNEIL CONS	800MG;10MG;165MG	N020958	001	Oct 16, 2000	Mar	CAHN
---	-------------	------------------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Jul	DISC
---	------------------	---------	---------	-----	--------------	-----	------

>A>	TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012	Nov	NEWA
-----	-----------------	---------	---------	-----	--------------	-----	------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Jul	DISC
---	------------------	---------	---------	-----	--------------	-----	------

>A>	TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012	Nov	NEWA
-----	-----------------	---------	---------	-----	--------------	-----	------

TABLET, CHEWABLE; ORAL

CHILDREN'S ZYRTEC ALLERGY

MCNEIL CONS	5MG	N021621	003	Nov 16, 2007	Oct	CAHN
-------------	-----	---------	-----	--------------	-----	------

+	10MG	N021621	004	Nov 16, 2007	Oct	CAHN
---	------	---------	-----	--------------	-----	------

CHILDREN'S ZYRTEC HIVES RELIEF

MCNEIL CONS	5MG	N021621	005	Nov 16, 2007	Oct	CAHN
-------------	-----	---------	-----	--------------	-----	------

+	10MG	N021621	006	Nov 16, 2007	Oct	CAHN
---	------	---------	-----	--------------	-----	------

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@	ACTAVIS ELIZABETH	5MG	A078615	003	Dec 28, 2007	Oct	DISC
---	-------------------	-----	---------	-----	--------------	-----	------

@	10MG	A078615	004	Dec 28, 2007	Oct	DISC
---	------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUN PHARM INDS LTD	5MG;120MG	A090922	001	Sep 28, 2012	Sep	NEWA
--------------------	-----------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+	CAREFUSION	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Aug	CAHN
---	------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP SINGLE SWABSTICK

+	CAREFUSION	2%;70% (1.75ML)	N021555	002	May 10, 2005	Aug	CAHN
---	------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP TRIPLE SWABSTICK

+	CAREFUSION	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Aug	CAHN
---	------------	-----------------	---------	-----	--------------	-----	------

CHLORASCRUB MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar	CAHN
---	------------	-------------------	---------	-----	--------------	-----	------

CHLORASCRUB SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar	CAHN
---	------------	-----------------	---------	-----	--------------	-----	------

CHLORASCRUB SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar	CAHN
---	------------	-------------------	---------	-----	--------------	-----	------

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DEXTROMETHORPHAN POLISTIREX

TRIS PHARMA INC	EQ 30MG HBR/5ML	A091135	001	May 25, 2012	May	NEWA
-----------------	-----------------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

STRIDES ARCOLAB LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888 001	Mar 05, 2012	Feb	NEWA
---------------------	---	-------------	--------------	-----	------

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

@ MCNEIL CONS

10MG

N020801 001 Sep 24, 1998 Mar CAHN

+

20MG

N020801 002 Dec 17, 2007 Mar CAHN

TABLET; ORAL

FAMOTIDINE

@ SANDOZ

10MG

A076101 001 Oct 21, 2002 Oct DISC

PEPCID AC

MCNEIL CONS

10MG

N020325 001 Apr 28, 1995 Mar CAHN

+

20MG

N020325 002 Sep 23, 2003 Mar CAHN

PEPCID AC (GELTAB)

MCNEIL CONS

10MG

N020902 001 Aug 05, 1999 Mar CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS

30MG

A091567 002 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD

30MG

A079112 002 Feb 08, 2012 Jan NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS

30MG

A091567 001 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD

30MG

A079112 001 Feb 08, 2012 Jan NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS

60MG

A091567 004 Feb 06, 2012 Jan NEWA

180MG

A091567 006 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD

60MG

A079112 004 Feb 08, 2012 Jan NEWA

180MG

A079112 006 Feb 08, 2012 Jan NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS

60MG

A091567 003 Feb 06, 2012 Jan NEWA

180MG

A091567 005 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD

60MG

A079112 003 Feb 08, 2012 Jan NEWA

180MG

A079112 005 Feb 08, 2012 Jan NEWA

IBUPROFEN

CAPSULE; ORAL

ADVIL LIQUI-GELS

>A>

+

PFIZER

EQ 200MG FREE ACID AND POTASSIUM
SALT

N020402 001 Apr 20, 1995 Nov CAHN

>D>

+

WYETH CONS

EQ 200MG FREE ACID AND POTASSIUM
SALT

N020402 001 Apr 20, 1995 Nov CAHN

ADVIL MIGRAINE LIQUI-GELS

>A>

+

PFIZER

EQ 200MG FREE ACID AND POTASSIUM
SALT

N020402 002 Mar 16, 2000 Nov CAHN

>D>

+

WYETH CONS

EQ 200MG FREE ACID AND POTASSIUM
SALT

N020402 002 Mar 16, 2000 Nov CAHN

IBUPROFEN

ACCUCAPS INDS

EQ 200MG FREE ACID AND POTASSIUM
SALT

A077338 001 Jul 10, 2009 Jan CAHN

PLD ACQUISITIONS

EQ 200MG FREE ACID AND POTASSIUM
SALT

A077338 001 Jul 10, 2009 Oct CAHN

SUSPENSION/DROPS; ORAL

PEDIATRIC ADVIL

>A>	+	PFIZER	100MG/2.5ML	N020812	001	Jan 30, 1998	Nov	CAHN
>D>	+	WYETH CONS	100MG/2.5ML	N020812	001	Jan 30, 1998	Nov	CAHN

SUSPENSION; ORAL

CHILDREN'S ADVIL

>A>		PFIZER	100MG/5ML	N020589	001	Jun 27, 1996	Nov	CAHN
>D>		WYETH CONS	100MG/5ML	N020589	001	Jun 27, 1996	Nov	CAHN

CHILDREN'S ADVIL-FLAVORED

>A>		PFIZER	100MG/5ML	N020589	002	Nov 07, 1997	Nov	CAHN
>D>		WYETH CONS	100MG/5ML	N020589	002	Nov 07, 1997	Nov	CAHN

TABLET, CHEWABLE; ORAL

CHILDREN'S ADVIL

>A>		PFIZER	50MG	N020944	001	Dec 18, 1998	Nov	CAHN
>D>		WYETH CONS	50MG	N020944	001	Dec 18, 1998	Nov	CAHN

JUNIOR STRENGTH ADVIL

>A>		PFIZER	100MG	N020944	002	Dec 18, 1998	Nov	CAHN
>D>		WYETH CONS	100MG	N020944	002	Dec 18, 1998	Nov	CAHN

TABLET; ORAL

IBUPROFEN

@ CONTRACT PHARMACAL

JUNIOR STRENGTH ADVIL

			200MG	A073691	001	Feb 25, 1994	Oct	DISC
>A>		PFIZER	100MG	N020267	002	Dec 13, 1996	Nov	CAHN
>D>		WYETH CONS	100MG	N020267	002	Dec 13, 1996	Nov	CAHN

IBUPROFEN SODIUM

TABLET; ORAL

ADVIL

+	PFIZER CONS HLTHCARE	EQ 200MG BASE	N201803	001	Jun 12, 2012	Jun	NEWA
---	----------------------	---------------	---------	-----	--------------	-----	------

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

	DR REDDYS LABS LTD	15MG	A202194	001	May 18, 2012	Apr	NEWA
	PERRIGO R AND D	15MG	A202319	001	May 18, 2012	Apr	NEWA
	WOCKHARDT LTD	15MG	A202727	001	May 18, 2012	Apr	NEWA
	PREVACID 24 HR						
+	NOVARTIS	15MG	N022327	001	May 18, 2009	Apr	CFTG

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

	WATSON LABS INC	1.5MG	A200670	001	Jul 12, 2012	Jun	NEWA
	PLAN B						
+	TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006	May	CAHN
	PLAN B ONE-STEP						
+	DURAMED	1.5MG	N021998	001	Jul 10, 2009	Jun	CFTG

LORATADINE

SYRUP; ORAL

LORATADINE

@ RANBAXY LABS LTD

TABLET, ORALLY DISINTEGRATING; ORAL

ALAVERT

>A>		PFIZER	10MG	N021375	001	Dec 19, 2002	Nov	CAHN
-----	--	--------	------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

ALAVERT

>D>	WYETH CONS	10MG	N021375 001	Dec 19, 2002	Nov	CAHN
-----	------------	------	-------------	--------------	-----	------

LORATADINE

>A>	PFIZER	10MG	A075822 001	Feb 10, 2003	Nov	CAHN
-----	--------	------	-------------	--------------	-----	------

>D>	WYETH CONS	10MG	A075822 001	Feb 10, 2003	Nov	CAHN
-----	------------	------	-------------	--------------	-----	------

MENTHOL; METHYL SALICYLATE

PATCH; TOPICAL

SALONPAS

>A>	HISAMITSU PHARM CO	3%;10%	N022029 002	Nov 05, 2012	Nov	NEWA
-----	--------------------	--------	-------------	--------------	-----	------

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

@ SANDOZ

EQ 200MG BASE

A074646 001	Jan 13, 1997	Oct	DISC
-------------	--------------	-----	------

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTINE

AVEVA

7MG/24HR

A074612 002	Jul 28, 2003	Apr	NEWA
-------------	--------------	-----	------

14MG/24HR

A074612 003	Oct 20, 1997	Apr	NEWA
-------------	--------------	-----	------

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL

NICOTINE POLACRILEX

PERRIGO R AND D

EQ 2MG BASE

A203690 001	Oct 09, 2012	Sep	NEWA
-------------	--------------	-----	------

EQ 4MG BASE

A203690 002	Oct 09, 2012	Sep	NEWA
-------------	--------------	-----	------

NIZATIDINE

TABLET; ORAL

AXID AR

>A>	+ PFIZER	75MG	N020555 001	May 09, 1996	Nov	CAHN
-----	----------	------	-------------	--------------	-----	------

>D>	+ WYETH CONS	75MG	N020555 001	May 09, 1996	Nov	CAHN
-----	--------------	------	-------------	--------------	-----	------

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

@ PADDOCK LLC

17GM/SCOOPFUL

A090567 001	Oct 15, 2009	Sep	DISC
-------------	--------------	-----	------

POTASSIUM IODIDE

SOLUTION; ORAL

THYROSHIELD

+ ARCO PHARMS LLC

65MG/ML

A077218 001	Jan 12, 2005	Oct	CAHN
-------------	--------------	-----	------

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC

EQ 150MG BASE

A200172 001	May 31, 2012	May	NEWA
-------------	--------------	-----	------

SHASUN CHEMS

EQ 75MG BASE

A201745 001	Feb 29, 2012	Feb	NEWA
-------------	--------------	-----	------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 11 NOVMEBER 2012

NO NOVEMBER 2012 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO NOVEMBER 2012 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ABACAVIR SULFATE</u>						
A091294 001					PC	Dec 16, 2012
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539 001	8148356	May 21, 2026	DP			
<u>ACETYLCYSTEINE - ACETYLCYSTEINE</u>						
A200644 001					>A> PC	May 29, 2013
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N202450 001	5840279	Jun 21, 2016	DP		NCE	Jul 23, 2017
	6071498	Jun 21, 2016	DP			
	6681768	Aug 07, 2022	DP			
	6750226	Sep 05, 2020	DS DP U-1264			
	7078412	Jul 16, 2020	DS DP U-1263			
	8051851	Apr 22, 2027	DP			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
	8241649	Dec 23, 2022	DP			
<u>ALBUMIN HUMAN - OPTISON</u>						
N020899 001					M-120	Aug 17, 2015
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	6446627	Dec 18, 2017	DP			
	8132712	Sep 07, 2028	DP			
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N020983 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>ALCAFTADINE - LASTACAF</u>						
N022134 001	5468743	Nov 21, 2013	DS DP			
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N202344 001	7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 001	8168616	Jul 05, 2025	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 002	8168616	Jul 05, 2025	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	8112290	Jul 31, 2030	U-1225			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 001	>A> 5840722	Nov 24, 2015	U-821			
	>A> 5840722	Nov 24, 2015	U-1297			
	RE42462	Jul 29, 2018	DS			
<u>AMBRISANTAN - LETAIRIS</u>						
N022081 002	>A> 5840722	Nov 24, 2015	U-821			
	>A> 5840722	Nov 24, 2015	U-1297			
	RE42462	Jul 29, 2018	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N020965 001	8216289	May 01, 2018	U-289			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	8101599	May 16, 2023	DP			
<u>AMOXICILLIN - MOXATAG</u>						
N050813 001	>A> 8299052	May 07, 2027	U-1304			
<u>APREPITANT - EMEND</u>						
N021549 001	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N021549 002	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N021549 003	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	6589508	Apr 03, 2013	U-793			
	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N021248 001	8273379	Nov 10, 2018	U-1291			
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE</u>						
A091211 001					PC	Mar 13, 2012
<u>AVANAFIL - STENDRA</u>						
N202276 001	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	7501409	May 05, 2023	DP			
<u>AVANAFIL - STENDRA</u>						
N202276 002	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	7501409	May 05, 2023	DP			
<u>AVANAFIL - STENDRA</u>						
N202276 003	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	7501409	May 05, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AXITINIB - INLYTA</u>						
N202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AXITINIB - INLYTA</u>						
N202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N202236 001	8163723	Aug 29, 2023	U-81		NC	May 01, 2015
	8163723	Aug 29, 2023	U-77			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-644			
	8168620	Feb 24, 2026	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 001	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 002	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N202813 001	5605674	Feb 25, 2014	DP		NP	Mar 23, 2015
	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 001					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
					PED	Sep 20, 2015
					PED	Sep 20, 2013
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 002					NCE	Mar 20, 2013
					ODE	Mar 20, 2015
					PED	Sep 20, 2015
					PED	Sep 20, 2013
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N050819 001	8288434	Aug 05, 2029	DP U-124			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N022185 001					I-659	Oct 17, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BIMATOPROST - LATISSE</u>						
N022369 001	8101161	May 25, 2024	U-1218			
	8101161	May 25, 2024	U-1217			
	8263054	Aug 25, 2023	U-1277			
<u>BIMATOPROST - LUMIGAN</u>						
N022184 001	8278353	Mar 16, 2025	DP			
	>A> 8299118	Mar 16, 2025	U-1295			
	>A> 8309605	Mar 16, 2025	U-1294			
	>A> 8309605	Mar 16, 2025	U-1293			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Dec 15, 2014	DS DP U-1232			
	5196404	Dec 15, 2014	DS DP U-1040			
	5196404*PED	Jun 15, 2015				
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	8119602	Mar 17, 2027	U-1233			
	RE43298	Feb 22, 2022	DS DP U-1128			
<u>BORTEZOMIB - VELCADE</u>						
N021602 001					NR	Jan 23, 2015
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N203341 001	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Sep 24, 2019	DS			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N203341 002	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Sep 24, 2019	DS			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	8133890	Apr 19, 2022	U-1235			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	8143239	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	8143239	Jan 29, 2023	DP U-1073			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 003					NDF	Aug 30, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 004					NDF	Aug 30, 2013
<u>BUTOCONAZOLE NITRATE - BUTOCONAZOLE NITRATE</u>						
A200923 001					>A> PC	May 14, 2013
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N203756 001					>A> NCE	Nov 29, 2017
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N203756 002					>A> NCE	Nov 29, 2017
<u>CALCIPOTRIENE - SORILUX</u>						
N022563 001	8263580	May 26, 2026	DP U-1280		I-657	Sep 27, 2015
<u>CARFILZOMIB - KYPROLIS</u>						
N202714 001	7232818	Apr 14, 2025	DS DP		NCE	Jul 20, 2017
	7417042	Jun 07, 2026	DS DP		ODE	Jul 20, 2019
	7491704	Apr 14, 2025	U-1260			
	7737112	Dec 07, 2027	DP			
	8129346	Dec 25, 2026	U-1260			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207297	Apr 14, 2025	DS DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 001	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 002	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 003	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 004	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N200327 001	8247400	Feb 10, 2031	DP U-282			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N200327 002	8247400	Feb 10, 2031	DP U-282			
<u>CEVIMELINE HYDROCHLORIDE - CEVIMELINE</u>						
A091260 001					PC	Apr 06, 2013
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7717889	Feb 27, 2025	DP U-1022			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CHOLINE C-11 - CHOLINE C-11</u>						
N203155	001				NCE W	Sep 12, 2017 Sep 12, 2017
<u>CICLESONIDE - ZETONNA</u>						
N202129	001	5482934	Oct 24, 2017	DS DP U-1002	NP	Jan 20, 2015
		5605674	Feb 25, 2014	DP		
		5683677	Nov 04, 2014	DP		
		5775321	Jul 07, 2015	DP		
		6006745	Dec 28, 2016	DP		
		6036942	Apr 30, 2013	DP		
		6120752	May 13, 2018	DP		
		6264923	May 13, 2018	DP		
<u>CICLOPIROX - LOPROX</u>						
N021159	001	8227490	Sep 16, 2017	U-1256		
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N202535	001				NP	Jul 16, 2015
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156	001	5856346	Jan 05, 2021	DS DP U-893		
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156	002	5856346	Jan 05, 2021	DS DP U-893		
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078223	001				PC	Jun 30, 2012
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078854	001				PC	Jun 30, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A077665	002				PC	Nov 13, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A091023	001				PC	Nov 13, 2012
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N203100	001	5814639	Sep 29, 2015	DS DP		
		5914331	Jul 02, 2017	DS		
		5922695	Jul 25, 2017	DS U-257		
		5935946	Jul 25, 2017	DS DP U-257		
		5977089	Jul 25, 2017	DS DP U-257		
		6043230	Jul 25, 2017	U-257		
		6642245	Nov 04, 2020	U-257		
		6703396	Mar 09, 2021	DS DP		
		7176220	Nov 20, 2023	DS DP U-257		
		7635704	Jan 12, 2026	DS DP U-257		
		8148374	Sep 03, 2029	DS DP U-1279		
<u>COLCHICINE - COLCRYS</u>						
N022352	001	7964648	Oct 06, 2028	U-1161		
		8097655	Oct 06, 2028	U-1020		
<u>CRIZOTINIB - XALKORI</u>						
N202570	001	8217057	Nov 06, 2029	DS DP		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CRIZOTINIB - XALKORI</u>						
N202570 002	8217057	Nov 06, 2029	DS DP			
<u>CYSTEAMINE HYDROCHLORIDE - CYSTARAN</u>						
N200740 001					NP ODE	Oct 02, 2015 Oct 02, 2019
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	8129342	Nov 28, 2020	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	>A> 5843946	Dec 01, 2015	DP U-1305			
	>A> 5843946	Dec 01, 2015	DP U-744			
	>A> 5843946	Dec 01, 2015	DP U-903			
	>A> 5843946	Dec 01, 2015	DP U-935			
	>A> 5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	>A> 6037157	Jun 26, 2016	U-1209			
	>A> 6037157	Jun 26, 2016	U-1305			
	>A> 6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	>A> 6335460	Aug 25, 2012	DS DP U-935			
	>A> 6335460	Aug 25, 2012	DS DP U-1209			
	>A> 6335460	Aug 25, 2012	DS DP U-1305			
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-1209			
	>A> 6703403	Jun 26, 2016	U-1305			
	>A> 6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-1209			
	>A> 7470506	Jun 23, 2019	U-1305			
	>A> 7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	>A> RE43802	Oct 19, 2016	U-1305			
	>A> RE43802*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 002	>A> 5843946	Dec 01, 2015	DP U-1305			
	>A> 5843946	Dec 01, 2015	DP U-744			
	>A> 5843946	Dec 01, 2015	DP U-903			
	>A> 5843946	Dec 01, 2015	DP U-935			
	>A> 5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	>A> 6037157	Jun 26, 2016	U-1209			
	>A> 6037157	Jun 26, 2016	U-1305			
	>A> 6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	>A> 6335460	Aug 25, 2012	DS DP U-935			
	>A> 6335460	Aug 25, 2012	DS DP U-1209			
	>A> 6335460	Aug 25, 2012	DS DP U-1305			
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-1209			
	>A> 6703403	Jun 26, 2016	U-1305			
	>A> 6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-1209			
	>A> 7470506	Jun 23, 2019	U-1305			
	>A> 7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	>A> RE43802	Oct 19, 2016	U-1305			
	>A> RE43802*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 003	>A> 5843946	Dec 01, 2015	DP U-1305			
	>A> 5843946	Dec 01, 2015	DP U-744			
	>A> 5843946	Dec 01, 2015	DP U-903			
	>A> 5843946	Dec 01, 2015	DP U-935			
	>A> 5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	>A> 6037157	Jun 26, 2016	U-1209			
	>A> 6037157	Jun 26, 2016	U-1305			
	>A> 6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	>A> 6335460	Aug 25, 2012	DS DP U-935			
	>A> 6335460	Aug 25, 2012	DS DP U-1209			
	>A> 6335460	Aug 25, 2012	DS DP U-1305			
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-1209			
	>A> 6703403	Jun 26, 2016	U-1305			
	>A> 6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-1209			
	>A> 7470506	Jun 23, 2019	U-1305			
	>A> 7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	>A> RE43802	Oct 19, 2016	U-1305			
	>A> RE43802*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 004	>A> 5843946	Dec 01, 2015	DP U-1305			
	>A> 5843946	Dec 01, 2015	DP U-744			
	>A> 5843946	Dec 01, 2015	DP U-903			
	>A> 5843946	Dec 01, 2015	DP U-935			
	>A> 5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	>A> 6037157	Jun 26, 2016	U-1209			
	>A> 6037157	Jun 26, 2016	U-1305			
	>A> 6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	>A> 6335460	Aug 25, 2012	DS DP U-935			
	>A> 6335460	Aug 25, 2012	DS DP U-1209			
	>A> 6335460	Aug 25, 2012	DS DP U-1305			
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-1209			
	>A> 6703403	Jun 26, 2016	U-1305			
	>A> 6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-1209			
	>A> 7470506	Jun 23, 2019	U-1305			
	>A> 7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	>A> RE43802	Oct 19, 2016	U-1305			
	>A> RE43802*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 005	>A> 5843946	Dec 01, 2015	DP U-1305			
	>A> 5843946	Dec 01, 2015	DP U-744			
	>A> 5843946	Dec 01, 2015	DP U-903			
	>A> 5843946	Dec 01, 2015	DP U-935			
	>A> 5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	>A> 6037157	Jun 26, 2016	U-1209			
	>A> 6037157	Jun 26, 2016	U-1305			
	>A> 6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	>A> 6335460	Aug 25, 2012	DS DP U-935			
	>A> 6335460	Aug 25, 2012	DS DP U-1209			
	>A> 6335460	Aug 25, 2012	DS DP U-1305			
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-1209			
	>A> 6703403	Jun 26, 2016	U-1305			
	>A> 6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-1209			
	>A> 7470506	Jun 23, 2019	U-1305			
	>A> 7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	>A> RE43802	Oct 19, 2016	U-1305			
	>A> RE43802*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 006	>A> 5843946	Dec 01, 2015	DP U-1305		>A> D-129	Dec 13, 2013
	>A> 5843946	Dec 01, 2015	DP U-744		>A> NPP	Dec 16, 2014
	>A> 5843946	Dec 01, 2015	DP U-903		>A> PED	Jun 16, 2015
	>A> 5843946	Dec 01, 2015	DP U-935		>A> PED	Jun 13, 2014
	>A> 5843946	Dec 01, 2015	DP U-1209			
	>A> 5843946*PED	Jun 01, 2016				
	>A> 6037157	Jun 26, 2016	U-1305			
	>A> 6037157	Jun 26, 2016	U-935			
	>A> 6037157	Jun 26, 2016	U-1209			
	>A> 6037157*PED	Dec 26, 2016				
	>A> 6248775	Aug 13, 2014	DS			
	>A> 6248775*PED	Feb 13, 2015	U-1305			
	>A> 6335460	Aug 25, 2012	DS DP U-935			
	>A> 6335460	Aug 25, 2012	DS DP U-903			
	>A> 6335460	Aug 25, 2012	DS DP U-1209			
	>A> 6335460	Aug 25, 2012	DS DP U-1305			
	>A> 6335460	Aug 25, 2012	DS DP U-744			
	>A> 6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-1209			
	>A> 6703403	Jun 26, 2016	U-1305			
	>A> 6703403	Jun 26, 2016	U-935			
	>A> 6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-935			
	>A> 7470506	Jun 23, 2019	U-1209			
	>A> 7470506	Jun 23, 2019	U-1305			
	>A> 7470506*PED	Dec 23, 2019				
	>A> 7700645	Dec 26, 2026	DS DP			
	>A> 7700645*PED	Jun 26, 2027				
	>A> RE42889	Oct 19, 2016	DP			
	>A> RE42889*PED	Apr 19, 2017				
	>A> RE43596	May 09, 2017	DS DP			
	>A> RE43596*PED	Nov 09, 2017				
	>A> RE43802	Oct 19, 2016	U-1305			
	>A> RE43802*PED	Apr 19, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001	>A> 5843946	Dec 01, 2015	DP U-1305			
	>A> 5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	>A> 6037157	Jun 26, 2016	U-1209			
	>A> 6037157	Jun 26, 2016	U-1305			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	>A> 6335460	Aug 25, 2012	DS DP U-1209			
	>A> 6335460	Aug 25, 2012	DS DP U-1305			
	6335460*PED	Feb 25, 2013				
	>A> 6703403	Jun 26, 2016	U-1305			
	>A> 6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	>A> 7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017	U-1305			
	>A> RE43802	Oct 19, 2016	U-1305			
	>A> RE43802*PED	Apr 19, 2017				
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	5925730	May 18, 2021	DS DP U-943			
<u>DESLOTRADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N021313 001	8187630	Dec 19, 2020	DP U-1017			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 001	8269040	Jul 05, 2027	DS			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 002	8269040	Jul 05, 2027	DS			
<u>DEXAMETHASONE - OZURDEX</u>						
N022315 001	8088407	Oct 20, 2020	DP U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N050818 001	8101582	Dec 19, 2027	DP U-1082			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 001	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N021879 001	8227484	Jul 17, 2023	U-1093			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	8097651	Jun 16, 2026	DS DP U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	8110606	Feb 24, 2029	U-980			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N020947 001	8217078	Jul 10, 2029	U-1248			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	8153616	Jan 30, 2028	U-1240		I-648	Mar 14, 2015
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212 001					I-653 ODE	Jun 13, 2015 Jun 13, 2019
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM</u>						
N021394 001	8263647	May 30, 2022	DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 001	8247402	Mar 30, 2021	DS DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	8247402	Mar 30, 2021	DS DP			
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N202667 001					NP	Feb 01, 2015
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	8206740	Dec 24, 2025	DP U-925			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	5223510	Jul 26, 2013	DS DP U-992			
	5223510	Jul 26, 2013	DS DP U-1261			
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 001					NS	Mar 01, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5811423	Aug 07, 2012	U-750			
	5811423	Aug 07, 2012	U-1170			
	5922695	Jul 25, 2017	DS U-750			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-750			
	5935946	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-750			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	U-750			
	6043230	Jul 25, 2017	U-1170			
	6642245	Nov 04, 2020	U-750			
	6642245	Nov 04, 2020	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	>A> 6280959	Oct 30, 2018	DS DP U-930			
	>A> 6280959	Oct 30, 2018	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-930			
	>A> 8052993	Aug 01, 2027	DP U-930			
	>A> 8052993	Aug 01, 2027	DP U-1306			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	>A> 6280959	Oct 30, 2018	DS DP U-930			
	>A> 6280959	Oct 30, 2018	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-930			
	>A> 8052994	Aug 01, 2027	DP U-930			
	>A> 8052994	Aug 01, 2027	DP U-1306			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	>A> 6280959	Oct 30, 2018	DS DP U-930			
	>A> 6280959	Oct 30, 2018	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-930			
	>A> 8062665	Aug 01, 2027	DP U-930			
	>A> 8062665	Aug 01, 2027	DP U-1306			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 004	>A> 6280959	Oct 30, 2018	DS DP U-930			
	>A> 6280959	Oct 30, 2018	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-930			
	>A> 8071129	Aug 01, 2027	DP U-930			
	>A> 8071129	Aug 01, 2027	DP U-1306			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 005	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> NCE	Nov 20, 2013
	>A> 6280959	Oct 30, 2018	DS DP U-1306		>A> ODE	Nov 20, 2015
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7452874	May 24, 2021	DS DP			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-930			
	>A> 8052995	Aug 01, 2027	DP U-1306			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001	8080551	Apr 11, 2023	DS DP		NCE	May 20, 2016
	8101629	Aug 09, 2022	DP			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N021752 001	5922695	Jul 25, 2017	DS U-1259			
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	DP U-541			
	6043230	Jul 25, 2017	DP U-1170			
	6043230	Jul 25, 2017	DP U-1259			
	6043230	Jul 25, 2017	DP U-248			
<u>ENTECAVIR - BARACLUDE</u>						
N021797 001					NPP	Oct 12, 2015
<u>ENTECAVIR - BARACLUDE</u>						
N021797 002					NPP	Oct 12, 2015
<u>ENTECAVIR - BARACLUDE</u>						
N021798 001					NPP	Oct 12, 2015
<u>ENZALUTAMIDE - XTANDI</u>						
N203415 001	7709517	Aug 13, 2027	DS DP		NCE	Aug 31, 2017
	8183274	May 15, 2026	U-1281			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 001	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 001					PC	Jun 17, 2012
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 002					PC	Jun 17, 2012
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N201532 001	8097648	Jan 22, 2021	U-1096			
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 001					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 002					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 003					PC	Sep 10, 2012
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 003	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 004	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESTRADIOL - MINIVELLE</u>						
N203752 001	>A> 6841716	Apr 27, 2020	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 002	>A> 6841716	Apr 27, 2020	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 003	>A> 6841716	Apr 27, 2020	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N203752 004	>A> 6841716	Apr 27, 2020	DP			
<u>ESTRADIOL - VAGIFEM</u>						
N020908 002	>A> 5860946	Jul 01, 2017	DP			
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ETONOGESTREL - NEXPLANON</u>						
N021529 002					NP	May 31, 2014
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237			
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-256			
	7037917	Dec 13, 2020	DS DP U-1237			
	7037917	Dec 13, 2020	DS DP U-1016			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 003	6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	6878717	Nov 05, 2019	U-1237		NCE	Jan 18, 2013
	6878717	Nov 05, 2019	U-1016			
	7037917	Dec 13, 2020	DS DP U-1237			
	7887845	Mar 25, 2019	DP			
	8003789	Nov 01, 2019	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR</u>						
N022334 004	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 001	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	7297703*PED	Jun 06, 2020			PED	Apr 29, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 002	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	7297703*PED	Jun 06, 2020			PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 003	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	7297703*PED	Jun 06, 2020			PED	Apr 29, 2014
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001					M-113 M-111	Oct 19, 2014 Oct 19, 2014
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002					M-113 M-111	Oct 19, 2014 Oct 19, 2014
<u>EZETIMIBE - ZETIA</u>						
N021445 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 004					M-109	Jan 24, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 001					M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002					M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003					M-112	Feb 09, 2015
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N022519 001	8309127	Jul 18, 2026	DP			
	>A> 8318202	Jul 18, 2026	DP			
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 001	8124125	Oct 01, 2024	DP U-1234			
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118 002	8124125	Oct 01, 2024	DP U-1234			
<u>FENTANYL - SUBSYS</u>						
N202788 001					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 002					NP	Jan 04, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N202788 003					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 004					NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788 005					NP	Jan 04, 2015
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	8092832	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 001	8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 002	8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 001	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 002	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 003	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 004	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 005	7579019	Jan 22, 2020	U-767			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	6858650	Jul 03, 2022	DS	U-913		
	8088398	Jun 07, 2027	DP	U-913		
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	6858650	Jul 03, 2022	DS	U-913		
	8088398	Jun 07, 2027	DP	U-913		
<u>FINGOLIMOD - GILENYA</u>						
N022527 001	6004565	Sep 23, 2017	U-1086			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N021112 001	8247395	Oct 22, 2022	DP			
<u>FLUOCINONIDE - VANOS</u>						
N021758 001	8232264	Mar 09, 2023	DP			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N022051 001	8062264	Apr 05, 2026	DP			
	8147461	Mar 10, 2025	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 002	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 003	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 002	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 003	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116 001					NPP PED	Apr 27, 2015 Oct 27, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 002	5512570	Mar 04, 2014	U-850			
	5538982	Jul 23, 2013	U-850			
	5716942	Feb 10, 2015	U-850			
	7214692	Sep 18, 2012	U-850			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N02244 001	6204257	Jul 01, 2022	DS DP U-945			
<u>FULVESTRANT - FASLODEX</u>						
N021344 001					>A> M-123	Nov 09, 2015
<u>GABAPENTIN - GRALISE</u>						
N022544 001	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 002	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 002					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 003					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE</u>						
N021357 004					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK</u>						
N021358 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK</u>						
N021358 002					I-654	Jul 06, 2015
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	6676929	May 04, 2020	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	6676929	May 04, 2020	DP			
<u>GADOXETATE DISODIUM - EOVIAT</u>						
N022090 001	5798092	Aug 25, 2015	DS DP			
	6039931	Nov 13, 2021	U-1239			
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N022571 001					ODE	Jul 28, 2017
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 001					PC	Sep 26, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369	002				PC	Sep 26, 2012
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020	001				PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020	002				PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020	003				PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020	004				PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020	005				PC	Mar 20, 2013
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217	004	5702725	Jul 07, 2014	DP U-1043	NDF	Mar 01, 2013
		5914131	Jul 07, 2014	DP U-1043		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N202057	001	8188146	Jan 27, 2020	DS DP		
		8293727	Feb 09, 2030	U-1287		
		8293728	Feb 09, 2030	U-1287		
		8298554	Apr 29, 2030	DP		
	>A>	8314086	Feb 09, 2030	U-1287		
	>A>	8318715	Feb 09, 2030	U-1287		
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588	001				ODE	Dec 19, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588	002				ODE	Dec 19, 2015
<u>IMIQUIMOD - ZYCLARA</u>						
N022483	001	8236816	Dec 11, 2029	U-68		
		8299109	Dec 11, 2029	U-68		
<u>IMIQUIMOD - ZYCLARA</u>						
N022483	002	8222270	Dec 11, 2029	U-68		
<u>INGENOL MEBUTATE - PICATO</u>						
N202833	001	6432452	Aug 19, 2018	DS U-68	NCE	Jan 23, 2017
		6844013	Aug 19, 2018	DS DP U-1221		
		7410656	Aug 19, 2018	DS U-1222		
		8278292	Feb 20, 2027	DS DP		
<u>INGENOL MEBUTATE - PICATO</u>						
N202833	002	6432452	Aug 19, 2018	DS U-68	NCE	Jan 23, 2017
		6844013	Aug 19, 2018	DS DP U-1221		
		7410656	Aug 19, 2018	DS U-1222		
		8278292	Feb 20, 2027	DS DP		
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N021172	001	5866538	Jun 19, 2017	DP		
		5866538*PED	Dec 19, 2017			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N021172 004	>A> 5547930	Sep 28, 2013	DS DP			
	>A> 5618913	Jun 07, 2014	DS DP			
	>A> 5618913*PED	Dec 07, 2014				
	>A> 5834422	Sep 28, 2013	DP U-471			
	>A> 5840680	Sep 28, 2013	DS DP U-471			
	>A> 5866538	Jun 19, 2017	DP			
	>A> 5866538*PED	Dec 19, 2017				
	>A> 6004297	Jan 28, 2019	DP			
	>A> 6235004	Jan 28, 2019	DP			
	>A> RE41956	Jan 21, 2021	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N021172 002	>A> 5547930	Sep 28, 2013	DS DP			
	>A> 5618913	Jun 07, 2014	DS DP			
	>A> 5618913*PED	Dec 07, 2014				
	>A> 5834422	Sep 28, 2013	DP U-471			
	>A> 5840680	Sep 28, 2013	DS DP U-471			
	>A> 5866538	Jun 19, 2017	DP			
	>A> 5866538*PED	Dec 19, 2017				
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 PENFILL</u>						
N021172 003	>A> 5547930	Sep 28, 2013	DS DP			
	>A> 5618913	Jun 07, 2014	DS DP			
	>A> 5618913*PED	Dec 07, 2014				
	>A> 5834422	Sep 28, 2013	DP U-471			
	>A> 5840680	Sep 28, 2013	DS DP U-471			
	>A> 5866538	Jun 19, 2017	DP			
	>A> 5866538*PED	Dec 19, 2017				
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N020986 003	>A> 5618913	Jun 07, 2014	DS DP			
	>A> 5618913*PED	Dec 07, 2014				
	>A> 5866538	Jun 20, 2017	DP			
	>A> 5866538*PED	Dec 20, 2017				
	>A> 6004297	Jan 28, 2019	DP			
	>A> 6004297*PED	Jul 28, 2019				
	>A> 6235004	Jan 28, 2019	DP			
	>A> 6235004*PED	Jul 28, 2019				
	>A> RE41956	Jan 21, 2021	DP			
	>A> RE41956*PED	Jul 21, 2021				
<u>INSULIN ASPART RECOMBINANT - NOVOLOG INNOLET</u>						
N020986 004	>A> 5618913	Jun 07, 2014	DS DP			
	>A> 5618913*PED	Dec 07, 2014				
	>A> 5866538	Jun 20, 2017	DP			
	>A> 5866538*PED	Dec 20, 2017				
	>A> RE41956	Jan 21, 2021	DP			
	>A> RE41956*PED	Jul 21, 2021				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N020986 002	>A> 5618913	Jun 07, 2014	DS DP			
	>A> 5618913*PED	Dec 07, 2014				
	>A> 5626566	May 06, 2014	DP			
	>A> 5626566*PED	Nov 06, 2014				
	>A> 5693027	Dec 02, 2014	DP			
	>A> 5693027*PED	Jun 02, 2015				
	>A> 5866538	Jun 20, 2017	DP			
	>A> 5866538*PED	Dec 20, 2017				
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N021536 001	5750497	Jun 16, 2019	DS DP U-668		M-117 M-115	May 18, 2015 Apr 06, 2015
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N021536 002	>A> 5750497	Jun 16, 2019	DS DP U-668			
	>A> 5866538	Jun 20, 2017	DS DP			
	>A> 6004297	Jan 28, 2019	DP			
	>A> 6011007	Feb 02, 2014	DS DP U-668			
	>A> 6235004	Jan 28, 2019	DP			
	>A> 6869930	Feb 02, 2014	DS DP U-668			
	>A> RE41956	Jan 21, 2021	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET</u>						
N021536 003	>A> 5750497	Jun 16, 2019	DS DP U-668			
	>A> 5866538	Jun 20, 2017	DS DP			
	>A> 6011007	Feb 02, 2014	DS DP U-668			
	>A> 6869930	Feb 02, 2014	DS DP U-668			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL</u>						
N021536 004	>A> 5750497	Jun 16, 2019	DS DP U-668			
	>A> 5866538	Jun 20, 2017	DS DP			
	>A> 6011007	Feb 02, 2014	DS DP U-668			
	>A> 6869930	Feb 02, 2014	DS DP U-668			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG</u>						
N020563 001					NR	Oct 12, 2015
<u>INSULIN LISPRO RECOMBINANT - HUMALOG PEN</u>						
N020563 002					NR	Oct 12, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001	5310912	Feb 25, 2013	DS			
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 001					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 002					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 003					PC	Sep 26, 2012
<u>IRON SUCROSE - VENOFR</u>						
N021135 001					NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFR</u>						
N021135 002					NPP	Sep 21, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IRON SUCROSE - VENOFER</u>						
N021135 004					NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 001	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 002	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 003	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 004	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	7495103	May 20, 2027	DS DP		NCE ODE	Jan 31, 2017 Jan 31, 2019
<u>IVERMECTIN - SKLICE</u>						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	8026238	Oct 19, 2018	DP U-1213			
<u>KETOCONAZOLE - XOLEGEL</u>						
N021946 001	8232276	Nov 24, 2020	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	8008338*PED	Nov 24, 2027				
	8207215	May 28, 2024	U-1251			
	8207215*PED	Nov 28, 2024				
<u>LACOSAMIDE - VIMPAT</u>						
N022253 001	RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 002	RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 003	RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 004	RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022254 001	RE38551	Mar 17, 2022	DS DP U-911			
<u>LACOSAMIDE - VIMPAT</u>						
N022255 001	RE38551	Mar 17, 2022	DS DP U-914			
<u>LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE</u>						
A079081 001					PC	May 15, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
	8288415	Jul 24, 2016	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
	8288415	Jul 24, 2016	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
	8288415	Jul 24, 2016	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
	8288415	Jul 24, 2016	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
	8288415	Jul 24, 2016	DS DP			
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 001					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 002					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 003					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021035 004					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVETIRACETAM - KEPPRA</u>						
N021505 001					NPP PED	Dec 16, 2014 Jun 16, 2015
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022064 001	5698558	Jul 26, 2013			U-812	
	5698558*PED	Jan 26, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022157 001	5698558	Jul 26, 2013	U-852			
	5698558*PED	Jan 26, 2014				
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N021623 001	6465709	Jul 07, 2020	DP			
<u>LINACLOTIDE - LINZESS</u>						
N202811 001	7304036	Jan 28, 2024	DS DP U-1278		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
<u>LINACLOTIDE - LINZESS</u>						
N202811 002	7304036	Jan 28, 2024	DS DP U-1278		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	6303661	Apr 24, 2017	U-774		M-121	Aug 13, 2015
	6303661	Apr 24, 2017	U-1270		M-118	Aug 13, 2015
	6890898	Feb 02, 2019	U-493			
	6890898	Feb 02, 2019	U-1270			
	7078381	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-1270			
	7459428	Feb 02, 2019	U-493			
	7459428	Feb 02, 2019	U-1270			
	8119648	Aug 12, 2023	U-774			
	8119648	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-775			
	8178541	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-1245			
	8178541	Aug 12, 2023	U-1244			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 001	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 002	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	>A> 6004297	Jan 28, 2019	DP		M-115	Apr 06, 2015
	>A> 6235004	Jan 28, 2019	DP			
	8114833	Aug 13, 2025	DP			
	>A> RE41956	Jan 21, 2021	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 001	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	>A> 8309613	Dec 24, 2024	U-688			
	>A> 8309613*PED	Jun 24, 2025				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 002	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	>A> 8309613	Dec 24, 2024	U-688			
	>A> 8309613*PED	Jun 24, 2025				
<u>LORCASERIN HYDROCHLORIDE - BELVIQ</u>						
N022529 001	6953787	Apr 10, 2023	DS DP U-1253		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	6953787	Apr 10, 2023	DS DP U-1252			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1255			
	8273734	Apr 10, 2023	U-1254			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N202872 001					>A> NDF	Sep 28, 2015
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8114890	Sep 05, 2020	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
<u>LUCINACTANT - SURFAXIN</u>						
N021746 001	>A> 5407914	Nov 17, 2013	DS DP U-1242			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 001					D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 002					D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 003	5532372	Jul 02, 2013	DS		D-134 NCE	Apr 26, 2015 Oct 28, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 004	5532372	Jul 02, 2013	DS		D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT</u>						
N022372 001	>A> 6946149	Mar 07, 2023	DP U-837			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 001					M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 002					M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406 001					PC	Feb 13, 2013
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406 002					PC	Feb 13, 2013
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 001	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 002	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 003	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 004	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET</u>						
N021410 005	8236345	Oct 07, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 001	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 002	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 003	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 001	8247425	Dec 31, 2030	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 002	8247425	Dec 31, 2030	U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 003	8247425	Dec 31, 2030	U-1185			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 001	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 002	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 003	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 004	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 001					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 002					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 003					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N202100 001					NDF	Aug 27, 2015
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	7651698	Sep 11, 2022	U-1051			
<u>MIFEPRISTONE - KORLYM</u>						
N202107 001					NP >A> ODE	Feb 17, 2015 Feb 17, 2019
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	6602911	Jan 14, 2023	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	6602911	Jan 14, 2023	U-882			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	6602911	Jan 14, 2023	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	6602911	Jan 14, 2023	U-882			
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N050781 001	6682348	Mar 29, 2022	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 001	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			
	7982049	Nov 04, 2023	DP			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 002	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			
	7982049	Nov 04, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MITOMYCIN - MITOSOL</u>						
N022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 001	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 002	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 001					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409 001					NPP	Mar 26, 2015
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 001	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 002	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 003	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 004	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 005	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321 006	7682633	Jun 19, 2027	U-1241			
	8158156	Jun 19, 2027	U-1241			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N019599 002					NS	Jan 13, 2015
<u>NEPAFENAC - NEPAFENAC</u>						
N203491 001					NP	Oct 16, 2015
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 001					>A> NPP	Nov 08, 2015
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 002					>A> NPP >A> NDF	Nov 08, 2015 Mar 25, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE - NICODERM CQ</u>						
N020165 004	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 005	8075911	May 22, 2021	DP			
<u>NICOTINE - NICODERM CQ</u>						
N020165 006	8075911	May 22, 2021	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 001	8163904	Aug 23, 2028	DS DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068 002	8163904	Aug 23, 2028	DS DP			
<u>NITRIC OXIDE - INOMAX</u>						
N020845 002	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
	8282966	Jun 30, 2029	U-1286			
	8282966*PED	Dec 30, 2029				
	8291904	Jan 06, 2031	DP U-1226			
	8291904*PED	Jul 06, 2031				
	8293284	Jun 30, 2029	U-1286			
	8293284*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 003	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
	8282966	Jun 30, 2029	U-1286			
	8282966*PED	Dec 30, 2029				
	8291904	Jan 06, 2031	DP U-1226			
	8291904*PED	Jul 06, 2031				
	8293284	Jun 30, 2029	U-1286			
	8293284*PED	Dec 30, 2029				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705 002	7872049	Mar 14, 2028	DP U-39			
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N203585 001	>A> 6987103	Jun 28, 2023	U-1300		NCE	Oct 26, 2017
	>A> 7842687	Mar 16, 2019	DS DP U-1299		>A> ODE	Oct 26, 2019
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N202810 001	>A> 7722898	Apr 13, 2027	DP		>A> NDF	Oct 19, 2015
	>A> 7910131	Apr 13, 2027	U-1298			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N202810 002	>A> 7722898	Apr 13, 2027	DP		>A> NDF	Oct 19, 2015
	>A> 7910131	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N202810 003	>A> 7722898	Apr 13, 2027	DP		>A> NDF	Oct 19, 2015
	>A> 7910131	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285 001	8119148	Dec 19, 2020	DP U-724			
	8119148*PED	Jun 19, 2021				
<u>OXYBUTYNIN - ANTUROL</u>						
N202513 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
	8241662	Apr 26, 2020	U-318			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N022204 001	8241662	Apr 26, 2020	U-318			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 001	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-443			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 002	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-443			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 003	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-443			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 004	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-443			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 005	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-443			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 006	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-443			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 007	8114383	Oct 10, 2024	DP			
	8309060	Nov 20, 2023	DP U-443			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 001	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 002	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 003	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 004	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 005	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 006	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 007	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	>A> 8329216	Feb 04, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	5439686	Feb 22, 2013	DP U-1290		I-658	Oct 11, 2015
	5439686	Feb 22, 2013	DP U-1092			
	5498421	Mar 12, 2013	DP U-1092			
	5498421	Mar 12, 2013	DP U-1290			
	5498421	Mar 12, 2013	DP U-634			
	6096331	Feb 22, 2013	DP U-1092			
	6096331	Feb 22, 2013	DP U-1290			
	6096331	Feb 22, 2013	DP U-633			
	6506405	Feb 22, 2013	DP U-1092			
	6506405	Feb 22, 2013	DP U-1290			
	6506405	Feb 22, 2013	DP U-633			
	6537579	Feb 22, 2013	U-632			
	6537579	Feb 22, 2013	U-1290			
	6537579	Feb 22, 2013	U-1092			
	7820788	Mar 03, 2024	DP U-1092			
	7820788	Mar 03, 2024	DP U-1290			
	7923536	Dec 09, 2023	U-1117			
	7923536	Dec 09, 2023	U-1290			
	8034375	Aug 13, 2026	U-1290			
	8138229	Dec 09, 2023	DP U-1092			
	8138229	Dec 09, 2023	DP U-1290			
	8268348	Feb 21, 2026	U-1290			
	>A> 8314156	Dec 09, 2023	U-1290			
	RE41884	Aug 14, 2016	U-1290			
	RE41884	Aug 14, 2016	U-1117			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 001	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	5254556*PED	Apr 15, 2014				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 002	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	5254556*PED	Apr 15, 2014				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 003	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	5254556*PED	Apr 15, 2014				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 004	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	5254556*PED	Apr 15, 2014				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 005	5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	5254556*PED	Apr 15, 2014				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 004					I-625 M-93 NCE	Apr 30, 2013 Jul 29, 2019 Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 001					NCE	May 17, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 002					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 003					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 001	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 002	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 003	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 004	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 005	8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 006	8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 001	>A> 7105530	Oct 19, 2023	DS DP		I-649	Apr 26, 2015
	8114885	Dec 19, 2021	DS DP		ODE	Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 002	>A> 7105530	Oct 19, 2023	DS DP		I-649	Apr 26, 2015
	8114885	Dec 19, 2021	DS DP		ODE	Apr 26, 2019
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 007	7084245	May 12, 2024	DS DP	U-1238		
	7414105	May 12, 2024	DS DP	U-1238		
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026		U-1238		
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026		U-1238		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 001	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 002	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 001	>A> 7772209	Nov 24, 2021	U-1296		M-122	Oct 17, 2015
	>A> 7772209	Nov 24, 2021	U-1077			
	>A> 7772209*PED	May 24, 2022				
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 002	>A> 7772209	Nov 24, 2021	U-1296		M-122	Oct 17, 2015
	>A> 7772209*PED	May 24, 2022				
<u>PERAMPANEL - FYCOMPA</u>						
N202834 001	>A> 6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 002	>A> 6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 003	>A> 6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 004	>A> 6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 005	>A> 6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 006	>A> 6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 003	6149938	Jul 23, 2018	DP U-1243			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 001	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 002	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 003	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 004	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 001					PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 002					PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 003					PC	Feb 13, 2013
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	8133883	Apr 14, 2023	DP U-282			
<u>POSACONAZOLE - NOXAFIL</u>						
N022003 001	8263600	Apr 01, 2022	DP			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 001	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 002	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISONE - RAYOS</u>						
N202020 001	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024	U-1292			
<u>PREDNISONE - RAYOS</u>						
N202020 002	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
	8309124	Apr 23, 2024				
<u>PREDNISONE - RAYOS</u>						
N202020 003	8168218	Jan 07, 2028	DP U-1269			
	8309124	Apr 23, 2024	U-1292			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE	
<u>PREGABALIN - LYRICA</u>								
N021446 001	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
<u>PREGABALIN - LYRICA</u>								
N021446 002	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
<u>PREGABALIN - LYRICA</u>								
N021446 003	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
<u>PREGABALIN - LYRICA</u>								
N021446 004	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
<u>PREGABALIN - LYRICA</u>								
N021446 005	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
<u>PREGABALIN - LYRICA</u>								
N021446 006	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
<u>PREGABALIN - LYRICA</u>								
N021446 007	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
<u>PREGABALIN - LYRICA</u>								
N021446 008	6001876	Dec	30, 2018	U-819	Y	I-651	Jun	20, 2015
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
<u>PREGABALIN - LYRICA</u>								
N022488 001	6001876	Dec	30, 2018	U-819	Y			
	6001876	Dec	30, 2018	U-55	Y			
	RE41920	Dec	30, 2018	U-1250				
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>								
N021438 001	6500454	Oct	04, 2021	DP				
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>								
N021438 002	6500454	Oct	04, 2021	DP				
<u>RABEPRAZOLE SODIUM - ACIPHEX</u>								
N020973 001	>A> 5045552	May	08, 2013	U-385				
	>A> 5045552*PED	Nov	08, 2013					

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RABEPRAZOLE SODIUM - ACIPHEX</u>						
N020973 002	>A> 5045552	May 08, 2013	U-385			
	>A> 5045552*PED	Nov 08, 2013				
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001					M-114	Mar 28, 2015
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
	8183226	Jun 22, 2019	U-116			
<u>REGORAFENIB - STIVARGA</u>						
N203085 001	7351834	Jan 12, 2020	DS		NCE	Sep 27, 2017
<u>REPAGLINIDE - PRANDIN</u>						
N020741 001	6677358	Jun 12, 2018	DS DP U-1265			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 002	6677358	Jun 12, 2018	DS DP U-1265			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 003	6677358	Jun 12, 2018	DS DP U-1265			
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	RE43390	Apr 12, 2021	DS DP U-805			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N022560 001	8246989	Jan 16, 2026	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RITONAVIR - NORVIR</u>						
N022417 001	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2925				
<u>RIVAROXABAN - XARELTO</u>						
N022406 001	>A> 7592339	Dec 11, 2020	U-1303		>A> I-662	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1302		>A> I-661	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1301		>A> I-660	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1200			
	>A> 7592339	Dec 11, 2020	U-1167			
<u>RIVAROXABAN - XARELTO</u>						
N022406 002	>A> 7592339	Dec 11, 2020	U-1303		>A> I-662	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1302		>A> I-661	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1301		>A> I-660	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1200		>A> NCE	Jul 01, 2016
	>A> 7592339	Dec 11, 2020	U-1167			
<u>RIVAROXABAN - XARELTO</u>						
N022406 003	>A> 7592339	Dec 11, 2020	U-1303		>A> I-662	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1302		>A> I-661	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1301		>A> I-660	Nov 02, 2015
	>A> 7592339	Dec 11, 2020	U-1200			
	>A> 7592339	Dec 11, 2020	U-1167			
<u>RIVAROXABAN - XARELTO</u>						
N202439 001	>A> 7157456	Feb 08, 2021	DS DP U-1302			
	>A> 7157456	Feb 08, 2021	DS DP U-1301			
	>A> 7592339	Dec 11, 2020	U-1303			
	>A> 7592339	Dec 11, 2020	U-1302			
	>A> 7592339	Dec 11, 2020	U-1301			
	>A> 7592339	Dec 11, 2020	U-1200			
	>A> 7592339	Dec 11, 2020	U-1167			
<u>RIVAROXABAN - XARELTO</u>						
N202439 002	>A> 7157456	Feb 08, 2021	DS DP U-1302			
	>A> 7157456	Feb 08, 2021	DS DP U-1301			
	>A> 7592339	Dec 11, 2020	U-1303			
	>A> 7592339	Dec 11, 2020	U-1302			
	>A> 7592339	Dec 11, 2020	U-1301			
	>A> 7592339	Dec 11, 2020	U-1200			
	>A> 7592339	Dec 11, 2020	U-1167			
<u>RIVASTIGMINE - EXELON</u>						
N022083 005	5602176	Feb 11, 2014	DS DP U-322		NS	Aug 31, 2015
	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001	4977138	Aug 22, 2013	DS DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 001	>A> 8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 002	>A> 8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 003	>A> 8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 004	>A> 8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 005	>A> 8303986	Apr 12, 2021	DP			
<u>ROPINIROLE HYDROCHLORIDE - REQUIP XL</u>						
N022008 006	>A> 8303986	Apr 12, 2021	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 004	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N021829 005	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 006	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 001	7750028	Oct 19, 2018	U-106			
<u>RUFINAMIDE - BANZEL</u>						
N021911 002	7750028	Oct 19, 2018	U-106			
<u>RUFINAMIDE - BANZEL</u>						
N021911 003	7750028	Oct 19, 2018	U-106			
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	6740669	Nov 14, 2022	DS DP			
	7750028	Oct 19, 2018	U-106			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N022181 001	>A> RE43797	Nov 17, 2024	U-1156			
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			M-61	Aug 30, 2015
					PED	Mar 01, 2016
					PED	Nov 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534	Mar 27, 2012	DS DP		M-61	Aug 30, 2015
	5250534*PED	Sep 27, 2012			NDF	Nov 20, 2012
					PED	Mar 01, 2016
					PED	May 20, 2013
<u>SILDENAFIL CITRATE - REVATIO</u>						
N203109 001					NDF	Aug 30, 2015
					PED	Mar 01, 2016
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 001	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 002	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 003	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 001	6699871	Jul 26, 2022	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 002	6699871	Jul 26, 2022	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 003	6699871	Jul 26, 2022	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 004	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1191			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1189			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1193			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1189			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 005	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1191			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1189			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1193			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1189			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 006	6303661	Apr 24, 2017	U-1188			
	6699871	Jul 26, 2022	DS DP U-1188			
	6890898	Feb 02, 2019	U-1191			
	6890898	Feb 02, 2019	U-1190			
	6890898	Feb 02, 2019	U-1189			
	7078381	Feb 02, 2019	U-1188			
	7125873	Jul 26, 2022	DP U-1193			
	7125873	Jul 26, 2022	DP U-1192			
	7125873	Jul 26, 2022	DP U-1190			
	7125873	Jul 26, 2022	DP U-1189			
	7326708	Apr 11, 2026	DS DP U-1188			
	7459428	Feb 02, 2019	U-1189			
	8168637	Jun 26, 2022	DP U-1188			
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N203922 001					ODE	Jan 14, 2018
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	8263650	Dec 22, 2019	DP U-1102			
	8263650	Dec 22, 2019	DP U-1101			
	>A> 8324275	Dec 22, 2019	U-1102			
	>A> 8324275	Dec 22, 2019	U-1101			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N203923 001					ODE	Jan 14, 2018
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N021148 008	>A> 6716198	Jun 05, 2021	DP			
	>A> 6899699	Jan 02, 2022	DP			
	>A> 7686786	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N021148 009	>A> 6716198	Jun 05, 2021	DP			
	>A> 6899699	Jan 02, 2022	DP			
	>A> 7686786	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N021148 010	>A> 6716198	Jun 05, 2021	DP			
	>A> 6899699	Jan 02, 2022	DP			
	>A> 7686786	Aug 03, 2026	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 004	>A> 6004297	Jan 28, 2019	DP			
	>A> 6235004	Jan 28, 2019	DP			
	>A> RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 005	>A> 6004297	Jan 28, 2019	DP			
	>A> 6235004	Jan 28, 2019	DP			
	>A> RE41956	Jan 21, 2021	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 006	>A> 6004297	Jan 28, 2019	DP			
	>A> 6235004	Jan 28, 2019	DP			
	>A> RE41956	Jan 21, 2021	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N021148 007	>A> 6004297	Jan 28, 2019	DP			
	>A> 6235004	Jan 28, 2019	DP			
	>A> RE41956	Jan 21, 2021	DP			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	7776007	Nov 22, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Dec 25, 2025	DP			
	8241244	Nov 21, 2022	DP			
	8267903	Mar 18, 2023	DP			
	>A> 8287489	Dec 06, 2024	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N022458 001	8227230	Feb 24, 2024	DS DP		NCE	May 01, 2017
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N203794 001	6071970	Jun 06, 2017		U-1289	NCE	Nov 20, 2013
	7994364	Jun 27, 2025	DS DP	U-1289		
	RE39593	Aug 05, 2022	DS DP	U-1289		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	6071970	Jun 06, 2017		U-1276	I-656	Aug 28, 2015
	6071970	Jun 06, 2017		U-1178		
	7994364	Jun 27, 2025	DS DP	U-1276		
	7994364	Jun 27, 2025	DS DP	U-1178		
	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP	U-1178		
	RE39593	Aug 05, 2022	DS DP	U-1276		
	RE39593	Aug 05, 2022	DS DP	U-1178		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	6071970	Jun 06, 2017		U-1276	I-656	Aug 28, 2015
	6071970	Jun 06, 2017		U-1178		
	7994364	Jun 27, 2025	DS DP	U-1276		
	7994364	Jun 27, 2025	DS DP	U-1178		
	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP	U-1178		
	RE39593	Aug 05, 2022	DS DP	U-1276		
	RE39593	Aug 05, 2022	DS DP	U-1178		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	6071970	Jun 06, 2017		U-1276	I-656	Aug 28, 2015
	6071970	Jun 06, 2017		U-1178		
	7994364	Jun 27, 2025	DS DP	U-1276		
	7994364	Jun 27, 2025	DS DP	U-1178		
	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP	U-1178		
	RE39593	Aug 05, 2022	DS DP	U-1276		
	RE39593	Aug 05, 2022	DS DP	U-1178		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP U-1178			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAZAROTENE - FABIOR</u>						
N202428 001					NDF	May 11, 2015
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID</u>						
N017858 001					ODE	Aug 13, 2019
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		M-61	May 30, 2015
	8026276*PED	Jul 20, 2026			ODE	May 30, 2014
	>A> 8299116	Jul 25, 2023	DP		PED	Nov 30, 2015
	>A> 8299116*PED	Jan 25, 2024			PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001	5922695	Jul 25, 2017	DS U-999		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-250		PED	Jul 18, 2015
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-1275			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 002	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 003	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 004	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-1275		PED	Sep 24, 2017
	5922695*PED	Jan 25, 2018			PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N022577 001	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-999		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-1275		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N202992 001	5459163	Oct 17, 2012	DP		NCE	Sep 12, 2017
	5679709	Oct 21, 2014	DP U-1285			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N202992 002	5459163	Oct 17, 2012	DP		NCE	Sep 12, 2017
	5679709	Oct 21, 2014	DP U-1285			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N022505 002	5861379	May 26, 2015	DS DP U-1100		NCE	Nov 10, 2015
	6020311	May 26, 2015	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 002					NP	Apr 29, 2014
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 003					NP	Apr 29, 2014
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N202763 001					NP	Feb 14, 2015
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N203214 001	>A> 6956041	Dec 08, 2020	DP		>A> NCE	Nov 06, 2017
	>A> 6965027	Mar 25, 2023	DS			
	>A> 7091208	Dec 08, 2020	U-247			
	>A> 7265221	Dec 08, 2020	DS			
	>A> 7301023	May 23, 2022	DS			
	>A> RE41783	Dec 08, 2020	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N022275 001	5258510	Nov 02, 2012	DS DP			
<u>TOLVAPTAN - SAMSCA</u>						
N022275 002	5258510	Nov 02, 2012	DS DP			
<u>TOLVAPTAN - SAMSCA</u>						
N022275 003	5258510	Nov 02, 2012	DS DP			
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 002					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 004					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 005					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002					NPP	Jul 15, 2014
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 002	8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 001					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 002					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 003					PC	Jun 27, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N022430 001	8273795	Mar 04, 2025	U-1182			
<u>TRAVOPROST - TRAVATAN Z</u>						
N021994 001	8268299	Oct 13, 2029	DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	8133893	Mar 13, 2029	DS DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N022048 001	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029	U-1258			
	8211880	Mar 10, 2029	U-1257			
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N022278 001					ODE	Feb 20, 2016
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 001	8273876	Jul 23, 2027	U-1288			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 002	8273876	Jul 23, 2027	U-1288			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 003	8273876	Jul 23, 2027	U-1288			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 004	8273876	Jul 23, 2027	U-1288			
<u>VEMURAFENIB - ZELBORAF</u>						
N202429 001	8143271	Jun 21, 2026	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VINCRIStINE SULFATE - MARQIBO KIT</u>						
N202497 001	5543152	Jun 20, 2014	DP		NP	Aug 09, 2015
	5741516	Jun 20, 2014	DP		ODE	Aug 09, 2019
	5814335	Jun 20, 2014	DP			
	6723338	Mar 31, 2020	U-1271			
	7247316	Sep 25, 2020	DP			
	7887836	Mar 31, 2020	U-1271			
<u>VISMODEGIB - ERIVEDGE</u>						
N203388 001	7888364	Nov 11, 2028	DS DP		NCE	Jan 30, 2017

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	7456219	Mar 11, 2027	DS			
	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023	U-892			
	RE38506	Nov 29, 2013	DS DP			
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 001					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 002					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 003					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 004					PC	Aug 29, 2012
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 001	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 002	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>